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Background   
Elderly people who demonstrate memory impairment that falls short of dementia, are 
referred to as having amnestic Mild Cognitive Impairment (aMCI).  AMCI patients have an 
elevated risk of developing dementia, although not all will do so.  Clinical criteria for 
Alzheimer’s Disease (AD) and aMCI do not specify how impairment of a cognitive nature 
should be defined.  The process of differentially diagnosing these conditions can be 
improved, if knowledge of neuropsychological measures that best discriminate between 
neurodegenerative and non-neurodegenerative cognitive impairment is used to implement 
diagnostic criteria for aMCI and AD.   
 
Aims 
We sought to 1) determine the frequency of aMCI referrals to our specialist memory clinic, 
2) characterise the detailed neuropsychology of a group of patients with aMCI, 3) determine 
the utility in differential diagnosis and test-retest reliability of these neuropsychological 
measures, and 4) establish a subset of neuropsychological measures that were of prognostic 
utility in aMCI.   
 
Methods 
The case notes of 187 consecutive referrals received by our Royal Edinburgh Hospital 
memory assessment service across an 18-month period were reviewed retrospectively and 
numbers of patients fulfilling aMCI criteria were recorded.  The baseline neuropsychological 
performances of 46 patients with aMCI, 20 patients with very early stage AD, 20 elderly 
patients with depressive symptoms and 24 healthy elderly participants were compared in 
order to determine their usefulness in differential diagnosis. AMCI participants were 
followed-up across an average of 4 years. Baseline neuropsychological performances of the 
aMCI dementia converters and aMCI non-converters were compared.  Logistic regression 




One quarter of referrals received by our memory assessment service met criteria for aMCI, 
most of whom displayed additional neuropsychological impairments of a non-memory 
nature, all the while performing above the highest cut off points on even the most 
comprehensive dementia screening measures.  A number of neuropsychological measures 
were highly sensitive and specific to early AD however, similar combinations of both high 
sensitivity and specificity to aMCI were not achieved.  Forty one percent of patients 
presenting to our service who fulfilled criteria for aMCI, received a clinical diagnosis of 
dementia across an average 4-year period. Performances on a comprehensive cognitive 
screening measure and a measure of delayed word recognition accuracy at baseline, 
classified 74% of aMCI patients comprising our clinic sample in accordance with their 
prognostic fate.   
 
Conclusion 
A significant proportion of patients presenting to specialist memory clinics display episodic 
and semantic memory/ or executive impairment that falls short of dementia and that is not 
detectable using traditional bedside screening measures. The vast majority of such patients 
(i.e. 72%) experience persisting or progressive cognitive impairment, and a significant 
proportion (41%) go on to receive a clinical diagnosis of dementia.  The baseline 
neuropsychological performance of aMCI patients who do and do not develop dementia 
differs, and contributes over and above clinical information to the prediction of long-term 
diagnostic outcome.  The high frequency with which aMCI is encountered in clinical 
practice, coupled with the minority of aMCI patients who experience resolution of their 
cognitive impairment, and the sensitivity and prognostic utility of several 
neuropsychological tasks, has implications for the clinical management of patients with 





Dementia is a syndrome of acquired intellectual impairment of sufficient severity to interfere 
with social or occupational functioning caused by brain dysfunction (Salmon and Bondi 
2009). Current diagnostic criteria for dementia require that a deficit and decline in memory 
must be present, along with at least one other area of cognitive disturbance (American 
Psychiatric Association 1994;McKhann et al. 1984), although the cognitive aspects of 
clinical criteria proposed for the less commonly encountered focal dementia subtypes vary 
(Mendez et al. 2009;Mesulam 2001;Neary et al. 1998). 
 
The history of dementia can be traced back to just over one hundred years ago to clinical 
descriptions of a 51-year-old lady with ‘pre-senile’ dementia in whom the histopathological 
hallmarks of AD were later discovered.  The identification of a disease substrate forced a 
gradual shift in the conceptualisation of dementia away from that of an unexplained 
disturbed behavioural state towards a medical syndrome.  The later (1976) discovery of 
identical histopathological changes in the brains of patients with the more commonly 
encountered ‘senile’ dementia provided the impetus for large scale research into the cause, 
neuropathologic features and clinical characteristics of dementia. 
 
In 2007 there were estimated to be 683,597 people with dementia in the UK, equating to one 
in every 88 persons of the entire UK population (Knapp and Prince 2007).  The number of 
people with dementia within the UK is forecast to increase by 38% over the following 15 
years and by 154% over the next 45 years, such that it is expected that there will be 
1,735,087 people with dementia residing within the UK by 2051. The prevalence of 
dementia is known to double every five years up until the age of 84 years, with the largest 
proportion of sufferers aged between 75-89 years. The present nation-wide total cost of 
dementia (including formal care agencies as well as the financial value of unpaid informal 
i.e. family care) is estimated at £17.03 billion.  Future costs will obviously rise considerably 
in line with the projected increase in dementia prevalence.  
 
Reaching a diagnosis of dementia at an early stage is important for a number of reasons. It 
allows time for the patient and his/her family to plan for the future and to attend, in a pre-
emptive manner, to financial and treatment matters.  The extent to which the patient can 
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effectively contribute to such planning will be dependent upon his/her cognitive capabilities 
(as dictated to a large extent by the stage of the illness).  Diagnosing dementia at an early 
stage provides a context from which the patient and family may understand disease related 
cognitive and behaviour changes and their functional impact(s), as well as the opportunity 
for specialists to educate and advise on symptom management.  Early diagnosis has also 
been shown to facilitate caregiver participation and ease caregiver stress, delaying the point 
at which the patient requires full-time institutionalised care (Weimer and Sager 2009).  
Pharmacological treatment may also help to slow the progression of symptoms (Lopez-Pousa 
et al. 2005).  
 
Dementia therefore poses a considerable and increasing challenge to society.  Diagnosing the 
condition at an early stage is both clinically and economically advantageous and likely to 
become increasingly important with the advent of disease modifying or halting agents.  
 
The clinical application of neuropsychology is concerned with the behavioural expression of 
brain dysfunction (Lezak 2004).  Neuropsychology is applied within clinical settings to assist 
with identification, differential diagnosis, management and rehabilitation of brain injuries, 
including brain injury arising within the context of neurodegenerative illness. Whilst viewed 
as giving rise to ‘diffuse’ cognitive impairment, neurodegenerative diseases were of limited 
interest to neuropsychologists who sought to unravel the brain’s basis for cognitive function 
through the use of dissociation techniques.  During the early 1980’s however, the 
development of standardised cognitive assessment techniques and clinical criteria for 
dementia allowed reliable diagnoses to be made at a much earlier disease stage.  As a result, 
traditional conceptualisations of dementia as giving rise to ‘generalised impairment of 
intellect’ were replaced with the notion of a syndrome that gave rise to ‘symptoms that were 
reflective of the underlying disease topography’.  The neuropsychological study of 
neurodegenerative disease grew out of this more ‘contained’ view of neurodegenerative- 
based brain damage. 
 
Major developments in our understanding of the order of progression of cognitive symptoms 
in dementia have followed.  Neuropsychological research has facilitated the differentiation 
of cognitive changes that occur as a normal consequence of aging, from those that signal the 
onset of a dementia syndrome, the differential diagnosis of a wide variety of dementia 
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subtypes, and the identification and detailed characterisation of the cognitive changes and 
underlying cognitive processes that comprise the manifesting signs of many of these.   
 
In the case of AD (the most common form of dementia accounting for 62% of all UK 
dementia diagnoses (Knapp and Prince 2007)), a wealth of neuropsychological evidence 
shows that episodic memory impairment, characterised by rapid forgetting (Attix & Welsh-
Bohmer, 2006) is usually the earliest and most salient aspect of the syndrome and that 
numerous features of memory task performance (i.e. savings or delayed recall, reduction of 
retrieval demands, serial position effect, semantic encoding benefits & intrusion errors) can 
be used to differentiate AD from normal aging with very high degrees of accuracy (Salmon 
and Bondi 2009). The rapid forgetting that characterises the earliest stages of the AD disease 
process is most easily demonstrated using neuropsychological tasks that that impose delay 
intervals, requiring the patient to retain newly learned material across time. By contrast, 
immediate (as assessed by measures of forward digit span) and long-term memories remain 
intact in the early stages.  
 
As the neuropathology of AD spreads beyond medial temporal lobe structures into areas of 
the association cortices of the temporal lobe and frontal lobes (Braak and Braak 1991), 
aspects of semantic memory, language and attention/executive function become increasingly 
impaired, making it difficult for patients’ to retrieve words and names (of people and places) 
and to generate these at pace, in accordance with a specified category.  It becomes 
progressively difficult for patients to understand complex or lengthy syntax and grammer, 
affecting their ability to comprehend spoken language and instruction.  
 
Aspects of frontal or executive functioning, specifically the ability to divide one’s attention 
between two things at pace, to forward plan and problem solve, also become impaired, 
leading to an increasing loss of functional independence. The emergence of impairments of a 
visuospatial nature (in the non-aytipical i.e. Posterior Cortical Atrophy or visual variant of 
AD) is generally thought to arise secondarily to the above changes (Perry and Hodges 2000) 
and deficits of this nature can be elicited via the administration of complex 2-D copying or 
self-drawing (i.e. clock drawing) tasks.  Impairments of this nature frequently give rise to 
difficulties with topographical orientation and spatial layout making it increasingly difficult 
for the patient to venture outwith his/her immediate and familiar environment alone. 
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Advances in our understanding of the staging of cognitive deficits in AD have formed the 
platform for the past decade’s focus on its’ pre-clinical stage.  The drive to facilitate AD 
diagnosis at an earlier stage of the disease course has been fuelled by a number of factors, 
including evidence in support of the existence of a long prodromal phase to the 
neurodegenerative illnesses, the availability of drug therapy for AD, and patient requests for 
prognosis and treatment.   
 
Current clinical criteria for AD require cognitive decline and impairment to be present in at 
least one domain in addition to memory (American Psychiatric Association 1994;McKhann 
et al. 1984).  Functional impairment is a further requirement. It is apparent however, that 
impairment(s) in different cognitive domains and functional decline(s) do not emerge 
simultaneously.  It has therefore been argued that the sequential nature of symptom 
emergence in the earliest AD disease stages is more commensurate with a continuum of 
cognitive impairment as opposed to the dichotomous (i.e. impairment present or absent) 
approach enlisted by current diagnostic criteria (Hachinski 2008). 
 
Memory complaints can predate other cognitive symptoms and functional decline by 
considerable intervals (Amieva et al. 2005).  This observation begs the question of whether 
any aspect(s) of the cognitive performances of persons with memory, but not additional 
functional impairment, could be used to reliably pre-empt a future diagnosis of AD, or 
‘reduce the threshold at which we are willing to arrive at a diagnosis of AD in accordance 
with existing clinical criteria’ (Chertkow et al. 2007). 
 
One factor complicating the detection of AD at an earlier stage, is the high prevelance (i.e. 
25-50%) of comorbid depression and mild cognitive impairment among the elderly.  
‘Depression is a mood disorder that produces sadness, negative self-regard, loss of interest in 
life and disruptions of sleep, apetite, thinking and energy levels’ (Steffens and Potter 2008).  
A depressive episode is diagnosed if, and when, the above symptoms are deemed 
troublesome enough to be interfering with daily life and they have persisted for more than 
two weeks.   
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A majority of studies (Kohler et al. 2009;Rapp et al. 2005;Thomas et al. 2009) although not 
all (Fischer et al. 2008) report impaired neuropsychological performance among elderly 
depressed patients relative to age and IQ matched controls.  
 
Cognitive deficits are most commonly noted in the domains of processing speed, episodic 
memory and effortful tasks tapping aspects of executive functioning (Steffens and Potter 
2008), although there is considerable variability among studies, some of which may be 
attributable to the heterogeneity of cognitive measures employed.  Some studies have 
reported evidence of fairly generaised cognitive deficits across a wide range of domains i.e. 
executive functioning, processing speed, episodic and semantic memory (Herrmann et al. 
2007;Kohler et al. 2009) whilst others have reported more isolated and distinctive profiles of 
cognitive impairment (Rapp et al. 2005;Thomas et al. 2009) that correspond with age of 
onset of the first depressive episode.  
 
With specific reference to the latter observation, there is evidence to suggest that late onset 
depression (LOD) (i.e. when the first depressive episode occurs after the age of 50 yrs) is 
associated with greater levels of imparment of attention and executive function (Herrmann et 
al. 2007;Kohler et al. 2009;Rapp et al. 2005) and processing speed (Herrmann et al. 2007) 
than recurrent or early onset (i.e. first episodic before the age of 50 yrs) depression.  Greater 
levels of executive and episodic memory compromise have been demonstrated in association 
with elderly depressed patients with an increased number of deep white-matter 
hyperintensities (Steffens and Potter 2008), and it is hypothesized that the executive deficits 
in the LOD group may therefore arise, together with depressed mood, as a result of 
subcortical vascular pathology.   
 
Conversely, some research suggests that memory deficits may be more focally affected 
among older individuals with a history of recurrent depression beginning earlier in life i.e. 
EOD (Rapp et al. 2005).It has been argued that such observations are in keeping with 
findings of significant hippocampal volume loss in EOD which is postulated to arise as a 
consequence of depression related stress related hypercortisolemia having a toxic effect on 
the hippocampus, disrupting regulation of glucocorticoid secretion resulting in hippocampal 
atrophy.   Of note, however, is that fact that the episodic memory impairments where 
documented in sufficient detail, appear to reflect difficulty at the levels of learning and 
unsupported delayed free recall as opposed to cued recall or recognition (Rapp et al. 
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2005;Thomas et al. 2009). In addition, there remains uncertainty also as to what extent the 
cognitive deficits seen in association with depression among the elderly might be 
underpinned by a more generalized slowing of information processing ability, as has been 
argued in the case of normal aging (Salthouse 1996). 
 
Regardless of the lack of clarity surrounding the neuropsychological profile of deficits 
accompanying depression in the elderly, cognitive impairments of a significant magnitude 
are frequently observed among this patient group, the assessement of which consequently 
forms an integral part of the early and differential diagnosis of AD and aMCI. 
 
Measurement of cognitive function represents just one, all be it an important, approach to 
detecting and diagnosing AD at a very early and pre-clinical stage. Other work has looked at 
the ability of imaging (for the most part MRI scanning), biomarkers (i.e. total tau, AB42 & 
Phospho-tau) and changes of a behavioural nature to predict the future onset of clinically 
diagnosable AD. A recent meta-analysis of imaging and biomarkers for AD (Schmand et al. 
2010) indicated some promise for the CSF markers in so far as there overall predictive 
accuracy levels were similar to that of memory impairment four years prior to the point of 
diagnosis.  Furthermore, the effect sizes for the CSF markers were largest when assessed 
longer before the point of diagnosis.  However, atrophy of the hippocampus or other MTL 
structures was found to be a less accurate predictor of future AD than memory impairment, 
and the largest effect sizes, (which are themselves likely to represent an underestimation 
owing to the removal of variability inherent in the inclusion of memory impairment as a 
selection criteria for a majority of studies), were seen association with measures of delayed 
memory recall. Other forms of neuroimaging i.e. PET and fMRI, were not evaluated as part 
of this analysis and their comparative contribution to the early and pre-clinical detection of 
AD therefore remains to be determined.  There is also evidence to suggest that behavioural 
symptoms such as depression (Steffens and Potter 2008) and apathy (Bartolini et al. 2005) 




1.1 MCI : Application of criteria and prevalence in specialist 
memory clinics 
 
The term Mild Cognitive Impairment (MCI) was adopted by Petersen and colleagues 
(Petersen et al. 1999) who tracked the longitudinal course of a group of 76 cognitively 
impaired, non-demented patients.  After 4 years, 48% had developed dementia, with an 
annual mean conversion rate of 12% as compared to 1-2% in an age matched community 
control group.  Petersen (Petersen et al. 1999) proposed that these mildly cognitively 
impaired patients were in a transitional state, between normal ageing and very early 
Alzheimer’s disease (AD). A set of criteria for MCI was established requiring that a patient 
have (1) a memory complaint, (2) retain normal activities of daily living and (3) normal 
levels of general cognitive function and (4) display objective evidence of abnormal memory 
for age (5) fulfilling criteria for dementia.  
 









Prior to this, a variety of terms had been used to denote persons with cognitive impairment 
falling short of dementia (Collie and Maruff 2002). These terms differ from the Petersen 
MCI criteria on a number of levels including (1) the normative cut off points and (2) 
comparison groups that are used to define cognitive impairment, (3) the number and type of 
cognitive domain(s) affected and most importantly (4) the presumed underlying cause(s) of 
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cognitive impairment.  Criteria for mild cognitive impairment (MCI) are unique in that they 
represent an initial attempt to define features of the dementias in their preclinical phases.  
 
Work subsequent to the publication of initial criteria for MCI indicated that not all elderly 
persons with cognitive impairment falling short of dementia exhibit an isolated memory 
complaint (Economou et al. 2007;Gualtieri and Johnson 2005;Loewenstein et al. 
2006a;Riberio et al. 2006). The original criteria were expanded to accommodate this (see 
Figure 1.2). 
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Petersen and colleagues (Petersen 2004;Petersen 2005c) identified four MCI subtypes in 
accordance with the presence of memory (amnestic) or other forms (non-amnestic) of 
cognitive deficit, and single or multiple domains of cognitive impairment.  It was anticipated 
that this more precise characterisation of the cognitive presentation of MCI sufferers would 
facilitate greater comparability of research findings and determination of differing prognoses 
for the MCI subtypes. 
 
Two further amendments to Petersen’s (Petersen et al. 1999) MCI criteria have been 
proposed subsequent to their initial publication, in recognition of growing evidence to 
suggest that relatively few MCI sufferers exhibit isolated memory impairment and retain 
preserved complex activities of daily living. The International Working Group on Mild 
Cognitive Impairment (Winblad et al. 2004) has recommended that these aspects of the MCI 
criteria be ‘loosened’ to allow for some degree of impairment in non-memory and functional 
performance.  One problematic consequence of the recommended changes is a resultant 
blurring of boundaries between MCI and early AD, as the absence of functional and multi-
domain cognitive impairment in MCI could no longer be used to differentiate these patient 
groups.  
 
Despite the evolving nature of it’s criteria, in 2001 MCI was endorsed as a useful clinical 
construct by the American Academy of Neurology (Petersen 2004) and clinicians were urged 
to identify and monitor such patients for their increased risk of developing a subsequent 
dementia.  Petersen’s original and revised MCI criteria have subsequently gained widespread 
acceptance among specialist research centres (Petersen and O'Brien 2006) and clinicians 
(Mitchell et al. 2008) although research has continued to focus on the amnestic single and 
amnestic multi-domain subtypes.  A case for the inclusion of the amnestic MCI subtype in 
the Diagnostic and Statistical Manual Version 5 (DSM-V) has been made (Petersen and 
O'Brien 2006) on grounds that there is an increasing need for clinicians to be able to 
recognize and treat dementias at an earlier stage, and as a clinical entity, MCI fulfils 
comparable numbers of the criteria that are typically used to classify DSM disorders 
(Kendell 1989).   
 
Consideration of MCI as a diagnostic entity reinforces the need for clinicians and researchers 
to be able to differentiate this group of patients from their age contemporaries and from 
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patients with early AD. Even without diagnostic status, initial findings indicate that between 
20% (Lehrner et al. 2005) and 23% (Alladi et al. 2006) of all referrals received at specialist 
memory clinics comprise patients who fulfil Petersen’s MCI criteria. This would suggest that 
the clinical assessment and wider management of MCI already comprises a significant part 
of the specialist practitioner’s workload, although the extent to which these estimates 
generalise to other memory clinics remains unclear. 
 
Figure 1.3  Theoretical progression of the transition from normal ageing to 
Alzheimer’s Disease 
 
Probable AD in accordance with NINCDS-ADRDA (McKhann et al. 1984) and DSM-IV (American 
Psychiatric Association 1994) criteria; Definite AD in accordance with autopsy findings (Mirra et al. 
2009); MCI in accordance with Petersen’s (Petersen et al. 1999) criterion. 
 
Whilst there is general consensus regarding the plausibility of a long prodromal phase to the 
dementias, and hence the theoretical construct that underlies MCI (see Figure 1.3), a good 
deal of controversy persists regarding how best to apply MCI criteria.  The bulk of ongoing 
debate centres around which cognitive measure(s) at which cut off point(s) should be used to 
objectively establish impairment in memory and other cognitive domains. It is well 
established that cognitive test sensitivities and specificities to aMCI vary (Alladi et al. 
2006;Dierckx and Engelborghs 2007;Grundman et al. 2004;Loewenstein et al. 2006a;Lonie 
et al. 2008). As a consequence, choice of cognitive measure, or indeed the number of 
measures (Brooks et al. 2007;De Jager and Budge 2005;Loewenstein et al. 2006b) used to 
define MCI could conceivably affect both the cognitive and affective make-up of the MCI 
group, and in turn, longitudinal outcome. 
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As with test selection, there is relatively little information to inform the selection of cut off 
values in establishing episodic and non-amnestic cognitive deficits in MCI.  With the 
exception of Grundman’s proposed research criteria (Grundman et al. 2004), which 
arbitrarily specifies a performance of 1.5 SD below age and education matched controls on 
the delayed recall component of the logical memory subtest from the now outdated Revised 
Wechsler Memory Scale (WMS-R; (Wechsler 1987)) this issue has not been resolved.  The 
research criteria have not been adopted uniformly, indeed there is evidence to suggest that 
defining memory impairment in this manner can lead to false positive MCI diagnoses 
(Brooks et al. 2007). Performance levels of between -1 and -2SD below age norms have 
typically been applied as a means of establishing episodic memory impairment in MCI. 
Comparison groups have comprised age and IQ (Alladi et al. 2006;Rentz et al. 2004), age 
and education matched healthy elderly (Artero et al. 2006;Loewenstein et al. 2007a;Visser 
and Verhey 2008) or published age matched normative data (Fox et al. 1998;Godbolt et al. 
2004).  
 
Elevated rates of conversion from MCI to dementia (relative to general population estimates 
of 1-2% / annum), have however been reported in association with the use of -1SD (Geslani 
et al. 2005;Schmidtke and Hermeneit 2007), -1.5SD (Artero et al. 2003), -2SD (Palmer et al. 
2007) cut off values to define episodic memory impairment in MCI. There is some evidence 
to suggest that greater levels of baseline episodic memory impairment are associated with a 
greater likelihood of progression to dementia during follow-up (Daly et al. 2000;Palmer et al. 
2003). 
 
For reasons outlined above, the neuropsychological aspects of the MCI classification have 
been deemed the most poorly defined (Portet et al. 2006).  Some authors have downplayed 
such concerns by emphasizing that the diagnosis of MCI is ‘not a neuropsychological one 
but rather a judgment call on the part of the clinician’ (Petersen et al. 1999;Petersen and 
O'Brien 2006). It is nonetheless clear that cognitive testing forms a central component of the 
MCI criteria & hence the wider diagnostic decision-making process.  Without specification 
of precise measures, cut off values and normative comparison groups, variability in the case 
definition of MCI persists, with the potential to affect outcome and comparability of study 
findings.  The neuropsychological aspects of MCI require further study prior to the 
establishment of criteria that can be applied clinically in a consistent manner.   
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On the basis of findings to date, it was predicted that 1) patients who fulfil Petersen’s MCI 
criteria would comprise a significant number of referrals to our Older Adult 
Neuropsychological Assessment Service and that 2) the bulk of MCI patients would 
demonstrate memory as well as other domains of cognitive impairment on comprehensive 
neuropsychological assessment.  We further hypothesized that 3) the classification of MCI 
subjects as normal, single or multi-domain, amnestic or non-amnestic would vary widely in 
accordance with the neuropsychological measure(s) and psychometric cut off points used to 
apply Petersen’s MCI criteria.   
 
1.2 Characterisation and differentiation of early AD and aMCI 
from normal ageing and depression using 
neuropsychological tasks  
 
1.2.1 Cognitive Screening  
Clinician surveys indicate that the Mini Mental State Examination (Folstein et al. 1975) is 
the most commonly used cognitive screening instrument in clinical practice (Shulman et al. 
2006).  Despite this, its ability to differentiate MCI sufferers from healthy and depressed 
elderly controls is not well established.  Significant differences in the MMSE scores of these 
patient groups have been reported inconsistently and where they do exist, would appear to 
have little clinical meaning, ranging in magnitude from a minimum of less than one scale 
point (Ravaglia et al. 2005) to a maximum of just under 2 points (Slavin et al. 2007).  As a 
majority of MCI patients score above the commonly used MMSE cut-offs 24/30 and 26/30, 
there is a considerable overlap in the scores of patients with MCI and age matched healthy 
controls.  Much higher cut off scores, that fall within what is typically viewed as a normal 
range i.e. 28/30, are required to achieve an adequate level of sensitivity to combined groups 
of highly educated dementia and MCI sufferers (O'Bryant et al. 2008).  As a result, the 
sensitivity of the MMSE to MCI is low with few exceptions (Callahan et al. 2002), ranging 
between 1% (Sager et al. 2006) and 49% (Ravaglia et al. 2005). 
 
Longitudinal studies examining the prognostic value of MMSE scores in MCI have either 
found no difference in the baseline MMSE scores of well individuals who later develop MCI  
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(Fox et al. 1998;Meyer et al. 2002;Tang-Wai et al. 2003) and MCI patients who develop AD 
(Meyer et al. 2002), or they have reported statistically significant differences between non-
converters and converters to dementia that are of an insufficient magnitude to be of clinical 
utility at an individual patient level (Aharonson et al. 2007;Amieva et al. 2005;Marcos et al. 
2006).  
 
The Addenbrookes Cognitive Examination (ACE; (Mathuranath et al. 2000) is a more 
extensive cognitive screening instrument, incorporating all of the items from the MMSE.  
This screening measure was more recently developed with the remit of improving early 
detection and differential diagnosis of dementia.  Each of the primary domains of cognitive 
functioning (Lezak 2004) are sampled, and contribute to an overall score out of 100.   
 
The ACE has become an increasingly popular cognitive assessment tool in both clinical 
(Alladi et al. 2006;Bak et al. 2005;Dudas et al. 2005a;Galton et al. 2005;Larner 2005;Larner 
2006) and research practice (Clague et al. 2005;Dudas et al. 2005b;Estevez-Gonzalez et al. 
2004;Thompson et al. 2002) within the UK.  It appears to be sensitive to a relatively broad 
range of dementia presentations (Bak et al. 2005;Mathuranath et al. 2000) as well as to MCI 
(Alladi et al. 2006;Dudas et al. 2005a;Lonie et al. 2008).  In an initial validation study 
comprising 115 patients with dementia and 124 age and education matched normal controls, 
a cut off score of 83/100 on the ACE showed higher sensitivity, specificity and positive 
predictive power for dementia than the MMSE alone (at cut offs of 27 and 24/30).  Other 
studies have documented the test’s specificity against major depression (Dudas et al. 2005a) 
and predictive validity in questionable dementia sufferers (Galton et al. 2005). 
 
Sensitivity of the ACE to MCI and its specificity against affective disorders has not been 
replicated outside the author’s (Mathuranath et al. 2000) research group.  Furthermore, the 
prognostic power of the ACE in isolation, as it relates to MCI (Petersen et al. 1999) remains 
to be determined.  It is conceivable that scores below the suggested dementia cut off points 
of 83 or 88/100 might provide a good indication of the likelihood of progression to dementia 
among MCI sufferers.  If so, this would equip the clinician with a relatively quick and easy 
means of determining the likely prognosis for individual members of this patient group. 
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On the basis of the above, it was hypothesized that 1) in comparison with the MMSE, the 
more extensive ACE would better differentiate between healthy elderly controls and patients 
with MCI.  It was also anticipated that 2) the baseline ACE score of the MCI participants 
would be a significant predictor of longer-term outcome, with lower baseline scores posing 
an elevated risk of dementia. 
 
1.2.2 Episodic Memory  
Since criteria for MCI were initially proposed (Petersen et al. 1999), a number of studies 
have sought to characterise the more detailed neuropsychology of this patient group. By 
definition, assessment of episodic memory functioning has routinely formed part of these 
studies, and the largest effect sizes, (where reported), are typically found in association with 
episodic memory measures (Alladi et al. 2006;Loewenstein et al. 2007b;Lonie et al. 2008). 
MCI research criteria proposed by Grundman et al (Grundman et al. 2004), specifying the 
use of a 1.5sd or more below age norms cut off point on the now outdated Logical Memory 
subtest from the WMS-R (Wechsler 1987) to establish objective evidence of episodic 
memory impairment, have not been universally adopted.  Instead, a wide range of paradigms 
are being used to assess recent memory functioning in MCI.    
 
Episodic memory paradigms can be categorised on a number of levels including (a) the 
nature of the material that is to be remembered i.e. verbal, visual or spatial (b) the extent to 
which cues are provided at recall i.e. free recall (without any cueing) or recognition (c) the 
number of learning trials provided (d) the length of time between encoding and recall i.e. 
immediate vs. delayed recall and (e) the nature of the memory to be formed i.e. an 
association between two or more items or a list of unrelated items. The paradigm that is 
employed, together with the specific measure that is chosen to assess episodic memory will 
determine (1) which component(s) of memory processing are evaluated (i.e. encoding, 
storage or retrieval) and (2) the likelihood of identifying an existing memory deficit (i.e. the 
test’s sensitivity). 
 
It remains unclear which type of memory paradigm and which specific 
neuropsychological memory measures are best suited to assessing the episodic 
memory failure in MCI and pre-clinical dementia, and differentiating these patient 
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groups from the healthy and depressed elderly (Lowndes and Savage 2007).  Whilst a large 
number of studies have demonstrated impairments of delayed free recall in both MCI and 
AD (Archer et al. 2006;Arnaiz et al. 2004;Belleville et al. 2007;Bennett et al. 2006;Clague et 
al. 2005;Hudon et al. 2006;Kalbe et al. 2005;Nordahl et al. 2005;Perrotin et al. 2007;Riberio 
et al. 2006;Rose et al. 2006;Schrijnemaekers et al. 2006) deficits on such measures are not 
necessarily specific to MCI or pre-clinical AD and are also seen in association with 
depression and anxiety (Fossati et al. 2004;Swainson et al. 2001) and other non-AD forms of 
dementia (Salmon and Bondi 2009). As a consequence, Dierckx et al (Dierckx et al. 
2007;Dierckx and Engelborghs 2007) have proposed the use of delayed cued recall or 
recognition measures, assuming that reduced reliance on executive aspects of memory 
performance results in greater specificity for MCI as it represents pre-clinical AD. In the 
latter study, a cued recall screening test gave 83% sensitivity and 85% specificity in 
discriminating individuals with AD from individuals with depression, however whilst the 
specificity held (85%), the test’s sensitivity was seen to decrease (58%) for the comparable 
MCI vs. depression discrimination. 
 
Relatively few cross-sectional studies have examined the specificity of poor episodic 
memory performance to MCI, and more importantly, pre-clinical AD. Several other studies 
that have examined this issue report the ability of cued recall measures to correctly classify 
subjects in accordance with their diagnostic group i.e. depression, mild cognitive 
impairment, normal control or early AD (Dierckx and Engelborghs 2007;Ritter et al. 
2006;Swainson et al. 2001).  In the latter studies, MCI patients not only exhibited deficits on 
the task as a whole, but were also readily divisible in terms of those whose performance 
mirrored the AD as opposed to the combined depression & healthy control groups.  These 
findings suggest that cued recall measures may be a particularly useful means of delineating 
episodic memory impairment in MCI, as failure on such measures is likely to represent an 
underlying pre-clinical AD process as opposed to depression or other non-progressive 
psychiatric conditions.  
 
Whilst several authors have reported impaired cued recall performance in MCI (Barbeau et 
al. 2004;De Jager et al. 2003;Dierckx and Engelborghs 2007;Greenaway et al. 2006;Ritter et 
al. 2006), others have not (Arnaiz et al. 2000;Crowell et al. 2002;Dudas et al. 2005b;Godbolt 
et al. 2005;Hudon et al. 2006;Westerberg et al. 2006).  Arnaiz et al (Arnaiz et al. 2000) failed 
to find any significant difference in the performance of MCI patients and healthy age and 
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education matched controls on a measure of cued story recall, although deficits were 
apparent on the free recall components of this task.  Similarly, Crowell et al (Crowell et al. 
2002) found that one quarter of their MCI sample performed at ceiling levels on the 
recognition trial of the cognitive component of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD).  In another study, gist recognition memory, as defined by 
the number of semantically related false positive errors, was comparable among groups of 
MCI sufferers and age/education matched controls (Hudon et al. 2006).  The dissociation 
between intact performance on forced choice recognition paradigms and impaired 
performance on yes/no recognition paradigms in MCI observed by Westerberg and 
colleagues (Westerberg et al. 2006) suggests that early neuropathological changes in the 
hippocampal and entorhinal cortex may give rise to recollection but not familiarity failure.  
Such findings raise uncertainty as to whether recognition paradigms are adequately sensitive 
to detect episodic memory failure in MCI and pre-clinical AD. 
 
On the basis of previous findings of intact delayed recognition performance among aMCI 
sufferers (Arnaiz et al. 2000;Crowell et al. 2002;Dierckx and Engelborghs 2007;Dudas et al. 
2005b;Godbolt et al. 2005;Hudon et al. 2006;Westerberg et al. 2006) together with the 
comparatively high general levels of cognitive functioning characterising our early AD and 
MCI participant groups, it was hypothesized that cued recall measures of episodic memory 
functioning would lack sensitivity to episodic memory failure in MCI and early AD whilst 
retaining adequate specificity (against depression and normal ageing). 
 
Much of the selection of episodic memory measures in the assessment of MCI has been 
based on 1) availability of testing materials, 2) familiarity of the administrator with tests, and 
3) ease of administration, rather than knowledge of the earliest sites of neuropathological 
change in pre-clinical AD and of which aspects of episodic memory function are likely to 
show compromise as a result (Lowndes and Savage 2007).  The hippocampal and wider 
medial temporal lobe structures are known to form a vital component of the neuroanatomical 
circuitry that underlies the acquisition and consolidation of new information (Squire 1992).  
Consequently, the primary impairment in typical early AD is a failure of the 
encoding/consolidation process, as a result of medial temporal lobe (MTL) pathology.  
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The most widely accepted theory of MTL functioning is that it receives afferent information 
and binds it together to encode the complex relational structure of personal experiences 
(Cohen et al. 1999;Wallenstein et al. 1998).  This includes the formation of conjunctions 
between spatial, temporal, perceptual, semantic, and affective information (Cohen and 
Eichenbaum 1993).  Episodic memory measures such as the Paired Associate Learning 
Subtest from the Cambridge Automated Neuropsychological Touch Screen Assessment 
Battery (CANTAB (Robbins et al. 1994)) that require pairing of information across different 
modalities, have consequently been identified as important paradigms in the differential 
diagnosis of MCI as it represents pre-clinical AD. 
 
The Paired Associate Learning (PAL) subtest from the CANTAB is known to be sensitive to 
episodic memory failure in early and pre-clinical Alzheimer’s disease (Ahmed et al. 
2008b;Fowler et al. 1995;Lee et al. 2003;O'Connell et al. 2004;Swainson et al. 2001) and 
objective memory complaints (Cargin et al. 2006;DeJager et al. 2002). Several studies have 
also reported that the PAL shows good specificity to early AD against depression (Swainson 
et al. 2001) and non-AD forms of dementia (Lee et al. 2003).  
 
Three studies have reported on the predictive validity of the PAL subtest from the CANTAB 
Battery (Ahmed et al. 2008b;Blackwell et al. 2004;Fowler et al. 2002).  Fowler et al (Fowler 
et al. 1997;O'Connell et al. 2004) observed a significant deterioration in PAL scores across 
an initial 6 month period in a group of 9/21 questionable dementia sufferers, all of whom 
went on to develop AD over the course of the proceeding 2 years. The number of errors 
made at the 6-pattern stage of the PAL subtest from the CANTAB was reportedly the most 
predictive (of a group of 7 episodic memory measures) in determining diagnostic outcome at 
32 months in a further study (Blackwell et al. 2004). In a more recent study, Ahmed et al 
(Ahmed et al. 2008b) found that aMCI sufferers made a significantly greater number of 
errors than age/education matched controls at the 6 box stage of PAL at baseline.  However, 
no differences were noted in the error rates of those MCI patients who developed dementia 
across the following 12 months and those who did not.  Applying a cut off score of 14 errors 
at the 6 box level of PAL gave perfect sensitivity and negative predictive values at the 
expense of considerably lower (i.e. 55%) levels of specificity and positive predictive values 
(PPV).  By combining the PAL error score with the Total ACE score, perfect sensitivity to 
pre-clinical AD was retained in the context of much improved levels of specificity (i.e. 82%; 
PPV=78%).  The latter study has several limitations, including the very small number of 
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aMCI patients (n=18) followed up, and the short (i.e. 12 month) duration of follow-up, and 
would therefore benefit from replication with larger aMCI sample sizes and longer follow-up 
periods. 
 
Whilst the above findings offer some preliminary hope of reaching a means of identifying 
AD in a pre-clinical phase, only one longitudinal study using the PAL subtest from the 
CANTAB battery, wherein MCI has been defined according to current criteria (Petersen et 
al. 1999), has been conducted (Ahmed et al. 2008b). As noted above, this study comprised a 
very small number of aMCI patients who were followed up for a relatively short time period 
(i.e. 12 months). Furthermore, the specificity of PAL against depression (Swainson et al. 
2001) has not been replicated.  Lastly, the limited follow-up periods of between 1-3 years 
have not allowed for determination of prognosis across longer time periods, which is a 
necessity in view of our knowledge of the relatively long i.e. up to 9 year prodromal AD 
phase (Amieva et al. 2005;Fox et al. 1998;Hodges et al. 2006). 
 
For the purposes of the current study, it was predicted that 1) the PAL subtest of the 
CANTAB Battery would better discriminate between normal healthy elderly controls, 
elderly persons with depressive symptoms and AD and MCI than the more traditional paper 
and pencil tests of episodic memory function.  It was further hypothesized that 2) the number 
of errors made at the 6 box level of the PAL at baseline would be a significant predictor of 
progression to dementia in aMCI. 
 
Memory impairment on a background of preserved other areas of cognitive functioning 
forms the core for Petersen’s original MCI criteria. Despite this, MCI subjects with isolated 
episodic memory deficits appear to comprise a relatively small proportion of the wider MCI 
group (Alladi et al. 2006;Loewenstein et al. 2006a;Lonie et al. 2008;Nordlund et al. 2005).  
Studies employing comprehensive neuropsychological batteries have consistently revealed 
evidence of additional impairments, in the cognitive domains of semantic memory and 
executive functioning, and less consistently those of psychomotor processing speed and 
visuospatial function (Alladi et al. 2006;Economou et al. 2007;Gualtieri and Johnson 
2005;Loewenstein et al. 2006a;Loewenstein et al. 2007b;Lonie et al. 2008;Nordlund et al. 
2005;Riberio et al. 2006).   
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Where a range of measures from each of the latter domains are employed, the presence or 
absence of a cognitive deficit, relative to the performance of age matched controls, is seen to 
vary in accordance with the specific measure that is used (Duong et al. 2006) and the general 
level of functioning of the MCI group.  Despite this, relatively few studies have sought to 
compare the sensitivities of non episodic memory measures in MCI (for exceptions see 
(Adlam et al. 2006;Ahmed et al. 2008a;Belleville et al. 2007;Joubert et al. 2008;Murphy et 
al. 2006;Stockholm et al. 2006;Vogel et al. 2005), with even fewer simultaneously 
examining the specificity of non-memory measures to MCI. Such information is important in 
determining the optimal means of defining MCI criteria as it represents preclinical dementia. 
 
1.2.3 Semantic Memory  
1.2.3.1 Object knowledge 
Semantic memory refers to one’s store of knowledge about worldly objects, their properties, 
functions and associations.  Semantic memory can be differentiated from episodic memory 
in that semantic memories are retained independently of the context in which they were 
learnt.  Observations of impaired performance on measures of semantic memory function in 
both MCI (Nutter-Upham et al. 2008) and preclinical AD (Auriacombe et al. 2006) sufferers, 
are consistent with our knowledge of the early spread of Alzheimer pathology from the 
medial aspects of the temporal lobe laterally into the temporal neocortex (Braak and Braak 
1991).  
 
A variety of paradigms have been adopted to assess semantic memory function.  Among 
these, measures of verbal fluency and confrontation naming are quick and easy to administer 
and among the most widely used measures of semantic memory function in the assessment 
of MCI. Both early AD and MCI are associated with impaired performance on measures of 
confrontation naming ability (Adlam et al. 2006;Ahmed et al. 2008a;Duong et al. 
2006;Joubert et al. 2008) and verbal, in particular, category fluency (Henry et al. 
2004;Murphy et al. 2006).  
 
The Graded Naming (GNT; (McKenna and Warrington 1980)) and Boston Naming Tests 
(BNT; (Kaplan et al. 1983)) are among the most popular standardised measures of 
confrontation naming ability. To date, selection of confrontation naming measures in the 
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assessment of MCI has been governed by the availability of local normative data, with UK 
based studies having typically employed the GNT (Alladi et al. 2006;Blackwell et al. 
2004;Swainson et al. 2001), where American based research has favoured the BNT 
(Loewenstein et al. 2006a;Petersen et al. 1999).  Both measures were initially validated using 
aphasic patient groups without mention of inclusion of elderly patients for whom aphasia has 
arisen within the context of a dementia.  Indeed, the validation sample for the 60-item 
version of the BNT did not include subjects over the age of 59 years. Both measures have 
subsequently been shown to discriminate between healthy elderly and mildly impaired AD 
patients (Chosak 2000;Thompson et al. 2002) and there is also evidence to suggest that even 
moderate levels of depression have little effect on the BNT performance of elderly subjects 
(Spreen and Strauss 1998). 
 
Several recent studies have reported significantly poorer performances of MCI patients on 
the GNT relative to healthy age matched controls (Ahmed et al. 2008a;Alladi et al. 
2006;Dudas et al. 2005b).   However, earlier findings are somewhat incongruous with these 
results.  Godbolt et al., (Godbolt et al. 2004), failed to find any impairment in performance 
on the GNT in a group of 19 early onset autosomal dominant familial AD sufferers in their 
pre-symptomatic and symptomatic (pre-diagnostic) phases. Similarly, Perry & Watson 
(Perry et al. 2000) failed to find any significant difference in the GNT performances of 
patients with minimal stage AD and age matched controls.  Furthermore, Swainson et al 
(Swainson et al. 2001) reported that performance on the GNT failed to differentiate a group 
of Questionable Dementia sufferers (QD) from a combined group of depressive and healthy 
age matched subjects.   
 
No study to date has reported on the prognostic utility of poor performance on this task in 
MCI sufferers who fulfil Petersen’s MCI criteria, although De Jager et al, (De Jager et al. 
2005;De Jager and Budge 2005) found that impaired GNT performance at baseline was 
indicative of a persisting MCI diagnosis across a 4 year period.  Findings regarding the 
prognostic utility of baseline GNT scores in QD sufferers are mixed.  In one study, baseline 
GNT score was found to be a significant predictor of future conversion to dementia 
(Blackwell et al. 2004), whereas Thompson et al (Thompson et al. 2002) observed 
unimpaired baseline GNT performance in a relatively small number (i.e. 6/7) of QD sufferers 
who went on to receive a diagnosis of AD within a two year period.  Finally, a 6 year 
longitudinal follow-up of patients at risk of developing early onset autosomal dominant 
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familial AD also failed to find deficits in the GNT performances of future converters either 
on initial / baseline testing or at the point at which a clinical diagnosis of AD is reached (Fox 
et al. 1998). 
 
Similarly Albert et al (Albert et al. 2001) found no significant difference in the baseline BNT 
performance of control subjects and MCI patients who went on to develop AD.  Studies 
comparing BNT performance across groups of MCI or QD patients and healthy age matched 
controls have also given mixed results, with some reporting significant differences in favour 
of controls (Loewenstein et al. 2007b;Petersen et al. 1999) and others reporting no group 
differences (Balthazar et al. 2007;Greenaway et al. 2006).   
 
Despite mounting evidence highlighting the importance of assessing semantic memory 
function in MCI and possible early AD cases (Hodges and Patterson 1995;Lam et al. 
2006;Mickes et al. 2007), no direct comparison of the relative sensitivities of these two 
confrontation naming measures to MCI, preclinical and early AD has been undertaken.  
Furthermore, their specificity to MCI as distinct from the cognitive effects of depression, and 
the prognostic validity of the GNT in an MCI sample defined in accordance with Petersen’s 
criteria has not been studied.   
 
Within the present series of studies we therefore sought to 1) compare the relative 
sensitivities of the BNT and GNT to aMCI and early AD as well as 2) their specificities 
against the normal aging process and depressive symptoms and to 3) determine the 
prognostic significance of these measures in relation to MCI as defined by Petersen. In view 
of the absence of any preceeding literature in the first case and the contradictory nature of 
existing prognostic findings relating to QD and preclinical AD, no directional hypotheses 
were made.   
 
1.2.3.2 Person Specific Knowledge 
More recent research has examined the performance of early AD and MCI’s patient’s on 
measures of person specific semantic knowledge, as assessed by famous face naming tasks. 
There is accumulating evidence to suggest that measures of face naming ability may be more 
sensitive to early semantic memory compromise in AD and MCI than are object naming 
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measures (Ahmed et al. 2008a;Clague et al. 2005;Dudas et al. 2005b;Estevez-Gonzalez et al. 
2004;Thompson et al. 2002;Vogel et al. 2005). Furthermore, preliminary findings would 
suggest that performance on measures of face naming ability may be of value in 
distinguishing between MCI subjects who are likely to progress to dementia over the course 
of the following 1-2 year period and those who do not.  Thompson et al (Thompson et al. 
2002) reported that of 7 from 28 Questionable Dementia of the Alzheimer Type (QDAT) 
patients who progressed to dementia over a 1-2 year time interval, 6 of these exhibited 
impaired face naming ability on initial testing.  This compared with intact face naming 
performance for 17 of the 21 QDAT who did not progress to dementia.  
 
This pattern of findings (i.e. face < object naming) has recently been replicated using famous 
buildings (Ahmed et al. 2008a) and public event (Joubert et al. 2008) recall tasks implying 
that representation or access to knowledge of unique semantic exemplars (as in the case of 
famous faces, buildings and public events) may be more vulnerable to early Alzheimer 
pathology than representation or access to knowledge of objects, where multiple 
representations of a single item exist within the lexicon.   
 
Findings of superior sensitivity of face over object naming tasks to early semantic memory 
deficits in AD and MCI have been replicated on one occasion only outside the Graded Faces 
Naming Test (Hodges et al. 1993) developer’s research group.  There are no reports 
pertaining to the specificity of poor performance on tests of face naming ability against 
depression or other psychiatric or neurological conditions that frequently co-exist in older 
adult populations with memory complaints.  Of the two studies that have reported on the 
prognostic utility of face naming measures in MCI, follow-up periods for each have been 
short (i.e. 1-2 years).  Furthermore, different famous face naming tasks were employed in 
each of these studies. In both studies, the research group comprised the author of the face 
naming test that was employed.  The findings therefore require replication and extension to 
determine specificity against depression and long-term (i.e. > 2 years) prognostic utility. 
 
For the purposes of the present study, it was hypothesized that 1) the GFT, as a person 
specific naming task, would be more sensitive than both the BNT and GNT to semantic 
memory failure in MCI and early AD and that 2) baseline performance on this measure 
would contribute significantly to the prediction of conversion from aMCI to dementia. 
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1.2.4 Verbal Fluency  
Verbal fluency tasks are an equally popular means of assessing semantic memory function in 
early AD and MCI patients.  As they are brief to administer and easy to score, fluency 
measures frequently form part of bedside cognitive screening instruments and evaluations. A 
recent meta-analysis demonstrated that AD patients are significantly more impaired on 
measures of semantic than lexical fluency (Henry et al. 2004). This pattern of impairment of 
verbal fluency measures is qualitatively distinct from the usual finding of superior semantic 
fluency in healthy controls (Spreen and Strauss 1998). As the category task is thought to 
rely more heavily on access to representations of semantic concepts than the letter task, the 
pattern of findings in AD is presumed to reflect degradation in the structure, content or 
activation of the semantic memory system (Auriacombe et al. 2006;Jefferies and Lambon 
Ralph 2006;Jones et al. 2006). 
 
Patients in the pre-clinical stages of AD exhibit a semantic fluency deficit, at a time when 
lexical fluency performance remains intact (Auriacombe et al. 2006;Beatty et al. 
2002;Swainson et al. 2001). Similarly, patients who fulfil criteria for Amnestic Mild 
Cognitive Impairment (aMCI; (Grundman et al. 2004;Petersen et al. 1999)) generate fewer 
words from a specified category than do age matched controls. In contrast, they perform at 
normal levels on lexical fluency tasks (Alladi et al. 2006;Dudas et al. 2005b;Lonie et al. 
2009a;Murphy et al. 2006). 
 
A pattern of worse semantic than lexical fluency has also been reported in patients with 
depression (Christensen et al. 1997;Zakzanis et al. 1998), although a more recent review 
suggests equal impairment of performance across the two fluency tasks, thought to reflect a 
generalised reduction in processing speed (Henry and Crawford 2005).  
 
If semantic and lexical fluency discrepancy scores are abnormal in some patients with aMCI, 
their magnitude and direction may prove helpful in diagnosis and/or prognosis. As an 
individually calibrated marker of performance, the direction of the discrepancy would have 
the advantage of being free from the need for age, gender, education or IQ-dependent cut off 
values, which require a sizable normative comparison group. 
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Furthermore, if depressive symptoms were associated with equivalent reductions in lexical 
and semantic task performance (as the processing speed account would predict), then fluency 
discrepancy scores might also be of value in distinguishing between depressive and early 
Alzheimer related cognitive impairment.  
 
One study has reported on the use of semantic-lexical fluency discrepancy scores in 
detecting MCI.  Murphy et al (Murphy et al. 2006) demonstrated a progressive advantage 
(controls > aMCI > AD) in semantic, relative to phonemic fluency, with difference scores 
between tasks distinguishing each group from the others with medium to large effect sizes 
ranging from 0.49 to 1.07. However, this study lacked the important inclusion of a 
depressive control group matched for general level of cognitive functioning and support 
needs.  The differential diagnosis of depression and early stage dementia in the elderly is 
notoriously difficult (Lezak 2004), and it is for this reason important to establish the extent 
to which poor performance on a cognitive measure is attributable to an underlying 
neurodegenerative disease process as opposed to an affective disorder.  As such, it remains 
uncertain to what degree the pattern of lexical>semantic fluency performance is specific to 
aMCI and AD and whether a similar pattern of findings might generalise to the use of 
alternative letters, (in particular those that already form part of widely used dementia 
screening instruments such as the ACE).  The prognostic significance of this pattern of 
fluency performance has not been studied. 
 
It was hypothesized that fluency discrepancy scores would be a sensitive and specific means 
of differentiating MCI and early AD patients from healthy elderly controls and elderly 
controls with depressive symptoms. 
 
1.2.5 Executive Function  
Executive function is an umbrella term describing a number of different cognitive processes 
(i.e. abstract reasoning, divided attention, inhibition, mental flexibility, self-monitoring, 
planning, problem solving, working memory) that serve a ‘global processing control 
function’ (Attix and Welsh-Bohmer 2006) facilitating pre-meditated, purposeful and goal 
directed behaviour.  Executive functions are thought to be mediated in part by structures 
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within the frontal brain cortex and damage to this region has been associated with 
impairment in each of the processes outlined above (Lezak 2004).   
 
A number of studies have demonstrated the presence of deficits of an executive nature in 
preclinical AD (Backman et al. 2005) and early AD (Egerhazi et al. 2007;Perry et al. 
2000;Stockholm et al. 2006). MCI patients have been shown to perform significantly less 
well than their age peers on a range of standardised executive measures including the 
Wisconsin Card Sorting Test (WCST; (Clague et al. 2005), Similarities subtest from the 
WAIS-III  (Loewenstein et al. 2007b), The Spatial working memory subtest from the 
CANTAB battery (Collie et al. 2002;Egerhazi et al. 2007), digit span subtest from the 
WAIS-III; forwards (Dudas et al. 2005b;Lu et al. 2005) and backwards (Crowell et al. 
2002;Lu et al. 2005), spatial span subtest from the WAIS-III; forwards and backwards 
(Levinoff et al. 2006) and the Brown-Peterson procedure (Belleville et al. 2007).  By 
contrast, performance on a range of measures assessing aspects of planning, estimation and 
problem solving ability has failed to discriminate between MCI sufferers and age matched 
controls (Collie et al. 2002;Egerhazi et al. 2007;Levinoff et al. 2006;Nordlund et al. 
2007;Swainson et al. 2001).   
 
As is true for other domains of cognition, there is some preliminary evidence to suggest that 
the ability to detect early compromise of an executive nature in MCI and preclinical AD 
varies in accordance with the aspect of executive functioning that is assessed, and the 
specific measure that is employed.  Belleville et al (Belleville et al. 2007) demonstrated that 
divided attention was impaired in MCI, whereas this group performed at similar levels to age 
matched controls on measures tapping other aspects of attention control (i.e. mental 
manipulation and inhibition). As the Petersen-Brown task that was employed to assess 
divided attention also required patients to retain three consonants across a 30 second delay 
period, and MCI patients were found to be impaired on this task without a divided attention 
component, it was not clear whether their reduced performance was reflective of defective 
divided attention or rather short term memory.  Similarly, an impairment of response 
inhibition in MCI patients documented using an experimental paradigm (The flanker task; 
(Wylie et al. 2007) has not been observed on several standardized clinical measures of 
response inhibition such as the Stroop; (Belleville et al. 2007;Hudon et al. 2006;Kramer et al. 
2006;Nordlund et al. 2007) and the Hayling; (Belleville et al. 2007).  
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The most consistent deficits of an executive nature in MCI have been reported in association 
with performance on Part B of the Trail Making Test (TMT Part B; (Reitan 1985) (Alladi et 
al. 2006;Archer et al. 2006;Arnaiz and Almkvist 2003;Crowell et al. 2002;Loewenstein et al. 
2007b). These findings imply compromise to complex attentional functions such as dual 
processing, working memory and the shifting and division of attention in the pre-clinical 
phase of AD.  Deficits of this nature are a well established feature of early AD (Della Sala 
and Logie 2001;Parasuraman and Haxby 1993) and at least one study suggests that poor 
performance on Part B of the TMT is a significant predictor of time to progression from MCI 
to a clinical diagnosis of AD (Blacker et al. 2007). In a recent meta-analysis however, 
Herrmann et al  (Herrmann et al. 2007) concluded that executive deficits, as assessed by 
TMTB among other measures, are also common among elderly depressed patients, 
particularly those suffering with a late onset depression. As such, it would seem important to 
establish the specificity of poor performance on part B of the TMT to MCI prior to 
determining the predictive capabilities of this measure.  
The dual task measure similarly assesses the ability to co-ordinate the simultaneous 
performance of multiple tasks and is purported to be a sensitive marker of executive failure 
in early AD (Baddeley et al. 1986;Collette et al. 1999;Della Sala et al. 1995;Greene et al. 
1995). The measure was developed by Baddeley and colleagues in order to evaluate the 
central executive component of working memory (Baddeley and Hitch 1974). Figure 1.4 
depicts the model of working memory. Within this model, the role of the central executive is 
to coordinate the simultaneous operation of the other components.  In doing so, the central 
executive facilitates temporary retention of new information in a short term store and the 
maintenance of such information via mental rehearsal so that mental manipulation can be 
carried out in an online manner.  By comparing performance in a dual task situation to 
performance on the same tasks performed alone, it is suggested that any drop in performance 
can be attributed to a failure of the central executive.  
Figure 1.4  Baddeley and Hitch (1974) Model of Working Memory 
                                                             Short term Visual Store 
            
                  Visuospatial Sketchpad       Visuospatial Sketchpad 
 
                                                                   Central Executive 
                      Phonological Loop                     Phonological Loop 
 
                                                               Short term Verbal Store 
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Dual task deficits have been reported in association with AD (Baddeley et al. 2001;Logie et 
al. 2004) although not consistently (Greene et al. 1995;Perry et al. 2000), and in elderly 
patient’s without a dementia diagnosis with Dementia Rating Scale Scores falling below 
123/144 (where 123 is the suggested cut off point for dementia) (Holtzer et al. 2004).  As 
performance on the dual task can be seen to vary in a qualitative as well as quantitative sense 
(i.e. no decrement vs. decrement), it is potentially well suited for use as a tool in early 
differential diagnosis of AD as has been described as a ‘viable and fruitful approach to the 
development of clinical tools’ (Della Sala and Logie 2001). Furthermore, dual-task 
performance is reportedly insensitive to the normal ageing process, in so far as the individual 
components of the overall task rely on different modalities (i.e. visual vs. auditory) and that 
these single components are adjusted so that difficulty levels are equal across comparison 
groups (Baddeley et al. 1986;Della Sala and Logie 2001). 
 
Studies that have examined the performance of depressed patients on dual task measures, 
without adjusting the levels of performance on the component tasks performed singly to 
those of controls, show mixed results, some reporting a dual task decrement in association 
with depression (Arnett et al. 1999;Lemelin and Baruch 1998) and others reporting the 
opposite pattern of findings i.e. a greater dual task decrement in controls than patients with 
depression (Thomas et al. 1999).  A more recent study, in which levels of performance on 
the component parts of the dual task were matched across groups, found a significantly 
greater dual performance deficit in depressed patients that was seen to persist with remission 
(Nebes et al. 2001). 
 
No study to date has reported on the dual task performance of patient’s who fulfil Petersen’s 
criteria for MCI, or examined the longitudinal course of dual task performance in this patient 
group.  As noted above, there are mixed findings relating to the sensitivity of the Dual Task 
to executive compromise in early AD and depression. The measure’s potential utility in the 
early identification of pre-clinical AD therefore remains uncertain. 
 
It was hypothesized that measures of divided attention and dual task performance but not 




1.2.6 Visuospatial Function and Processing Speed  
Alongside attention, episodic, semantic, working memory and executive functioning, visuo-
construction and processing speed comprise the remaining two sub-domains of cognitive 
processing as established by neuropsychological profiles in different forms of dementia 
(Lezak 2004).  Deficits in the latter two domains have also been reported in association with 
amnestic MCI, albeit, with considerably less frequency than other cognitive domains. Such 
observations would fit well with what is known of the temporal sequence of 
neuropathological change in AD, where neurofibrillary tangles are seen to accumulate within 
the medial and lateral portions of the temporal lobe prior to spreading to posterior 
association cortices (Braak and Braak 1991). 
 
In the assessment of MCI, visuo-spatial and constructional abilities have been most 
frequently assessed with copied drawing tasks, such as the Rey Complex Figure Test (Rey 
1941).  Several authors have reported significantly lower mean performances of MCI 
patients relative to healthy elderly controls on the copy component of the RCFT (Alladi et al. 
2006;Archer et al. 2006). There are a number of other formal neuropsychological measures 
comprising one or more subtests that have been designed to assess visuo-spatial, visuo-
constructional and visuo-perceptual abilities.  A majority of studies employing measures of 
visuospatial/constructional and perceptual ability have failed to reveal significant differences 
in the performance of MCI patients and age matched controls on the RCFT-copy (Adlam et 
al. 2006;Dudas et al. 2005b;Kalbe et al. 2005;Lambon et al. 2003;Nordlund et al. 2007) the 
Block Design subtest from the Wechsler Adult Intelligence Scale – III (WAIS-III;(Wechsler 
1997) (Bennet 2006; Greenaway 2006; Levinoff 2006; Nordlund 2007), the Visual Object 
and Space Perception Battery (VOSP;(Warrington and James 1991) (Adlam et al. 
2006;Archer et al. 2006;Clague et al. 2005;Dudas et al. 2005b;Nordlund et al. 2007) and the 
constructional praxis component of the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD; (Morris et al. 1989) (Bennett et al. 2006;Crowell et al. 2002). 
 
Such observations are in keeping with the findings of a recent meta-analytic review of 
cognitive impairment in pre-clinical AD (Backman et al. 2005), where smaller differences in 
the performances of pre-clinical AD and healthy elderly on measures of visuo-spatial ability 
were observed relative to tests of episodic memory, global cognitive function and processing 
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speed. There is relatively little information addressing the prognostic validity of impaired 
visuo-spatial and constructional ability in MCI. Some authors report baseline visuo-
perceptual (Marcos et al. 2006) visuo-constructional (Artero et al. 2003) performances as 
significant predictors of future conversion to AD and others have found no association 
between visuo-spatial performance and risk of AD (Aggarwal et al. 2005;Albert et al. 
2007;Albert et al. 2001). The heterogeneous nature of AD presentations is well established 
(Caine and Hodges 2001), and it is possible that the assessment of visuo-spatial function may 
be of greater importance in younger MCI patients given the evidence to suggest that atypical 
(i.e. visual) presentations of AD are more common among early onset sufferers (Black 
1996). 
 
Whilst early AD, pre-clinical AD, and aMCI clinical presentations are not typically 
associated with the reductions in psychomotor processing speed that accompany the 
subcortical dementias, recent meta-analytic findings indicate that pre-clinical AD patients 
(Backman et al. 2005) process information at a slower speed than their age matched 
contemporaries.  Neuropsychological assessment of processing speed most frequently 
comprises a timed task requiring both motor and cognitive input (i.e. a visuomotor 
processing speed task) examples of which include, the Digit Symbol subtest from the WAIS-
III (Wechsler 1997), Part A of the Trail Making Test (TMTA; (Reitan 1985)) and the 
Symbol Digit Modality Test (SDMT; (Smith 1982). Of these, TMTA has been the most 
popular choice in assessing psychomotor speed in MCI.  A majority of studies have failed to 
find a difference in the time taken by MCI patients and healthy elderly controls to complete 
this task (Archer 2006;  Arnaiz 2000; Belleville 2007; Bennett 2006; Crowell 2002; 
Greenaway 2006; Kalbe 2005; Westerberg 2006) but see (Alladi et al. 2006;Arnaiz et al. 
2000), suggesting that visuo-motor processing speed (when assessed in this manner among 
smaller MCI patient groups) may lack sensitivity to MCI.  It was therefore hypothesized that 
the time taken to complete TMTA would not differ between MCI and healthy elderly control 
participant groups 
 
1.3 Predicting conversion from aMCI to dementia using 
neuropsychological measures 
Current MCI criteria do not specify the manner in which cognitive deficits should be 
defined. There is, as a result, scope for variability in the case definition of MCI in terms of 1) 
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the number of cognitive domains that are impaired 2) the number and nature of episodic 
memory measures that are used to detect memory impairment and 3) the severity of episodic 
memory impairment that is observed.  Each of these factors could conceivably affect the 
proportion of MCI sufferers who go on to develop dementia as well as the rate at which 
progression to dementia occurs.  A greater understanding of the influence that variability in 
MCI case definition has on clinical outcome would inform the use of more detailed cognitive 
criteria that are better able to identify a more homogenous group of pre-clinical dementia 
sufferers. 
 
1.3.1 Impairments of a non-episodic memory nature as predictors of 
progression to dementia 
Since the original MCI criteria were expanded in recognition of four subtypes (see figure 1.2 
above), interest has developed in the prognostic significance of multiple vs. single domain 
amnestic MCI.  Research has thus far focused on whether deficits in domains other than that 
of episodic memory function are predictive of future conversion to dementia and whether 
greater numbers of impaired cognitive domains at baseline are associated with an increase 
risk of conversion from MCI to dementia. 
  
In relation to MCI as it is defined by Petersen (Petersen et al. 1999), poorer baseline 
performance on measures of processing speed (Aggarwal et al. 2005;Amieva et al. 
2004;Bennett et al. 2002;Tabert et al. 2006), semantic memory function (Bennett et al. 
2002;Estevez-Gonzalez et al. 2004), and less frequently visuo-perception (Marcos et al. 
2006) and executive functioning (Perri et al. 2007) have been reported as significant 
predictors of future conversion to dementia across 2-10 year time periods.  Where ‘at risk’ 
groups have been defined by some means other than Petersen’s MCI criteria, semantic 
memory measures are the most frequently reported significant predictors of conversion to 
dementia (Artero et al. 2003;Galton et al. 2005;Guarch et al. 2004) behind episodic memory 
tasks. 
 
By comparison, relatively few studies have addressed the influence that the number of 
cognitive domains impaired at baseline has on risk of conversion to dementia.  In a 2 year 
retrospective evaluation of 48 non-demented and non-depressed elderly patients with clinical 
and neuropsychological evidence of memory deficits, Bozoki et al., (Bozoki et al. 2001) 
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found significantly higher rates of conversion to AD among the MCI patients with multi-
domain amnestic (48% & 77%) as compared to single domain amnestic MCI subtype (6% & 
24%) in the 2nd and 4th years of follow-up respectively. A similar pattern of findings was 
reported by Tabert et al., (Tabert et al. 2002) who observed a significantly greater proportion 
of multi-domain amnestic MCI patients (50%) convert to AD across a three year time period 
than patients with single domain amnestic MCI (10%).  By contrast, Storandt et al., (Storandt 
et al. 2006) reported similar rates of progression (0.5SD/year on a psychometric composite), 
mean survival times to a Clinical Dementia Rating scale score of 1, and neuropathologic 
diagnoses of AD, among 32 individuals with single and 90 people with multiple domain 
amnestic MCI subtype.  As such, the extent to which the co-existence of cognitive deficits 
outwith the domain of episodic memory places MCI sufferers at increased risk of conversion 
to dementia, remains uncertain.   
 
On the basis of what is known of the topographical spread of AD pathology in the preclinical 
and early AD phases (Braak and Braak 1991) and the necessity for evidence of cognitive 
impairment in at least one non-memory domain in order to fulfil DSM-IV criteria for AD, a 
positive association between the number of domains of cognitive impairment, as well as the 
presence of semantic memory impairment in addition to that of episodic memory, and risk of 
conversion to dementia might be expected.  It was therefore hypothesised that a greater 
extent of non-memory impairment in aMCI at baseline would be associated with greater risk 
of conversion to dementia at long term follow-up. 
 
1.3.2 Consistency of episodic memory impairment as a predictor of 
progression to dementia 
Several studies have documented a lack of temporal stability and poor predictive validity for 
conversion to AD using the original Petersen criteria (De Jager and Budge 2005;Ritchie et al. 
2001), suggesting that reliance on the use of a single episodic memory measure to define 
objective memory deficit may give rise to unstable MCI diagnoses (Brooks et al. 2007). 
Reduced motivation, lapse of attention or distraction could conceivably give rise to test 
failure among the normal elderly, during a single evaluation. Whilst the use of combined 
memory test scores has been found to provide better sensitivity to MCI than single tests (De 
Jager and Budge 2005), uncertainty remains as to what effect consistency of impairment 
across multiple episodic memory tests might have on the stability of MCI classification as 
well as long-term diagnostic outcome. 
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Rotrou et al., (de Rotrou et al. 2005) followed-up a group of 130 sixty to eighty-year old 
healthy autonomous volunteers who undertook a comprehensive neuropsychological battery 
of tests (assessing aspects of language, memory and executive function) at baseline, 6 and 12 
months.  The authors observed a good deal of instability of MCI classification, with 48% of 
participants who performed more than 1.5 standard deviation below control means on one or 
more neuropsychological measure at baseline, no longer doing so when re-tested 12 months 
later.  Furthermore, the MCI subjects who remained impaired at the 12 month follow-up had 
low scores at baseline on three tests or more, compared with one or two failed tests for those 
MCI participants who normalised. Twelve of thirteen participants, who failed three tests or 
more at baseline, remained impaired at their 12-month follow-up.  The authors concluded 
that in normal elderly, failing three tests or more could be more predictive of pathological 
outcome than failing one or two tests whilst conceding that it was entirely possible that the 
group of unstable MCI sufferers remained at higher future risk of dementia conversion than 
their non-MCI counterparts. Cognitive deficits of an unstable nature have also been observed 
in a small group of pre-clinical AD sufferers across the early prodromal years (Hodges et al. 
2006). 
 
Insofar as one might expect the base rates of ‘impaired’ performance on two measures of 
episodic memory function among normal elderly controls to be lower than for a single 
measure, demonstration of impairment on multiple measures of episodic memory function in 
defining Petersen’s MCI criteria, may allow for the maintenance of adequate levels of 
sensitivity to MCI whilst simultaneously reducing the risk of false positive and unstable MCI 
classifications. 
 
It was therefore hypothesized that increased pervasiveness of the episodic memory 
impairment displayed by aMCI patients at baseline, would be associated with an elevated 
risk of receiving a diagnosis of dementia over time.  
 
To summarise, performance on one or more specific neuropsychological task(s), the 
consistency of the episodic deficit at baseline and the extent to which impairments in other 
cognitive domains are present, may help to predict long-term outcome in aMCI.  The relative 
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contribution of each of these in predicting the clinical course of aMCI remains to be 
determined.  
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2.  Materials & Methods 
 
2.1 Participants 
In this thesis, 46 patients with aMCI; 20 outpatients with depressive symptoms; 24 healthy 
control patients and 21 patients with mild AD were studied.   
 
2.1.1 aMCI  
The 46 aMCI patients were recruited over a 4-year period (Sept 2003 – Sept 2007) from 
tertiary referrals to the Royal Edinburgh Hospital Neuropsychological Assessment Service 
and met criteria for aMCI (Petersen et al., 1999). The service operates at a tertiary referral 
level, with the bulk of patients referred from Lothian-wide Old Age Consultant Psychiatrists 
and lesser numbers from Geriatricians and Neurologists.   
 
Thirty seven of the 46 MCI participants also underwent psychiatric evaluation prior to their 
clinical neuropsychology consultation. All aMCI patients in our sample had presented to 
their GP with memory complaints, that were (other than those for whom no family or friend 
was present at interview n=2) corroborated by an informant and had undergone routine 
medical and blood screening for dementia. Patients were referred to consultants in Old Age 
Psychiatry (n=71) or Medicine of Old Age (n=16) for further evaluation of their memory 
complaints.  Each of the 87 MCI patients who were invited to participate in our study had 
also been referred for, and completed, a clinical neuropsychological assessment prior to 
study entry. 
 
Clinical neuropsychological assessments varied in their length and content according to the 
patient’s cognitive capabilities, willingness to participate and the nature of the referral 
question.  Typically, assessments included a structured clinical interview followed by a 
measure of overall level of cognitive functioning together with one or more measures 
assessing episodic and semantic memory, language, visuo-spatial and executive function. 
There was a considerable degree of overlap in the tests employed in clinical practice and 
those comprising the research battery such that the baseline clinical assessment for the aMCI 
patient group was used as the baseline study assessment.  Where necessary, outstanding tests 
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from the study battery were administered on a separate occasion, no more than 3 months post 
the baseline clinical assessment.  
 
Although a cut off value of 1.5SD is commonly applied as a means of delineating cognitive 
impairment in MCI in the research literature, in clinical neuropsychological practice, it is 
desirable to demonstrate some reliability of performance across tests.  In view of this, and 
the above average mean pre-morbid IQ estimate for the MCI group, both the severity and 
consistency of impaired cognitive performance at the initial clinical neuropsychological 
assessment were used as criterion for recruiting MCI participants. Two sets of criteria were 
applied in recruiting MCI participants based on their clinical neuropsychological findings. 
Using criterion A, cognitive impairment was defined by a performance of 1sd or more below 
published age means (Benedict et al. 1998;Graham 2004;Saxton et al. 2000;Spreen and 
Strauss 1998;Tombaugh et al. 1999;Tombaugh 2004;Warrington 1997) on two or more 
measures assessing a single cognitive domain (see Table 2.1 for a breakdown of measures in 
accordance with the cognitive domains broadly assessed).  For criterion B, cognitive 
impairment was defined in terms of a performance 1.5sd or more below published normative 
age means (Benedict et al. 1998;Graham 2004;Saxton et al. 2000;Spreen and Strauss 
1998;Tombaugh et al. 1999;Tombaugh 2004;Warrington 1997) on at least one test.  
 
All MCI patients who were invited to take part in the study met criterion A (in relation to 
published age norms (Benedict et al. 1998;Graham 2004;Saxton et al. 2000;Spreen and 
Strauss 1998;Tombaugh et al. 1999;Tombaugh 2004;Warrington 1997) at their initial clinical 
neuropsychological consultation.  A breakdown of MCI study participants in accordance 
with criterion A and B, on the basis of their baseline study neuropsychological performance 
is provided in Figure 2.1 at the end of the flowchart. 
 
In all cases, levels of cognitive performance and / or everyday functioning, based on 
cognitive screening measures, clinical interview and the informed opinion of an experienced 
clinical neuropsychologist, were considered sufficiently preserved to prevent a diagnosis of 
dementia being made.  Participants in whom a functional cause to cognitive complaints was 
suspected or established following clinical interview and or the administration of mood 
screening instruments, were excluded. 
 
 47 
Figure 2.1  Recruitment flowchart and classification of MCI subtypes at 
baseline 
 
Criterion A, > or = 1sd below healthy elderly age and IQ matched study control group on 2 or more 
cognitive measures of a single domain; Criterion B, > or = 1.5sd below healthy elderly age and IQ 
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Table 2.1  Numbers of persons followed up for between 1 - 5 years as a 















1 2 2 0 4 
2 8 9 1 18 
3 13 15 3 31 
4 10 10 5 25 
5 3 3 1 7 
 
Twenty-nine of 46 of the aMCI group underwent neuroimaging at some point during the 
course of the study. Nine subjects underwent CT scanning, 2 underwent SPECT & a further 
6 underwent DTI.  Four aMCI participants underwent both CT and SPECT scanning and 3 
underwent CT, SPECT and DTI.  Two aMCI participants underwent CT and DTI scanning 
with each of the remaining 3 undergoing combinations of CT, SPECT & MRI; CT, SPECT 
& DIT and fMRI & DTI, respectively. Amnestic MCI patients, who were exhibiting 
evidence of significant and predominant cerebro-vascular disease or other predominant 
changes of a non-atrophic nature on neuroimaging prior to their study participation that 
could account for their cognitive presentation, were excluded from the study (see Table 2.2 
for details of inclusion and exclusion criteria).  Seventeen aMCI participants did not undergo 
any form of neuroimaging making it impossible to rule out the presence of structural or non-
atrophic change in these cases. 
 
2.1.2 Early Alzheimer’s Disease 
Twenty one patients with a NINCDS/ADRDA (McKhann et al. 1984) diagnosis of probable 
AD were identified as part of a clinical audit of service referral numbers and diagnoses. All 
early AD patients scored 17/30 or above on the Mini Mental State Examination (MMSE; 
(Folstein et al. 1975) and 58/100 or above on the more comprehensive Addenbrookes 
Cognitive Examination (ACE; (Mathuranath et al. 2000) indicating a relatively mild disease 
severity. Patients with known and potentially confounding co-morbid medical, psychiatric or 
neurological conditions (i.e. stroke or cerebro-vascular disease, head injury, alcoholism, 
schizophrenia, etc.), as established by way of review of medical notes, were excluded (Table 
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2.2).  For one of the early AD participants, MRI scanning that was carried out at a later date 
as part of a related MRI-DTI imaging study, confirmed the presence of a possible carotid 
artery occlusion.  In a further case, MRI-DTI scanning conducted post recruitment phase, 
revealed evidence of a possible arterial venous malformation. Neither of the participants was 
excluded from the study, and both participants are represented in the tables, figures and 
analyses comprising early AD participants. 
2.1.3 Healthy Elderly Controls 
As healthy controls we recruited 24 spouses or carers of patients who had attended the 
Neuropsychological Assessment Service.  Participants with known and potentially 
confounding co-morbid medical, psychiatric or neurological conditions (i.e. stroke or 
cerebrovascular disease, head injury, alcoholism, schizophrenia, etc.), as established by way 
of structured interview, were excluded (see Table 2.2).   
2.1.4 Depressive Elderly Controls 
In an attempt to ensure a control group of similar illness severity and general level of 
functioning to the aMCI patients, we recruited 20 outpatients with depressive symptoms 
from hospital outpatient clinics and day hospitals, who were receiving the same level of 
outpatient care as our aMCI group.  All participants in this group presented with depressive 
symptoms, thought not to be primarily organic in nature, yet known to have effects on 
cognitive functioning both during illness and after recovery (Herrmann et al. 2007). 
We considered matching of illness severity to be important, as in clinical practice the 
differentiation of severe depression and early dementia states is less problematic than 
separating the sequelae of the milder forms of these disorders.  We included patients with a 
variety of disorders, as the type of depression does not appear to influence the magnitude of 
cognitive deficit (Christensen et al., 1997).  As with the other participant groups, patients 
with any co-morbid medical, neurological or additional psychiatric condition with the 
potential to affect cognitive function were excluded by way of review of the medial notes. 
The mean Geriatric Depression Scale (GDS; (Yesavage et al. 1983) score for this group was 
19 (SD=5.24; 95% CI= 16.55-21.45) indicating mild-moderate, clinically significant levels 
of depressive symptoms.   Information pertaining to the date of onset of depressive illness 
(i.e. before or after 60 years of age/ early or late onset) and the presence or absence of deep 
white matter hyperintensities on neuroimaging, both of which have been found to affect the 
neuropsychological status of depressed elderly individuals (Steffens, 2008), was not 
collected.  The interpretation of the neuropsychological performances of the depression 
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control group was limited by the absence of this information (see limitations section Chapter 
7 for fuller discussion). 
Table 2.2  Participant Inclusion / Exclusion Criteria 
 
MCI = Mild Cognitive Impairment; Pre-morbid IQ=Intelligence Quotient; AD=Alzheimer’s disease; 
GDS= Geriatric Depression Scale; MMSE=Mini Mental State Examination. 
Participant 
Group 
Inclusion Criteria Exclusion Criteria 
aMCI 
 
Subjective complaints of memory difficulty and /or 
decline 
Performance greater than one standard deviation 
below age and IQ mean on at least two measures of 
episodic memory function 
Functional decline very minimal or absent – structured 
clinical interview 
Does not fulfil diagnostic clinical criteria for dementia 
>55 years of age 
 
Untreated/ or unsuccessfully treated 
depressive illness – medical notes 
History of Head Injury 
History of Stroke, epilepsy or other 
neurological condition(s) 
Medical condition(s) that might 
account for memory loss i.e. 
hypothyroidism 
< 55 years of age 
Evidence of significant and 
predominant cerebro-vascular 
disease on neuroimaging 
Diagnosis of dementia 
Controls >55 years of age 




<55 years of age 
Current depressive illness – self 
reported low mood  
Subjective cognitive complaints 
Medical or neurological condition 
known to be associated with 
cognitive impairment 
Early AD Diagnosis of AD NINCDS & DSM-IV 
MMSE score 20/30 or greater  
>55 years of age 
Matched for age, Pre-morbid IQ, sex distribution to MCI 
and control group 
 
<55 years of age 
Co-morbid untreated/unsuccessfully 
treated depressive disorder – 
medical notes  
Co-morbid neurological or medical 
condition that is known to be 
associated with cognitive impairment 
Significant degree of cerebrovascular 




Diagnosis of Major depression 
Or 
Currently receiving hospital treatment for depressive 
symptoms 
>55 years of age 
Matched as far as possible in terms of age, pre-morbid 
IQ, sex districution to aMCI, control & early AD group 
<55 years of age 
Diagnosis of dementia 
Subjective cognitive complaints 
documented in medical notes or 
evident during testing 
GDS<10 
Co-morbid neurological or medical 
condition that is known to be 
associated with cognitive impairment 
evident in the medical notes or 
dudring testing 
Abnormalities on neuroimaging as 
evidence in the medical notes 
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Fourteen of twenty patients comprising the elderly depressive normative sample had a 
diagnosis of major depressive disorder.  The remaining participants met DSM-IV criteria for 
Dysthymic disorder (n=4), Bipolar I Disorder (most recent episodic depressed n =1) or 
Anxiety Disorder (n=1). Sixteen of the 20 depressive participants were being treated with 
antidepressant medication at the time of their study participation.  Of the remaining 4, 2 were 
taking anxiolytic forms of medication and two were receiving intervention of a non-
pharmaceutical nature only. A summary table of diagnostic and treatment details for the 
depression group can be found in Table 8.1 of the Appendix. 
 
2.2 Neuropsychological Measures and Psychometric Test 
Properties 
All four patient groups undertook the following battery of neuropsychological tests at 
baseline; Addenbrookes Cognitive Examination (ACE; (Mathuranath et al. 2000)), Mini 
Mental State Examination (MMSE; (Folstein et al. 1975)), National Adult Reading Test 
(NART; (Nelson and Willison 1991)), Paired Associate Learning Test from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB, PAL; (Morris et al. 1987)), Rey 
Complex Figure Test (ROCF; (Rey 1941)), Hopkins Verbal Learning Test-Revised (HVLT-
R; (Brandt 1991)), Graded Naming Test (GNT; (McKenna and Warrington 1980)), 
Edinburgh Exemplar Naming Test (EENT; JAL)), Boston Naming Test (BNT; (Kaplan et al. 
1983)), Graded Faces Test (GFT; Graham, personal communication 2004), Category fluency 
using the categories ‘animals’, ‘fruits’ & ‘vegetables’, Controlled Oral Word Association 
Task using the letters ‘F’, ‘A’ & ‘S’ (COWAT; (Spreen and Strauss 1998)), Dual-Task 
(Della Sala, personal communication, 2004; (Della Sala 2005)) and the Trail Making Test 
(TMT; (Reitan 1985)).  Classification of each of these tasks in accordance with their broad 
associations with specific cognitive domains is provided in Table 2.3. A brief description and 
summary of the relevant psychometric properties for each of these measures is provided 
below.  
 
Depression patients were also administered the Geriatric Depression Scale (GDS; (Yesavage 
et al. 1983)) as a means of ensuring they met inclusion criteria for this group.  MCI patients 
were re-administered the neuropsychological test battery annually for the duration of their 
participation in the study (which ranged from a minimum of 2, to a maximum of 5 years).  
16 of 24 healthy elderly control participants undertook the neuropsychological test battery on 
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two occasions, at varying 1 – 3.5 year intervals. At the final assessment, the primary carer 
(or a close friend where the latter was not available) of every MCI patient also completed a 
set of functional scales detailing perceived changes in their ability to carry out higher level 
(Farias et al. 2006) as well as more rudimentary activities of daily living and personal and 
self maintenance tasks (Lawton and Brody 1969).  Details of the neuropsychological 
assessment protocol at each stage of follow-up, for all participant groups, are tabulated in 
Table 8.2 of the Appendix.  An indication of broad groupings of neuropsychological 
measures in accordance with their cognitive domain coverage is provided in Table 2.3 
below. 
 
Table 2.3  Neuropsychological measures grouped in accordance with 
cognitive domain coverage 
Cognitive Screening Measures MMSE, ACE 
Pre-morbid IQ NART-R 
Episodic Memory PAL, RCFT, HVLT-R 
Semantic Memory  GNT, EENT, BNT,GFT, Category fluency 
Attention and Executive Functions TMT A & B, COWAT, Dual Task 
Functional Ability Everyday functioning, PSMS, ADLS 
Mood GDS 
 
2.2.1 Cognitive Screening 
2.2.1.1 Mini-Mental State Examination (MMSE; (Folstein et al. 1975)) 
The MMSE is a brief cognitive screening measure requiring less than 10 minutes to 
administer.  It is usually administered as a means of establishing an individual’s overall level 
of general cognitive functioning.  It is presently the most widely used cognitive screening 
instrument for dementia (Lezak 2004). The MMSE samples a restricted set of cognitive 
functions including concentration and working memory, language and praxis, orientation, 
memory and attention span.  The measure comprises 19 questions yielding a possible total of 
30 points.  Cut off scores of 27/30 and 24/30 are usually applied in determining the 
likelihood of dementia or some other form of organic brain pathology, with variability in 
accordance with the age and education level of the individual patient (Lopez et al. 2005).  
Scores of between 21-26/30 are taken as indicative of mild cognitive impairment, 11-20/30 
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as indicative of moderate levels of impairment and those below 10 signify severe cognitive 
impairment (Folstein et al. 2001). 
 
Scores on the MMSE are positively influenced by education and negatively by age, whereas 
gender appears to have little effect on MMSE performance. Pre-morbid IQ estimates have 
also been shown to influence MMSE score in mild and moderate AD (Starr and Lonie 2007). 
Some authors have reported high test-retest reliabilities of between r=0.89 and r=0.99 over 
24-hour and 4 week periods for non-demented and dementia patient samples, respectively 
(Lezak 2004).  Others have reported 95% confidence intervals for true scores as large as 10 
points for an obtained score of 23/30 (Lopez et al. 2005). Despite such variability, the 
performance of healthy older adults is generally considered to be stable over the longer term 
(Lezak 2004). 
 
2.2.1.2 Addenbrookes Cognitive Examination (ACE; (Mathuranath et al. 
2000)) 
The ACE is a more comprehensive cognitive screening measure than the MMSE, requiring 
around 15-20 minutes to administer.  The measure synthesises all of the existing MMSE 
items with components of well established neuropsychological tasks.  The ACE was 
developed with the aim of increasing the sensitivity of existing screens to milder forms of 
cognitive impairment and assisting in the early differential diagnosis of the dementias.  The 
test includes a total of 32 items covering the domains of attention/concentration, orientation, 
recall, memory, verbal fluency, language, and visuospatial abilities, yielding a maximum 
score of 100. Sub-scores may be calculated for each of the above domains. As the ACE 
comprises all of the MMSE items it is possible to derive a separate MMSE score 
simultaneously. 
 
The ACE is sensitive to dementia using a cut off value of <88/100 (sensitivity = 93%).  
There is, however, no data reporting on practice effects or test re-test reliability among the 
healthy elderly. Total ACE scores are known to correlate very highly with MMSE scores 
(r=0.92(Larner 2005)). More favourable sensitivity, specificity and positive predictive values 
for dementia relative to non-dementia (Bier et al. 2004;Mathuranath et al. 2000) and 
Questionable Dementia patients who do, versus to those who don’t convert (Galton et al. 
2005) to dementia have been reported for the ACE as compared to the MMSE. Specificity to 
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dementia (spec = 96%) is reportedly similar for ACE and MMSE at cut offs of 83/100 & 
27/30 respectively) but less for the ACE (42.6%) than the MMSE (53.8%) using the higher 
88/100 ACE cut off (Bier et al. 2004). The ACE has also been shown to discriminate, albeit 
imperfectly, between elderly patients with dementia and those with affective disorders 
(Dudas et al. 2005a) and when administered in conjunction with measures of episodic 
memory, appears to be of utility in helping to identify aMCI sufferers who will convert to 
AD in the short term (Ahmed et al. 2008b). 
 
2.2.2 Episodic Memory  
2.2.2.1 CANTAB Paired Associate Learning Test (PAL; (Morris et al. 
1987)) 
The Paired Associate Learning (PAL) subtest from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB; (Morris et al. 1987)) is a computerised measure of 
visuospatial learning requiring participants to learn the locations of an increasing number 
(i.e. 1, 2, 3, 6, and then 8) of abstract patterns. The score of interest was the number of 
pattern-position errors made at the 6-pattern level as this has been previously shown to be 
sensitive to episodic memory impairment in MCI (Ahmed et al. 2008b;Alladi et al. 2006) as 
well as Questionable Dementia patients but not to depression (Swainson et al. 2001).  The 
total number of errors made at the 6 pattern level is also reportedly highly specific to 
memory impairment arising in from AD (O'Connell et al. 2004), although perhaps less 
sensitive (sensitivity = 68%) to early AD than initially reported. 
 
The PAL subtest is language free, reducing the potential for cultural bias.  Trials are graded 
in terms of their level of difficulty to ensure that instructions have been comprehended and to 
avoid floor and ceiling effects.  The computerised administration assists in ensuring that the 
test is given in a standardized manner. Normative data are available for 3000 healthy 
volunteers, banded according to age, gender and pre-morbid IQ.   
 
Acceptable to high levels of concurrent validity (0.39 – 0.67) and test-retest reliability (0.64 
– 0.88) have been reported for the PAL subtest of the CANTAB battery (Fowler et al. 1995). 
The PAL subtest is reportedly sensitive to small changes in episodic memory function across 
even relatively brief i.e. 6-12 month intervals (Fowler et al. 1997). The construct validity of 
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the PAL subtest as a measure of medial temporal lobe integrity is well established by way of 
both animal lesion (Fray et al. 1996) & fMRI studies (Gould et al. 2005). 
 
2.2.2.2 Rey Complex Figure Test (RCFT; (Rey 1941)) 
This measure was designed to assess both visuospatial skill and visual memory (Rey 1941). 
In this task, participants are given a complex figure and are asked to make a copy of it 
without time restriction. Immediately after presenting the figure and again following a 30-
minute delay, participants are required to reproduce the figure from memory. Three 
measures of interest were obtained including (each with a total possible score of 36 points); 
the copy score, the immediate recall score and the delayed recall score out of a possible total 
of 36 points.  Healthy control subjects generally obtain similar scores on the immediate and 
delayed components of the RCFT, reflecting an ability to retain the bulk of new information 
that has been encoded over the short term.  By contrast, poor performance on the recall 
components of the RCFT has been observed in AD patients (Lezak 2004), in keeping with 
the encoding and consolidation deficits that are known to characterise this patient group. 
 
The effect of age appears to be minimal on the copy component (Mitrushina et al. 1999), 
however, a decline in recall performance is seen in association with both advancing age and 
fewer years of education.  High inter-scorer reliability values of between r = 0.91 to 0.98 
(Lezak 2004) and r = 0.80 to 0.99 (Mitrushina et al. 1999) have been reported for all 
components of this task.  Test-retest reliability coefficients are somewhat lower, ranging 
between r = 0.56 to 0.68 for the copy and from r= 0.57 to 0.77 for the 3-minute delayed 
recall component, when administered thrice yearly (Mitrushina et al. 1999). 
 
 
2.2.2.3 Hopkins Verbal Learning Test – Revised (HVLT-R; (Brandt 
1991)) 
All groups completed the Hopkins Verbal Learning Test – Revised (HVLT-R; (Brandt 1991) 
a test of verbal episodic recognition and recall memory and new learning ability.  
Participants are required to recall as many words as possible immediately following 
presentation of a 12-item word list across three consecutive learning trials.  3 categories, i.e. 
‘Animals’, ‘Precious Stones’ & ‘Dwellings’, with four words belonging to each, make up the 
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12-item list. Measures include; total number of words recalled across three registration trials 
(max=36), total number of words recalled following a 30-minute delay (max=12) and a 
discrimination index score representing a participant’s ability to discriminate between old 
and new list items. The total number of words recalled immediately following list 
presentation provides a measure of new learning ability, while the number of words recalled 
after a short delay serves as a measure of delayed verbal recall ability.  
 
The HVLT-R has been shown to be sensitive and specific to the early stages of AD 
(sensitivity = 98%;  spec=95% ) as well as to MCI (sensitivity = 78%; spec = 80%; (De 
Jager et al. 2003).  The absence of ceiling effects in a 70-88 year old age group (Lezak 
2004), high sensitivity and specificity values in relation to dementia, together with a lack of 
need to adjust for education level (Vanderploeg et al. 2000), make it of potential utility as a 
dementia screening measure (Hogervorst et al. 2002).  Validity of the total recall and 
recognition discrimination index has been established by way of significant relationships 
between these and corresponding indices from other well established episodic memory 
measures (Lezak 2004).  
 
Significant learning effects (Z = 5.80) for the total number of words recalled across the three 
trials of version 1 of the HVLT have been demonstrated across 2-3 year periods in healthy 
elderly controls (Schrijnemaekers et al. 2006) but not in early AD or MCI sufferers.  
Significant negative associations between age and male gender but not education and HVLT 
total trials recall for Form 1 have been documented in a large sample of older adults 
(Vanderploeg et al. 2000). Statistically significant 9 month stability coefficients of a similar 
magnitude to those reported for other clinical episodic memory measures have been 
documented for total recall (r = 0.50), true (r = 0.66) and false positives (r = 0.42) in a small 
group (n=45) of healthy elderly adults (Rasmusson et al. 1995).  
 
2.2.3 Semantic Memory and Language  
Participants completed the Graded Naming Test (GNT; (McKenna and Warrington 1980)), 
the Graded Faces Test (GFT; personal communication, 2004), the Boston Naming Test 
(BNT; (Kaplan et al. 1983)), the Edinburgh Exemplar Naming Test (EENT: JAL Author) 
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and the Category Fluency Test with the categories ‘Animals’, ‘Fruits’ & ‘Vegetables’(Lezak 
2004).  
 
2.2.3.1 Graded Naming Test (GNT; (McKenna and Warrington 1980)) 
The GNT requires participants to name 30 line drawings of increasing difficulty, with early 
items named by control subjects without difficulty.  There is a mixture of animate and 
inanimate objects. Items comprising the latter part of the test are less familiar and less 
frequently encountered such that many normal controls fail to name these items.  Unlike the 
BNT, many items might be considered biased toward the British Culture (i.e. sporran, mitre, 
tassel, latch and bellows). Of the 100 normal control subjects (age range 18-76) comprising 
the normative group for the initial validity study, scores ranged from 20-100% (McKenna & 
Warrington, 1980).   
 
Pre-morbid IQ has been shown to correlate significantly with GNT total score (Bird et al. 
2004) however no effect of age was observed in this sample of 188, 40-70 year old healthy 
adults and only a minimal age effect was noted in a more recent standardisation sample 
comprising 305 adults between the ages of 18-77 years (Warrington 1997).  The authors of 
the former study simultaneously documented good test-retest reliability (r = 0.92), significant 
yet moderate practice effects (in the order of one additional point) and a small reliable 
change index score of 5 points. The sensitivity of the GNT to gradual changes in 
performance within a neurological sample across a two year period was also established 
(Bird and Cipolotti 2007). 
 
2.2.3.2 Boston Naming Test (BNT; (Kaplan et al. 1983)) 
The BNT requires participants to name 60 line drawings of increasing difficulty.  A 20 
second naming interval is provided, following which a semantic cue is provided, along with 
another 20 second naming interval (i.e. for harmonica – it is a musical instrument) in cases 
where no response has been made.  The black and white line drawings comprise a mixture of 
animate and inanimate objects.  The measure was administered in keeping with standardised 
clinical practice where participants were first asked to name item 30 and continued with 
subsequent items in their correct numerical order in cases where the initial 8 responses 
provided were correct.  Where errors are recorded prior to reaching item 37, the examiner 
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administers items in a backward direction from 29, up until 8 consecutive correct responses 
have been recorded.  Following this, the remainder of the test items post item 30), are 
administered.  The test was terminated following the recording of 8 incorrect consecutive 
item responses. 
 
Mitrushina and Satz (Lezak 2004) report an absence of practice effects on the BNT, at one 
year intervals.  High response consistency (80%) has been documented in AD patients at 6 
month retest intervals (Spreen and Strauss 1998). Whilst a significant positive relationship 
between education and BNT performance is known to exist, the association with gender is at 
best inconsistent (Lezak 2004). Minor age related declines in BNT performance are thought 
to appear relatively late (i.e. from the age of 70 onwards, perhaps later i.e. 80+ in more 
highly educated elderly) alongside increased variability among the elderly normal population 
(Lezak 2004). 
 
2.2.3.3 Edinburgh Exemplar Naming Test (EENT; JAL) 
The EENT was developed by the author (JAL) in an effort to improve the sensitivity of 
existing confrontation naming measures to early semantic memory failure. In this test, the 
participant is required to name 50 line drawings of low frequency, animate objects with 
sizable feature overlap.  One point is received for every correct animal name provided.  
Participants obtain a score out of a total possible 50 points.  It is assumed that animate 
members of a single exemplar category sharing appearance and activity based features will 
prove more difficult for early and pre-clinical AD patients to name than items belonging to 
unique categories, without shared features.  This predicted pattern of test failure would fit 
well with what is understood of the graded manner in which the semantic system fails in the 
temporal lobe variant of the Frontotemporal lobe dementias, where degradation in detail 
pertaining to the different exemplars belonging to a specific category is observed prior to the 
point at which the patient demonstrates a complete loss of knowledge for the category as a 
whole.  The psychometric properties of this test have not been established. 
 
2.2.3.4 Graded Faces Test (GFT; personal communication, 2004) 
The GFT requires participants to name a series of 30 black and white photographs of famous 
faces.  The faces comprise a combination of famous politicians, statesperson, actors, 
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musicians or athletes.  Fifteen of these were recently famous people and 15 were non-recent 
celebrities.  Thirty faces were selected from a database of 250 famous faces spanning the 
second half of the 20th century.  The items were graded in difficulty to match the items from 
the GNT (i.e. In the GNT ‘buoy’ was named by 97% of controls; In the GFT ‘Adolf Hitler’ 
was named by 97% of controls).  The age of the items (i.e. recent versus non-recent) was 
balanced throughout the levels of difficulty. One point is given for every correct full name 
provided such that participants obtain a score out of a total possible 30 points (Thompson et 
al. 2002). 
 
There is no published data pertaining to the relationship between age, IQ, education or 
gender or test re-test reliability and performance on the GFT.  Preliminary normative data 
comprising 22 healthy elderly (mean age = 66 years 11 months SD 7 years 12 months) 
community dwelling, highly educated UK residents, were obtained by way of personal 
correspondence with Dr Kim Graham, a co-developer of the GFT. The mean total naming 
score for this sample was 22.09 (standard deviation = 3.28). The sensitivity of face naming 
tasks to early AD and MCI has been well documented within the test developers research 
group (Ahmed et al. 2008a;Clague et al. 2005;Dudas et al. 2005b;Thompson et al. 2002). 
 
2.2.3.5 Category Fluency (Animals + Fruits + Vegetables; (Lezak 2004)) 
Participants were also asked to complete a Category Fluency Task, requiring them to 
produce as many animals as they could in a one minute time period.  The procedure was then 
repeated for fruits and finally for vegetables.  Two scores were derived; one representing the 
total number of animals generated in one minute (Animals) and another representing the total 
combined number of animals, fruits and vegetables produced across their respective one 
minute time intervals (Total Category Fluency). 
 
Moderate one month test re-test reliabilities (r = 0.56) & practice effects in the order of just 
over 1 point together with large reliable change indices (lower = -7.6; upper = 10.5) and an 
absence of correlation with age or IQ have been reported in association with the animal 
fluency task (Bird et al. 2004).   
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2.2.4 Attention, Executive Function & Processing Speed 
2.2.4.1 Trail Making Test (TMT A and B; (Reitan 1985)) 
All participant groups completed the Trail Making Tests, Parts A and B (TMT A & B; 
(Reitan 1985). This test provides a measure of scanning, visuomotor tracking, divided 
attention and cognitive flexibility (Lezak 2004). Participants were required to join numbered 
circles in ascending order (Part A) and numbers and letters in ascending alternating sequence 
(Part B) at pace and the time to completion is recorded. The time taken for participants to 
complete TMT A represents a measure of psychomotor processing speed, while TMT B also 
adds a divided attention component. By subtracting the time to completion for TMT A of 
this test from TMT B, a measure of the ‘executive’ functioning component, or ‘attentional 
demands’ can be acquired independently of processing speed.  
 
According to Lezak (Lezak 2004), there is a positive correlation with age and TMT 
performance with performance times increasing significantly with each succeeding decade. 
By contrast, performance on Part B of the TMT correlates negatively with years of 
education.  Reported reliability coefficients vary with most above r = 0.6 and several in the 
r= 0.9 and more in the r= 0.8 range.  Practice effects are usually seen on both parts of the 
TMT with effects on Part A more likely to reach significance as a result of the greater 
variability in TMTB performances.  However, an absence of practice effects has been 
documented across longer i.e. one year test re-test intervals in one study.  Depression has 
been found to have a slowing effect on TMTB that interacts with age, such that elderly 
depressed patients require a disproportionately greater amount of time to complete this than 
emotionally stable elderly subjects or depressed younger ones.  The normative distribution 
for TMT scores is known to be positively skewed such that cut off (as opposed to graded) 
scores are considered most appropriate for use within a clinical context (Lezak 2004). 
 
2.2.4.2 Dual Performance Task (Della Sala, personal communication, 
2004; (Della Sala 2005)  
All participants completed the revised dual performance task which was generously provided 
to us by Della Sala and colleagues (Della Sala, personal communication, 2004; (Della Sala 
2005). This pencil and paper test of divided attention was created to tap functions associated 
with the central executive component of working memory. It consists of 2 tasks (a digit span 
task and a visuospatial tracking task) that are each performed on their own before being 
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performed concurrently. Firstly, participants’ digit span was determined. This involved 
repeating strings of digits read by the test administrator at a rate of approximately 2 per 
second. Initially, 2-digit strings were presented and these increased one digit at a time on 
condition that the participant correctly recited 5 of 6 examples of each length. When the 
participant failed to recite 2 or more strings of the same span, the digit span for that person 
was considered to be the previous length. No time limit was used at this stage. Having 
determined the participants’ individual digit span, participants had 90 seconds to recite as 
many digit strings (fixed at the individual participants’ digit span) as possible. Responses 
were recorded as correct for each digit recited in the correct order. 
 
Following this, participants completed the tracking task. This involved participants tracing a 
line through circles on an A3 sized sheet of paper in the experimental trail, with a short 
practice session prior to this. Participants had 90 seconds for this trial, and the number of 
circles reached during this time was recorded. The final trial was the concurrent dual task. 
Here participants had 90 seconds to simultaneously recite digit strings fixed at their digit 
span as well as carrying out the visuo-spatial tracking task. In order to take into account the 
various strategies one may adopt in performing the two tasks simultaneously, an overall 
decrement score was calculated using the following formula: 
 
µ = [1-(Pm + Pt/2)] * 100 
 
where µ is the combined dual task score, Pm is the proportional loss in span performance 
between single (Ps) and dual task (Pd) conditions, [(Ps  - Pd]/ Ps] while Pt is the equivalent 
proportional tracking score. Thus a score of 100 would represent no dual task decrement and 
lower scores reflect greater dual task decrements.  
 
Correlations between dual task performance, gender and education are reportedly 
insignificant and re-test reliability values moderate at best (r=0.49; (Rabbitt 1997). 
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2.2.4.3 Controlled Oral Word Association Test (COWAT; (Spreen and 
Strauss 1998)) 
All participants completed the COWAT using the letters ‘F’, ‘A’ & ‘S’.  The participants 
were required to generate as many words as possible beginning with each of these letters, 
within separate one minute time frames.  Further instruction was given not to include names 
of people or places or proper nouns in general.  Participants were also required to produce 
different words rather than use the same words with different endings.  The number of words 
produced for each letter was added to give a ‘Total Verbal Fluency score’. 
 
A similar procedure was also undertaken using the letter ‘P’, within the context of the ACE.  
Here, the number of words generated beginning with the letter ‘P’ were summed to give a ‘P 
words Verbal Fluency score’. 
 
There is variability in the reported effects of age on COWAT scores in the elderly, with 
some studies revealing a significant negative relationship and others no relationship (Lezak 
2004;Spreen and Strauss 1998). Education may be a moderating factor as no significant 
effect of age was noted in a group of highly educated elderly from 75 years onwards whilst a 
significant decline was noted in a less educated subgroup from the age band 50-54 years 
(Lezak 2004).  The total number of words produced on the COWAT has been shown to 
correlate with performance on the NART (r = 0.67) whereas gender appears to have no 
discernable effect on COWAT scores.  A one year test re-test reliability of r = 0.71 has been 
reported for a healthy elderly sample and inter-scorer reliability is reportedly near perfect.  
Practice effects of one point together with a test re-test reliability of r = 0.65 has been 
documented in a sample of adult epileptic patients, retested following 8 months. Slightly 
higher re-test reliabilities (r = 0.76 – 0.87) were reported in a sample of HIV positive adults 
tested three times across an 18 month period (Spreen and Strauss 1998). 
 
2.3 Functional and Mood Scales 
2.3.1 Measure of Everyday Functioning (Farias et al. 2006) 
The Measure of Everyday Functioning is an informant based questionnaire comprising a 
total of 30 statements for which the primary carer is required to rate each statement by 
comparing current abilities to those observed 10 years ago.  The informant ascribes a score 
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of between 1 and 4 where 1 represents an improvement or no change in the designated 
ability and 4 indicates that the patient is consistently much worse.  A score of 0 is marked 
when the skill in question does not apply to, or form part of the patients’ everyday repertoire 
of activities. Statements are grouped in accordance with their reliance on the integrity of 
different cognitive abilities including memory, language, planning, organisation and divided 
attention.   
 
Functional items were selected from a range of existing scales on the basis of their ability to 
assess high-level everyday skills. A rating scale was applied (as described above) in place of 
a dichotomous ‘dependent’ versus ‘independent’ system of scoring to facilitate measurement 
of more subtle or mild changes in function that fall short of leading to complete dependence 
on others.  A reference point of 10 years prior was chosen as it was thought to provide 
enough of a time lapse that no deterioration in function would likely have been present at 
that time (Farias et al. 2006).  
 
For the purpose of this study, both raw total scores and total score as a proportion of the 
items of personal relevance (i.e. after omitting those items deemed no to apply) were 
calculated for every aMCI patient at his/her final follow-up assessment, where higher scores 
signify greater levels of impairment of higher-level everyday activities. 
 
Previous findings from the validation study indicate that MCI participants exhibit 
significantly greater levels of impairment than healthy age matched controls on 73% of items 
on the everyday memory scale, 61% of items on the everyday planning and 55% on the 
everyday organisational items, 28% of the everyday language and 22% of the everyday 
divided attention items.  The dementia group was significantly more impaired than both the 
MCI and healthy elderly control group on all 74 items comprising the scale (Farias et al. 
2006) 
 
2.3.2 Personal Self Maintenance Scale (PSMS; (Lawton and Brody 
1969)) 
The PSMS is a six item scale, rating self-care ability in the domains of feeding, grooming, 
bathing, toileting, personal hygiene and dressing.  Primary care givers are required to 
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endorse the appropriate rating (1-5) for each area of personal care, where increasing ratings 
reflect poorer self maintenance and independence levels.  As all items require a rating of a 
least 1, only a single total rating score was derived for this measure, with greater overall 
scores reflecting lower personal self maintenance abilities. 
 
The scale’s validity has been established by way of correlations with several other 
established measures of functional health, cognitive status, behaviour and adjustment rating 
scales within a group of 180 care home applicants. Reproducibility coefficients of 0.96 are 
reported for the PSMS alongside inter-rater reliabilities of between 0.87 and 0.91 (Lawton 
and Brody 1969). 
 
2.3.3 Independent Activities of Daily Living Scale (IADLS; (Lawton and 
Brody 1969)) 
The IADL scale is an 8 item scale assessing the patient’s ability to perform the following 
tasks; using the telephone, preparing food, shopping, laundering, completing household 
tasks, responsibility for medications, management of financial matters and mode of 
transportation.  The patient’s primary care giver is required to denote, on a scale of between 
1 and 3, 4 or 5, the level at which the patient is able to engage in, or carry out activities in 
each of these areas.  Higher scores signify a greater degree of dependence on others and a 
score of 0 implies that the activity in question is not applicable in that it would not 
previously have been performed by the patient.   
 
As the total score is somewhat dependent on the applicability of the activities in question to 
each individual patient, two scores were derived, 1) a total score, where higher scores are 
broadly indicative of greater levels of functional dependence and 2) a proportionate score, 
where the total score is expressed as a function of the maximum number of available points 
(i.e. following omission of any points allocated to any activity that has been endorsed as ‘not 
applicable’). 
 
The scale’s validity has been established by way of correlations with several other 
established measures of functional health, cognitive status, behaviour and adjustment rating 
scales, within a group of 180 care home applicants.  Extensive testing of the reliability of the 
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IADL has not been conducted, although high correlations between independent ratings for 12 
elderly nursing home applicants, based on information obtained within a single interview, 
have been documented (Lawton and Brody 1969). 
 
2.3.4 Geriatric Depression Scale (GDS; (Yesavage et al. 1983)) 
The GDS is a 30 item ‘yes/no’ answer scale that was constructed for the purposes of brief 
screening for depression amongst the elderly, with less emphasis on somatic symptoms, age 
appropriate questions and a simplified method of response. Of the 30 items, 20 indicate the 
presence of depression when answered positively, while 10 others indicate depression when 
answered negatively (Yesavage et al. 1983).  The number of endorsed items is summed, with 
higher scores, particularly those greater than 10, being associated with depression or the 
possibility thereof (Brink et al. 1982).  The former authors reported sensitivity and 
specificity values to depression of 84% and 95%, respectively applying a cut off score of 
11/30. In the original validation study, normal elderly controls obtained a mean total score of 
5.75 (SD = 4.34) as compared to significantly higher scores of mildly (15.05; SD = 6.50) and 
severely depressed (22.85; SD = 5.07) elderly outpatients (Yesavage et al. 1983). High levels 
of validity and one week test re-test reliability (r = 0.85) were also reported.  
 
2.4 Outcome Variables 
In recognition of the variety of possible longterm outcomes seen in association with aMCI 
(Ahmed et al. 2008b;Lee et al. 2006;Schmidtke and Hermeneit 2007), at the final follow-up 
assessment, MCI participants were assigned to 1 of 4 groups in accordance with whether 
their cognitive deficits had remained stable - stable MCI; their psychometric performance 
was normal - normal; They had declined psychometrically over the course of their 
participation in the study but did not meet DSM-IV criteria for dementia – decline; or they 
had declined sufficiently on a cognitive level and exhibited associated areas of functional 
impairment to fulfil DSM-IV or other published non-Alzheimer consensus criteria for 
dementia - dementia.  Assignment to each of these four groups was carried out in accordance 
with the criterion outlined below.  
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2.4.1 Stable MCI 
Stable MCI participants were those exhibiting evidence of impaired episodic memory 
function at baseline and subjective memory complaints, with or without deficits in additional 
non- 
episodic memory domains, who continue to perform at least 1.5 SD below norms on two or 
more episodic memory measure at final follow-up but do not show evidence of significant 
cognitive decline in non-memory domains (as defined by a deterioration in performance on 
two or more executive or semantic memory measures of a magnitude found in less than 2.5% 
of an age/IQ matched sample over an average 3.17 year period). 
 
Criterion 
1.5 SD or more below control mean on two or more neuropsychological measures at final 
assessment  
AND 
No evidence of significant declines in non-memory domains (as defined by a decline of a 
magnitude that would be expected to occur in less that 2.5% of a normative sample over the 
course of the study on two or more tests within a given cognitive domain). 
 
2.4.2 Normal  
Normal participants were those performing within 1.5SD of the control mean on at least 7 
out of 8 episodic memory measures at final follow-up. 
 
Criterion 
1.5 SD or more below control mean on a maximum of one neuropsychological measure at 
final assessment 
 
2.4.3 Declining MCI  
Declining MCI participants were performing at least 1.5 SD below age norms at baseline on 
one or more measures of episodic memory function or at least 1 SD below age norms at BL 
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on two or more measures of episodic memory function (+ or – other domains of cognitive 
impairment) and exhibiting decline of a magnitude that would be expected to occur in less 
that 2.5% of a normative sample over the course of the study on either two measures of 
semantic memory functioning or two measures of executive ability.  Declining MCI 
participants did not meet criteria for dementia on account of their sound functional abilities.   
 
Criterion 
1.5  SD or more below control mean on two or more neuropsychological measures at final 
assessment. 
AND 
Evidence of significant declines in a non-memory domain(s), as defined by a decline of a 
magnitude that would be expected to occur in less that 2.5% of a normative sample over the 
course of the study on two or more measures assessing a specific non-memory domain i.e. 
semantic memory or executive function. 
AND 
No evidence of significant functional decline (as defined by 3 or more ratings of 3 or 4 in 2 
or more non-memory domains on the MCI ADL scale). 
OR 
No evidence of decline in two or more areas of the ADL scale. 
 
The different thresholds for varying items of the ADL scale were applied in an attempt to 
capture the point at which the level of performance for each item was suggestive of 
functional impairment.  For example, for item C, relating to food preparation, it is plausible 
that a married 70-year-old man, without functional impairment, does not ‘plan, prepare and 
serve adequate meals independently (1)’, or indeed ‘prepare adequate meals if supplied with 
ingredients (2)’ whereas an inability to maintain an adequate diet, would be suggestive of 
some significant functional difficulty. 
 
Memory complaints were universal amongst the MCI cohort at baseline and DSM-IV 
clinical criteria for dementia requires evidence of additional non-memory domain(s) of 
cognitive impairment that cause significant impairment in social and/or occupational 
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functioning.  As such, patients whose carer’s were not (1) rating several aspects of their non-
memory functioning as ‘consistently a little (3) or much worse (4)’ at the study endpoint, or 
(2) endorsing clear evidence of decline in more than one activity listed in the Instrumental 
Activities of Daily Living Scale (Lawton and Brody 1969), were considered insufficiently 
functionally impaired to fulfil DSM-IV criteria for dementia. 
 
2.4.4 Dementia 
Dementia was diagnosed in accordance with DSM-IV criteria for AD where the 
development of multiple cognitive deficits manifested by both memory impairment together 
with one or more of language disturbance, apraxia, agnosia or executive functioning and 
criteria for continuing cognitive decline were defined by the following criteria. 
 
Criterion 
1.5 SD or more below control mean on one or more episodic memory measures (ACE 
immediate recall, ACE delay, PAL 6 box errors, HVLT total trials, HVLT delayed recall, 
HVLT Discrimination Index (DI) score, RCFT immediate recall, RCFT delay).  
OR 
Meets published clinical criteria for one of the non-AD or vascular forms of dementia. 
AND 
Evidence of significant declines in non-memory domains (as defined by a decline of a 
magnitude that would be expected to occur in less that 2.5% of a normative sample over the 
course of the study on two or more measures assessing either semantic memory or executive 
function. 
 
That cognitive deficits cause significant impairment in social or occupational functioning 
and represent a significant decline from a previous level of functioning was defined by the 






Evidence of significant functional decline (as defined by 3 or more ratings of 3 or 4 in 2 or 
more non-memory domains on the MCI ADL scale). 
OR 
Evidence of decline in two or more areas of the ADL scale (Lawton and Brody 1969), rated 
in accordance with criteria previously described (see Appendix 8.4.2 for copy of the 
Instrumental Activities of Daily Living Scale) 
 
All MCI participants had undergone one or more prior consultation(s) with their general 
practitioner as well as either a Consultant Old Age Psychiatrist’s or a Consultant 
Geriatrician, prior to being referred for neuropsychological assessment.  In addition, 22/46 
aMCI participants underwent some form of neuroimaging facilitating the screening out of 
other central nervous systems and systemic conditions that can cause progressive deficits in 
memory and cognition.  All participants who were categorised as having developed dementia 
by the study endpoint fulfilled the criterion below. 
 
Criterion 
1.5 SD or more below control mean on two or more episodic memory measures (ACE 
immediate recall, ACE delay, PAL6 box errors, HVLT total trials, HVLT delayed recall, 
HVLT DI, RCFT immediate recall, RCFT delay).  
AND/OR 
1.5 SD or more below control mean on two or more non-episodic memory measures (EENT, 
GNT, BNT, GFT, Category fluency total, FAS total, TMTA, TMTB, Dual Performance 
Combined score, RCFT copy). 
AND 
Displaying evidence of significant declines in non-memory domains (as defined by a decline 
of a magnitude that would be expected to occur in less that 2.5% of a normative sample over 
the course of the study on two or more tests of a cognitive domain other than that of (or in 
conjunction with) memory. 
AND 
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Displaying evidence of significant functional decline (as defined by 3 or more ratings of 3 or 
4 in 2 or more non-memory domains on the MCI ADL scale). 
OR 
Evidence of decline in two or more areas of the IADL scale (Lawton and Brody 1969). 
 
Diagnoses of other non-AD forms of dementia (Vascular dementia, VD; frontal variant 
Frontotemporal dementia, fvFTLD; Semantic dementia, SD; Primary progressive aphasia, 
PPA; Dementia with Lewy Bodies, DwLB) were made in accordance with established 
criteria (2002;McKeith et al. 1999;Mesulam 2001;Neary et al. 1998) by way of reference to 
the existing neuropsychological data within the context of a clinical interview with the 
patient and his/her carer at the final follow-up assessment, or within the context of a clinical 
neuropsychological consultation.   
 
2.5 Additional Medical Information 
We also recorded the number of MCI patients who were receiving anticholinesterase and/or 
antidepressant drug therapy at their final assessments (see Table 8.3 Appendix B).  The level 
of service use at the time of the final follow-up assessment was recorded for each of the 46 
MCI participants, both in terms of the type of professional contact(s) they were receiving 
(i.e. GP, Consultant Psychiatry, Clinical Psychology, Community Psychiatric Nurse, Social 
Services or none) and the frequency of consultations over the past 12 month period.  Note 
was also made of any co-morbid medical conditions that were documented in the medical 
notes.  Where a clinical diagnosis of dementia had been made post study entry, this was also 
recorded along with type, where this had been specified.  The above details are tabulated in 
section 8.2 of the Appendix.
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3. The Prevalence and Neuropsychological Characterisation 
of aMCI 
(Published in part in British Journal of Psychiatry. 2008 Jan; 192:59-64.) 






There is current interest in exploring the different subtypes of mild cognitive impairment 
(MCI) in terms of their epidemiology.  
Aims 
To examine the frequency of MCI subtypes presenting to a memory clinic. 
Method 
Consecutive tertiary referrals (n=187) were psychiatrically evaluated; 45 patients met criteria 
for amnestic mild cognitive impairment (aMCI).   
Results 
Patients who fulfil Petersen’s criteria for MCI represent one fifth of all referrals made to our 
specialist memory clinic.  
Conclusions 




The practical utility of screening for MCI within the general population has been questioned, 
on grounds that a significant portion of those who are identified as suffering with MCI either 
do not wish to pursue any further investigation, or have an identifiable medical cause for 
their cognitive impairment (Jicha 2008).  By contrast, those patient’s who have been referred 
to specialist memory clinics and found to fulfil criteria for MCI, have actively sought 
consultation, are more likely to have undergone relevant physical screening to rule out any 
medical cause for their symptoms, and are arguably of clinical importance in this regard.    
 
Whilst a number of studies have reported MCI prevalence estimates for the general 
population (Blossom et al. 2007;Busse et al. 2003;Panza et al. 2005;Pioggiosi et al. 2006), 
there is little information regarding the frequency with which MCI is encountered at a 
specialist clinical level (i.e. within a memory clinic setting).  This is important to know, as 
there is evidence to suggest that both assessment (Lonie et al. 2008) and treatment (Akhtar et 
al. 2006;National Collaborating Centre for Mental Health 2006) approaches for MCI may 
differ from those that are recommended in established dementia cases. 
 
In view of the ageing population, the availability of memory treatment agents, and the 
current clinical and research emphasis on early diagnosis, one might expect that MCI 
referrals comprise a significant proportion of overall referrals received within specialist 
memory clinic settings.  The results of existing studies suggest this may be the case.  Lehrner 
et al., (Lehrner et al. 2005) reported that approximately one-fifth of the patients seeking help 
in their outpatient memory clinic were identified as having aMCI.  A similar proportion of 
MCI type referrals (23%) were also received by the Cambridge Memory Clinic across a 21 
month period (Alladi et al. 2006).  A lower proportion of MCI referrals (12.7%) have, 
however, been reported more recently, in connection with a newly established UK memory 
clinic (Popoola et al. 2008). 
 
As such, whilst there is reason to suspect that a significant portion of the patients presenting 
to specialist memory clinics might fulfil criteria for MCI, there presently exists a small 
amount of conflicting data informing the prevalence of MCI within memory clinic settings.   
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As a prelude to cross-sectional and longitudinal neuropsychological analyses of our aMCI 
cohort, we sought to determine the proportion of referrals made to The Edinburgh 
Neuropsychological Assessment Service for Older People fulfilling criteria for aMCI.  On 
the basis of figures reported by two other well established neurology lead memory clinics, 
we hypothesised that patient’s fulfilling aMCI criteria (Petersen et al. 1999;Petersen 
2004;Petersen 2005a) would comprise a significant (i.e. >20%) proportion of consecutive 
referrals received by our clinic across an 18 month time interval. 
 
3.1.3 Method 
We retrospectively analysed 187 consecutive referrals to the Edinburgh Neuropsychological 
Assessment Service for Older People between the months of September 2004 and April 
2006.  Referrals were received at a tertiary level, stemming from consultants in older age 
psychiatry, geriatric medicine and neurology.  All of these patients had undergone 
comprehensive psychiatric evaluation, relevant medical screening (including a standard 
battery of screening blood tests) and neuroimaging (computed tomography and/or magnetic 
resonance imaging or single-photon emission computed tomography) prior to being referred 
to our service.  All but three patients were over the age of 50 years. 
 
The original criteria for MCI set out by Petersen et al (Petersen et al. 1999) require that a 
person must present (1) with a memory complaint, (2) show evidence of objective memory 
decline in relation to age and education, (3) demonstrate preservation of other areas of 
cognitive function and (4) activities of daily life and (5) not fulfil criteria for dementia. 
Because it has since become apparent that not all persons who demonstrate cognitive 
impairment short of dementia have a ‘memory’ complaint, we utilised the recently expanded 
criteria that include persons with non-memory complaints (single domain non-memory MCI) 
as well as those exhibiting multiple domains of cognitive impairment who nonetheless fail to 
fulfil criteria for dementia (multiple domains slightly impaired) (Petersen, 2005;Petersen, 
2004). The Mini-mental State Examination (MMSE; Folstein et al, 1975) and Addenbrookes 
Cognitive Examination (ACE; Mathuranath et al, 2000) were administered as a means of 
establishing the patient’s general level of cognitive functioning. Level of everyday 
functioning was examined by way of the Clinical Dementia Rating Scale (Morris,1993) 
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within the context of a clinical interview with the patient and his/her primary carer, where 
available. 
 
A total of 112 patients fulfilled either one or more of the following exclusion criteria and 
were therefore excluded from the analyses: dementia (MMSE < 24/30 or ACE <80/100 and 
DSM-IV, depression (as assessed either by way of formal psychiatric consultation or, in a 
small proportion of cases, by a score of greater than 10 on the Geriatric Depression Scale 
(GDS; Yesavage et al, 1982) or clinical assessment by the author (JAL), or one or more 
medical or psychiatric conditions that could conceivably account for the patient’s cognitive 
impairment (i.e. head injury, schizophrenia, evidence of stroke or tumour on neuroimaging, 
alcoholism, epilepsy, cranial radiotherapy)  
 
Of the remaining 75 patients, 15 showed cognitive impairments outside the domain of 
episodic memory, 15 returned a ‘normal’ cognitive profile and 45 showed memory function 
impaired for age (with or without additional areas of cognitive impairment).  
 
3.1.3.1 Neuropsychological Assessment Measures 
Details of the neuropsychological assessment battery are provided in section 2.2 of Chapter 2 
Materials and Methods.   
 
3.1.3.2 Comparison with other memory clinics 
We searched the literature for studies employing neuropsychological test batteries similar to 




3.1.4.1 Results of literature search 
We identified one other study reporting consecutive referrals to a memory clinic using 
similar diagnostic criteria and assessment measures (Alladi et al, 2006).   
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Figure 3.1  Flowchart of aMCI referrals to the Edinburgh Older Adult 
Neuropsychological Assessment Service (September 2004 – April 2006) 
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3.1.4.2 Comparability of aMCI Referral Patterns  
A striking similarity in referral patterns was observed between our Neuropsychological 
Assessment Service for Older Adults and data reported from the Cambridge Memory Clinic 
(Alladi et al. 2006).  Data from the latter study are presented below our figures in 
percentage format in red (Figure 3.1), for comparative purposes.  When the 150 pre-excluded 
referrals from the Cambridge Memory Clinic were accounted for, just over half (i.e. 60%) of 
referrals from both centres were excluded due to an established dementia or depressive 
disorder or one or more medical condition(s) that could account for the patient’s cognitive 
impairment (chi² = 0.015; p= 0.90). Close to 40% of referrals from both centres fell within 
the non-demented and non-depressed category (chi² = 0.000; p = 0.995). Just over half of 
these patients in both centres met Petersen’s (1999 & 2004) criteria for aMCI (chi² = 0.46; p 
= 0.50) representing close to one fifth of overall referrals from both centres. Of the 
remaining 40% of non-demented, non-depressed patients, half demonstrated cognitive 
deficits of a non-amnestic variety (in one or more domains), and half returned ‘normal’ 
cognitive profiles. 
 
Although referral patterns for aMCI were similar across the two centres, there was a greater 
proportion of non-amnestic MCI patients and fewer visual only aMCI patients in our sample 
(chi² = 13.23 (3 df); p = 0.004; Fisher-Freeman-Halton exact test p =0.003). 
3.1.5 Discussion 
In this study we have shown that non-depressed, non-demented persons who fulfil Petersen’s 
(1999 & 2004) criteria for aMCI, make up a significant proportion of referrals to our Old 
Age Clinical Neuropsychology service. Roughly one quarter of all referrals received across 
an 18-month period met Petersen’s (1999 & 2004) criteria for aMCI. This is an almost 
identical proportion of patients to that reported in a recent study by the Cambridge Memory 
Clinic (22.78%) (Alladi et al, 2006) and a very similar figure to the 20% of patients seeking 
help in Lehrner et al’s (2005) clinic who met criteria for aMCI.  
 
It is conceivable that the considerably lower MCI referral rate reported by the Cork 
University Hospital Memory Clinic was a reflection of its recent establishment, or the fact 
that this clinic, in contrast to the others, was Psychiatry lead.  Surprisingly, the level at which 
referrals are received (i.e. whether primary, as in the Cambridge Memory Clinic or tertiary, 
as in our clinic) appears not to influence the proportion of MCI-type referrals that are 
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received. Thus, although by no means universally adopted, it appears that both the concept 
and criteria for aMCI are applicable and, indeed, a necessary adjunct to clinical practice.  
 
It is unusual for MCI patients to present with predominant psychiatric or neurological 
complaints, and pharmaceutical options are presently unavailable to MCI sufferers on the 
National Health Service (NHS).  By contrast, there are a number of well established 
cognitive rehabilitative techniques that have been validated for use in MCI (Akhtar et al. 
2006); Kapur and Wilson, personal communication, 2008). Furthermore, traditional 
dementia screening measures that are commonly utilised as a means of establishing a 
patient’s overall level of cognitive functioning are insensitive to cognitive deficits in MCI 
(Lonie et al. 2008) and influenced by IQ (Starr and Lonie 2007).  MCI patients may perform 
within normal age limits on even the most comprehensive of these (Alladi et al. 2006;Lonie 
et al. 2008).  
 
The above observations, together with the frequency with which MCI is encountered at 
specialist levels, raises the question of whether a different or wider mix of skill base may be 
necessary, within specialist memory clinics, to meet the more comprehensive psychometric 
assessment and non-pharmaceutical treatment needs of this patient group.   
 
3.1.6 Conclusion 
MCI is an important diagnosis within specialist secondary and tertiary referral based 
memory clinic settings. The large proportion of referrals of this nature received by our own 
and other memory clinics highlights a need for evidence-based guidance as to how these 




3.2 Neuropsychological Characterisation and Classification 
of aMCI 




There is current interest in exploring the different subtypes of mild cognitive impairment 
(MCI), in terms of their cognitive profile.  
Aims 
To document detailed neuropsychological profiles of patients with the amnestic subtype. 
Method 
Consecutive tertiary referrals (n=187) were psychiatrically evaluated. A group of 46 patients 
with aMCI as well as 24 healthy controls took part in a thorough neuropsychological 
examination. 
Results 
Of the 46 aMCI patients who were examined in greater neuropsychological detail, 36 were 
performing 1 SD or more below the control mean on 2 or more episodic memory measures 
and 39 were performing 1.5 SD or more below the control mean on 1 or more of these 
measures. Four returned a psychometrically ‘normal’ profile.  A majority, i.e. 32-34 were 
exhibiting evidence of additional non-memory impairment. The aMCI group performed 
significantly less well than controls on all but 6 of the neuropsychological measures that 
were administered. The mean ACE score of the aMCI participants who were exhibiting 
impairment on 3 or more episodic memory measures was significantly lower than for those 
showing impairment on 1 or 2 measures.  Isolated memory impairment was rare.   
Conclusions 
Amnestic MCI is an important diagnosis in secondary and tertiary memory clinics.  Memory 
impairments rarely present in isolation.  There is scope to improve the efficacy and 




Following publication of the initial set of criteria for MCI (Petersen et al. 1999), Petersen 
and colleagues (Grundman et al. 2004) proposed research criteria with a cut-off for verbal 
recall performance as objective evidence of episodic memory impairment. This approach has 
been challenged because it excludes patients who display exclusively visual episodic 
memory impairment (Alladi et al, 2006). Moreover, no justification for the choice of the 
outdated WMS-R version of the logical memory subtests is provided, and recent findings 
suggest that assessing episodic memory function in this manner may result in false positive 
MCI classifications (Brooks et al. 2007). 
 
There is evidence to suggest that pure amnestic MCI (aMCI single domain) is rare; (Alladi et 
al. 2006;Hodges et al. 2006;Kramer et al. 2006;Tabert et al. 2006) and MCI case definition 
varies as a function of the neuropsychological tests used (Alladi et al, 2006; Loewenstein et 
al, 2006). It is not clear how MCI criteria might best be translated into clinical practice and 
there remains wide variability in terms of how aMCI criteria are applied, with regards the 
type and number of cognitive measures used to assess for impairment and the cut off points 
used to define impairment.  
 
The second aim was to examine the diagnostic profile of aMCI patients referred to our 
tertiary assessment service and to evaluate a comprehensive battery of neuropsychological 
measures for its usefulness in this patient group.  It was hypothesized that 1) a majority of 
MCI patients would demonstrate memory as well as other domains of cognitive impairment 
on our carefully selected neuropsychological assessment battery and that 2) classification of 
MCI participants (i.e. as normal, single or multi-domain amnestic or non-amnestic) would 
vary in accordance with the neuropsychological measures(s) and psychometric cut off points 
used to apply Petersen’s MCI criteria and 3) a negative association between MCI patient’s 
general level of cognitive functioning (as assessed by the total score obtained on the ACE 
and MMSE, and the number of impaired episodic memory measures was further predicted. 
 
3.2.3 Method 
A comprehensive neuropsychological battery of tests was administered to 46 patients with 
aMCI and 24 healthy elderly controls. Details of the participant groups and 
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neuropsychological assessment measures are provided in sections 2.1 & 2.2 of Chapter 2 
Materials and Methods, respectively.   
 
We present detailed neuropsychological baseline findings for 33 of the 45 patients who were 
identified in a retrospective analysis of referral types received between the months of 
September 2004 and April 2006, together with a further 16 MCI patients who were recruited 
through the Neuropsychological Assessment Service for Older People after this date (see 
Figure 3.1 Flowchart of referrals). All 46 aMCI subjects who consented to taking part in our 
study fulfilled inclusion / exclusion criteria for aMCI as outlined in Table 2.2. Twenty-four 
healthy elderly control participants were also recruited through a local dementia support 
group or were spouses or carers of patients who had attended the Neuropsychological 
Assessment Service, and met inclusion / exclusion criteria as outlined in Table 2.2. 
 
3.2.3.1 Statistical Analysis 
MCI patients were classified by subtype (i.e. single domain amnestic, multiple domain 
amnestic, non-amnestic single or multi) on the basis of their baseline performance on our 
study battery of neuropsychological measures, in accordance with both Criteria A (using a 
cut off of 1SD or more below control mean on two or more tests) and Criteria B (using a cut 
off of 1.5 SD or more below control mean on one or more test). We calculated z scores to 
determine where scores fell below the 10th percentile of control performances.  Independent 
sample t-tests, with bonferroni corrections for multiple comparisions (and analysis of 
covariance where group differences in the demographic variables of age or FSIQ reached 
statistical significance), were carried out to compare group mean performances on each of 
the neuropsychological variables included in our study battery. As visual inspection together 
with a one-sample Kolmogorov-Smirnov goodness-of-fit test indicated that some of the data 
was not normally distributed, group comparisons were also conducted using the Mann-
Whitney test. 
 
In order to determine whether there is an association between general level of cognitive 
function and the consistency of episodic memory impairment, we divided the aMCI patients 
into two groups: those who displayed episodic memory impairment on 2 or fewer measures 
(where impairment was defined by a performance below the 10th%ile of the control group) 
and those who showed impairment on more than two measures. Their ACE and MMSE 
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scores were compared using an independent sample t-test.  This analysis was repeated using 
the Mann-Whitney test (as visual inspection and one-sample Kolmogorov-Smirnov 
goodness-of-fit test indicated that the data were not normally distributed).  
3.2.4 Results 
From a group of 46 MCI patients recruited in this manner, 36 also performed at least 1 SD 
below our control mean on two or more of the episodic memory tasks that comprised the 
research battery, hence fulfilling Criteria A for aMCI.  Thirty nine of the 46 participants met 
the more commonly applied psychometric cut off of a performance 1.5  SD or more below 
our age matched control mean on at least one episodic memory test from the research battery 
(fulfilling Criteria B for aMCI).   
 
Four subjects exhibited no psychometric evidence of memory impairment relative to our 
control group on the study battery (despite having performed at least 1 SD below age norms 
on two or more episodic memory measures during their clinical neuropsychology 
consultation).  Six MCI participants performed at least 1SD below the control mean on 1 
episodic memory test from the research battery only.  
 
When the non-episodic memory performance of the MCI participants (relative to the healthy 
elderly control group), was broken down in a similar manner, 32 participants were displaying 
impairments of 1SD or greater on at least 2 non-memory measures (in accordance with 
Criteria A), whilst 34 were exhibiting an impairment of 1.5 SD or more on 1 or more non-
memory measure (in accordance with Criteria B). 
 
Table 3.1  Breakdown of MCI subtypes following baseline neuropsychological 













8 28 6 4 46 
Criteria B. 8 31 4 3 46 
Criteria A: performance of 1SD or more below age and IQ matched study control mean on two or 
more tasks; Criteria B: performance of 1.5 SD or more below and and IQ matched study control mean 
on one or more tasks 
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Table 3.2  Demographic data and performance of healthy controls (n=24) and 
amnestic MCI (n=46) on our neuropsychological test battery. 
*** = p<.001, ** = p<.01, * = p<.05, (ns) = non-significant, (ns adj) = non-significant following 
Bonferroni correction for multiple comparisons 
+ The p value for Mann-Whitney test is provided where a discrepancy in significance findings was 
observed across parametric and non-parametric methods of analysis and assumptions of equal 
variances or normal distribution were not met. 









Age 70.8 (7.8) 73.9 (6.4) 0.080 ns 
NART IQ 118.5 (3.3) 116.8 (7.6) 0.193 ns 
MMSE (30) 29.0 (0.8) 28.4 (1.5) P<0.01** ns adj 
ACE    
ACE total (100) 94.5 (3.2) 89.5 (5.5) P<0.001*** 
ACE Immediate recall (21) 20.3 (1.0) 20.2 (1.4) 0.291 ns 
ACE delay (7) 6.4 (0.8) 4.3 (2.2) P<0.001*** 
RCFT Scores    
REY copy (36) 34.2 (2.4) 34.0 (2.4) 0.378 ns 
REY immediate recall (36) 18.9 (5.9) 13.0 (6.8) P<0.01** ns adj 
REY delayed recall (36) 17.5 (6.9) 11.6 (6.9) P<0.01** ns adj 
HVLT-R Scores    
HVLT-R total recall (12) 23.4 (5.1) 19.1 (4.8) P<0.001*** 
HVLT-R delayed recall (12) 8.1 (2.7) 4.7 (3.3) P<0.001*** 
HVLT-R DI (12) 9.9 (1.8) 8.3 (2.5) P<0.01** ns adj 
PAL 6 errors 7.9 (6.7) 17.0 (14.3) P<0.01** ns adj 
Trail Making Test     
TMT A (seconds) 40.2 (10.5) 45.2 (18.8) 0.238 ns 
TMT B (seconds) 88.7 (30.7) 120.6 (68.7) P<0.05* ns adj 
  +0.06 ns  
COWAT (FAS) 47.6 (14.3) 44.6 (11.7) 0.176 ns 
Dual Task 







Category fluency 51.4 (11.8) 36.4 (11.2) P<0.001***                     
EENT (50) 49.0 (4.8) 45.1 (5.4) P<0.01** ns adj 
Graded Faces Test (30) 20.7 (3.6) 16.9 (5.0) P<0.001*** 
Graded Naming Test (30) 23.8 (3.1) 20.7 (4.1) P<0.01** ns adj 
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In table 3.1 it can be seen that in applying Criterion A (i.e. a performance of at least 1SD 
below age/IQ matched control mean on 2 or more measures), 8 could be classified as single 
domain amnestic MCI and 31 as multi-domain amnestic MCI.  Of the remaining 7, 4 
demonstrated no psychometric evidence of memory or any other domain of cognitive 
impairment relative to our healthy control group on the measures that formed part of the 
selected study battery, whilst 3 demonstrated impairments on two or more non-memory 
measures only. 
 
Applying Criterion B (i.e. a performance of a least 1.5 SD below age/IQ matched control 
mean on 1 or more measures), 8 could be classified as single domain amnestic MCI and 28 
as multi-domain amnestic MCI.  Of the remaining 10, 6 demonstrated no psychometric 
evidence of memory or any other domain of cognitive impairment relative to our healthy 
control group on the measures that formed part of the selected study battery, whilst 4 
demonstrated impairments on two or more non-memory measures only. 
 
MCI and control participants did not differ significantly in terms of age t(1.78) = 0.08, 
p>0.05 or estimated pre-morbid IQ t(-0.14) = 0.193, p >0.05. These findings were replicated 
using non-parametric means of analysis (i.e. Mann-Whitney test). Despite a mean ACE score 
that exceeded suggested cut-off points for dementia (89/100) the MCI group performed at 
significantly lower levels on a number of neuropsychological measures that were 
administered including the ACE total and delayed story recall scores, the HVLT-R total and 
delayed recall scores, the BNT, GFT and the category fluency task. The findings were 
identical when the groups were compared using non-parametric methods of analysis (Mann-
Whitney), with the exception of Part B of the Trail Making Test, where group differences in 
performance just failed to reach significance (U=426, p=0.060, r=-0.186) even prior to 
correction for multiple comparison.  
 
All group means are based on numbers between 23-24 for controls and 44-46 for the MCI 
group, with the exception of the GNT, where data are based on 43 MCI and 19 control 
participants only.  Baseline scores on the GNT were missing for 5 control and 3 MCI 
patients as this measure was added to the research battery shortly after study onset.  Baseline 
RCFT data was also missing for one MCI participant, who declined to engage in this test as a  
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Table 3.3  Performance of patients with amnestic mild cognitive impairment on 
neuropsychological measures  
ACE, Addenbrookes Cognitive Examination; aMCI, amnestic mild cognitive impairment; BNT, 
Boston Naming Test; EENT, Edinburgh Exemplar Naming Test; GFT, Graded Faces Test; GNT, 
Graded Naming Test; HVLT-R, Hopkins Verbal Learning Test – Revised; PAL, CANTAB Paired 
Associate Learning Test; TMT, Trail Making Test; RCFT, Rey Complex Figure Test. 
 
 
Measure                                                                            Patients Performing below 10th percentile of 
control group performance n (%) 
Episodic Memory 
    HVLT_R total recall 11 (24) 
    HVLT_R delayed recall 22 (49) 
    HVLT_R discrimination index 17 (38) 
    Any HVLT-R measure 28 (62) 
    PAL 6 box errors 21 (46) 
    Rey Complex Figure Test delayed recall 14 (32) 
    Rey Complex Figure Test immediate recall 18 (41) 
    ACE immediate name and address recall 10 (22) 
    ACE delayed name and address recall 28 (61) 
Patients with impairment on 1 measure only 5 (11) 
Patients with impairments on 2 or more measures 35 (76) 
Patients with impairments on 3 or more measures 26 (57) 
Patients with impairments on 4 or more measures 17 (37) 
Semantic Memory / Language 
    BNT 17 (37) 
    EENT 13 (29) 
    GFT 18 (40) 
    GNT 15 (35) 
    Category Fluency 25 (57) 
Participants showing impairment on one or more 
semantic memory measure 
35 (76) 
Attention / Executive Function 
    TMT Part B 15 (33) 
    COWAT (FAS) 3 (7) 
    Dual Task 2 (5) 
Visuospatial Function 
    Rey Complex Figure Copy 4 (9) 
Visuomotor Processing Speed 
    TMT Part A 8 (17) 
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result of its challenging nature. The immediate and delayed components of the RCFT were 
not administered to one further MCI participant, for no apparent reason.  One MCI 
participant refused to attempt the HVLT and as such 45/46 MCI baseline scores for the 
HVLT indices are available.  Baseline scores on the EENT, GFT & Dual Task were not 
obtained for 1,1 & 2 MCI patients respectively, due to time constraints.  Animal and single 
letter fluency data only (i.e. not the additional categories of fruits and vegetables or the letter 
F,A & S) were collected for a further 3 patients (2 and 1, respectively) for no apparent 
reason.  NART estimates of pre-morbid IQ were not obtained for one each of our control and 
MCI participants and it is again unclear why the data was not collected in this case. 
 
As in the Cambridge Memory Clinic study, not all aMCI participants demonstrated 
impairment across all episodic memory measures: 6 (13%) performed above the 10th%ile of 
the control mean on all episodic memory measures, 5 (11%) showed impairment on a single 
test, 8 (17%) showed impairment on two memory measures and the remaining 27 (59%) 
were impaired on three or more tests.   
 
Mean ACE scores for participants who were impaired on three or more episodic memory 
measures (M=87.54, SE=1.02) were significantly lower t(44) = 0.003, p<0.01 than for those 
showing impairment on two or fewer measures (M=91.95, SE=1.13). The difference in mean 
MMSE scores of the two MCI groups (M=28.04, SE=0.27; M=28.75, SE=0.35) was almost 
significant t(44)=0.053, p>0.05. 
 
With reference to a performance falling below the 10th%ile of our control group, just over 28 
(61%) of our aMCI participants showed both verbal and visual episodic memory impairment.  
Although a significant proportion 11 (24%) demonstrated memory impairment of a verbal 
nature only, just 1 of our patients exhibited a pure visual memory deficit. 
 
Only 6 (13%) of our aMCI patients exhibited an isolated impairment of episodic memory 
function.  All but three of the other patients (i.e. 37/46) exhibited deficits in one or more 
additional domains of cognition, mostly that of semantic memory function, followed by 




The applicability of Petersen’s (Grundman et al. 2004) research criteria to clinical practice 
has recently been challenged on the grounds of exclusion of a significant number of patients 
who display episodic memory impairment of a visual nature only (Alladi et al, 2006). In 
contrast to the results of Alladi et al’s (2006) study, around half of the aMCI subjects in our 
study showed impairment of verbal and visual memory, whilst all of the remaining subjects 
exhibited memory impairment of a verbal nature only. Only one of 46 MCI participants in 
our sample displayed an isolated impairment of visual episodic memory. 
 
A recent study (Loewenstein et al, 2006) supports the notion that the type of episodic 
memory measure used may affect whether or not impairments are detected – a point we will 
return to later in the discussion. However, the absence of patients showing episodic memory 
impairment of a solely visual nature in our sample cannot be readily explained in terms of 
differential test sensitivities as near identical neuropsychological measures were used in 
previous studies (e.g. Alladi et al, 2006) to assess visual memory function. Only a small 
proportion of our aMCI patients demonstrated impairment on the visual episodic memory 
tasks per se. Administrative procedures might go some way to explain this observation. 
Specifically, our inclusion of an immediate Rey Complex Figure recall trial may have 
resulted in higher delay scores (Lezak et al, 2004), thus serving to reduce the sensitivity of 
this measure in our aMCI group. 
 
Findings of studies examining patients who are ‘at risk’ of developing AD suggest that 
measures of verbal episodic memory are most sensitive to changes early in the disease 
course, followed by measures of visual memory (Collie and Maruff, 2000). It is therefore 
conceivable, taking into account our aMCI group’s higher mean ACE score, that our aMCI 
sample contains a greater number of patients who are at an earlier stage of their disease 
course. Longitudinal follow-up, in particular observation of annual performances on these 
visual episodic memory measures, will determine whether this is indeed the case. 
 
Recently, several studies have drawn attention to the substantial variability in MCI case 
definition as a function of the specific neuropsychological tests used (Alladi et al, 
2006;Loewenstein et al, 2006). Consistent with this, in our study there was variability among 
aMCI patients as to which and how many episodic memory measures were impaired. This 
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finding was previously demonstrated (Alladi et al, 2006) and highlights the inherent 
difficulty in specifying the use of any single measure as a means of establishing impaired 
episodic memory function in aMCI. It would appear entirely reasonable and indeed a matter 
of good clinical practice to seek to establish consistency in performance across a range of 
episodic memory measures in defining aMCI and it will be of interest to see whether this is a 
significant determinant of outcome. 
 
The variability in case definition of aMCI as a function of the cognitive measures employed, 
coupled with the inherent difficulties in specifying the use of a single common measure in 
the evaluation of aMCI, poses a major challenge for clinicians.  Our findings would suggest 
that in employing Petersen’s criteria for MCI, a patient could conceivably be classified as 
aMCI single domain, aMCI multiple domain, or ‘worried well’ depending on the cognitive 
measures that were employed.  If the MCI subdivisions prove useful in a prognostic sense, 
the means by which the cognitive aspects of the criteria are put into operation by clinicians 
will require further clarification. 
 
Mean scores on cognitive screening measures were significantly lower for subjects showing 
impairment on more than one episodic memory measure. This may reflect a more advanced 
disease course of this group. It is also possible that the single measure impairment group will 
prove to be a less stable one over time, with a number of patients returning normal 
neuropsychological profiles when re-tested. Alternatively, in cases where subjects show 
impairment on a single verbal memory measure only, this may have arisen secondarily to 
impairment in another cognitive domain, for example expressive language or 
attention/executive function (in which case the subject might be more accurately 
conceptualised as non-amnestic MCI). These possibilities and the prognostic implications of 
consistency and pervasiveness of impaired episodic memory performance(s) remain to be 
examined by way of longitudinal follow-up. 
 
Our study adds to the growing body of evidence supporting the scarcity of a pure amnestic 
MCI syndrome (Kramer et al, 2006;Tabert et al, 2006;Alladi et al, 2006) and demonstrates 
that additional impairment often goes unnoticed unless participants undergo thorough 
neuropsychological assessment. Amongst 46 patients with aMCI only 6 patients (13%) 
presented with isolated memory impairment. This figure is well within the range of 
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previously reported rates. For example, Tabert and colleagues (2006) found that, following 
comprehensive neuropsychological assessment, only 19% of their aMCI cases were suffering 
from pure aMCI, whilst this figure reached 35% in Alladi et al’s (2006) recent study. 
 
It should be borne in mind, however, that the rate of cases with purely amnestic MCI will 
vary in accordance with how impairment is defined. For example, Kramer and colleagues 
(2006) showed that the number of cases that classified as pure aMCI was considerably 
higher (27%) when a cut-off of 1.5 standard deviation below the mean, as opposed to 1 
standard deviation (resulting in a 5% rate), was used. It therefore remains a possibility that 
our less stringent definition of impairment (i.e. below the 10th percentile of healthy controls) 
may have resulted in an overestimation of the frequency of cases with non-pure aMCI. 
Identifying accompanying non-memory cognitive impairment nonetheless appears important 
in light of recent evidence indicating higher risk of conversion to AD in aMCI patients who 
show additional areas of cognitive impairment as compared to patients with pure aMCI 
(Tabert et al, 2006).   
 
The results of the present study are also consistent with evidence indicating accompanying 
semantic memory impairment in aMCI (Alladi et al. 2006;Grundman et al. 2004;Hodges et 
al. 2006;Riberio et al. 2006;Tabert et al. 2006), with just 6 patients of 46 exhibiting episodic 
memory impairment in isolation, and 36 of the remaining 40 displaying evidence of semantic 
memory compromise. This finding may reflect an increased risk of conversion to AD from 
aMCI, although early semantic memory failure is by no means specific to AD (Clague et al. 
2005;Graham et al. 2004), and whilst some studies report prognostic significance of 
performance on semantic memory measures (Artero et al. 2003;Blackwell et al. 
2004;Estevez-Gonzalez et al. 2004), others have failed to do so (Beatty et al, 2002). The 
stage at which impairments in this domain become apparent does appear to vary in 
accordance with the sensitivity of the measure employed (Hodges et al, 2006). The intact 
performance of aMCI subjects on measures of lexical (letter) fluency, also previously 
reported (Alladi et al, 2006;Hodges et al, 2006), would suggest that the ‘initiation’ aspects of 
semantic fluency tasks do not pose any difficulty to aMCI patients. 
 
In view of the sound mean performances of our aMCI subjects on cognitive screening 
measures (MMSE = 28/30; ACE = 89/100) it seems unlikely that consideration of such 
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scores will be of any value in ruling out the presence of additional domains of cognitive 
impairment. Reliance on clinical judgement to determine the presence/absence of additional 
domains of subtly impaired cognition, will similarly likely prove difficult when dealing with 
patients of above average pre-morbid IQ’s who are performing at sound levels on cognitive 
screens.  Taken together, the above observations raise the question of whether global 
screening measures coupled with clinical judgment are a sufficient means of investigating 
MCI, and if not, whether additional resources or an expanded skill base will be required to 
assess this population appropriately. 
 
Our results reveal an absence of any significant difference in performance of aMCI and 
control groups on measures of visuo-spatial function and processing speed. In depth 
longitudinal evaluation of neuropsychological performance in MCI and Questionable 
Dementia (QD) suggests that visuo-spatial functions tend to fail secondarily to episodic 
memory and category fluency performances (Hodges et al, 2006;Perry and Hodges, 2000), 
although some heterogeneity is known to exist (Caine and Hodges, 2001). It is therefore 
once again possible that our failure to demonstrate group differences on a visuo-spatial 
copying task reflects an earlier disease stage of our aMCI sample. Alternatively, it is 
conceivable that varied and somewhat subjective scoring methodology for the Rey Complex 
figure copy task across different studies may be responsible for this finding. 
 
Cross-sectional findings pertaining to visuomotor processing speed in MCI vary, with some 
studies reporting significant differences between MCI and control groups (Arnaiz et al. 
2000;Grundman et al. 2004;Nordlund et al. 2005) and others, as ourselves, failing to do so 
(Albert et al. 2001;Crowell et al. 2002;Fox et al. 1998). The disparity in findings may simply 
reflect the heterogeneity of aMCI or alternatively disease stage. Group differences in 
processing speed might be more likely to exist where MCI samples contain significant 
numbers of patients in the pre-clinical stages of a subcortical dementia of a cerebrovascular 
nature. For example, there is some evidence to suggest a disproportionately strong 
association between perceptual speed and parkinsonian signs in MCI (Boyle et al, 2005). 
 
It is noted that our aMCI sample was characterised by a high-average level of estimated pre-
morbid general intellectual function, which of course introduces problems of generalising 
these findings other aMCI samples.  Similar issues were present in a recent comparable study 
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(Alladi et al, 2006), although other socio-demographic characteristics (i.e. gender, ethnicity, 
education and occupation) were not reported, preventing further comparison between this 
and our study.  There may therefore be a need to replicate these findings employing greater 
numbers of age and IQ matched healthy controls and aMCI patients with pre-morbid levels 
of intelligence together with other socio-demographic markers more closely resembling the 
general population mean. 
 
3.2.6 Conclusion 
In summary, MCI patients make up a significant number of referrals to ours and other older 
adult memory assessment services, with the most common MCI referral subtype in our 
sample being that of aMCI, followed by equal numbers of non-amnestic MCI and ‘worried 
well’. Relatively few aMCI patients exhibit episodic memory compromise in isolation and 
fewer still show a visual but not verbal episodic memory deficit. Both the concept and 
criteria for MCI therefore appear to be a relevant and indeed a necessary adjunct to clinical 
practice.  
 
The current findings highlight the inherent difficulties of specifying a single measure in the 
assessment of memory and other cognitive functions in MCI, whilst at the same time 
emphasising the need for clarification of the means by which MCI criteria can be put into 
operation clinically. 
 
Initial attempts at better defining neuropsychological aspects of the aMCI criteria have been 
made (Grundman et al. 2004), however their application in a clinical sense remains 
inconsistent and their poor definition has not gone unnoticed (Portet et al, 2006). The 
existence of a number of neuropsychological measures of well documented sensitivity in 
aMCI and the strikingly similar mean performances of different clinic aMCI groups on such 
measures would suggest this need not be the case. Although the importance of exercising 
clinical judgment in arriving at a diagnosis of MCI cannot be ignored, it would nonetheless 
seem inevitable that further definition of the neuropsychological aspects of MCI criteria will 
be needed to facilitate identification of the MCI subtypes and to further our understanding of 
their respective prognoses. 
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4. Sensitivity and Specificity of Neuropsychological 
Measures to aMCI (Parts 4.1 – 4.5) 
 
4.1 Cognitive screening in aMCI: A comparison of the ACE 
and MMSE. 




Patients with mild cognitive impairment account for a significant number of referrals to old 
age psychiatry services and specialist memory clinics. The cognitive evaluation of such 
patients is commonly restricted to brief dementia screens, with no consideration to their 
suitability for assessing MCI. 
Aims 
To compare the abilities of two common screening instruments, the ACE and the MMSE, to 
detect MCI and early AD, and differentiate these conditions from cognitive changes that 
arise within the context of normal aging and depressive symptoms.  
Method 
The discriminative capacity of MMSE and ACE scores for 46 participants with MCI, 20 
elderly out-patients with depressive symptoms, 20 early AD patients and 24 healthy age 
matched controls was determined by way of group mean comparisons and Regional 
Operating Characteristics (ROC) analyses. Healthy and depressive elderly control 
participants were examined seperately allowing us to test the robustness of previous findings 
purporting the ACE’s specificity against depression. Where significant group differences 
existed on both screening measures, AUC, sensitivity, specificity, negative and positive 
predictive values were compared. 
Results 
The early AD participant group obtained significantly lower scores on both screening 
measures, in comparison with each of the other groups. MCI participants performed 
significantly less well than healthy age matched controls on the ACE, whereas the MMSE 
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failed to differentiate between these two groups. After adjusting for significant group 
differences in pre-morbid IQ levels, elderly patients with depressive symptoms could not be 
differentiated from the MCI or healthy control groups on the basis of their total scores on 
either screening test.  
Conclusions 
Whilst adequate to detect early AD using the higher cut off point (27/30), the MMSE lacks 
sensitivity to MCI.  Comprehensive cognitive screening measures such as the ACE fare 
better, but still lack sensitivity to mild cognitive changes among the intellectually higher 
functioning elderly.  In screening for early AD, but not MCI, both measures show adequate 
specificity against cognitive difficulties arising within the context of depressive symptoms.  
 
The findings support the use of higher cut off values for the MMSE and ACE in screening 
for early AD whilst underscoring the need for fuller neuropsychological evaluation of 




Cognitive screening measures are widely used in clinical practice to help to determine the 
likely cause of a patient’s cognitive complaints.  To ensure evidence-based practice, it is 
necessary to know the diagnostic accuracy of the screening measure(s) being applied in this 
manner. Amongst the elderly, there are a number of conditions that may give rise to a loss of 
cognitive function.  Of these, Alzheimer’s disease (AD), (in its early and prodromal phases) 
and depression, are among the most common.  Difficulties with differentially diagnosing 
each of these conditions are well established (Lezak 2004;O'Carroll et al. 1994). 
 
Clinician surveys indicate that the Mini Mental State Examination (MMSE; (Folstein et al. 
1975)) is the most commonly used cognitive screening instrument in clinical practice 
(Shulman et al. 2006).  Two cut off values for the MMSE; 24/30 or 27/30 are usually 
applied.  Their application varies in accordance with the educational background of the 
examinee and the relative importance of achieving high levels of sensitivity or specificity to 
dementia. Although the measure’s sensitivity to AD is well established (Petersen et al. 
1994), its ability to differentiate persons with aMCI from the healthy and depressed elderly is 
not.   
 
Significant differences in the MMSE scores of these patient groups have been reported 
inconsistently and where they do exist, would appear to have little clinical meaning, ranging 
in magnitude from a minimum of less than one scale point (Ravaglia et al. 2005), to a 
maximum of just under 2 points (Slavin et al. 2007).  As a majority of MCI patients score 
above the commonly used MMSE cut-offs (i.e. 24/30 and 27/30), there is considerable 
overlap in the scores of patients with MCI and age matched healthy controls.  Recent 
findings suggest that a much higher cut off score that falls within what is typically viewed as 
a normal range i.e. 28/30, is required to achieve an adequate level of sensitivity to combined 
groups of highly educated dementia and MCI sufferers (O'Bryant et al. 2008).   
 
Furthermore, there are a number of studies reporting low sensitivity values to MCI (Callahan 
et al. 2002;Ravaglia et al. 2005;Sager et al. 2006) as well as to the mild cognitive deficits 
that are known to accompany late life onset depression (Rajji et al. 2009).  These findings 
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raise questions as to the appropriateness of screening with the MMSE where cognitive 
disturbances are mild. 
 
In recognition of the important role of neuropsychological evaluation in facilitating early and 
differential dementia diagnoses, Mathuranath et al (Mathuranath et al. 2000) developed the 
Addenbookes Cognitive Examination (ACE).  The ACE is a more comprehensive bedside 
cognitive screening measure, which incorporates all items of the MMSE together with items 
from several other well-established neuropsychological tests, with the effect of sampling a 
wide range of cognitive abilities. As with the MMSE, the ACE is relatively straightforward 
to administer requiring around 15 minutes. 
 
The ACE  has become an increasingly popular cognitive assessment tool in both clinical 
(Alladi et al. 2006;Bak et al. 2005;Dudas et al. 2005a) and research practice (Clague et al. 
2005;Dudas et al. 2005b) within the UK. It appears to be sensitive to a relatively broad range 
of dementia presentations (Davies, 2007; Bak 2005, Mathuranath 2000) and the findings of 
several recent studies, among the author’s own research group, suggest it may also be 
sensitive to cognitive deficits in MCI (Ahmed et al. 2008b;Alladi et al. 2006;Dudas et al. 
2005a;Lonie et al. 2008).   
 
In an initial validation study comprising 115 patients with dementia and 124 age and 
education matched controls, a cut off score of 83/100 on the ACE showed higher sensitivity, 
specificity and positive predictive power for dementia than the MMSE alone, at cut offs of 
24/30 and 27/30 (Mathuranath et al. 2000).  Another study has documented the test’s 
specificity against major depression (Dudas et al. 2005a).  
 
Sensitivity of the ACE to MCI and its specificity against affective disorders has not been 
replicated outside the author’s (Mathuranath et al. 2000) research group.  Furthermore, the 
mean age of the dementia and control groups was notably young in the initial validation 
study (i.e. 66.6 (8.9) for the dementia group, and 64.4(9.3) for the controls) as well as in the 
subsequent study examining specificity against affective disorders (AD group mean age = 68 
years; NC = 64 years; Affective = 54.4 years).  This raises the question of whether the 
findings from these studies are applicable to the ‘older’ old (i.e. 75 years and older), who 
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represent a far greater proportion of dementia sufferers and patients presenting to outpatient 
memory clinics.   
 
In this study we therefore sought to compare the abilities of the MMSE and ACE to 
differentiate between groups of MCI, healthy and depressed elderly and early AD sufferers.  
We further sought to determine the discriminatory capacity of each screening measure at 
different cut off points, within a sample of elderly who more closely resemble the average 
age of persons attending geriatric outpatient clinics with cognitive complaints. On the basis 
of existing findings we predicted that the ACE, but not the MMSE, would be sensitive to 
MCI whilst retaining specificity against the cognitive effects of depressive symptoms within 
our comparatively ‘older’ participant sample. 
 
4.1.3 Method 
Groups of aMCI (n=46), Early AD (n=20), elderly patients with depressive symptoms 
(n=20) and healthy elderly control participants (n=24) completed measures of FSIQ (NART) 
and general cognitive ability (MMSE & ACE). The measures comprised part of a larger 
battery of neuropsychological tests administered at the initial baseline assessment of a 5 year 
longitudinal study on MCI.  All participants therefore met inclusion and exclusion criterion 
for their respective groups, as specified in Chapter 2, Materials and Methods ,Table 2.2 
Details of the method of subject recruitment together with psychometric and administrative 
characteristics of the neuropsychological measures employed can also be found within 
Chapter 2, Materials and Methods, sections 2.1 and 2.2.   
 
4.1.3.1 Statistical Analyses 
Group differences in NART FSIQ, age, MMSE and ACE were analysed using the Kruskal-
Wallis Test as assumptions of normality and homogeneity of variance were not universally 
met (specifically the distribution of age scores for the early AD participants, FSIQ scores for 
the MCI group, and  MMSE scores for the control, depression & MCI groups were 
abnormal).  Furthermore, variances in FSIQ, ACE and MMSE scores across groups were 
non-homogenous. Where significant group differences were found, post hoc contrasts were 
carried out using the Mann-Whitney test with Bonferroni adjustment set at 0.05 / number of 
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contrasts performed i.e. (p < 0.008).  Group differences in gender proportions were examined 
using the Chi-squared test.  
 
The comparison of MMSE and ACE group means was repeated using a multivariate 
ANCOVA with NART FSIQ as a covariate, given the significantly lower mean FSIQ score 
of the AD group relative to both MCI (p = 0.007) and CT (p = 0.002) groups (see table 4.1.4, 
means (SD) of clinical and demographic data).  The ANCOVA was followed up with pair 
wise comparisons using the Bonferroni method of correction for multiple comparisons. The 
ANCOVA and Kruskal-Wallis methods of analyses were inspected for consistency.  
 
Where significant between group differences were present on both screening instruments, 
sensitivity and specificity values were generated using ROC analysis allowing for 
comparison of the discriminative utility of each screening test. 
4.1.4 Results 
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ACE, Addenbrookes Cognitive Examination; AD, Alzheimer’s Disease, aMCI, amnestic Mild 
Cognitive Impairment; M, male; F, female; NART, national adult reading test; MMSE, mini mental 
state exam; * group differences were no longer significant following adjustment for pre-morbid IQ 
estimate (ANCOVA) 
 
From table 4.1.4 it is apparent that the AD group performed significantly less well than all 
other groups on both screening measures (AD vs. MCI, ACE; U=85.0, r= -0.64, MMSE; 
U=106.5, r= -0.62; AD vs. C, ACE; U=5.5, r= -0.83, MMSE; U=34.5, r= -0.75; AD vs. D, 
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ACE; U=41.0, r= -0.68, MMSE; U=44.0, r= -0.68), where r represents the approximate 
effect size using the equation r = Z/square root N (Field 2005).  Furthermore, the mean total 
ACE score for the MCI participant group was significantly lower than that of the normal 
elderly control group (U=253.0, r= -0.44), whereas mean total MMSE scores for these 
groups did not differ (U=416.5, r=-0.21).  
 
The covariate NART FSIQ was significantly related to ACE and MMSE scores 
[F(1,103)=15.19, p <0.05, r=0.35; F(1,106=7.72, p<0.05, r=0.26]. The effect of participant 
group on total ACE and MMSE scores was also significant after controlling for NART FSIQ 
[F(3,106) = 29.39, p < 0.05; F(3,106) = 26.12, p < 0.05].  Pair wise comparisons revealed 
that group differences in mean total ACE scores for the Control and Depression participants 
(i.e. Depression < CT) no longer reached significance once the effects of FSIQ were 
controlled for  t(41) = 2.46, p = >0. 5.  Findings across the two methods of analysis did not 
otherwise differ.  
 
Figure 4.1  ROC curves comparing the abilities of the ACE and MMSE to 
discriminate MCI and AD participants from controls and each other.  
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Figure 4.1 shows mean total scores on both the ACE and MMSE discriminate the early AD 
patients from all other participant groups with similar levels of accuracy and demonstrates 
that the ACE has greater combined sensitivity and specificity in distinguishing healthy 
elderly from MCI participants than the MMSE, for which discriminative capacity fails to 
reach significance. 
Table 4.2  Positive and Negative Predictive Values for differing ACE and MMSE 
cut off points as a function of participant group  
 
ACE, Addenbrookes Cognitive Examination; AD, Alzheimer’s Disease; MCI, Mild Cognitive 




Screening Measure / 
cut off point 
 
Predictive value 












MMSE 24/30 100 77.78 100 49.44 
MMSE 27/30 85 57.14 82.35 56.16 
ACE 83/100 78.26 88.65 50 48.75 
ACE 88/100 66.67 94.59 70.97 59.32 
1 - Specificity 
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Table 4.3  Validity of cognitive screening measures in differentiating AD and 
MCI from the healthy and depressive elderly at two commonly applied cut off 
points 
Group Comparison Screening 
measure 
Cut-off Sensitivity % Specificity % AUC Sig  















































































































ACE, Addenbrookes Cognitive Examination; AD, Alzheimer’s Disease; AUC, Area Under Curve; D, 
Depression; C, Control; MCI, amnestic Mild Cognitive Impairment; MMSE, mini mental state exam; 








Figure 4.2  Total score on the ACE as a function of participant group 
 
 
Figure 4.3  Total score on the MMSE as a function of participant group 
 
 
Table 4.3 displays the sensitivity, specificity and areas under the curve (AUCs) relating to 
the two most commonly applied cut off values for each screening measures.  An increase in 
sensitivity and loss of specificity is universally observed in conjunction with the use of the 
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Total score on the MMSE 
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higher cut off values (with the exception of the MMSE where cut off scores of both 24/30 
and 27/30 retain 100% specificity in differentiating AD and MCI from healthy controls in 
our sample).  Satisfactory (i.e. >80%) sensitivity and specificity combinations are observed 
for the differentiation of 1) early AD patients from elderly with depressive symptoms using 
the higher MMSE cut off of 27/30; 2) early AD patients from healthy controls using the 
higher cut off point for the MMSE 27/30 or the ACE 88/100; and 3) early AD patients and 
MCI participants using the higher cut off point for the MMSE 27/30.  The sensitivity of both 
the MMSE and the ACE (at high and low cut off points) to MCI is low, at the expense of 
high specificity against normal aging.  The highest overall discriminative value (AUC = 
0.99) relates to the ability of the ACE to differentiate between early AD patients and the 
healthy elderly.  Good levels of overall discrimination in differentiating AD from elderly 
patients with depression and those with MCI (AUC = 0.89; 0.88 respectively) are also seen 
in association with this screening measure. 
 
As expected, the highest negative (NPV) and positive predictive values (PPV) were observed 
for the classification of AD patients amongst combined depressive and normal elderly 
controls, where PPV represents the percentage of participants scoring below a designated 
level with a diagnosis of AD and NPV represents the percentage of participants scoring 
above this level without an AD diagnosis.  More specifically, the highest PPV was observed 
in association with the lower boundary MMSE cut off score of 24/30, where 100% of 
persons performing below this level had a diagnosis of early AD.  NPV’s were highest for 
the higher cut off value of the ACE, where 94% of persons scoring above this level were 
either normal elderly or depressive elderly control participants as opposed to early AD 
patients.  
 
In relation to the classification of MCI participants amongst normal and depressive elderly 
controls, PPV’s were highest for the MMSE where 82% of persons obtaining a score of less 
than 27/30 and 100% of those scoring less than 24/30 met criteria for MCI.  NPV’s were 
universally low (i.e. <60%). 
 
Figures 4.2-4.3 illustrate the limited overlap in total ACE and MMSE scores obtained 
amongst the early AD and healthy elderly control participants.  By contrast, a considerable 
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Our findings indicate that both the MMSE and the ACE differentiate early AD patients from 
elderly patients with depressive symptoms, healthy elderly controls and patients with MCI, 
with a similar degree of overall accuracy.  Similar levels of sensitivity and specificity to 
dementia have been reported previously for both the MMSE (at a cut off of < or = 24/30, 
sensitivities = 0.52, 0.49, 0.52 and specificities =100, 0.96, at a cut off of < or = 27/30, 
sensitivities = 0.8, 0.83, 0.74 and specificities =100, 0.72, 0.96) and the ACE (at a cut off of 
< or = 83/100, sensitivities =0.75, 0.87, 0.82 and specificities =100, 0.71, 0.96) at a cut off of 
< or = 88/100, sensitivities = 0.90, 0.98, 0.93, 0.93 and specificities = 0.96, 0.59, 0.71, 0.82 
(Bier et al. 2004;Bier et al. 2005;Dudas et al. 2005a;Mathuranath et al. 2000). 
 
One exception is noted.  Specificity levels are greater in ours and the study by Mathuranath 
et al., (Mathuranath et al. 2000) in comparison to Bier et al., (Bier et al. 2004;Bier et al. 
2005).  This is likely to reflect the greater heterogeneity and overall pathological loading of 
Bier et al’s control group (which is reported to include patients with MCI, vascular lesions, 
progressive isolated memory impairment, mood disorders as well as cognitive impairments 
as a result of toxic exposure).  It is not clear whether this control group was matched to that 
of the dementia group for age, education or pre-morbid IQ, which further complicates cross 
study comparison of findings.  Finally the mean age of the control group is somewhat lower 
than that of our own (i.e. 67.3 years compared to 72.4 years) in this study.   
 
The MMSE was associated with higher positive predictive values for dementia and MCI than 
the ACE.  This finding contrasts that of Mathuranath at el (Mathuranath et al. 2000) who 
report ‘similar specificities to dementia but poorer sensitivity and predictive values for the 
MMSE.  Close inspection of the table of  PPVs, however, suggests that at higher i.e. 40% 
base rates, (which represent levels likely encountered within specialist memory clinic 
settings such as our own), there is little difference in the PPV of these instruments with the 
exception of a lower PPV in association with the higher cut off point for the ACE. The latter 
observations are in keeping with our own findings, and the lower PPV values reported 
overall in our own study likely reflect the higher general level of cognitive functioning of our 
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dementia group (i.e. ACE 76/100 as compared to 64/100), and/or the inclusion of a wider 
range of dementia diagnoses in the Mathuranath study.  
 
Our findings together with previous results (Mathuranath et al. 2000) suggest that clinicians 
can be confident that where MMSE scores fall below 24/30 among those with above average 
pre-morbid intellect, cognitive impairment is likely to represent an Alzheimer or other 
dementia process as opposed to cognitive changes that relate to mild-moderate depressive 
symptoms or the normal aging process (PPV at a base rate of 40% range from 0.89 – 100%). 
Conversely, in accordance with the present findings, a score of above 88/100 on the more 
comprehensive ACE, equally likely signifies the absence of a clinically diagnosable AD 
process (PPV = 0.95).  
 
Although the ACE shows greater sensitivity to MCI than the MMSE, overall sensitivity 
levels were low in the present study.  Previous research examining the discriminatory 
abilities of the more recent version of this test (ACE-R) also reports significant differences in 
mean group performances of the MCI participants (n=23) relative to the Control and AD 
groups (n=23 for both).  However, sensitivity and specificity values were not reported in 
association with these findings (Mioshi et al. 2006) and the authors acknowledge ‘it is not 
clear whether these findings would apply equally to an older patient group’. 
 
Together with the low NPV for the MMSE and ACE at both higher and lower cut off values, 
the low sensitivity values reported in the present study suggest that a large proportion of 
elderly patients who report cognitive complaints yet score above ACE and MMSE cut off 
points will demonstrate evidence of cognitive compromise relative to their age/IQ 
contemporaries on formal measures of their neuropsychological functioning.  Indeed, our 
findings would suggest that around half of all elderly patients who fulfil Petersen’s criteria 
for MCI (Petersen et al. 1999) may fall into this category.  These patients are therefore likely 
to be diagnosed as worried well or cognitively normal where screening instruments are used 
as the sole means of investigating their cognitive complaints.  
 
Unlike Dudas et al (Dudas et al. 2005a) who reported a significantly lower mean total ACE 
score for a group of 60 elderly patients with affective disorders relative to 127 elderly 
controls, no differences in the total mean ACE scores of elderly patients with depressive 
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symptoms and healthy controls were found following adjustment for FSIQ in the present 
study.  Whilst the mean scores on the ACE were similar across the two studies (i.e. Affective 
/ depression groups = 89/100 / 89.5/100; Control groups = 93.9/100 / 94.5/100) the mean 
ages of both participant groups in Dudas et al., (Dudas et al. 2005a) study were notably 
younger than in our study (i.e. Affective/depression groups = 54.4 years/ 74 years; Control 
groups = 64.4 years / 71 years) and it is not clear that the significant differences in the ages 
of the affective and control groups were accounted for. Furthermore, the authors comment 
that the absolute difference in the mean ACE scores for the affective and control groups was 
very small (i.e. 89 + -8.2 vs. 93.9 + -3.5, respectively).  It is therefore possible that the 
inclusion of NART FSIQ as a co-variate (in our own analysis), together with the smaller 
number of participants used, resulted in a loss of power.  As close to half of the patients 
included in the affective group of the Dudas et al., (Clague et al. 2005) study, as well as our 
own, met criteria for major depression, our negative findings do not appear to be accountable 
for, in terms of variability, in levels of depressive symptoms across studies.  
 
4.1.6 Conclusion 
Overall scores on both the ACE and MMSE discriminate patients with AD from normal 
elderly controls, MCI patients and elderly patients with depressive symptoms with little 
difference in rates of overall accuracy. The MMSE is insensitive to Mild Cognitive 
Impairment amongst the elderly with high average pre-morbid ability.  Even with the use of 
more comprehensive bedside cognitive screening instruments such as the ACE, our ability to 
detect cognitive impairments that do not amount to a frank dementia remains unacceptably 
low, implying that large numbers of elderly patients presenting with memory complaints 
who are cognitively evaluated in this manner may be mistakenly categorised as ‘worried 
well’ or ‘normal for age’. The ACE and MMSE appear to be relatively specific against the 
known cognitive effects of depressive symptoms, although this finding would benefit from 
replication in a larger group of patients with moderate to severe levels of depressive 
symptoms matched for age and pre-morbid IQ. 
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4.2 A comparison of free and cued episodic memory 





Neuropsychological assessment, in particular evaluation of episodic memory, is one of the 
most sensitive means of detecting cognitive impairment and identifying individuals in the 
early and pre-clinical stages of Alzheimer’s disease.  Despite this, there is little information 
to guide the selection of memory paradigms in the assessment of these conditions with tasks 
usually chosen independently of knowledge of the neuropathogenisis and cognitive 
neuropsychology of AD.   
Aims 
To compare the abilities of cued and free recall episodic memory measures to discriminate 
between MCI and early AD patients and the healthy or depressive elderly. It was 
hypothesized that 1) a computerised cued recall measure of cross modal associative learning 
would better discriminate between the above patient groups than more traditional paper and 
pencil memory tasks 2) free recall tasks would be more sensitive to memory failure in AD 
and MCI than cued recall paradigms and 3) cued recall measures would show greater 
specificity against depression and normal aging than measures of free recall ability. 
Method 
The discriminative capacities of 2 cued (1 verbal and 1 visual) and 4 free recall measures (3 
verbal and 1 visual) for groups of 46 participants with MCI and 20 with early AD relative to 
a combined control group comprising 20 elderly out patients with depressive symptoms, and 
24 healthy age matched elderly, were determined by way of group mean comparisons. As the 
focus here was on the practical application and selection of memory measures in the clinical 
detection and differential diagnosis of AD and aMCI, as opposed to exploring the specific 
cognitive effects of depressive symptoms on memory function, the healthy and depressive 
elderly control groups were combined for the present analysis.  Where significant group 
differences were found, AUC, sensitivity and specificity values were computed by way of 
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The early AD and MCI participants performed more poorly than the combined control group 
on all episodic memory measures other than PAL, where the difference in error rates 
between the control and MCI groups just failed to reach significance (p=0.051).  
 
The discriminative capacities of each of the six memory measures in differentiating early AD 
patients from the combined control groups were consistently high, ranging from a minimum 
of AUC 0.904 for HVLT-R delay to a maximum of 0.943 for PAL.  AUC’s were moderate 
for the MCI vs. control comparisons (AUC 0.6 PAL – 0.7 ACE and HVLT-R delay).   
 
Each of the 6 memory measures was highly sensitive to AD and highly specific against 
normal aging and depressive symptoms.  None of the 6 memory measures was associated 
with high levels of sensitivity and specificity in discriminating MCI from the combined 
control groups. 
 
When either specificity or sensitivity was pre-set at the level of 0.80, free recall measures 
provided a marginally better balance of these two indices than cued recall measures, in 
differentiating both MCI and AD from the combined control groups. 
 
Conclusions 
Both cued and free recall memory paradigms differentiate early AD from normal aging and 
cognitive difficulties associated with depressive symptoms with high levels of sensitivity and 
specificity.  At a designated minimum ‘acceptable’ level of sensitivity (i.e. 0.8), cued recall 
measures were not associated with higher levels of specificity in discriminating early AD or 
MCI participants from controls. None of the memory measures were adequately sensitive 
and specific to MCI, although free recall measures showed the best combination of these 
properties.  These findings support the use of free recall as opposed to cued recall measures 
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in the early differential diagnoses of AD and MCI whilst highlighting the limitations of 
existing memory measures in differentially diagnosing MCI.  
 
4.2.2 Introduction  
Episodic memory impairment is the hallmark of aMCI, pre-clinical and early AD.  The 
importance of diagnosing AD accurately, at an early stage, is widely recognised and among 
other advantages facilitates patient access to treatment and appropriate forms of support.  
Neuropsychological assessment, in particular evaluation of episodic memory, is one of the 
most sensitive means of detecting cognitive impairment and identifying individuals in the 
early and pre-clinical stages of Alzheimer’s disease (Lowndes and Savage 2007).  
Consequently, memory assessment in the early and differential diagnosis of AD has formed 
the focus of a large number of research studies (Ahmed et al. 2008b;Clague et al. 
2005;Fowler et al. 1995;Fowler et al. 1997;Fowler et al. 2002;Graham et al. 2004;Greene et 
al. 1996;Lee et al. 2003;Scahill et al. 2005;Swainson et al. 2001).  
 
Episodic memory tasks vary on a number of levels such as, the nature of the material to be 
learned i.e. verbal, visual or spatial (or any combination of these), the type of learning 
required i.e. associative (i.e. the pairing or linking of information) or non-associative (i.e. 
single word list learning), and the extent to which recall is supported or cued i.e. recognition 
or free recall.  There is evidence to suggest that variability in these aspects of memory tasks 
can influence the diagnostic performances of episodic memory measures (Lowndes and 
Savage 2007;Pike and Savage 2008). 
 
The sensitivity of delayed free recall paradigms to aMCI (Alladi et al. 2006;Lonie et al. 
2008), pre-clinical (Collie and Maruff 2000;Grober and Kawas 1997) and early stage AD 
(Bondi et al. 2008) is well established, and a majority of studies investigating the 
longitudinal course of aMCI have employed one or more delayed free recall paradigm as the 
primary measure of episodic memory function.  Furthermore, among patients fulfilling 
Petersen’s criteria for aMCI (Petersen et al. 1999), effect sizes, where these are reported, are 
generally largest for measures of free relative to cued recall (or other non-memory tasks) 
(Alladi et al. 2006;Backman et al. 2005;Lonie et al. 2008).  Other studies have likewise 
reported greater sensitivity of free relative to cued recall memory paradigms in association 
with early AD (O'Connell et al. 2004) and pre-clinical AD sufferers (Fowler et al. 1995).  
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Whilst sensitive to early memory failures of a pathological basis, free recall measures lack 
specificity against depression (Lichtenberg et al. 1995;Zakzanis et al. 1998), and other non-
AD forms of dementia (De Jager et al. 2003). 
  
Dierckx et al (Dierckx and Engelborghs 2007) therefore proposed the use of a delayed cued 
recall measure in differentiating between early AD, MCI and elderly controls with and 
without depression. The underlying assumption was that by minimising reliance on the 
executive aspects of memory performance, greater specificity to AD, and MCI, as it 
represents pre-clinical AD, could be achieved.  Using this approach and applying a cut of 
value of 8 / 12 for the combined total number of words and object location pairings recalled 
following a delay and with cueing, high levels of sensitivity to AD (83%) and specificity 
against depression (85%) were achieved. Sensitivity to MCI was, however, considerably 
lower (53%), and the authors attributed this to the heterogeneous nature of the MCI 
participant group, only a portion of whom would likely progress to AD over time.  
 
Whilst several additional studies have reported favourable performances of cued recall 
measures in discriminating between groups of depressive, MCI, NC and early AD patients 
(Bennett et al. 2006;Ritter et al. 2006;Swainson et al. 2001) others have reported insufficient 
sensitivity of cued recall measures to MCI and pre-clinical AD, relative to healthy age 
controls (Arnaiz et al. 2000;Crowell et al. 2002;Dudas et al. 2005b;Godbolt et al. 
2005;Hudon et al. 2006;Westerberg et al. 2006).  
 
Attention has also been drawn to the importance of incorporating knowledge of the 
neuropathogenesis of AD into the selection of memory paradigms for its early stage 
assessment (Fowler et al. 1995;Lowndes and Savage 2007;Pike and Savage 2008).  It has 
been proposed that the cross modal (i.e. pairing of visual and spatial information) associative 
learning requirements of the PAL from the CANTAB battery closely reflect the role of 
medial temporal lobe structures, where new information is bound together in order to encode 
the complex relational structure of personal experiences (Fowler et al. 1997;Swainson et al. 
2001).  For this reason, the PAL subtest from the CANTAB battery, which requires pairing 
of visual and spatial information, is thought to represent a valuable paradigm for the 
assessment of episodic memory function in early AD.  
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The sensitivity of PAL to memory failure in early AD is well established (Fowler et al. 
1995;Lee et al. 2003;Swainson et al. 2001), although there is little information regarding it’s 
differential diagnostic performance in relation to other, more traditional paper and pencil 
delayed free recall measures (O'Connell et al. 2004). 100% specificity values were reported 
for a small sample of 34 AD and 16 healthy age matched controls (O'Connell et al. 2004). 
High specificity values have also been reported in relation to a sample of depressed elderly 
(Swainson et al. 2001) and patients with diagnoses of frontal and semantic variant FTLDs 
(Lee et al. 2003). Several studies have also reported higher numbers of errors made across 
the learning trails of PAL in association with MCI (Ahmed et al. 2008b;Alladi et al. 
2006;Collie et al. 2001;Egerhazi et al. 2007;Lonie et al. 2008;Petersen et al. 1999) although 
the predictive validity of this heightened error count remains controversial (Ahmed et al. 
2008b;Blackwell et al. 2004;Fowler et al. 2002).  The specificity of PAL against depression 
has not been replicated outside the author’s research group.   
 
Memory assessment is a key component in the diagnosis of early AD and MCI, where 
performance on bedside cognitive assessment can remain inside normal limits. There is 
considerable scope for variation in the application of memory tasks within this context, 
which has the potential to affect the diagnostic contribution of cognitive assessment to the 
early and differential diagnosis of AD and MCI.  In clinical practice, the key challenge lies 
in differentiating memory complaints arising in the context of a depressive illness or as part 
of the normal aging process, from those that represent a prelude to dementia. By contrast, 
relatively little importance is attached to detailed investigation of memory impairment 
accompanying symptoms of depression in the elderly.  As such, comparative performances 
of combined groups of healthy and depressive elderly, with MCI and early AD patients are 
of primary importance in a clinical sense. 
 
 In this study we therefore sought to determine 1) whether sufficient levels of sensitivity to 
MCI and AD could be retained alongside improved specificity against normal aging and 
depression with the use of cued as opposed to free recall paradigms to assess episodic 
memory function. We further sought to 2) compare the diagnostic performance of the PAL to 
that of the more traditional non-computerised and non-associative episodic memory tasks in 




Groups of healthy elderly (n=24), depressive elderly (n=20), early AD (n=20) & MCI 
participants ( n=46) were administered several measures of episodic memory function 
including The Hopkins Verbal Learning Test - Revised, The Rey Complex Figure Test, The 
Paired Associated learning subtest from the CANTAB and the delayed recall component of 
the name and address task from the Addenbrookes Cognitive Examination (ACE) together 
with a measure of pre-morbid IQ (NART) and two cognitive screening measures (MMSE & 
ACE).  These measures were administered as part of a wider neuropsychological test battery.   
Details of the method of subject recruitment, participant characteristics together with 
psychometric and administrative characteristics of the cognitive screening measures 
employed can also be found within Chapter 2, Materials and Methods, sections 2.1 and 2.  
4.2.4 Statistical Analysis 
Differences in gender proportions between participant groups were examined using the chi-
square test.  Differences in the mean age of the participant groups were analysed using One-
way Anova. Visual inspection of the data together with Kolmogorow-Smirnov tests revealed 
that the distributions of NART estimated FSIQ scores for the combined (healthy and 
depressive) control groups and MCI participants were not normal.  Group differences in 
NART FSIQ scores were therefore examined using non-parametric methods i.e. the Kruskal-
Wallis test followed by Mann Whitney post hoc comparisons comparing NART estimated 
FSIQ scores of the MCI and early AD groups with that of the combined depressive and 
healthy elderly control groups with Bonferroni level of correction set at p<0.025 accounting 
for the two comparisons. 
 
As the NART estimated FSIQ score was significantly lower for the early AD group relative 
to the combined controls, an ANCOVA was carried out with NART FSIQ as covariate to 
examine group differences in scores on each of the 6 memory measures.  Group comparisons 
in performance on the 6 memory measures were repeated using the Kruskal-Wallis test 
followed by Mann-Whitney post hoc comparisons (with the Bonferroni level of correction 
set at p<0.004) as assumptions of normality and homogeneity of variance were not 




Although the NART estimated mean FSIQ scores of the MCI and combined control groups 
were not significantly different, assumptions of normality and homogeneity of variance were 
not universally met. The Kruskal-Wallis test was therefore carried out to test for group 
differences in scores on each of the 6 memory measures.  This was followed up with group 
comparisons using the Mann-Whitney procedure (with the Bonferroni level of correction set 
at p<0.004) as described above.  
ROC analyses were carried out for both group comparisons (i.e. AD vs. Dep + CT & MCI 
vs. Dep + CT) and all memory measures. Sensitivity values were set at 0.8 and 
corresponding specificity and cut off values were reported for each of the memory measures 
and both group comparisons.  With specificity values set at 0.8, corresponding sensitivity 
and cut off values were reported for the two group comparisons on all memory measures. 
 
Table 4.4  Episodic memory and demographic data for Early AD, MCI and 
combined healthy and depressive controls  
 Early AD 
(n=16-20) 





 Mean(SD) Median(range) Mean(SD) Median(range) Mean(SD) Median(range) 
 Sig of F-value Sig of U-value Sig of F-value Sig of U-value   
NART 
FSIQ 112.20 (1.57) 110 (99-124) ** 116.78 (1.13) 120.00(92-126) 117.56 (0.08) 118 (100-126) 
Age 
(years) 75.30 (1.46) 78.00 (64-86) 73.89 (0.95) 74.50 (58-85) 72.25 (1.12) 72.00 (59-85) 
Gender 




39.69 (2.79)*** 42.50(13-50)*** 17.04 (2.10) 14.50 (0-49) 11.77(1.61) 9.00 (0-50) 
HVLT 
DI 4.63 (0.68)*** 5.00 (-2-11)*** 8.33 (0.38)** 8.00 (1-12)*** 9.61(0.31) 10.00 (3-12) 
HVLT 
Total 12.79 (1.16)*** 14.00 (4-22)*** 19.11(0.72)** 19.00 (10-31)** 22.05 (0.90) 21.50 (9-34) 
HVLT 
Delay 1.42 (0.64)*** 0.00 (0-10)*** 4.71(0.50)*** 5.00 (0-11)*** 7.39 (0.46) 8.00 (0-12) 
RCFT-
Delay 2.65 (0.85)*** 0.00(0-14)*** 11.55 (1.03)** 11.50 (0-28)** 15.84 (1.05) 16.00 (0-31) 
ACE-
Delay 1.35 (0.45)*** 0.00(0-7)*** 4.30 (0.32)** 5.00 (0-7)*** 5.75 (0.26) 6.00 (0-7) 
Significance of difference in mean score relative to combined control mean - * p<0.05; **p<0.01; 
***p<0.001; FSIQ = Full Scale Intelligence Quotient; M=male; F=female, PAL=Paired Associate 
Learning Test; HVLT = Hopkins Verbal Learning Test - Revised; DI=Discrimination Index; 
Total=total number of words recalled across the three learning trials; Delay=total number of words 




Table 4.5  Sensitivity and specificity values with corresponding cut off values 




Sens > or = 0.8 (cut off 
score) 
Spec Spec > or = 0.8 (cut off 
score) 
Sens 
Cued Recall Measures     
PAL 
AD vs. CTs   (0.94) 














AD vs. CTs   (0.92) 













Free Recall Measures     
HVLT-R delay  
AD vs. CTs   (0.90) 














AD vs. CTs   (0.94) 














AD vs. CTs  (0.92) 













HVLT-R total  
AD vs. CTs  (0.88) 













Spec = the highest value associated with a sensitivity value of 0.8 or above; Sens = the highest value 
associated with a specificity value of 0.8 or above 
 
There was no significant association between participant group and gender, chi-squared (2) = 
2.07, p>0.05. The mean ages of the participant groups did not differ, F(2, 107)=1.51, P>0.05. 
NART estimated FSIQ scores for the MCI and combined control groups did not differ (U= 
924.5, ns, two tailed, r=-0.04) whereas the NART estimated FSIQ score for the AD group 




ANOVA findings revealed that the mean performance of the combined control group was 
significantly higher than that of MCI participants on all memory measures (HVLT-R DI, 
F(1, 87) = 6.92, p=0.01, r=0.27; HVLT-R delay, F(1,87) = 15.61, p=0.00, r=0.39; HVLT-R 
total, F(1,87) = 6.56, p=0.01, r=0.26; RCFT delay, F(1,86)=8.53, p=0.004, r=0.30; ACE 
delay, F(1,88)=12.38, p=0.001, r=0.35 other than the PAL, F(1, 87) = 3.903, p=0.051, 
r=0.21), where differences in group means just failed to reach significance.  
 
These findings were replicated using non-parametric group comparison methods (HVLT-R 
DI, U=683.00, p=0.000, one tailed , r=-0.27, HVLT-R delay, U=549.50, p=0.000, r=-0.38, 
HVLT-R total, U=667.50, p=0.004, r=-0.28 ;RCFT delay, U=633.00, p=0.002, r=-0.30, ACE 
delay, U=593.50, p=0.000, r=-0.36; PAL, U=787.00, p=0.052, r=-0.18. 
 
ANVOCA revealed that the covariate FSIQ, was significantly related to performance on the 
delayed recall component of the ACE F(1, 54)=13.12, p=0.001; the total number of words 
recalled across the three learning trial of the HVLT-R F(1,54)=5.286, p=0.025 and the 
number of words from the HVLT-R recalled following a delay F(1,54)=6.03, p=0.017 but 
none of the remaining memory measures (p>0.05 in all cases). After controlling for group 
differences in FSIQ, the mean performances of the early AD group were significantly lower 
than that of the control group on all 6 of the memory measures (HVLT-R DI control 
mean(SD)=9.54(0.38), AD mean(SD)=4.56(0.65), [F(1, 54) = 41.52, p = 0.000, r=0.66; 
HVLT-R delayed recall control mean(SD)=7.19(0.46),  AD mean(SD)=2.21(0.80), 
[F(1,54)=27.34, p=0.000, r=0.58;HVLT-R total recall control mean(SD)=21.88(0.87), AD 
mean(SD)=14.67(1.45), [F(1,54)=16.45, p=0.000, r=0.48; ACE delayed recall control 
mean(SD)=5.55(0.26), AD mean(SD)=1.98(0.46), [F(1,54)=43.53, p=0.000, r=0.66; PAL 6 
box error score control mean(SD) 11.93(1.71), AD mean(SD)=38.60(2.96), [F(1,54)=57.89, 
p=0.000, r=0.72; Rey Figure delayed recall control mean(SD)=15.74(0.98), AD 
mean(SD)=4.05(1.70), [F(1,54)=33.63, p=0.000, r=0.62. 
 
These findings were replicated using non-parametric group comparison methods with the 
following results: HVLT-R DI control median (range)=10.00(3-12), AD median (range) =5(-
2 -  -11),  U=69.50, p=0.000, r=-0.66; HVLT-R delayed recall control median(range) 
=8.00(0-12) , AD median(range) =0.00(0-10), U=80.00, p=0.000, r=-0.64; HVLT-R total 
recall control median(range) =21.50(9-24), AD median(range) =14(4-22), U=100.00, 
 115 
p=0.000, r=-0.60; ACE delayed recall control median(range)=6.00(0-7), AD 
median(range)=0.00(0-7), U=67.00, p=0.000, r=-0.69; PAL 6 box error score control 
median(range)=9.00(0-50), AD median(range)=42.50(13-50), U=39.50, p=0.000, r=-0.68; 
Rey Figure delayed recall control median(range)=16.00(0-31), AD median(range)=0.00(0-
14), U=53.00, p=0.000, r=-0.70. 
 
AUC’s were universally high for the AD vs. combined control group comparison: HVLT DI 
= 0.92, HVLT delayed recall = 0.90, HVLT total recall across learning trials = 0.88, ACE 
delayed recall = 0.92, PAL 6 box error = 0.94 and Rey delayed recall = 0.94 and moderate 
for the MCI vs. combined control group comparison (see Table 4.5); 0.64, 0.71, 0.66, 0.72, 
0.60, 0.67 respectively. 
 
At a pre-set specificity level of 0.8, the sensitivities of cued and free recall measures to AD 
ranged from 0.73 for the HVLT total recall across the learning trials to 0.94 for the total 
number of errors made at the 6 box level of PAL.  The sensitivities of the free recall tasks to 
MCI were a little higher than that of the cued recall measures, but remained low (see Table 
4.5).  At a pre-set sensitivity level of 0.8, the specificity values associated with the free recall 
measures for both group comparisons were consistently a little higher than those associated 
with cued recall measures, but remained low for the MCI comparison. 
 
Percentage’s of MCI, healthy and depressive elderly participants with overlapping scores 
ranged between 0% for the PAL 6 box error and ACE delayed recall scores to a maximum of 
4.5% for the total number of words recalled across the three learning trials of the HVLT-R. 
The percentage of early AD, CT and Depressive participants with overlapping scores on the 
memory measures were as follows: HVLT-DI=19.04%, HVLT delayed recall=7.94%, HVLT 
total recall across three learning trials=33.33%, PAL 6 box errors=41.67%, ACE delayed 
recall=0%, Rey complex figure test delayed recall=39.06%.  Dot plots of individual 
participant data points on each of the episodic memory measures are included in section 8.3 
of the Appendix. 
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4.2.6 Discussion  
There are a number of levels on which episodic memory paradigms can vary.  Their 
application to the assessment of early and pre-clinical AD is, however, frequently undertaken 
without knowledge or consideration of how this may influence the diagnostic performance of 
the memory test.  In this study we have compared the discriminative abilities of 6 well 
known episodic memory measures among groups of early AD, MCI, healthy and depressive 
elderly with a view to 1) testing the robustness of previous findings of superior diagnostic 
capacity of PAL over more traditional paper and pencil episodic memory tasks 2) 
demonstrating superior sensitivity of free as opposed to cued recall tasks to memory 
impairment in MCI and AD and 3) demonstrating superior specificity of cued (as compared 
to free) recall measures against normal aging and depressive symptoms among the elderly. 
 
From the AUC’s reported in the first column of Table 4.5, it is apparent that each of the 6 
memory measures discriminated early AD patients from healthy and depressive elderly 
controls with high levels of overall accuracy.  Whilst the PAL and the delayed recall 
component of the RCFT were associated with the highest levels of diagnostic accuracy 
(94%), several other of the more traditional paper and pencil style episodic memory tasks, 
including the HVLT-R, and the delayed recall component from the ACE, achieved similar 
levels of overall diagnostic accuracy.  
 
In recognition of the necessity to achieve high levels of both sensitivity and specificity in 
clinical practice, these parameters were consecutively pre-set to a minimum of 80% and the 
resulting highest combinations of the two were determined for each memory measure.  At a 
pre-set minimum specificity value of 80%, the PAL was the most sensitive of the episodic 
memory measures to early AD, and was also associated with the largest percentage (i.e. 
41%) of non-overlapping scores across early AD, normal and depressive elderly participant 
groups.  On closer examination of individual scores, (see figure 8.1 Appendix C) it is 
apparent that only 2 of the 16 early AD patients obtained error scores of less than 34 at the 6 
box level, the removal of which would result in a considerably higher percentage, (i.e. 94 %) 
non-overlapping participant scores.  The latter is similar to the non-overlapping score 
percentage of 93% reported by Swainson et al. (Swainson et al. 2001) in a slightly larger 
sample of 26 mild AD patients. 
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However, the PAL lacked sensitivity to MCI with the difference in the mean number of 
errors made at the 6 box level failing to distinguish these participants from a combined group 
of depressive and healthy elderly controls.  As a result, the overall diagnostic accuracy of the 
PAL was lower than for measures of delayed free recall.  Swainson et al.(Swainson et al. 
2001) similarly failed to differentiate between groups of Questionable Dementia sufferers 
and combined healthy and depressive elderly control groups using the PAL and Fowler et al. 
(Fowler et al. 1995) reported no difference in the PAL performance of QD participants and 
healthy elderly controls at their initial presentation, although differences in performance 
emerged with time and all of the QD went on to receive a clinical diagnosis of AD.   
 
By contrast, other authors have reported impaired performance on this measure in 
association with MCI as defined by Petersen (Ahmed et al. 2008b;Alladi et al. 2006;Lonie et 
al. 2008).  It is possible that these seemingly contradictory findings are attributable to the use 
of healthy age matched comparison groups as opposed to mixed depressive and healthy 
control groups and/or the heterogeneous nature of MCI itself, with scores of future non-
converters counterbalancing those of future dementia converters.  For these reasons it will be 
of interest to determine the discriminative capacity of the PAL once our MCI participants 
have been sub grouped in accordance with their long term diagnostic outcome. 
 
Whilst we failed to find evidence for greater overall diagnostic accuracy of free recall 
measures in differentially diagnosing early AD, the AUC’s of the two delayed verbal free 
recall measures were highest in differentiating MCI from the combined controls.  
Furthermore, although none of the memory measures yielded adequately high i.e. >80% 
combinations of both sensitivity and specificity to MCI relative to the combined depressive 
and healthy elderly control groups, the sensitivities of the free recall measures were higher 
than those of the cued recall memory measures (at pre-set minimum 80% specificity levels).  
This was also reflected in the highest AUC values observed for the delayed recall 
components of the HVLT-R and the ACE. A similar pattern of findings for specificity values 
were observed when sensitivity levels were pre-set at a minimum of 80%.  Together these 
findings support the use of free recall measures in the assessment of MCI and imply they can 
be applied without risk of loss of specificity.  More importantly, clinicians should be aware 
of the trade off between achieving high levels of sensitivity to memory impairment in MCI 
and specificity against normal aging and depression when assessing these patient groups. 
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Thus, the free recall measures employed within the present study appear equally as specific 
as cued recall measures in the differential diagnosis of early AD.  Some gain in sensitivity is 
seen using free recall memory measures in assessing MCI and this finding is in keeping with 
the larger effect sizes that have been reported in association with measures of free, relative to 
cued recall in MCI samples (Alladi et al. 2006;Lonie et al. 2008).  However no single 
memory measure provides acceptable combined levels of sensitivity and specificity and 
sensitivity levels remain universally low at acceptable (i.e. 80% or above) levels of 
specificity.  
 
In this study, patients who fulfilled Petersen’s (Petersen et al. 1999) MCI criteria performed 
significantly less well than a group of combined depressive and healthy elderly controls on a 
cued measure of delayed verbal recognition but not on a cued measure of visuo-spatial 
learning ability.  The differences in findings across the two measures are conceivably 
accountable for by other (non-cued vs. free recall) levels of task variability such as the length 
of delay or the potential for interference from other tasks, and it is likely that these factors, 
together with variability in the general level of cognitive functioning and pathological make-
up of MCI samples account for some of the cross study inconsistency in reports of 
performance of MCI subjects on cued recall measures. 
 
With sensitivity levels pre-set at a minimum of 80%, there was no evidence for superior 
specificity of cued, over free recall tasks among the selected 6 memory measures. As noted 
above, however, the least degree of overlap in scores was observed for the PAL of the 
CANTAB battery in differentiating AD from combined controls, and this may be attributable 
to any number of factors including the associative, cross modal or cued aspects of the task. 
These findings have relevance for clinical practice where cut off points are routinely used to 
classify patients on an individual basis and imply that sound levels of specificity are 
attainable in relation to mild-moderate levels of depressive symptoms among the elderly in 
assessing for AD and MCI using free recall memory tasks.  
 
4.2.7 Conclusion  
To summarise, both cued and free recall memory paradigms differentiate early AD from 
normal aging and cognitive difficulties associated with depressive symptoms with high 
levels of sensitivity and specificity.  Whilst the PAL was the most sensitive of the 6 episodic 
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memory measures to AD, and was associated with the least degree of overlapping scores, 
several other more traditional paper and pencil measures achieved similar levels of overall 
diagnostic accuracy in classifying early AD patients, normal and depressive elderly. At a 
designated ‘acceptable’ minimum level of sensitivity (i.e. 0.8), the cued recall measures 
employed in the present study were not associated with higher levels of specificity in 
discriminating early AD or MCI participants from depressive and healthy elderly controls. 
None of the memory measures were adequately sensitive and specific to MCI, although free 
recall measures showed the best combination of these properties.  These findings support the 
use of free recall measures in the early differential diagnoses of AD and MCI and imply that 
the use of the PAL subtest from the CANTAB battery may be of particular value in 
safeguarding against false positive early AD diagnoses. The results also highlight the 
limitations of existing episodic memory measures in differentially diagnosing MCI.  
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4.3 A comparison of object and face naming tasks in the 





Although memory impairment is the defining characteristic of aMCI, there is evidence to 
suggest that impairments are also present in other cognitive domains and that these may be 
of importance in reaching an early diagnosis of AD.  Impairments of naming ability are 
frequently reported in association with aMCI, and are also known to co-exist with episodic 
memory impairment in the very early stages of AD.  Object naming ability has traditionally 
been assessed within English speaking cultures using one of two well-established 
neuropsychological measures i.e. the Boston Naming Test (BNT) or the Graded Naming 
Test (GNT).  It is unclear whether or not these measures perform comparably in a 
differential diagnostic sense. Furthermore some recent findings suggest that tests of person 
specific knowledge may be more sensitive to early semantic memory impairment in pre-
clinical and early AD than these more commonly applied object naming tasks. 
Aims 
In this study we investigate the relative diagnostic accuracy of 3 naming tasks (2 object and 
1 famous face) in classifying groups of early AD, aMCI, and combined healthy and 
depressive elderly controls. A decision to combine the healthy and depressive elderly control 
groups was made in accordance with the primary focus of the present study, in comparing 1) 
the sensitivities of face and object naming tasks to early AD pathology and 2) the abilities of 
the two most commonly used object naming tasks to differentatie between word finding 
difficulties due to early AD pathology as opposed to other conditions commonly encountered 
in clinical practice (i.e. normal aging and depression).  We sought to test the robustness of 
recent findings of superior and differential sensitivity of face as compared to object naming 
tasks to aMCI and early AD, as well as to establish the specificity of famous face naming 
against healthy and depressive elderly controls. We further sought to compare the 
performances of two well-established object naming tasks (BNT & GNT) in differentiating 
patients with early AD and MCI from the healthy and depressive elderly.  
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Methods 
The discriminative capacities of 3 naming tasks (2 object and 1 famous face) for groups of 
46 participants with MCI and 20 with early AD, relative to a combined control group 
comprising 20 elderly out patients with depressive symptoms, and 24 healthy age matched 
elderly, were determined by way of group mean comparisons. Where significant group 
differences were present, AUC, sensitivity and specificity values were computed by way of 
ROC analyses to facilitate comparison of their diagnostic utilities.  An object vs. face 
naming difference score was derived for each participant by subtracting the percentage of 
famous faces correctly named on the GFT from the average percentage of objects correctly 
named on the BNT and GNT. Group differences in the magnitude of mean object-face 
naming discrepancy scores were analysed to determine the specificity of a GFT < GNT 
pattern of performance to AD and MCI participant groups.  
Results 
The early AD participant group performed significantly less well than the combined control 
group on all three naming measures. The GFNT was the only measure of the three that 
discriminated MCI participants from a combined healthy and depressive elderly control 
group. The largest AUC’s were reported in association with the GFNT (AD vs. CT= 0.93; 
MCI vs. CT=0.66).  Whilst the magnitude of GNT-GFT difference scores did not differ 
significantly across the three participant groups, as a combined group, AD and MCI 
participants performed proportionately worse on the GFT relative to the GNT, than the 
combined (i.e. depressive and healthy) controls. 
Conclusion 
The GFNT appears to be a particularly sensitive measure of naming ability in the early 
stages of AD and in patients who fulfil Petersen’s criteria for MCI.  Preliminary findings 
further suggest that poor performance on this measure is relatively specific against the 
cognitive effects of normal ageing and depressive symptoms.  The GFNT may therefore be 
more suited for use in the early differential diagnosis of AD than traditional object naming 
tasks (which show similar and comparatively lesser levels of discriminative capacity).  The 
level of impairment on famous face naming task, in relation to object naming ability, was 
greater for combined groups of MCI and early AD patients than for healthy and depressive 
elderly controls, providing some tentative evidence for a selective vulnerability of face over 
object naming in AD. Further longitudinal analysis will allow for determination of the 





Although memory impairment is the defining characteristic of aMCI, there is evidence to 
suggest that impairments are also present in non-memory domains (Alladi et al. 
2006;Kramer et al. 2006;Lonie et al. 2008;Lonie et al. 2009b;Lonie et al. 2009a) and that 
these may be of importance in reaching an early diagnosis of AD.  Naming difficulty 
(anomia) is one of the most commonly reported cognitive complaints of a non-amnestic 
nature in early AD and aMCI.  Naming impairments have traditionally been documented 
clinically via performance on object naming tasks such as the Graded Naming Test (GNT; 
(McKenna and Warrington 1980;Warrington 1997) and the Boston Naming Test (BNT; 
(Kaplan et al. 1983).  
 
In AD, impairment on naming measures is attributed to deficient activation at the conceptual 
level of the semantic lexicon (conceptual-semantic) or at the final stages of name retrieval 
(lexical-semantic) or indeed both (Ahmed et al. 2008a;Grabowski 2008).  The 
neuroanatomical underpinnings of object and face naming, as determined by imaging 
studies, are known to overlap with the spread of pathology from the medial to the more 
lateral aspects of the temporal lobe that characterises the neocortical stage of AD (Braak and 
Braak 1991), thus providing a sound theoretical underpinning to naming impairments in 
early and pre-clinical AD (Grabowski 2008). Alternatively, if episodic and semantic memory 
were both equally dependent on the integrity of the medial temporal lobe structures, as 
proposed by Squire (Squire 1992), then pathology in this region alone could conceivably 
give rise to semantic memory impairments in early and pre-clinical AD. 
 
Not surprisingly then (if we are to assume that at least a proportion of those with aMCI will 
progress to AD) object naming impairments have also been reported in association with 
aMCI (Ahmed et al. 2008a;Alladi et al. 2006;Dudas et al. 2005b;Loewenstein et al. 
2006a;Lonie et al. 2008;Thompson et al. 2002).  More recently, however, the focus has 
shifted toward naming tasks comprising unique entities, such as famous faces, buildings or 
events, where each item is associated with a single representation within the semantic 
memory system and where attributes of that single representation are arbitrary (Ahmed et al. 
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2008a;Clague et al. 2005;Dudas et al. 2005b;Estevez-Gonzalez et al. 2004;Joubert et al. 
2008;Vogel et al. 2005).   
 
There is some preliminary evidence to suggest that naming tasks of this nature are 
differentially impaired in aMCI (Ahmed et al. 2008a;Clague et al. 2005;Joubert et al. 2008) 
and early AD (Thompson et al. 2002).  The greater sensitivity of face over object naming 
tasks has been attributed to the differing manner in which faces and objects are represented 
within the semantic memory system (Ahmed et al. 2008a;Grabowski 2008;Joubert et al. 
2008), (as noted above, in the case of faces, representations are singular and attributes are 
arbitrary) or alternatively to the existence of a unique neuroanatomical network dealing 
specifically with knowledge of faces (Estevez-Gonzalez et al. 2004).  Recent findings of a 
differential impairment of famous building and events knowledge in MCI would, however, 
argue against the latter explanation (Ahmed et al. 2008a;Joubert et al. 2008). 
 
It is argued that involvement of areas outwith the medial temporal lobe, in particular the 
temporal neocortex, as proposed by Braak (Braak and Braak 1991),  may be an important 
indicator of likely progression toward AD (Grabowski 2008).  For this reason, naming 
measures may prove useful in helping to differentiate MCI as it represents pre-clinical AD 
from other non-progressive conditions, such as depression, that also give rise to recent 
memory impairment.   
 
There is some preliminary evidence to support this claim, with two studies having reported a 
significantly poorer mean performances in pre-clinical AD sufferers relative to age matched 
controls, on measures of face naming ability (Estevez-Gonzalez et al. 2004;Vogel et al. 
2005).  Thompson et al (Thompson et al. 2002) also reported a NPV of .94 in association 
with the GFNT and positive predictive value of 1 for the GNT in detecting MCI as it 
represents the pre-clinical phase of AD, among a very small group of aMCI patients.  
 
Of note, however, the sensitivity of the GNT to pre-clinical AD was reportedly low (14%) in 
this, as well as other (Fox et al. 1998;Godbolt et al. 2004) studies (Blackwell et al. 2004).  
Albert et al (Albert et al. 2001) similarly failed to find any significant difference in the 
baseline BNT scores of QD patients who went on to develop dementia and those who did not 
and several (De Jager et al. 2003;Loewenstein et al. 2007b;Petersen et al. 1999) but not all 
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studies (Balthazar et al. 2007;Greenaway et al. 2006) have reported significantly lower BNT 
scores in association with MCI relative to age matched controls. 
 
If naming tasks were to be of diagnostic and/or prognostic utility in aMCI, as has been 
suggested, specificity against the normal aging process, as well as a range of non-progressive 
psychiatric and medical conditions would need to be high.  Whilst a differential GFNT 
deficit unique to AD (Clague et al. 2005) and MCI (Ahmed et al. 2008a;Joubert et al. 2008) 
has been reported, poor performance on the GFNT does not appear to be specific to AD, and 
has also been reported in association with other forms of dementia including vascular 
dementia, semantic dementia (Clague et al. 2005), and dementia with lewy bodies (Troster 
2009).  The specificity of face naming tasks against conditions of a non-progressive nature, 
such as depression, has not been examined. In the case of object naming, Swainson et al 
(Swainson et al. 2001) reported no difference in the performances of QD participants and a 
combined depressive and healthy elderly control group on the GNT, although the extent to 
which the QD group comprised patients who were in the pre-clinical phase of AD is unclear. 
 
In this study we investigate the relative diagnostic accuracy of 3 naming tasks (2 object and 
one face) in classifying groups of early AD, MCI, and combined healthy and depressive 
elderly controls. Within a clinical context, neuropsychological performance is used to assist 
in separating out the frequently simultaneously occurring effects of aging and depression on 
cognitive performance, from the early or pre-clinical cognitive manifestations of AD. The 
depressive and healthy elderly control groups, (who are well matched in terms of age, 
general levels of cognitive functioning and NART FSIQ), were therefore combined in an 
attempt to simulate clinical practice and maximise the clinical relevance of the study 
findings.  We sought to test the robustness of recent findings of a differential face naming 
deficit in MCI and early AD as well as to establish the specificity of this measure against 
normal aging and symptoms of depression among the elderly. We further sought to compare 
the performances of two well-established object naming tasks (BNT & GNT) in 
differentiating patients with early AD and MCI from the healthy and depressive elderly. 





Groups of healthy elderly (n=24), depressive elderly (n=20), early AD (n=20) & MCI 
participants ( n=46) were administered three naming measures, the Graded Naming Test 
(GNT), the Boston Naming Test (BNT) and the Graded Faces Naming Test (GFNT), 
together with two measures of global cognitive functioning (MMSE & ACE) and a measure 
of pre-morbid intellectual functioning (NART), as part of a wider neuropsychological test 
battery.   
 
Details of the method of subject recruitment, participant characteristics together with 
psychometric and administrative characteristics of the naming measures employed can be 
found within Chapter 2, Materials and Methods, sections 2.1 and 2.  
 
4.3.3.1 Statistical Analysis 
Differences in gender proportions between participant groups were examined using the chi-
square test.  In view of violations of the assumptions of both normality and homogeneity of 
variance (see below), differences in the mean age and NART FSIQ of the participant groups 
were analysed using the Kruskal-Wallis Test followed by Man-Whitney post hoc 
comparisons with the Bonferroni level of correction set at p<0.05 / the total number of 
comparisons.  
 
Visual inspection of the data together with Kolmogorow-Smirnov tests revealed that the 
distributions of BNT scores for the MCI and combined depressive and healthy control 
groups were not normal.  Distributions were also abnormal for the combined healthy and 
depressive control groups on the GNT and GFT; and for the MCI and combined control 
group FSIQ scores; and the age scores for the early AD participants. Furthermore, 
assumptions of homogeneity of variance were not universally met. 
 
As the NART estimated FSIQ score was significantly lower for the early AD group relative 
to the combined controls, an ANCOVA was carried out with NART FSIQ as a covariate to 
examine group differences in scores on each of the 3 naming measures.   
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As the NART estimated FSIQ scores of the MCI and combined control groups were not 
significantly different, but assumptions of normality and homogeneity of variance were not 
universally met for either of the two group comparisons, the Kruskal-Wallis test was also 
conducted to examine group differences in mean scores on each of the 3 naming measures.  
This was followed up with Mann-Whitney post hoc group comparisons (where the 
Bonferroni level of correction was set at p<0.05 / the total number of comparisons 
(accounting for the 6 comparisons). 
 
ROC analyses were used to compare the diagnostic accuracy of each of the three naming 
measures.  
 
Difference scores were calculated for each participant by subtracting the total number of 
famous faces correctly named on the GFNT from the total number of objects correctly 
named on the GNT.  Visual inspection together with Levene’s and Shapiro-Wilk tests 
revealed that the difference scores for each of the three participant groups were normally 
distributed and variances were homogenous. Mean difference scores for the three participant 
groups were therefore examined using ANCOVA to determine whether the pattern of 
performance on the two types of naming measures differed as a function of participant 
groups. Planned contrasts were also conducted to compare the magnitude of difference in 
GNT and GNFT scores across control and patient groups and across the two (i.e. MCI and 
early AD) patient groups. 
 
4.3.4 Results 
There was no significant association between participant group and gender, Chi-squared(2) = 
2.07, p>0.05.  The mean ages of the participant groups did not differ significantly, (H(2) = 
2.40, p>0.05).  NART FSIQ scores differed significantly as a function of participant group, 
(H(2) = 9.409, p<0.01). NART estimated FSIQ scores for the MCI (median=120) and 
combined healthy and depressive control group (median=118) did not differ significantly 
(U=924.5, ns two-tailed, r=-0.04), whereas the NART estimated FSIQ score of the early AD 
group (median=110.5) was significantly lower than that of the combined control group 
(median=118.00; U=231.00, p<0.01 two-tailed, r=-0.37). 
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The covariate NART FSIQ, was significantly related to naming performance on the BNT 
F(1,54)=16.17, p<0.001, r=0.48; the GNT F(1,54)=16.25, p<0.001, r=0.23 but not the GFT 
F(1,54)=1.271, p>0.05, r=0.15.  There was also a significant effect of participant group on 
naming ability (i.e. AD vs. CTs combined) after controlling for the effect of NART FSIQ; 
BNT F(1,54)=11.226, p<0.01, r=0.41; GNT F(1,54)=14.26, p<0.001, r=0.45; GFT 
F(1,54)=38.65, p<0.001, r=0.64).  
 
Table 4.6  Demographic and neuropsychological data for groups of aMCI, 

























































































GNT - GFNT 2.44 (4.98) 3.70 (5.02) 4.56 (2.68) _ _ 
FSIQ = Nart based Full Scale Intelligence Quotient; MMSE=Mini Mental State Examination; 
ACE=Addenbrookes Cognitive Examination; BNT=Boston Naming Test; GNT=Graded Naming 
Test; GFNT=Graded Faces Naming Test; MCI=Mild Cognitive Impairment; AD=Alzheimer’s 







Figure 4.4  Mean percentages of correctly named items on the object and face 
naming tasks as a function of participant group 
 
These findings were replicated using non-parametric analysis methods with the critical value 
for significance set at p<0.0083 on account of the 6 comparisons that were conducted (see 
below) (GNT, U=96.00, p<0.001, r=-0.58; BNT, U=124.00, p<0.001, r=-0.57; GFNT, 
U=56.50, p<0.001, r=-0.70).   
 
The mean number of faces correctly named by the combined control group was significantly 
higher than for the MCI participant group (U=624.50, p<0.01, r=-0.32).  Group differences 
otherwise failed to reach significance following Bonferroni corrections for multiple 
comparisons (with p <0.0083 set as the critical value for determining significance; BNT, 
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The mean GNT-GFT discrepancy scores for the 3 participant groups did not differ 
significantly F(2,97) = 1.46, p>0.05, r=0.17 however, planned contrasts revealed that the 
magnitude of the GNT-GFT score discrepancy was significantly greater for the combined 
patient (i.e. AD + MCI) than control (i.e. Depressive + Healthy elderly) group, t( 97)=1.70, 
p<0.05, r=0.17. No difference in the magnitude of GNT-GFT discrepancy was observed 
between the early AD and MCI patient groups, t(97)=0.65, p>0.05, r=.0.07  
 
Figure 4.5  ROC curves comparing the classification accuracies of the GNT, 
BNT and GFNT among MCI and combined healthy and depressive elderly 
control participants and early AD and combined control groups. 
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AUC’s for the AD vs. CT comparison were universally high (BNT=0.86; GNT=0.86; 
GFNT=0.93) but poor for the MCI vs. CT comparison (BNT=0.58; GNT=0.62; 
GFNT=0.66).  For both participant group comparisons, the GFNT was associated with the 
highest overall discriminative value.  
 
Figure 4.6  Dot plot of individual participant scores on the GFNT in 
accordance with participant group 
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Figure 4.7  Number of MCI participants performing 1.5 SD below healthy 
elderly control participants on the famous faces naming test 
 
 
Figure 4.8  Number of early AD patients performing 1.5sd below the healthy 




The high (i.e. AUC 0.86 – 0.93) levels of overall diagnostic accuracy reported in this study 





















Levels of diagnostic accuracy for the object naming tasks (AUC=0.86) were comparable to 
those seen in association with verbal learning tasks (i.e. HVLT-R total recall across three 
trials AUC = 0.88), and the choice of object naming task (i.e. BNT vs. GNT) appeared to 
have no effect on overall diagnostic accuracy.  Of greater note, the diagnostic accuracy of the 
famous face naming task was as high as that reported in association with a computerised 
measure of visuospatial associative learning ability (CANTAB PAL), suggesting that face 
naming tasks may be of equal importance as episodic memory measures in the 
neuropsychological evaluation of early AD.   
 
Whilst the findings are in keeping with the broader notion of failure(s) at one or more 
level(s) of the lexico-semantic system representing an early feature of AD, they do not 
address the precise level at which breakdown is occurring, or to what extent that breakdown 
is attributable to underlying temporal neocortical Alzheimer pathology.  It is nonetheless 
conceivable that the very high level of overall diagnostic accuracy observed in association 
with the GFNT is attributable to 1) the specificity of naming tasks to AD (against depression 
and normal ageing) as a proxy for pathological change in temporal neocortex, and/or 2) the 
preferential vulnerability of naming items with single arbitrary representations, within the 
semantic memory system seen in association with this pathological change.   
 
In the present study, object (i.e. GNT) and face naming (i.e. GFNT) tasks were not matched 
for difficulty, and it can be seen (figure 4.4) that each of the three participant groups 
obtained lower mean total scores on the famous face naming as compared to the graded 
naming task.  This finding is in keeping with that of Ahmed  et al (Ahmed et al. 2008a) 
where control patients displayed a similar pattern of performance across naming tasks i.e. 
GNT>GFT to that of MCI participants. Although the relative differences in mean scores on 
the GFT and GFNT (i.e. GNT-GFNT) did not differ significantly between our three 
participant groups, the magnitude of difference (i.e. an advantage of GNT over GFNT) was 
significantly greater for the combined patient (MCI or AD) vs. control groups. A similar 
observation was again made by Ahmed et al (Ahmed et al. 2008a) where differential 
impairment was reportedly significantly greater for the GFT than the GNT among MCI 
participants relative to healthy elderly controls.  Furthermore, with object and famous face 
naming tasks matched for levels of difficulty, Clague et al (Clague et al. 2005) reported 




Taken together, these findings provide some support for the specificity of selective 
vulnerability of famous face naming in AD, suggesting that unique exemplars may indeed be 
significantly more difficult to retrieve than common exemplars as a result of the AD disease 
process.  It should be noted, however, that the GFNT used by Clauge et al (Clague et al. 
2005), appears to differ from that utilised in the present study and that of Ahmed (Ahmed et 
al. 2008a), both of which comprised 30 as opposed to 32 famous faces, complicating study 
comparison. 
  
In the present study the GFNT was the only naming measure to differentiate between MCI 
and control participants.  Calgue et al (Clague et al. 2005) similarly reported a significant 
difference in the mean performances of QD sufferers and healthy elderly controls on the 
GFNT but not the GNT.  In a study by Vogel et al (Vogel et al. 2005) measures of famous 
face naming ability and category fluency, but not of object naming ability, differentiated 22 
pre-dementia AD sufferers from 58 matched controls. Thompson et al  (Thompson et al. 
2002) documented differences in the baseline performances of MCI patients who went on to 
develop dementia relative to those who do not, on the GFNT but not the GNT, whilst others 
have failed to demonstrate group differences in the performance of participants in the pre-
clinical phase of AD and age matched controls on the GNT (Fox et al. 1998;Godbolt et al. 
2004).  Our findings therefore add to a growing evidence base suggesting famous face 
naming measures may be more sensitive than object naming measures to the semantic 
impairment that characterises pre-clinical and early stage AD.   
 
The ability of the naming tasks to differentiate MCI sufferers from elderly control patients in 
the present study, was modest, at best, and although greatest for the famous face naming 
task, high levels (i.e. 96%) of overlapping scores among the MCI and combined control 
groups were apparent on this naming task.  A cut off score of 16/30 correctly classified 
88.6% of controls whilst essentially dividing the MCI participant group in half, with 18/44 
obtaining a score of less than 16/30 and the remaining 27/44 obtaining scores above this 
level.  It is plausible that the lower overall discriminative power of the naming tasks in 
relation to MCI reflects the heterogeneous nature of this participant group, some but not all 
of whom will likely progress towards a clinical diagnosis of dementia over time. 
Longitudinal follow-up of the MCI cohort will enable us to determine the prognostic 
significance of this split.   
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Higher levels of classification accuracy (i.e. 100% CT; 78% MCI) have been reported in 
association with this measure (Ahmed et al. 2008a) although it is noted that the control group 
comprised healthy non-depressed elderly as opposed to the combination of healthy and 
depressive elderly used in the present study.  Furthermore,  the mean general level of 
functioning of the MCI participant group as indicated by the ACE in the latter study (i.e. 
82/100, the suggested lower boundary cut off point for dementia (Mathuranath et al. 2000) 
was, however, somewhat lower than in the present study (89/100).  Together with the 
relatively low mean age (69.5 years) of MCI participants in the study by Ahmed (Ahmed et 
al. 2008a), this raises the possibility that at least some of the participants comprising this 
MCI group were in fact already in the early stages of AD.  Without knowledge of the fate of 
these MCI participants, it is difficult to extrapolate fully, the practical or theoretical meaning 
of the high classification rates reported.  
 
One limitation of the present line of research relates to the culturally bound nature of famous 
face, and to a lesser extent, object naming tasks.  As a result, the application of naming tasks 
within a study context varies widely, with very few studies to date having employed identical 
measures to address a common research question.  Thus whilst there is mounting evidence to 
suggest that famous face naming tasks are an important component of cognitive assessment 
in early AD, it will likely be necessary to replicate existing findings, that relate to a British 
patient population, among a range of additional face and object naming measures of 
relevance to patients with alternative cultural backgrounds.  
 
4.3.6 Conclusion 
Naming tasks appear to be important measures of cognitive function in the early and 
differential diagnosis of AD.   Measures of famous face naming ability are particularly 
sensitive to lexico-semantic deficits in the early stages of AD and in patients who fulfil 
Petersen’s criteria for aMCI.  Preliminary findings further suggest that poor performance on 
this measure is relatively specific against the cognitive effects of normal ageing and 
depressive symptoms.  The GFNT may therefore be more suited for use in the early 
differential diagnosis of AD than traditional object naming tasks (which show similar and 
comparatively lesser levels of discriminative capacity).  The level of impairment on a 
famous face naming task, in relation to object naming ability, was greater for combined 
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groups of MCI and early AD patients than for healthy and depressive elderly controls in the 
present study, providing some evidence for a selective vulnerability of face over object 
naming in AD. Further longitudinal analysis will allow for determination of the relative 
prognostic contributions of these 3 naming measures within our MCI sample. 
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4.4 Fluency discrepancy scores in the early and differential 
diagnosis of MCI and AD 




Episodic memory is compromised in amnestic Mild Cognitive Impairment (aMCI), but 
lesser deficits in other cognitive domains are also commonly observed and may be helpful in 
identifying this group. 
Aims 
The relative difference in performance on lexical and semantic fluency tasks may be a 
sensitive and specific measure in aMCI and early Alzheimer’s disease (AD). 
Method 
We compared four groups of participants, 35 early AD, 47 aMCI, 24 healthy controls, and 18 
depressive out-patient controls, on semantic and lexical fluency as well as other 
neuropsychological tests.  The elderly depressive group was examined independently of the 
healthy elderly control group in view of the discrepant meta-analytic findings for fluency 
performance patterns among patients with depression. 
Results 
Early AD and aMCI patients showed a distinct pattern of semantic impairment in the two 
fluency measures compared with the healthy and depressive controls. 
Conclusion 
The findings implicate early failure of the semantic memory system in aMCI and AD and 
suggest that consideration of the discrepancy in performance on semantic and lexical fluency 




A recent meta-analysis demonstrated that Alzheimer’s disease (AD) patients are significantly 
more impaired on measures of semantic than lexical fluency (Henry et al. 2004). Semantic 
memory impairment in AD is specific in that it is not associated with more generalised 
deficits in verbal intelligence or psychomotor speed. This pattern of impairment in verbal 
fluency measures is qualitatively distinct from the usual finding of superior semantic fluency 
in healthy controls (Spreen and Strauss 1998). As the category task is thought to rely more 
heavily on access to representations of semantic concepts than the letter task, the pattern of 
findings in AD is presumed to reflect degradation in the structure, content, or activation of 
the semantic memory system (Auriacombe et al. 2006;Jefferies and Lambon Ralph 
2006;Jones et al. 2006). 
 
Patients in the preclinical stages of AD exhibit a semantic fluency deficit, at a time when 
lexical fluency performance remains intact (Auriacombe et al. 2006;Beatty et al. 
2002;Swainson et al. 2001). Similarly, patients who fulfil criteria for amnestic mild cognitive 
impairment (aMCI; (Grundman et al. 2004;Petersen et al. 1999) generate fewer words from a 
specified category than do age-matched controls. In contrast, they perform at normal levels 
on lexical fluency tasks (Alladi et al. 2006;Dudas et al. 2005b;Lonie et al. 2008;Murphy et 
al. 2006). 
 
A pattern of worse semantic than lexical fluency has also been reported in patients with 
depression (Christensen et al. 1997;Zakzanis et al. 1998), although a more recent review 
suggests equal impairment of performance across the two fluency tasks that is thought to 
reflect a generalised reduction in processing speed (Henry and Crawford 2005). 
 
If semantic and lexical fluency discrepancy (FD) scores are abnormal in some patients with 
aMCI, their magnitude and direction may prove helpful in diagnosis or prognosis. As an 
individually calibrated marker of performance, the direction of the discrepancy would have 
the advantage of being free from the need for age, gender, education, or IQ-dependent cut-
off values, which require a sizable normative comparison group. 
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Furthermore, if depressive symptoms were associated with equivalent reductions in lexical 
and semantic task performance (as the processing speed account would predict), then FD 
scores might also be of value in distinguishing between depressive and early Alzheimer 
related cognitive impairment. To our knowledge, no study has examined semantic and 
phonemic fluency in aMCI compared with healthy controls, early AD patients and patients 
with depressive symptoms. 
 
Here, we aimed to (1) replicate the finding that patients with aMCI demonstrate a pattern of 
fluency performance similar to that observed in patients with early AD and (2) to investigate 
whether their FD performance is abnormal when compared to healthy controls and out-
patients with depressive symptoms. 
 
4.4.3 Method 
4.4.3.1 Patient groups 
We examined 47 patients with aMCI, 18 out-patients with depressive symptoms, 24 healthy 
control patients, and 35 patients with mild AD. The 47 aMCI patients were recruited over a 
3-year period (September 2003–September 2006) from tertiary referrals to our 
neuropsychological assessment service and met criteria for aMCI (Petersen et al. 1999). All 
aMCI patients underwent comprehensive neuropsychological and psychiatric evaluation, 
medical screening (including blood screen) as well as neuroimaging (CT and/or MRI or 
SPECT). Thirty-five patients with a NINCDS/ADRDA diagnosis (McKhann et al. 1984) of 
probable AD were identified as part of a clinical audit of service referral numbers and 
diagnoses. All early AD patients scored 17/30 or above on the mini mental state examination 
(MMSE; (Folstein et al. 1975) and 58/100 or above on the more comprehensive 
Addenbrookes Cognitive Examination (ACE; (Mathuranath et al. 2000) indicating a 
relatively mild disease severity. As healthy controls we recruited 24 spouses or carers of 
patients who had attended the neuropsychological assessment service. Participants with 
potentially confounding co-morbid medical, psychiatric, or neurological conditions (i.e. 




In an attempt to ensure a control group of similar illness severity and general level of 
functioning to the aMCI patients, we recruited 18 out-patients with depressive symptoms 
from hospital out-patient clinics and day hospitals, who were receiving the same level of out-
patient care as our aMCI group. All participants in this group presented with depressive 
symptoms, thought not to be primarily organic in nature, yet known to have effects on 
cognitive functioning both during illness and after recovery (Herrmann et al. 2007). We 
considered matching of illness severity to be important, as in clinical practice the 
differentiation of severe depression and early dementia states is less problematic than 
separating the sequelae of the milder forms of these disorders. Furthermore, fluency 
measures have been shown to be sensitive to even mild depressive symptoms (Ravdin et al. 
2003). We included patients with a variety of disorders, as the type of depression does not 
appear to influence the magnitude of cognitive deficit (Christensen et al. 1997). Patients with 
any co-morbid medical, neurological, or psychiatric condition with the potential to affect 
cognitive function were excluded. The mean geriatric depression scale score (Yesavage et al. 
1983) for this group was 14.3 (SD = 7.79) indicating mild, yet clinically significant levels of 
depressive symptoms. 
 
4.4.3.2 Neuropsychological measures 
Details of the method of subject recruitment, participant characteristics together with 
psychometric and administrative characteristics of the neuropsychological  measures 
employed can also be found within Chapter 2, Materials and Methods, sections 2.1 and 2.  
 
4.4.3.2.1 Verbal fluency 
All patients were given two versions of the verbal fluency task. In the lexical version, 
patients were asked to generate as many words as possible within 1 minute beginning with 
the letter ‘P’. The letter ‘P’ was chosen in place of the more widely known ‘F’, ‘A’, ‘S’ as it 
forms part of the ACE (Mathuranath et al. 2000). In the second task, patients were asked to 
provide as many animal names as possible in 1 minute, as a subtest of the ACE. Patients’ 
scores were z-transformed using control means and standard deviations to be able to 
compare lexical and semantic task performance. 
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4.4.3.2.2 Episodic memory 
All groups were administered the Hopkins verbal learning test – revised (HVLT-R; (Brandt 
1991) where measures of interest included; the total number of words recalled across three 
registration trials (max 36); total number of words recalled following a 30-minute delay 
(max 12); and a discrimination index score representing a participant’s ability to discriminate 
between old and new list items (max 12) and the Paired Associate Learning (PAL) subtest 
from the Cambridge automated neuropsychological test assessment battery (CANTAB; 
(Swainson et al. 2001). The score of interest for the latter measure was the number of 
pattern-position errors made at the six-pattern level.  
 
Healthy and depressed control participants, as well as aMCI and a subgroup of early AD 
patients also completed the Rey Complex Figure Test (RCFT; copy, immediate and delayed 
recall trials; (Rey 1941). The measure of interest for this analysis was the 30-minute delayed 
recall condition. 
 
4.4.3.2.3 Attention and executive function 
All participant groups completed the trail making tests, Parts A and B (TMT A and B; 
(Reitan 1985). TMT A serves as a measure of psychomotor processing speed, while TMT B 
also adds a divided attention component. By subtracting the time to completion for TMT A 
of this test from TMT B, a measure of the ‘executive’ functioning component can be 
acquired independently of processing speed. 
 
4.4.3.3 Statistical Analyses 
Data was analysed using SPSS 14.0 for Windows.  Z-scores were calculated for lexical and 
semantic fluency measures. A FD score was calculated for each participant by subtracting 
lexical fluency (P words) z-score from semantic fluency (animal words) z-score. 
Demographic variables and cognitive performance were examined using one-way group 
wise ANOVAs. As the group sizes were not equal, Tukey pair wise comparisons were 
carried out on all significant analyses when the assumption of homogeneity of variance was 
met, and Games–Howell pair wise comparisons were carried out when this assumption was 
violated. Reaction time data (e.g. TMT A and B) was log transformed prior to analysis in 




4.4.4.1 Participant characteristics 
Demographic characteristics are presented in Table 4.7. Groups did not differ in terms of age 
[F (3, 120) = 1.7; p =.17] or predicted pre-morbid IQ [F (3, 105) = 2.2; p = .10]. The 
estimated pre-morbid level of general intellectual functioning fell within a high average 
range for all four groups. There was a significant gender imbalance (F > M) in the depressive 
symptom group only (x2 = 5.6; p = .02; in all other cases p > .05). Patients with early stage 
AD performed at a lower level than all other groups on cognitive screening measures 
(MMSE: [F (3, 120) = 30.6; p < .0001]; ACE: [F (3, 120) = 30.6; p < .0001]); in all cases p < 
.0001. Total ACE scores of the aMCI group fell between that of the controls and early AD 
(MCI vs. C: p < .0001; MCI vs. AD: p < .0001) and was significantly different from both of 
these groups. By contrast, mean MMSE scores for control and aMCI groups did not differ. 
Mean total scores on both cognitive screening measures (MMSE and ACE) failed to 
discriminate the depressive control group from aMCI or healthy control participants. 
 
Table 4.7  Means (SD) of clinical and demographic data 
Variable Controls 
(C; N = 
24) 
Depressed 






(AD; N = 
35) 
Statistic Post hoc group 
differences  
(Tukey; Games-
Howell) p < .05 




F(3, 120) = 1.7; 
p = .17 
 
Gender 9 M: 15 F 4 M: 14 F* 18 M: 29 
F 
17 M: 18 
F 
Chi-square = 










F(3, 105) = 2.1; 
p = .10 
 




F(3, 120) = 30.6; 
p < .0001 
C,D,MCI > AD 




F(3, 120) = 64.5; 
p < .0001 
C > MCI; C, D, MCI 
> AD 
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; M, male; F, female; NART 
FSIQ, National Adult Reading Test Full Scale IQ; MMSE, mini mental state exam; ACE, 
Addenbrookes cognitive examination
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In keeping with proposed aMCI criteria (Petersen et al. 1999) patients with aMCI performed 
more than one standard deviation below age means on at least two formal measures of 
episodic verbal and visual memory, such as the HVLT total and delayed recall, the PAL task 
from the CANTAB, and the RCFT delayed recall. 
 
4.4.4.2 Fluency performances according to patient group 
4.4.4.2.1 Semantic fluency 
Mean scores and standard deviations for semantic fluency, lexical fluency, and 
semantic/lexical discrepancy are presented for each of the four patient groups in Table 4.8. 
As predicted, the mean semantic fluency score for the early AD group was significantly 
lower than all other patient groups (in all cases p < .0001). The aMCI patient group also 
generated significantly fewer animal names than did healthy controls ( p < .0001). The mean 
number of animals generated by both the aMCI and depressed groups fell between that of 
early AD and control participants and was significantly different from both of these groups 
(MCI vs. C: p < .0001; MCI vs. AD: p < .0001; D vs. C: p = .04; D vs. AD: p < .0001). 
4.4.4.2.2 Lexical fluency 
Lexical fluency scores were higher for the aMCI and healthy control groups than for the 
early AD patients (C vs. AD: p = .02; MCI vs. AD: p = .002). No other group differences in 
lexical fluency performance were observed. 
4.4.4.2.3 Fluency discrepancy scores 
The mean FD scores for aMCI and early AD patients were significantly higher than those of 
healthy control (MCI vs. C: p < .0001; AD vs. C: p < .0001) and depressed control groups 
(MCI vs. D: p = .01; AD vs. D: p = .001), but did not differ significantly from each other 
(MCI vs. AD: p = .72) (see Table 4.8). The negative mean discrepancy scores of the aMCI 
and early AD groups indicate that, on average, these patients generated fewer animals than 
‘P’ words within the 1-minute time frame. The opposite pattern (animals > P words) was 
observed for the healthy controls and the depressive control group, indicated by a positive 
mean score. Mean FD scores did not differ between the two control groups (C vs. D: p = 
.27). To assess the usefulness of FD scores in classifying patients in comparison to a more 
commonly used word list learning task, receiver operating characteristic (ROC) curves were 
constructed (Figures 4.10 – 4.12). Figures 4.10 and 4.11 demonstrate that the FD index has 
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greater sensitivity and specificity in distinguishing healthy and depressed control participants 
from those with aMCI, whereas delayed verbal recall ability retains superiority in the early 
AD versus healthy control comparison (Figure 4.12). The area under the curve for each of 
the three comparisons is as follows: C versus MCI: 0.84 (FD) and 0.78 (HVLT-delay); D 
versus MCI: 0.75 (FD) and 0.71 (HVLT-delay); C versus AD: 0.85 (FD) and 0.94 (HVLT-
delay). 
Table 4.8  Means (and SDs) for verbal fluency and other relevant measures of 
episodic memory, processing speed and executive function 
Variable  Controls 
(N = 24) 
Depressed 
(N = 18) 
aMCI 
(N = 47) 
Early AD 
(N = 35)* 























F(3, 120) = 
30.1; 
p < .0001 















F(3, 120) = 
5.2; 
p <=.002 
C, MCI > AD 
Fluency 
discrepancy 
z score 0.00 (0.86) -0.42 (0.69) -1.07(0.67) -1.24 
(0.79) 
F(3, 120) = 
17.1; 
p < .0001 





8.1 (2.7) 7.4 (3.6) 4.8 (3.3) 1.4 (2.8) F(3, 103) = 
19.8; 
p < .0001 
C, D > MCI, AD 
RCFT delay Raw 
score 
16.9 (6.8) 15.3 (6.4) 11.4 (6.9) 2.4 (3.9) F(3, 96) = 
16.3; 
p <.0001 
C, D, MCI > 
AD; C > MCI 




7.9 (6.7) 11.3 (7.6) 17.1 (14.5) 40.8 
(11.1) 
F(3, 109) = 
38.9; 
p < .0001 
AD > C, D,MCI; 
MCI > C 
TMT A+ (s) Raw 
score 
40.2 (10.5) 53.3 (22.6) 45.1 (18.9) 59.0 
(22.2) 
F(3, 104) = 
4.2; 
p = .007 
AD > C, MCI 
TMT B+ (s) Raw 
score 
88.7 (30.7) 140.2 (53.7) 117.1(66.1) 183.3 
(96.4) 
F(3, 106) = 
8.9; 
p < .0001 
AD > C, MCI; 
D > C 




48.5 (24.6) 86.9 (49.1) 72.0 (60.4) 92.0 
(56.8) 
F(3, 99) = 
2.8; 
p = .046 
 
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; HVLT-R delay, Hopkins verbal 
learning test-revised delayed recall; RCFT delay, Rey complex figure test delayed recall; PAL 6 box 
error, total number of errors made at the 6 pattern stage of the paired associated learning subtest from 
the CANTAB visual memory battery; TMT, trail making test; *AD group sample size varies by 
analysis; + Log transformed in order to increase normality of data set 
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4.4.4.3 Episodic memory 
By definition, the aMCI group performed at significantly lower levels than healthy controls 
on a number of verbal and visual episodic memory measures: HVLT total and delayed recall 
scores (total score [means (SD) for controls/patients]: 23.4 (5.1)/19.3 (4.6); t(2; 67) = 3.4, p 
= .01 and delayed recall: 8.1 (2.7)/4.8 (3.3); t(2, 67) = 4.2, p < :001); the PAL task from the 
CANTAB (7.9 (6.7)/17.1 (14.5); t(2, 68) = -3.7, p < .001); and the RCF delayed recall (16.8 
(6.8)/11.4 (6.9); t(2, 66) = 3.1, p = .003). 
 
Figure 4.9  Means and distribution of the differences (animals minus P-word) 




Figure 4.10  Receiver Operating Characteristic (ROC) curve for differentiating 
aMCI participants from healthy controls.  
 
Fluency Discrepancy: AUC = 0.837, p<0.0001; HVLT Delayed Recall: AUC = 0.777, p <0.0001  
 
Figure 4.11  Receiver Operating Characteristic (ROC) curve for differentiating 
aMCI participants from depressed controls 
 
Fluency Discrepancy: AUC = 0.751, p=0.002; HVLT Delayed Recall: AUC = 0.710, p =0.009 
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Figure 4.12  Receiver Operating Characteristic (ROC) curve for differentiating 
Alzheimer’s disease participants from healthy controls. 
 
Fluency Discrepancy: AUC = 0.854. p<0.0001; HVLT Delayed Recall: AUC = 0.940, p <0.0001 
 
4.4.4.4 Attention and executive function 
The early AD group were slower than healthy controls and aMCI patients to complete the 
TMT A (C vs. AD: p = .01; MCI vs. AD: p = .03). Furthermore, early AD and depressive 
control patients were on average slower than healthy controls to complete Part B of the TMT 
(C vs. AD: p < .0001; C vs. D: p = .02). A TMT B–A measure was calculated by subtracting 
the time to completion for Part A of the TMT from Part B of the same task. On analysis, 
there proved to be a marginally significant group difference (F (3, 99) = 2.8; p = .046); 
however none of the multiple comparison procedures reached significance. 
 
4.4.5 Discussion 
Our findings demonstrate that the pattern of performance on lexical and semantic fluency 
tasks is distinctly different in early AD and aMCI compared with healthy and depressive 
age-matched controls. Specifically, early AD and aMCI patients show a greater magnitude of 
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impairment in semantic, as compared to lexical fluency, relative to healthy age-matched 
controls (Lezak 2004;Spreen and Strauss 1998). 
 
The findings are consistent with longitudinal data demonstrating that semantic fluency 
deficits pre-date the lexical fluency impairment seen in the preclinical stages of AD 
(Auriacombe et al. 2006) and with cross-sectional data showing an impairment of semantic 
fluency in the absence of any lexical fluency deficit in aMCI (Alladi et al. 2006;Dudas et al. 
2005b;Lonie et al. 2008;Murphy et al. 2006). In cases where a lexical fluency deficit has 
been documented in aMCI or preclinical AD, the general level of cognitive function of the 
aMCI patients is often comparatively low, for example a mean MMSE of 24.5, compared to 
our early AD patient group of 24.9 (Jones et al. 2006).  
 
Our results implicate early failure of one or more aspect(s) of the semantic memory system 
in aMCI and early AD. They do not directly address the question of which mechanisms of 
the semantic memory system may be at fault. The relatively sound performance of our aMCI 
patients on additional measures of verbal initiation and speeded divided attention would 
suggest that these specific aspects of executive function do not underlie the semantic fluency 
deficit. Similarly, Auriacombe and colleagues (Auriacombe et al. 2006) failed to implicate 
executive processes in the verbal fluency decline characterising AD. It remains possible that 
the semantic fluency deficit seen in aMCI and early AD reflects degradation of amodal 
representations forming the semantic memory store, or failure of the executive processes that 
help to direct and control semantic activation of this store (Jefferies and Lambon Ralph 
2006). Detailed quantitative and qualitative longitudinal investigation of semantic memory 
function in an aMCI cohort will be required to differentiate between these possibilities.  
 
What appears increasingly clear, nonetheless, is the co-existence of cognitive deficits in 
domains other than episodic memory function in aMCI; most notably semantic memory 
deficits (Adlam et al. 2006;Alladi et al. 2006;Lam et al. 2006;Murphy et al. 2006;Perry and 
Hodges 2000;Riberio et al. 2006;Vogel et al. 2005). The original MCI criteria have been 
modified to some extent to reflect this (Petersen, 2004). FD scores performed as well as, if 
not better than delayed verbal recall measures in distinguishing between patients with aMCI 
or early AD and age-matched controls or depressive controls. The discrepancy score may 
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therefore be especially sensitive to semantic memory failure in aMCI. There are a number of 
reasons why this might be so. 
 
Verbal fluency scores are influenced by age and IQ (Lezak 2004;Spreen and Strauss 
1998;Tombaugh et al. 1999), and performance on the two types of fluency measures is 
known to correlate (Tombaugh et al. 1999). Applying generalised cut-off scores at an 
individual patient level could conceivably reduce the sensitivity of fluency measures to 
deficits of a small magnitude. Lexical fluency performance, which remains comparatively 
well preserved in preclinical and very early AD (Alladi et al. 2006;Dudas et al. 
2005b;Murphy et al. 2006) and is relatively insensitive to the effects of ageing in later life 
(Murphy et al. 2006), may act as a personalised benchmark, against which even subtle 
declines in an individual’s semantic fluency performance can be measured. At least one 
study has shown an enhanced ability to detect cognitive deficits of a progressive nature using 
individualised IQ adjusted rather than group norms (Rentz et al. 2004). Based on a similar 
rationale is the use of regression equations to calculate expected performance levels for the 
individual patient (Crawford and Garthwaite 2006;Rentz et al. 2004). 
 
An interesting observation was the comparative lesser ability of the FD score to discriminate 
early AD sufferers from healthy age-matched controls. Prior research with established AD 
sufferers suggests that the relative magnitude of phonemic and semantic fluency deficits 
remains constant across disease stages (Henry et al. 2004). This would imply that the 
discriminative power obtained for FD in the aMCI group should also be maintained in early 
AD. It is possible however that this argument does not hold in a preclinical disease phase; at 
which time the greater sensitivity of the discrepancy score may reflect semantic memory 
failure prior to disruption of wider executive processes. 
 
There is continuing debate as to which of the two cognitive domains, that is, semantic 
memory abilities or executive processes, constitutes the secondary area of impairment in 
early and preclinical AD. It is conceivable that as the disease progresses, ‘executive’ aspects 
of semantic retrieval may add to poor performance due to existing semantic memory 
dysfunction on category fluency tasks. When this occurs, deficits on lexical tasks would also 
be expected to be present. As lexical fluency performance declines, the discrepancy in 
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fluency performance may become a less sensitive measure of cognitive dysfunction than 
category fluency performance or delayed recall alone. 
 
In our study, the differential semantic fluency deficit was unique to early AD and aMCI 
patient groups suggesting that it may be of assistance in differentiating these groups from the 
healthy elderly or elderly patients with depressive symptoms. Other studies have found that 
comparison of performance on the two different types of fluency tests is helpful in 
distinguishing between certain dementia syndromes (Jones et al. 2006;Marczinski and 
Kertesz 2006). This level of discrimination may not be achievable by examination of fluency 
scores in isolation, or indeed by cognitive screening measures, both of which failed to 
discriminate between our aMCI and depressive control groups. 
 
The use of a single letter and category (i.e. P and animals), as opposed to an average of three 
(i.e. FAS or animals, fruits, and vegetables), might be expected to yield a less reliable 
fluency score, and it will be necessary to replicate the above findings in other clinical 
samples using alternative categories and letters. One recent study, comparing the number of 
animals with F-words generated, has demonstrated a similar ability to discriminate early AD 
and aMCI patients from healthy controls. This study lacked the important inclusion of a 
depressive control group matched for general level of cognitive functioning and support 
needs (Murphy et al. 2006). Furthermore, the advantage of the measures used in the current 
study is that they are obtainable within the context of a brief cognitive screening measure 
(ACE and ACE-R), without necessity for the administration of any supplementary tests. 
 
In order for FD scores to be of value in a differential diagnostic sense, they must facilitate 
discrimination between pathological and age appropriate performance at the individual 
patient level. Only one healthy control and one outpatient with depressive symptoms in our 
study obtained a higher lexical than category fluency score, but there was a good deal of 
directional variability in the early AD and aMCI patient groups. Hence the FD measure may 
prove to be of greatest assistance identifying those persons who are not likely to develop AD 
over time (negative predictive value). We are conducting longitudinal follow-up of the aMCI 
patients in order to determine whether or not this is the case. 
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Two previous studies have contrasted fluency difference scores in AD and healthy controls 
(Cerhan et al. 2002;Sherman and Massman 1999). In both, the overwhelming majority of 
AD patients demonstrated the expected semantic < lexical fluency performance pattern. 
However, the existence of a notable number of AD patients exhibiting the opposite pattern 
led both authors to conclude that the FD score may be of limited sensitivity. 
 
In the present study, optimal cut-off scores can be generated from the receiver– operator 
curves in Figure 2. For example, a cut-off of 3.5 and higher for the animal minus letter-P 
scores (or a difference of z scores of 2 37%) gives a sensitivity of 63 and 50% to aMCI in 
healthy volunteers and participants with depressive symptoms, respectively, but a very high 
specificity of 91% (Table 3). On the other hand, a more lenient cut-off of greater or equal to 
1.5 (z score of 2 72%) gives a sensitivity for aMCI or Alzheimer’s dementia versus controls 
of 88%, with a reduced specificity of 58 and 70%, respectively. 
 
4.4.6 Conclusion 
Our results indicate that the differential semantic fluency deficit seen in AD is also present in 
aMCI. They provide support for the presence of semantic memory impairment in the 
preclinical and very early stages of AD and emphasize the need to broaden the current 
conceptualisation of aMCI beyond that of a purely amnesic state.   
 
FD scores appear equally adept, if not superior, to episodic memory measures at identifying 
aMCI. Importantly, the presence of depressive symptoms in psychiatric outpatients does not 
appear to influence the relative performance on the two types of fluency measures, 
suggesting that consideration of FD may be of assistance in early differential diagnosis. 
Longitudinal follow-up of the aMCI will determine whether or not FD scores are of equal 
utility in a prognostic sense. 
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4.5 Dual Task Performance in early AD, aMCI and 
Depression. 




The dual task paradigm (Baddeley et al. 1986;Della Sala et al. 1995) has been proposed as a 
sensitive measure of Alzheimer’s dementia, early in the disease process. 
Aims 
Our aim was to investigate this claim. 
Methods 
We administered the modified dual task paradigm (utilising a pencil-and-paper version of a 
tracking task) to 33 patients with amnestic mild cognitive impairment (aMCI) and 10 with 
very early Alzheimer’s disease, as well as 21 healthy elderly subjects and 17 controls with 
depressive symptoms. All groups were closely matched for age and pre-morbid intellectual 
ability. 
Results 
There were no group differences in dual task performance, despite poor performance in 
episodic memory tests of the aMCI and early Alzheimer’s disease groups. In contrast, the 
Alzheimer patients were specifically impaired in the trail-making test B, another commonly 
used test of divided attention. 
Conclusions 





Alzheimer’s disease (AD) is the most common form of dementia, estimated to rise 
dramatically in the future (Wimo et al. 2003). Research has focused on early accurate 
diagnosis and intervention. The construct amnestic Mild Cognitive Impairment’ (aMCI; 
(Petersen et al. 2001) has become increasingly popular to predict those who are most at risk 
for developing dementia. It is considered a transitional stage between normal ageing and the 
earliest clinical diagnosis of AD (Petersen 2005c;Petersen and O'Brien 2006).  Research on 
clinic-based samples has suggested that the conversion rate from aMCI to dementia is 10–
15% per year (Petersen et al. 1999;Storandt et al. 2006) compared with between 1% and 2% 
in a normal age matched non-clinical sample. 
 
While primary impairment in very early AD includes episodic memory function, many 
authors have reported that attention and executive functioning are also vulnerable at this 
stage (Parasuraman and Haxby 1993;Perry and Hodges 1999). In particular, people with 
early AD exhibit marked difficulty dividing their attention between two concurrent tasks. By 
comparing performance of a synchronous dual task with that of identical task components 
done separately and consecutively, a deficit in dual performance can be attributed to failure 
of the central executive that coordinates the simultaneous operation of these components 
(Baddeley et al. 1986). One advantage of the dual task paradigm is that it avoids modality-
specific interference between tasks: the tracking task is presented visually and a manual 
response is required; information for the digit span task is presented aurally with a verbal 
response (Nebes et al. 2001) A further strength is that task demands can be fixed at 
individual ability levels, controlling for individual variation in performance in the 
component parts of the dual task. Therefore, each patient is his or her own control, adjusting 
for the generally poorer performance of AD patients in the baseline tasks (Logie et al. 2004). 
 
Research has suggested that failure of the ‘coordination’ function is characteristic of mild 
AD in a laboratory setting. Participants with mild AD appear to be impaired, irrespective of 
task demands, and this impairment has been found to worsen with illness progression 
(Baddeley et al. 1986; (MacPherson et al. 2004). Proponents of the dual task paradigm 
suggest such findings are in contrast to normal ageing, which they believe has a relatively 
minor effect on dual task performance (e.g. (Baddeley et al. 1986;Hartley and Little 
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1999;Logie et al. 2004); but see (Crossley and Hiscock 1992). The equipment used for this 
test is often an expensive computerized tracking device impractical for clinical settings (e.g. 
(Baddeley et al. 1991;Logie et al. 2004). Della Sala et al. (Della Sala et al. 1995) developed a 
modified pencil-and-paper version of the tracking component for the dual task. This has been 
reported to produce results comparable with the original instrument (Della Sala et al. 
1995;Sebastian et al. 2006). To our knowledge the dual task paradigm has not been 
investigated with a sample defined according to recent aMCI criteria (Petersen et al. 1999). 
 
The aim of this study was therefore to assess dual task performance in aMCI to ascertain 
whether this measure can be useful in the early diagnosis of AD.  As AD is associated with a 
specific impairment in the aspect of working memory that coordinates performance of two 
separate tasks, we predicted that the performance of people with aMCI and very early AD 
should be significantly lower than that of aged matched controls. Furthermore, the inclusion 
of a group of elderly patients with symptoms of depression would test the specificity of dual 
task impairments in AD. On the basis of the previous research, we predicted that the 




We examined 33 patients with aMCI, 10 early AD patients, 17 control out patients with 
depressive symptoms and 21 healthy elderly controls. Thirteen aMCI  participants showed an 
impairment of more than 2 standard deviations (SD) below our control mean on two or more 
tests, a further four showed impairments of 1.5 to 2 SD on two or more tests, 12 participants 
were impaired at 1–1.5 SD below control means on two or more tests, and the final four 
participants performed more than 1 SD below controls on one episodic memory test. Twenty 
four of the 33 aMCI underwent some form of neuroimaging before or during the study 
period in order to exclude non-neurodegenerative causes for their cognitive impairment. 
Mini Mental State Examination (MMSE) scores for the aMCI group ranged from 24 to 30, 
with a mean of 28.3. The final aMCI group consisted of 15 males and 18 females with a 
mean age of 73.3 years (range 58–85 years).  
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For the healthy elderly control group (MMSE 28–30), we recruited spouses or carers of 
patients who had attended the service. The healthy elderly control group was matched as 
closely as possible to the aMCI and early AD groups in terms of age and estimated pre-
morbid intelligence quotient (IQ). The final elderly control group consisted of eight males 
and 13 females with a mean age of 69.5 years (range 59–81 years).  
 
Ten participants diagnosed with AD, in accordance with National Institute of Neurologic, 
Communicative Disorders and Stroke–AD and Related Disorders Association (NINCDS-
ADRDA; (McKhann et al. 1984) and DSM-IV diagnostic criteria, took part in the current 
study. All early AD patients scored above 23/30 on the MMSE and above 65/100 on the 
more comprehensive Addenbrookes Cognitive Examination (ACE; (Mathuranath et al. 
2000)), indicating relatively mild disease. The final early AD group consisted of three males 
and seven females with a mean age of 73.6 years (range 65–81 years). 
 
Seventeen participants with depressive symptoms (MMSE 25–30) were recruited via local 
psychiatric out-patient clinics and day hospitals. In an attempt to match this patient group 
with the aMCI group in terms of illness severity, patients with milder forms of depression 
were included. Fifteen of the 17 participants were receiving treatment for their symptoms at 
the time of testing; all but two of these pharmaceutical in nature. As it has been suggested 
that type of depression does not influence the magnitude of cognitive deficits (Christensen et 
al. 1997), participants with a variety of disorders were included. Eight patients had a history 
of major depression, two of bipolar disorder, two were suffering from anxiety disorders with 
depressive features, three were considered Dysthymic and two were considered to be 
suffering with a subclinical level of depressive symptoms. Mean geriatric depression scale 
(30-item version) score for this group was 13.2 (range 0–27). The group consisted of three 
males and 14 females with a mean age of 73.3 years (range 65–84 years).  
 
4.5.3.2 Neuropsychological tests 
All participants completed a variation on the modified dual task paradigm (Della Sala, 
personal communication, 2008; (Della Sala 2005)) together with the MMSE, ACE, NART, 
HVLT-R, PAL, TMTA & B.  Further details of the method of subject recruitment, 
participant characteristics together with psychometric and administrative characteristics of 
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the cognitive screening measures employed can be found within Chapter 2, Materials and 
Methods, sections 2.1 and 2.  
 
The primary measure of interest was the combined dual task score as denoted by µ 
µ=(1-[(Pm+Pt)/2])*100 
where m is the combined dual task score, Pm is the proportional loss in span performance 
between single (Xsingle) and dual task (Xdual) conditions, [(Xsingle – Xdual)/Xsingle] 
while Pt is the equivalent proportional loss in tracking score. Thus a score of 100 would 
represent no dual task decrement and lower scores reflect greater dual task decrements.  
 
Each of these measures has been shown to be sensitive to very early AD (Blackwell et al. 
2004;Chen et al. 2000;Hogervorst et al. 2002;Nathan et al. 2001;Stockholm et al. 
2006;Swainson et al. 2001). Neuropsychological assessments lasted approximately 90 min in 
total. The order of test administration was identical for all assessments. 
 
4.5.3.3 Statistical Analysis 
Data were analysed using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Demographic variables were analysed using univariate analysis of variance (ANOVA), and 
Tukey honestly significantly different pair wise comparisons were carried out on all 
significant analyses where possible. Where the assumption of homogeneity of variance was 
not met, this was adjusted for using Games–Howell post-hoc pair wise comparisons, given 
that the sample sizes were unequal in the current analysis. A univariate ANOVA was carried 
out on the overall decrement score (see above). Decrement scores broken down into tracking 
decrement and digit span decrement were also calculated and examined using ANOVAs. 
Two participants in the early AD group were incapable of completing the TMT B; in these 















Age 69.5 (7.3) 73.1 (6.3) 73.3 (6.6) 73.60 (5.8) ns 
Gender 8M:13F 16M:22F 3M:14F 3M:7F ns 
NART 118.2 (2.9) 116.5 (8.1) 116.8 (6.2) 115.60 (5.5) ns 
MMSE+ 29.10 (.7) 28.47 (1.6) 28.59 (1.5) 25.00 (2.3) CT=MCI=Dep>AD 
ACE 94.57 (3.3) 89.87 (5.9) 91.71 (5.0) 76.70 (6.6) CT > aMCI>AD 
Dep>AD 
+  Games-Howell Multiple Comparison carried out due to lack of HOV; M = Male; F = Female; AD = 
Alzheimer’s Disease; aMCI = Amnesic Mild Cognitive Impairment; ACE = Addenbrookes Cognitive 
Examination. 
 
4.5.4.1 Participant characteristics 
Demographic matching characteristics are presented in Table 4.9. There were no group 
differences in age [F(3, 77)=1.73] or estimated pre-morbid full-scale IQ [F(3, 75)=0.55]. The 
mean MMSE score for the early AD group was, as expected, significantly lower than that of 
the other groups [F(3, 77)=17.70, p<0.0001] (AD v. healthy controls, p=0.001; AD v. 
controls with depressive symptoms, p<0.005; AD v. controls, p<0.005). No other group 
differences in mean MMSE score were noted. As expected, the early AD patients had 
significantly lower mean ACE scores than did all other groups [F(3, 77)=29.30, p<0.0001] 
(post-hoc tests as above in all cases, p<0.0001). The ACE also discriminated between normal 
elderly control participants and aMCI patients, with the latter group obtaining a significantly 
lower mean ACE score (post hoc p=0.01). 
 
4.5.4.2 Dual task performance 
Group means and SDs for the digit span task and the tracking measures of the modified dual 
task paradigm are presented in Table 4.10. Mean percentage scores for performance on the 
concurrent tasks, the digit span tasks and the visuospatial tracking tasks for each of the four 
groups are presented in Table 4.11. On carrying out a one-way non-repeated ANOVA on the 
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overall decrement score, no group difference was found [F(3, 77)=0.63]. Similarly, no 
significant group differences were found for any of the other component tasks or decrement 
scores.  
 
Table 4.10  Digit span and individual component measures of the dual task 
(span and tracking, performed separately and together) 
Task Controls 
(n = 21) 
Depression 
(n = 17) 
aMCI 
(n = 33) 
Early AD 
(n = 10) 
Digit span 
 
5.5 (0.7) 5.8 (1.0) 5.6 (0.9) 5.1 (0.7) 
Digit span (single) a 1.0 (0.03) 0.9 (0.05) 1.0 (0.05) 1.0 (0.03) 
Digit span (dual) a 0.9 (0.05) 0.9 (0.08) 0.9 (0.08) 1.0 (0.02) 
Tracking (single) b 141 (56.5) 140 (51.7) 126 (38.9) 120 (46.3) 
Tracking  
(dual) b 
122 (46.0) 126 (58.3) 114 (36.3) 107 (35.6) 
aMCI, Amnestic mild cognitive impairment; AD, Alzheimer’s Disease; Values are given as mean 
(standard deviation); a = Proportion of digits recalled in the correct position (1 = all correct); b = 
Number of circles joined in 90 second. 
 
Table 4.11  Percentage loss of performance in component tasks and overall 
decrement score during the dual task 
Task Controls 
(n = 21) 
Depression 
(n = 17) 
aMCI 
(n = 33) 
Early AD 
(n = 10) 
Digit span 96 (3.8) 97 (8.6) 98 (7.6) 100 (3.3) 
Tracking 90 (22.8) 88 (16.8) 92 (15.4) 93 (17.6) 
Overall decrement 93 (11.1) 92 (8.2) 95 (8.6) 97 (9.1) 
aMCI, Amnestic mild cognitive impairment; AD, Alzheimer’s disease; Values are given as mean 
(standard deviation); a percentage loss of performance scores were calculated as 
(1x[(XsinglexXdual)/Xsingle])*100 and the overall decrement score as mu=(1-[(Pm+Pt)/2])*100, as 
described in the Method section. 
 
4.5.4.3 Other cognitive functions  
Group mean scores and SDs for the HVLT-R, the number of errors at the six pattern level of 
the PAL and the TMT B are presented in Table 4.12. On analysing the HVLT-R delayed 
recall data, there was a significant group effect [F(3, 77)=12.39, p<0.0001]. On closer 
analysis, the AD group recalled significantly fewer words than the healthy control 
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(p<0.0001) and depression groups (p<0.0001). Similarly, the aMCI group performed more 
poorly than the healthy control (p<0.005) and depression groups (p<0.01). No significant 
difference was found between the AD and aMCI groups. The performance of the elderly 
control and depression groups on the HVLT-R delayed recall did not differ. However, the 
AD group made significantly more errors at the six pattern stage of the PAL compared with 
all other groups [F(3, 755)=22.82, p<0.0001] (post hoc tests comparing AD with other 
groups were in all cases p<0.0001). The aMCI group’s error scores fell between those of the 
healthy control and AD groups, and significantly differed from both of these (aMCI v. 
healthy controls, p<0.05; aMCI v. AD, p<0.0001). A significant group effect was also found 
for the TMT B [F(3, 77)=8.62, p<0.0001]. In the post hoc analyses, only the control and 
depression groups differed in terms of TMT B scores (p<0.05); participants with depressive 
symptoms took significantly longer to complete the task. However, once time to completion 
on TMT part A (a measure of psychomotor speed) was statistically controlled for, a different 
pattern of group differences emerged [F(3, 76)=7.76, p<0.0001]. Specifically, it was found 
that the participants with AD took longer to complete the second task compared with all 
other groups (aMCI v. AD, p<0.0001; healthy controls v. AD, p<0.0001; controls with 
depressive symptoms v. AD, p<0.05). The group difference between the control and 
depressive symptom groups was no longer significant. No other group differences were 
uncovered. 
 





(n = 21) 
Depression 
(n = 17) 
aMCI 
(n = 33) 
Early AD 





8.1 (2.8) 8.1 (3.3) 4.9 (3.3) 2.1 (3.7) Controls = depression > 
aMCI = AD 
PAL errors a 7.8 (6.9) 10.9 (7.8) 16.5 (12.9) 40.7 (10.6) Controls, depression, 
aMCI < AD 
Controls < aMCI 
TMT A 40.3 (11.2) 54.1 (23.1) 49.6 (36.1) 57.6 (25.3) - 
TMT B 87.6 (31.5) 134.2 (53.6) 106.3 (49.4) 216.7 (157.7) Controls < depression 
Controls, depression, 
aMCI < AD b 
a Games-Howell Multiple Comparison carried out due to lack of homogeneity of variance; b After 
removing effects of TMT A (see text); AD = Alzheimer’s Disease; aMCI = Amnesic Mild Cognitive 
Impairment; HVLT-R = Hopkins Verbal Learning Test-Revised; PAL Errors = 6 Pattern Stage errors 
from the Paired Associates Learning test; TMTA = Trail Making Test Part A; TMT B = Trail Making 




This study investigated the claim that the dual task paradigm can be used in the early 
diagnosis of dementia of the Alzheimer’s type. We assessed the concurrent performance of a 
visuospatial tracing task and a digit span forward task in four diagnostic groups with aMCI 
(MMSE 24–30), early AD (MMSE 23–29), symptoms of depression (MMSE 25-30) and 
healthy elderly controls (MMSE 28–30). Our results show that aMCI is not associated with 
impaired dual task performance; those with aMCI had comparable performance to healthy 
older adults and older adults with depressive symptoms. Our early AD group was similarly 
unimpaired on the modified dual task paradigm relative to depressive and non-depressive 
elderly control groups and the presence of depressive symptoms appeared to have no effect 
on dual task performance. By contrast, and indeed by definition, episodic memory 
impairments were present in the aMCI and early AD groups. The early AD group also 
exhibited an impaired ability to divide their attention at pace, as indicated by part B of the 
TMT.  
 
These results shed some light on previous findings. One line of research has suggested that 
dual task performance is vulnerable to the influence of AD, even early in the disease course 
(Baddeley et al. 2001;Logie et al. 2004). However, such studies generally involve 
participants varying in severity from minimal to mild AD. When participants with AD are 
divided by severity using the MMSE, only the more severely ill patients (e.g. MMSE <24) 
are impaired on the dual task paradigm (Crossley et al. 2004;Greene et al. 1995;Perry et al. 
2000). This result is in agreement with the absence of impairment on the dual task measure 
observed in the current study in early AD. The combined findings suggest that dual task 
impairments are generally not observed early on in the AD process, with MMSE scores 
above 23/30.  
 
Only one other study has investigated the dual task performance of a group of older adults 
with cognitive impairment without a diagnosis of dementia (Holtzer et al. 2004). Cognitively 
impaired adults, defined by a dementia rating scale (DRS) cut-off score of <124 (Mattis 
1988), performed two tasks in different modalities at the same time. Two combinations of 
tests were used: a visual cancellation task (where participants were required to cross out a 
specified stimulus type from a field of stimuli) combined with a digit span task, and the same 
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visual cancellation task combined with a verbal fluency task. The researchers report that 
their cognitively impaired group exhibited a significantly larger dual task decrement than age 
matched controls. However, the cognitively impaired group in the Holtzer et al. (Holtzer et 
al. 2004) study was identified solely on the basis of a DRS cut-off score falling at or below 
levels that are indicative of an underlying dementia. It is for this reason difficult to be certain 
of, or to compare, disease severity of this ‘minimally cognitively impaired’ group with other 
studies, which commonly use well-established clinical and research criteria to define patient 
groups. Furthermore, the cognitively impaired group in the Holtzer et al. (Holtzer et al. 
2004) study, were significantly less well educated than the control groups, while in the 
current study, participant groups were well matched both in terms of age and estimated 
levels of pre-morbid intelligence.  
 
Holtzer et al. (Holtzer et al. 2004) did not investigate the potential influence of depression on 
dual task performance. This is crucial where consideration is being given to the early and 
differential diagnostic value of a neuropsychological measure. Hasher & Zacks (Hasher and 
Zacks 1979;Mattis 1988) confirmed our result that people with depression show impaired 
attention during effortful processing tasks, for instance on measures of divided attention such 
as the TMT B (Mahurin et al. 2006;Nathan et al. 2001). Only one study has investigated the 
effect of depressive symptoms on Baddeley et al.’s (Baddeley et al. 1986) original dual task 
paradigm (Nebes et al. 2001). This indicated that people with depression had a significantly 
greater decrement in computerised tracking performance and a composite decrement 
measure than non-depressed controls. No study to date has investigated the effects of 
clinically depressed mood on the modified version of the dual task paradigm to replicate or 
contradict our negative result (Della Sala et al. 1995). A strength of the current investigation 
relates to the availability of additional neuropsychological data demonstrating the existence 
of significant episodic memory impairments in aMCI and early AD and additional 
impairment of speeded divided attention (as assessed by TMT B) in early AD. The TMT B 
assesses the ability to divide attention back and forth between multiple lines of thought 
(connecting numbers and letters, respectively), but differs from the dual task paradigm in 
that its different components are not drawn from separate modalities. Performance is thus 
more vulnerable to reduced processing capacity. Several previous studies have demonstrated 
that TMT B is impaired in the very early and even pre-clinical stages of AD (Alladi et al. 
2006;Baddeley et al. 1986;Baudic et al. 2006;Crossley et al. 2004;Crowell et al. 
2002;Lafleche and Albert 1995;Nathan et al. 2001;Perry et al. 2000), although its specificity 
for AD, as distinct from, for example, depression, has not been established.  
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The Holtzer et al. (Holtzer et al. 2004) study compared the dual task performance of 
minimally cognitively impaired participants only with their performance on tests comprising 
the single task conditions (i.e. visual cancellation, digit span and letter fluency). However, 
these tests are not, generally speaking, associated with impairments in very early and pre-
clinical AD and it is therefore not surprising that they are insensitive to cognitive deficits in 
the minimally impaired group, as was the case in this study.  
 
One important methodological feature may have influenced the current results: While those 
studies reporting general dual task impairment in early AD used both computerised and 
pencil-and-paper versions of the tracking task, only the modified version utilising the pencil-
and-paper tracking task (Della Sala et al. 1995) has been used in studies that separated 
participants by symptom severity. Thus, while patients who are minimally affected do not 
show impairments on the modified version of the task, it remains possible that they would 
show impairments if the test were more taxing – for instance if the dual task paradigm 
included the original computerised version of the tracking task. This version of the task 
requires increased effort and attention, as participants are required to adjust to an external 
influence (i.e. the speed of the light dot on the screen) rather than working at a self-defined 
rate. It may therefore be sufficiently taxing to identify those who are not picked up by the 
more straightforward pencil-and-paper tracking task. However, the paper and- pencil version 
(as opposed to the computerised task) is more likely to be adopted for widespread use in 
clinical and research practice, which underscores the relevance of our negative result.  
 
A further methodological issue is the variability of dual task administration, which can lead 
to difficulties comparing findings across studies. We administered each of the three trials in 
blocks of 90 seconds, while some previous studies set the trial time at 120 seconds (e.g. 
(Perry et al. 2000). Most dual task studies have utilised pencil-and-paper tracking tasks that 
required participants to cross out boxes on an A4-size sheet of paper to form a chain (e.g. 
(Baddeley et al. 1997). The current task required participants to trace a line through linked 
empty circles on an A3-size sheet. While the initial dual task paradigm involved recording 
the number of completely correct digit strings (Baddeley et al. 1986), many subsequent 
studies, including the current investigation, have calculated the number of digits recalled in 
the correct order for this measure. The significance of such alterations to dual task 
administration requires further investigation.  
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A partial alternative explanation for our negative result is that a majority of individuals 
forming our aMCI group may fail to convert to AD in the future. If this proves to be the case, 
then the absence of dual task impairment would not be surprising. The issue will be resolved 
through the longitudinal follow-up of participants with aMCI, currently underway. However, 
the sound performance of our early AD group on the dual task measure makes it more likely 
that the negative result for our aMCI patients is due to lack of test sensitivity rather than 
absence of underlying AD pathology. The impaired performance of the early AD group on 
an alternative popular measure of speeded divided attention implies that the dual task 
measure lacks sensitivity to very early changes of an attentional/executive nature in AD.  
 
4.5.6 Conclusion 
People with early AD and aMCI did not display impaired performance on the modified 
version of the dual task paradigm at a time when episodic memory, and in the case of early 
AD, speeded divided attention, were significantly impaired. The likely explanation is that the 
dual task paradigm is insufficiently sensitive for use as an adjunctive cognitive tool in the 
early diagnosis of AD. Future longitudinal research is needed to investigate the use of dual 
task tests of varying demand in aMCI and very early AD participants in an effort to 
determine the potential influence of task demands and complexity on performance. 
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5. Neuropsychological Test Performance Across Time 
 
5.1 Test re-test reliability of neuropsychological measures in 




In cases of very early AD and MCI, where associated functional declines are minimal and 
generalised intellectual decline is absent, it is often necessary to rely on psychometric 
evidence of cognitive decline in order to arrive at a diagnosis.  It is for this reason, crucial, 
that neuropsychological measures that are employed to assess cognitive performance in MCI 
and early AD are not only sensitive enough to detect mild impairments but also reliable 
enough to facilitate detection of mild declines in cognition over time. Few previous studies 
have examined the stability of performance of the healthy elderly on neuropsychological 
measures across time. 
Aims 
We therefore sought to establish the re-test reliability of the study neuropsychological 
assessment battery in a group of healthy, age and IQ matched control participants, prior to 
analysing the longitudinal neuropsychological performance of the aMCI sample.   
Methods 
Sixteen healthy elderly control subjects re-sat the neuropsychological assessment battery on 
a second occasion, across an average 28 month interval.  Baseline and re-test scores were 
compared by way of paired t-tests, where data were normally distributed, and the Wilcoxon 
test, where visual inspection together with Kolmogorov-Smirnoff Z tests revealed that data 
were not normally distributed and effect sizes were calculated where statistically significant 
differences in baseline and re-test scores were found.  Test re-test reliability was assessed 
using Person’s correlations for parametric data and Spearman’s rho for non-parametric data.  
Lower and upper 95% limits of agreement were calculated for the mean interval score for 
each variable, together with 95% upper and lower boundary confidence limits of difference 
values, in accordance with the methods for assessing agreement between measurement 
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proposed by Bland and Altman (Bland and Altman 1986). Repeatability coefficients were 
calculated where the baseline – re-test difference score did not reach significance.  
Results  
Significant improvements were apparent at retest on the ACE, HVLT-R total recall & RCFT 
delayed recall, whereas declines of a significant magnitude were noted in association with 
performance on the Category Fluency task and Part A of the TMT. The associated effect 
sizes for the above change scores were uniformly large, indicating the likely practical 
significance of these difference findings. The mean performances of the control group at 
baseline and follow-up did not differ significantly on the remaining neuropsychological 
measures. 
Re-test reliabilities were for the most part medium to large.  The magnitude of score change 
required to surpass the upper and lower 95% confidence limit ranged from a minimum of 1 
additional word for the total recall measure of the HVLT-R to a maximum of 4 additional 
words for the BNT, and a loss of 1 word for the total recall measure of the HVLT-R and 6 
points for the copy component of the RCFT, respectively. 
Conclusion  
In summary, reliable test performances were observed on a majority of neuropsychological 
tasks across a mean 28 month interval in our healthy elderly control group.  Practice effects 
were present for several episodic memory measures together with a widely used cognitive 
screening measure (ACE) and these should be taken into account when interpreting change 
in performance on such measures over time.  The ceiling effects (MMSE, ACE immediate 
recall, HVLT-DI, RCFT copy) and low re-test reliabilities (PAL, Dual Task) observed for 
several other tasks imply these measures may be less suited to monitoring cognitive 
performance and detecting small but significant changes in performance across time, in 
patients with mild cognitive difficulties.  The significant overall decline in the performance 
of the control group on several timed tasks cautions against the use of processing speed 
measures for monitoring purposes in an elderly population, without reference to reliable 




The concept of cognitive decline comprises a key component of MCI criteria (Petersen et al. 
1999) and is central to the diagnosis of early AD.  Reference points utilised to establish 
evidence of cognitive decline in clinical practice include estimates of pre-morbid levels of 
general intellectual functioning and prior performance psychometric measures.  In cases of 
very early AD and MCI, where associated functional declines are minimal and generalised 
intellectual decline is absent, it is often necessary to rely on psychometric evidence of 
cognitive decline in order to arrive at a diagnosis.  It is for this reason, crucial, that 
neuropsychological measures that are employed to assess cognitive performance in MCI and 
early AD are not only sensitive enough to detect mild impairments but also reliable enough 
to facilitate detection of mild declines in cognition over time. 
 
We therefore sought to establish the re-test reliability of the study neuropsychological 
assessment battery in a group of healthy, age and IQ matched control participants, prior to 
analysing the longitudinal neuropsychological performance of the aMCI sample.   
 
Few previous studies have examined the stability of performance of the healthy elderly on 
neuropsychological measures across time. Bird et al (Bird et al. 2004) reported high, one 
month test re-test reliabilities (r=0.92) for the GNT based on the performance of 106 normal 
adults with a mean age of 57 years and an estimated high average pre-morbid level of 
intellectual function. Reliable change indices corrected for practice effects of between -1.5 & 
+3.5 were provided, suggesting that the GNT may be a useful tool for monitoring even small 
cognitive changes.  The authors (Bird and Cipolotti 2007) later reported excellent test re-test 
reliabilities (i.e. r= 0.92) and slightly larger reliable change indices (+ & - 4.5) for the GNT 
in a large neurological sample re-tested within a two year period.   
 
The psychometric properties of the category fluency test, were also examined in the former 
study (Bird et al. 2004).  Moderate test re-test reliabilities (r=0.56), together with a 
statistically significant practice effect in the order of 1.3 points and reliable change indices 
corrected for practice of -7.6 & +10.5 were reported, using the category ‘animals’. Another 
study examining re-test reliability of the animal fluency task in British adult samples 
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reported standard error of prediction scores in the region of 4.33 words (Harrison et al. 
2000). To my knowledge, no study has reported on the test re-test reliability of the category 
fluency task in older adults using the combined categories of ‘animals’, ‘fruits’ & 
‘vegetables’. 
 
Three studies have examined the test re-test reliability of the HVLT.  As the total number of 
words recalled across the three learning trials is common to both the original (HVLT) and 
revised (HVLT-R) versions of the test, data from both are considered here. Schrijnemaekers 
et al., (Schrijnemaekers et al. 2006) reported significant learning effects for the total number 
of words recalled across the three trials of version 1 of the HVLT across a 2-3 year period in 
healthy elderly controls but not for small groups of early AD or MCI study participants.  
Duff et al., (Duff et al. 2007) reported a mean increase of 1 word for the total number of 
words recalled across the three learning trials of the HVLT-R following a 3 month interval in 
a very small sample (n=8) of elderly MCI patients.  Statistically significant 9 month stability 
coefficients (r = 0.50) have also been documented for the total number of words recalled 
across the learning trials of the HVLT, in a small group (n=45) of healthy elderly adults 
(Rasmusson et al. 1995).  
 
Mitrushina and Satz (Mitrushina and Satz 1995) report an absence of practice effects on the 
60 item version of the BNT, at one and two year intervals in a sample of 122 healthy 57-85 
year old volunteers with a mean high average full scale IQ. Moderate test re-test reliabilities 
were documented across the initial and final one year intervals (r=0.62 & 0.65, respectively) 
and a higher re-test reliability was observed across the 2-year interval (r=0.89).  Similarly, 
Zec et al., (Zec et al. 2005) reported small non-significant practice effects of between 0.21 
and 0.19 words on the 60 item version of the BNT in a large sample of healthy community 
dwelling elderly with a mean age of 67 years who were re-tested at 9-15 month (n=353) and 
one and a half year intervals (n=540).  Test re-test reliability between the first two BNT 
assessments undertaken by the sample was moderately high (r=0.76) and statistically 
significant for each of these intervals.  Some minor variations from the standardised 
administration procedures for the BNT were noted, including omission of prompts and time 
limitations, for the latter study. 
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Flanagan et al., (Flanagan and Jackson 1997) re-assessed 31 healthy older adults with a mean 
age of 64 years across brief (i.e. 7-17 day) intervals on the BNT (60 item version).  Although 
statistically significant improvements in performance at re-test were noted, scores were 
highly correlated (r=0.91) and the effect size for the mean difference score was relatively 
small (r=0.37), suggesting that the degree of improvement was of limited practical 
importance. In this study, 95% of participants scored within 2 points of their baseline BNT 
performance at re-test. 
 
Thus whilst statistically significant practice effects have been reported within a small sample 
of healthy elderly on the BNT across relatively brief time intervals, the degree of 
improvement noted was of a small magnitude and questionable clinical significance and 
practice effects have not been reported across longer re-testing intervals amongst the healthy 
elderly.  
 
Test re-test reliabilities as high as r=.890 and r=.83  were reported in the original 
standardisation sample for the MMSE (Folstein et al. 1975), in association with the same and 
different examiners, respectively.  Near perfect 4 week test re-test reliabilities (r = .99) were 
reported for the sample of dementia patients in this study (Lezak 2004).  Tombaugh 
(Tombaugh 2005) examined MMSE 3 month and 5 year re-test reliability and practice 
effects in 160 elderly persons (mean age 76 years) whose intact cognitive status was 
independently verified at follow-up. In this study, statistically significant practice effects 
were observed across the shorter (i.e. 3 months) but not longer (i.e. 5 year) intervals, where 
mean variation was of a magnitude of less than ½ a MMSE point and retest reliability was r 
= 0.65. 
 
Duff et al., (Duff et al. 2007) reported little mean change (i.e. -0.4) in total FAS score in a 
very small group of 8 highly educated older adults with MCI (mean age 72 years) across a 3 
month interval.  Harrison et al., (Harrison et al. 2000) documented high test-retest reliability 
(r = .82) for the COWAT in 90 middle aged British adults across variable 1-8 week intervals.  
Only 60% of this sample displayed improvements in their performance at second assessment, 
suggesting that practice effects are by no means universal. Reliable change indices were not 
reported.  A re-test reliability of r=.71 has also been reported for a sample of healthy elderly 
persons re-tested following a one year interval (Snow et al. 1988). The COWAT thus 
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appears to be a reliable measure across varying time intervals among the middle aged and 
healthy elderly. 
 
Reported reliability coefficients for the TMT vary within the healthy elderly, with most 
above r = 0.6, several at r = 0.9 and more within the r = 0.8 range (Spreen and Strauss 1998).  
Within a small sample of highly educated elderly patients (mean age 72 years) with MCI. 
Duff et al., (Duff et al. 2007) reported a mean increase of 8.5 seconds to complete TMTA on 
a second testing occasion (following a 3 month interval) together with an average decrease 
of 20 seconds in completing part B at re-test. Practice effects are usually seen on both parts 
of the TMT with effects on Part A more likely to reach significance as a result of the greater 
variability in TMTB performances.  An absence of practice effects has however been 
documented across longer i.e. one year re-test intervals in one study (Basso et al. 1999) and 
there is evidence to suggest that gains in performance as a result of previous exposure to Part 
B of the TMT may not be retained across longer (i.e. 3 month) time intervals (McCaffrey et 
al. 1992).   
 
Acceptable to high levels of test re-test reliability (0.64 – 0.88), together with an absence of 
practice effects have been reported for the total number of errors made on the PAL subtest of 
the CANTAB battery, across one month re-test intervals (Fowler et al. 1995) in small 
samples of healthy elderly and early stage AD patients. This subtest has also been shown to 
be sensitive to small changes in episodic memory function across even relatively brief i.e. 6-
12 month intervals (Fowler et al. 1997).  Significant practice effects were, however, 
observed within a sample of Questionable Dementia sufferers, resulting in a mean reduction 
of 4 errors across all learning trials on the second testing occasion. 
 
Three studies have reported on the test re-test reliability of the RCFT in older adult samples.  
Following a one year interval, Berry et al., (Berry et al. 1991) reported reliabilities of a 
moderate magnitude (.47-.59) for the immediate and 30 minute delay recall trials, and low 
reliability for the copy condition in a sample of 41 ‘normal’ elderly subjects. Mitrushina and 
Satz (Mitrushina and Satz 1991) similarly reported relatively a low test re-test reliability 
coefficient (.56-.68) for the copy version of the RCFT when administered to a group of 
elderly subjects thrice annually.  Re-test coefficients for the 3-mintue delay condition ranged 
from 0.57 to 0.77 across the three annual probes.   
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It has been noted, that the limited ranges of scores for the copy condition (as function of 
ceiling effects in the healthy elderly), may serve to artificially reduce the magnitude of the 
test re-test correlation coefficients (Meyers and Meyers 1995).  The authors report an 
absence of significant differences in scores on the copy component of the RCFT at 6 month 
re-test in a small (i.e. n-12) sample of ‘normal’ subjects and report re-test correlation 
coefficients of 0.76 for the immediate recall and 0.89 for the delayed recall components of 
the task.  The potential for contamination of the incidental nature of the learning paradigm to 
affect re-test recall performance is also noted. 
 
A relatively low test re-test reliability Pearson correlation coefficient of r=0.44 has been 
reported in association with the value of mu derived from the Dual Task performance of 33 
persons (Baddeley et al. 1997). The reliability of the memory span component of the dual 
task was noted to be especially low (r=0.36) in comparison with the tracking component of 
the task (r=0.76). Demographic details of the re-test sample and the re-test interval are not, 
however provided. 
 
There are no published test re-test reliability data for the EENT, or, to the best of my 









Table 5.1  Summary of test-retest reliability findings for neuropsychological 
measures comprising the research battery 











GNT Bird (2004) 0.92 1 (1.5-3.5) HA (106)   
 Bird (2007) 0.92 24 (-4.5-4.5) N   
Animal 



















 Duff (2007)  3  MCI (8)  1 
 Rasmusson (1995) 0.5   HE(45)   
BNT Flanagan (1997) 0.91 0.25–0.5 (-2–2) HE (31) (s) (0.37) 
 Mitrishina (1995) 0.62-0.98 12 & 24  HE (122) (ns)  
 Zec (2005) 
0.76 
 
9–15 & 18  HE (353 & 540) 
0.19-0.21 
(ns)  
MMSE Folstein (1975) 0.83–0.89      
 Lezak (2004) 0.99 1  Dem   





(FAS) Harrison (2000) 0.82 0.25–2  HE (90) (s)  
 Snow (1988) 0.71 12  HE (ns)  
 Duff (2007) 3   MCI (8)  -0.4 
TMTA Spreen (1998) 0.6–0.9      
 Duff (2007)  3  MCI  8.5 sec 
TMTB Spreen (1998) 0.6–0.9      
 Duff (2007)  3  MCI  -20 sec 
 Basso (1999)  12   (ns)  
PAL Fowler (1995) 0.64–0.88 1  HE;AD;QD   
RCFT copy Mitrushina (1991) 0.56–0.68 4  HE   
 Meyers (1995)  6  HA (12) (ns)  
RCFT 
immed Berry (1991) 0.47 12  HE (41)   
 Meyers (1995) 0.76 6  HA (12)   
RCFT delay Berry (1991) 0.59 12  HE (41)   
 Meyers (1995) 0.89 6  HA (12)   
Dual Task 
(mu) Rabbitt (1997) 0.44   (33)   
RCI = Reliable Change Index; EF= effect size; CS = Change Score; HA = healthy adults; N = 
neurological; HE = healthy elderly; MCI = Mild Cognitive Impairment; AD = Alzheimer’s Disease; 






Sixteen of 24 healthy elderly control subjects agreed to return to complete the 
neuropsychological assessment battery on a second occasion.  Parallel versions were 
available for two of the episodic memory measures comprising the research battery (HVLT-
R and RCFT).  Whilst no specific hypotheses were made regarding the predictive value of 
practice effects, a decision not to employ parallel test forms was taken in view of their 
potential added differential diagnostic or prognostic contribution (Schrijnemaekers et al. 
2006) as well as the scarcity of data pertaining to form equivalence (Brandt 1991) and the 
relatively long intervals between assessments.  Time intervals between first and second 
assessments ranged from 9 to 41 months with an average interval of just over two years 
(mean=28 months; SD=9.05) between test and re-test.   
Details of the method of subject recruitment,  participant characteristics together with 
psychometric and administrative characteristics of the cognitive screening measures 
employed can be found within Chapter 2, Materials and Methods, sections 2.1 and 2.  
 
5.1.3.1 Statistical Analysis 
 
Performances on each neuropsychological measure at baseline and follow-up were compared 
by way of paired t-tests, where data were normally distributed, and the Wilcoxon test, where 
visual inspection together with Kolmogorov-Smirnoff Z tests revealed that data were not 
normally distributed.  Test re-test reliability was assessed using Pearson’s correlations for 
parametric data and Spearman’s rho for non-parametric data. Where differences in baseline 
and retest scores were found to be statistically significant, effect sizes were calculated for the 
magnitude of score change using the equation below, as a means of ascertaining the likely 
practical significance of the difference score. 
[ r = square root t squared / t squared + df ] (Field 2005) 




Lower and upper 95% limits of agreement were calculated for the mean interval score for 
each variable, by subtracting 2 * the standard error of measurement (SEM) from the mean 
score change (T1-T2) to obtain the lower limit value and adding 2 * the SEM to the mean 
score change to obtain the higher limit value, in accordance with the methods for assessing 
agreement between measurement proposed by Bland and Altman (Bland and Altman 1986).   
 
As the limits of agreement are only estimates of the values which apply to the whole 
population (Bland and Altman 1986), 95% upper and lower boundary confidence limits of 
difference values were then calculated for each variable (by subtracting 2 * SD of the mean 
score change for each variable from the lower boundary limit value and adding 2 * SD of the 
mean score change to the higher boundary limit value), such that fewer than 2.5% of any 
given sample of healthy elderly would be expected to show a change of a greater magnitude 
in performance than that denoted by the upper confidence limit value over the average 28 
month period.   
 
Where change score distributions were not normally distributed (i.e. in the case of the 
immediate and delayed recall components of the ACE, the HVLT-R DI, the EENT and the 
copy component of the RCFT), upper and lower quartile range scores that most closely 
corresponded to the lowest and highest 5th%ile of change scores were obtained and 
compared to the boundary cut off points derived as above.  
 
For the immediate and delayed recall subtests of the ACE, reliable change index scores 
calculated in this manner were less conservative than those calculated based on assumptions 
of normality.  For the variables HVLT-DI, RCFT copy & PAL 6 box errors, variability in the 
reliable change indices obtained by these two methods were reflective of one or more 
outlying values. When the quartile ranges for HVLT-DI and RCFT copy change scores were 
re-examined following omission of their respective outliers, similar change index scores to 
those calculated based on the assumption of normal distributions were obtained (HVLT-DI = 
(-3 – 0); RCFT copy = (-3 - 1)).   
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For the purposes of subsequent analyses (see chapter 6), MCI participants who exhibited 
declines in performance falling outwith the upper confidence limit set for each 
neuropsychological variable, were considered to have undergone clinically significant levels 
of decline in test performance.  Conversely, improvements in performance of a magnitude 
greater than the upper set confidence limit were taken to a clinically significant level of 
improvement. 
 
All comparisons are based on a sample of 16 healthy elderly control subjects with the 




In Table 5.2 it can be seen that the control group performed at significantly higher levels at 
re-test as compared to baseline on the ACE total (t(15) = -2.24, p < .05), HVLT-R total (t(15) 
= -2.68, p < .05) and Rey Delayed recall (t(15) = -2.44, p < .05), respectively.  By contrast, 
significant declines in the mean performance of the control group on the Category Fluency 
(t(15) = 2.61, p < .05)  and Part A of the Trail Making Test (t(15) = -2.69, p < .05) were 
noted at re-test relative to baseline. Where statistically significant differences in baseline and 
follow-up scores were observed, associated effect sizes were uniformly large (i.e. > 
0.5;(Field 2005), indicating the likely practical significance of these difference findings. The 
mean performances of the control group at baseline and follow-up did not differ significantly 
on the remaining neuropsychological measures (in all cases p > .05).  
 
Re-test reliabilities for the control group were for the most part large (i.e. > .5), with the 
exception of the MMSE, the immediate recall sub component of the ACE, PAL errors at the 
6 box stage, the Discrimination Index from the HVLT-R, the paper and pencil Dual Task and 
the copy component of the RCFT, where correlations were of a medium (i.e. r= .3 – .5; in the 
case of the MMSE) and otherwise small (r =.3) magnitude. 
 
The magnitude of score change required to surpass the upper 95% confidence limit ranged 
from a minimum of 1 word for the total recall measure of the HVLT-R to a maximum of 4 
items for the BNT.  Conversely, with reference to lower 95% confidence boundaries, a  
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Table 5.2  Comparison of healthy elderly control performances on 
neuropsychological measures at baseline and follow-up 
*** = p<.001, ** = p<.01, * = p<.05, (ns) = non-significant; ACE, Addenbrookes Cognitive Examination; Immed, immediate recall of name and address; 
Delay, delayed recall of name and address; Conf, confidence; Diff, difference; HVLT-R, Hopkins Verbal Learning Test – Revised; Total, total words 
recalled; Delay, words recalled at delay; DI, discrimination index; PAL, CANTAB Paired Associated Learning; RCFT, Rey Complex Figure Test; BNT, 
Boston Naming Test; GNT, Graded Naming Test; GFT, Graded Faces Test; EENT, Edinburgh Exemplar Naming Test; C-Flu, total number of animals, fruits 
and vegetables; TMT, Trail Making Test; FAS, controlled oral word association test; a, Data analysed non-parametrically; ^, the median and range are given; 
^ upper and lower quartile ranges most closely corresponding to 95%ile cut off points following removal of outliers; EF, effect size; rel, reliability
Measure Baseline Mean 
(SE) ^ 































































































































































-2.70 – 1.71 
-4.35 – 3.59 
-2.00 – 1.19 
 




-0.47 – 0.64 
-1.78 – 2.45 
-2.99 – 3.80 
 




-5.01 – 3.50 
 
-2.46 – 1.66 
-2.00 – 1.19 
 
-3.66 – 3.98 
-4.53 – 2.87 
-2.01 – 2.39 
-1.82 – 2.06 




-2.78 – 1.52 
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minimum score change of -1 word was required for the total recall measure of the HVLT-R 
and a maximum of -6 points for the copy component of the RCFT.  
 
The lowest ACE value obtained for the control group at retest was 92/100, indicating the 
absence of any control participants who had developed a dementing illness during the course 
of the study 
5.1.5 Discussion 
The majority of neuropsychological measures in our study battery (i.e. 14/20) demonstrated 
adequate levels of re-test reliability (i.e. r > .5) amongst healthy elderly participants across 
time intervals ranging from 9 – 41 months, attesting to their general suitability of use in 
monitoring cognitive ability across time.  
 
The significant improvements in the follow-up performances of the control group on the 
ACE, RCFT delayed recall and HVLT-R total recall scores and the large effect sizes 
associated with the mean score changes warrant further discussion.  Practice effects in 
performance on the recall component of the HVLT were previously reported within a sample 
of healthy elderly (Schrijnemaekers et al., 2006).  The effects were not, however, observed 
within MCI and early AD samples.  
 
Several authors have postulated that the absence of practice effects in MCI and AD patient’s 
may be indicative of underlying disease pathology interfering with the ability of such 
patients to acquire and retain strategies to assist recall of new information across time (Darby 
et al. 2002;Schrijnemaekers et al. 2006)  It has consequently been suggested that observed 
lack of practice effects may be of potential utility in the identification of MCI and the early 
and differential diagnosis of AD. The relatively small reliable changes indices observed in 
association with this sample of healthy elderly would suggest that the learning component of 
the HVLT-R may be especially sensitive to small changes in verbal learning ability that are 
of a clinically significant magnitude. 
Alternate forms were not used in the present study, in view of the potential added predictive 
value of practice effects (or lack thereof), the relatively large i.e. 12 month re-test intervals 
and the scarcity of data attesting to form equivalence (Brandt 1991). Our findings would 
suggest that this may be a necessity if one wishes to avoid taking into account effects of 
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practice, even across relatively lengthy intervals. It is possible that the structured nature of 
the HVLT-R (i.e. with words belonging to one of four categories) makes it more susceptible 
to practice effects than other popular verbal list learning tasks i.e. RAVLT, with retention of, 
or familiarity with the semantic categories serving to enhance recall performance at re-test. 
Alternatively, some of the variability in re-test scores may be accountable for in terms of 
variability in the administration styles (i.e. clarity of speech and/ or time given to respond) of 
baseline and re-test examiners.  
 
Significant practice effects were also observed across an average 28-month period on the 
ACE, within our sample of healthy elderly control participants. These findings are of 
considerable clinical importance, as re-test data for the ACE is not available despite its 
widespread use in clinical practice as a means of monitoring cognitive deterioration and 
response to drug therapy in early AD and MCI patients. It is possible that some of this 
variation stems from the differing administration or scoring styles of the baseline and re-test 
examiners, although reference was made, by all examiners, to the published scoring and 
administration guidelines for the ACE in an attempt to minimise this risk. 
 
Our findings imply that failure to take into account practice effects on this popular bedside 
cognitive screening measure may lead to underestimation of the magnitude and clinical 
significance of small declines in total ACE scores.  There is also the risk of falsely 
attributing improvements in performance on the ACE to treatment effects. Although 
alternate forms have been developed for the revised version of the ACE i.e. ACE-R (Mioshi 
et al. 2006), information about form equivalence is lacking and it is unclear to what extent 
clinicians make use of the alternate forms.  Furthermore, whilst details of the name and 
address for recall vary between each version of the ACE-R, the remaining subtests are 
unchanged. For these reasons, our preliminary findings using the ACE suggest that 
replication in a larger sample of healthy elderly with the more recently devised ACE-R is 
warranted. 
 
Significant practice effects in the order of an additional 2 points, were also observed for the 
delayed recall component of the RCFT. The significance of practice effects has not been 
reported in previous research, although the potential for contamination of the incidental 
nature of the learning paradigm to affect re-test recall performance has been noted and it is 
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possible that even across the relatively lengthy re-test intervals comprising the present study, 
the loss of the ‘incidental’ learning and novelty components of this task affected recall at 
follow-up.  In view of the minimal instruction accompanying this task, one would not expect 
to observe large differences in an individual’s recall ability as a function of different 
examiners. Test re-test correlations for the RCFT in our sample of healthy elderly mirrored 
those of previous studies where the lowest correlation values (likely attributable to restriction 
of range in healthy elderly samples)  have generally been reported for the copy component 
(Berry et al. 1991;Meyers and Meyers 1995), and higher correlation coefficients are reported 
in association with delayed recall (Meyers and Meyers 1995;Mitrushina and Satz 1995).   
A significant increase was observed in the average time taken to complete Part A of the Trail 
Making Test at follow-up.  This finding is in keeping with a body of previous research work 
documenting a decline in psychomotor processing speed as a function of age (Lezak 2004) 
as well as with the broader view that declines in processing speed account for ‘much if not 
all of the measured changes in performance that occur with age’ (Salthouse 1996).  As the 
instructions, task and scoring requirements for Part A of the TMT are relatively straight 
forward, with no (or minimal) on-task examinee - examiner interaction, there is little reason 
to expect to observe low levels of inter-rater reliability for this task. The apparent sensitivity 
of measures of psychomotor processing speed to the effects of normal ageing within this and 
other studies implies that Part A of the Trail Making Test may lack the specificity required to 
differentiate between normal ageing and early dementia or track small but clinically 
significant declines in the cognitive function of individual patients across time.  
 
Significant declines in performance, across an average 28 month period, were also observed 
on the Category Fluency task. This finding was unexpected and at odds with previous 
findings of significant practice effects, in the order of +1.3 words, among 106 ‘normal’ 
adults with a mean age of 57 years (Bird et al. 2004). It is conceivable that the relatively 
short i.e. one month re-test interval for the former study facilitated practice effects whilst 
simultaneously eradicating the effects of cognitive aging on lexical retrieval.  Several studies 
have documented a decline in the number of animals generated within a 60 second time 
interval with advancing age (Fama et al. 1998;Lucas et al. 1998). There is some room for 
variability in scoring this task, with regards to the extent of ‘subcategorisation’ that is 
tolerated by the examiner (i.e. fish, salmon, bream, flathead, cod).  Furthermore, the extent to 
which the examinee feels at ease within the testing environment could conceivably influence 
his/her strategy and verbal generative capacity. As such, it is plausible that some the the re-
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test variability observed for this task is accountable for in terms of the use of different 
examiners at baseline and follow-up. The reliability coefficient for the category fluency task 
using animals, fruits and vegetables (r = .86) was a little higher than that previously reported 
(r=.56; (Bird et al. 2004), which is perhaps not surprising in view of the inclusion of 3 
categories, as opposed to just one, in the present study.  
 
The lowest test re-test reliability value was reported in association with the combined dual 
task score from Sergio Della Sala’s Dual Performance Task (Della Sala, personal 
communication, 2008; (Della Sala 2005).  Previous research findings have documented 
similarly poor test re-test reliability (Baddeley et al. 1997).  In keeping with previous 
findings, much of the instability in dual task performance amongst our healthy elderly 
control group stemmed from the digit span (r=.27) as opposed to the tracking (r=.48) 
component of this task.  It is plausible that the low test re-test reliability observed for the 
digit span component of this task was compounded by the use of different raters at baseline 
and re-test. This is problematic within the context of early detection of AD where both the 
sensitivity and reliability of neuropsychological measures needs to be high in order to detect 
clinically meaningful deficits and declines.  
 
The reliability coefficient for the number of errors made at the 6 box stage of the PAL 
subtest was disappointingly low (r= .12) and less favourable than corresponding values 
previously reported in association with total error numbers (Fowler et al. 1995).  The average 
age of healthy control participants (59 years), and the interval between re-test (i.e. 1 month) 
were considerably lower, in the latter study.  These factors together with the fact that the 
error score used in our study was derived from performance across a restricted number of 
trials (i.e. during the 6 box learning trials only), and examiners differed at follow-up, may 
account for some of the discrepancy in study findings.   
 
The similarly low re-test reliabilities observed for the MMSE, the discrimination index score 
from the HVLT-R and the immediate recall component of the ACE likely reflect the 
restricted range of scores, (i.e. MMSE at T1 28 min - 30 max; ACE immediate recall at T2 
19 min -21 max; HVLT-R DI at T2 9 min – 12 max) that was observed in association with 




In summary, reliable test performances were observed on a majority of neuropsychological 
tasks across a mean 28 month interval in our healthy elderly control group.  Practice effects 
were present for several episodic memory measures together with a widely used cognitive 
screening measure (ACE) and these should be taken into account when interpreting change 
in performance on such measures over time.  The ceiling effects (MMSE, ACE immediate 
recall, HVLT-DI, RCFT copy) and low re-test reliabilities (PAL, Dual Task) observed for 
several other tasks imply these measures may be less suited to monitoring cognitive 
performance and detecting small but significant changes in performance across time, in 
patients with mild cognitive difficulties.  The significant overall decline in the performance 
of the control group on several timed tasks cautions against the use of processing speed 
measures for monitoring purposes in an elderly population, without reference to reliable 








Cognitive impairment is known to predate the point at which a diagnosis of AD can be made 
on clinical grounds.  Neuropsychological performance in the years prior to diagnosis may 
therefore help to predict whether or not a patient with cognitive complaints will develop 
dementia.  The case definition of aMCI, within existing neuropsychological longitudinal 
follow-up studies, varies on a number of important levels, giving rise to disparity in reported 
annual rates of conversion from aMCI to dementia and complicating comparison of findings 
from different studies.  There is little information of an empirical nature addressing the 
impact that variability in the use of cognitive measures, psychometric cut-offs, and 
requirement(s) for single or multiple same domain impairment, has on risk of conversion 
from aMCI to dementia. If the predictive validities of one or more neuropsychological 
measures were replicable, they could be used as part of a wider cognitive evaluation within 
specialist memory clinic settings, to provide important information of a differential 
diagnostic and prognostic nature. 
Aims 
The study aimed to determine 1) the annual rate of conversion from aMCI to dementia 2) 
whether (and which) neuropsychological performance(s) at baseline could be used to 
distinguish between aMCI patients who would and would not go on to develop dementia 3) 
the robustness of previous longitudinal findings using the ACE, GNT and PAL in predicting 
conversion from aMCI to dementia, within a larger sample of aMCI patients with higher 
general level of cognitive functioning at baseline and across a lengthier period of follow-up, 
and 4) the levels of accuracy with which a combination of neuropsychological measures and 
clinical/demographic information could predict the fate of our aMCI cohort. 
Method 
46 patients with aMCI who underwent extensive neuropsychological assessment at baseline 
and annually thereafter, were followed up for an average of 4 years and classified as having 
developed dementia or not in accordance with the presence/absence of a clinical diagnosis of 
dementia recorded in their medical file at the study endpoint. Differences in baseline 
cognitive performances of converters and non-converters were analysed using independent 
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sample t-tests, and levels of classification accuracy were determined by way of sensitivity, 
specificity, positive and negative predictive values, ROC analysis and logistic regression. 
Results 
Forty one percent (18/44) of the aMCI participants had received a clinical diagnosis of 
dementia (mostly AD) by the study endpoint, yielding an annual conversion rate of 10% 
within our aMCI clinic sample.  Performance on 2 neuropsychological measures at baseline 
(but none of the demographic indices) differentiated converters from non-converters.  Using 
a combination of ACE and/or PAL the overall rate of classification accuracy 68% was lower 
than previously reported. A regression model containing both ACE total score and HVLT-R 
DI score yielded an overall classification accuracy (for aMCI converters vs. aMCI non-
converters) of 74%.   
Conclusion  
A significant proportion of patients fulfilling criteria for aMCI go on to receive a clinical 
diagnosis of dementia.  The vast majority of aMCI patients within our sample displayed 
persisting or progressive impairment of a cognitive nature over the course of the study.  
Performance on two neuropsychological measures at baseline was helpful in discriminating 
between future aMCI converters and non-converters beyond demographic information. 
Bedside cognitive screening scores falling above cut off point for dementia are not 
necessarily commensurate with the absence of a pre-clinical dementia. The pervasiveness of 
the memory impairment in aMCI together with the high risk of conversion to dementia and 
predictive validity of several cognitive measures has implications for the clinical 
management of patients with aMCI. 
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6.1.2 Introduction 
Criteria for aMCI were devised in an attempt to capture and define the pre-clinical phase of 
AD.  There is evidence to suggest, however, that in its current form, aMCI comprises a 
heterogeneous group of patients (Blossom et al. 2007;Chertkow et al. 2007), some of whom 
will progress to dementia with time and others who will not (Visser et al. 2006).  The clinical 
usefulness of MCI as a diagnostic label has been challenged on these grounds (Petersen 
2005b) .  To maximise the diagnostic value of aMCI, criteria must give rise to a more 
homogenous group of pre-clinical dementia sufferers.  To this end, criteria should be applied 
in a manner that reflects our current knowledge of the predictive value of specific 
neuropsychological measures and their combinations. The application of MCI criteria in 
clinic and population settings is known to give rise to different subsets of patients who show 
different rates of conversion to dementia over time (Chertkow et al. 2007). Consideration of 
which cognitive measures to employ in the assessment of aMCI should therefore be context 
specific. 
 
A number of clinic-based longitudinal studies have sought to characterise the 
neuropsychological profiles of aMCI patients who do and do not go on to develop dementia, 
and to determine the predictive value of performance on neuropsychological measures 
among patients with aMCI.  A summary of study characteristics and primary findings can be 
found in Table 6.7. There is considerable variability in the length of follow-up, the general 
levels of cognitive functioning of the aMCI cohorts at baseline (as indicated by mean MMSE 
scores), the mean ages of the aMCI cohorts, and the neuropsychological measures and cut 
off levels for impairment that are employed to define aMCI.  
 
Even across studies that are clinic based, it is conceivable that such variability could 
influence the annual rate of conversion from aMCI to dementia that is observed.  As the 
prodromal phase of AD is likely to extent beyond a two-year period (Amieva et al. 2005) a 
substantial number of these studies with shorter follow-up periods risk false assignment of 
MCI non-converters. Furthermore, in the case of shorter follow-up periods, one might expect 
the baseline neuropsychological performances of the preclinical dementia participants to 
show greater impairment than would be present earlier on (i.e. 4 years before onset) in the 
course of their illness.  This would in turn have the effect of increasing the magnitude of 
predictive validities associated with baseline performance on neuropsychological tasks. A 
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relatively small number (i.e. 2/14) of existing clinic based aMCI longitudinal studies report 
follow-up periods extending beyond 3 years (Fox et al. 1998;Tabert et al. 2006).  For one of 
these, the aMCI cohort comprised participants of a younger age with an established family 
history of AD who were asymptomatic at baseline, complicating comparison with other non-
familiar, symptomatic ‘older’ aMCI cohorts (Fox et al. 1998). 
 
Similarly, where cognitive screening scores (at study entry) fall below the commonly applied 
MMSE cut off for dementia (i.e. 27/30), one might also expect to see greater levels of 
baseline neuropsychological impairment, which would facilitate the discrimination of future 
MCI converters and non-converters. To this end it should be noted that in just 3 of the 14 
clinic based longitudinal studies identified, (where the relevant data is provided), the 
baseline mean MMSE score for the MCI converter group falls above the higher cut off for 
dementia (i.e. 27/30). Levels of educational attainment for the aMCI participants were in all 
cases average at least, suggesting that an underlying dementia process might well have been 
suspected on the basis of even the most rudimentary of cognitive screening instruments 
alone, leading one to question the requirement for fuller cognitive evaluation. 
 
The comprehensiveness of the neuropsychological battery employed and the appropriateness 
(on both theoretic and empirical grounds) of test selection might also be expected to 
influence predictive validity findings. Whilst there is a good deal of variability in tests 
employed across existing clinic studies, several measures included in our own research 
battery (i.e. MMSE, ACE, semantic fluency, COWAT, BNT, famous face naming, PAL, 
TMTB and GNT) have been investigated previously, and found to differentiate MCI future 
converters from non-converters (Ahmed 2008b; Albert 2001; Amieva 2004; Blackwell 2004; 
Estevez-Gonzalex 2004; Griffith 2006; Lee 2006; Rami 2007; Tabert 2006; Thompson 
2002). 
 
Consistent across all studies is the finding of one or more measures of episodic memory 
function as a significant predictor of future conversion to dementia among MCI patients. 
There is nonetheless a good deal of variability in terms of the precise measure of episodic 
memory function chosen and the nature of the memory paradigm. Furthermore, where 
additional non-memory measures have been reported as significant co-predictors, these have 
included measures of processing speed (Albert et al. 2001;Tabert et al. 2006), and object 
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naming tasks (Blackwell et al. 2004).  High levels of discrimination between aMCI and 
normal controls have been reported in association with composite scores derived from 
performances across a range of memory and non-memory tasks (Loewenstein et al. 2007b).  
Despite this, only one clinic-based study of MCI patients has investigated the predictive 
validity of baseline composite scores for neuropsychological tasks.  Perri et al (Perri et al. 
2007) reported a sensitivity of 75% and a specificity of 68% for conversion from MCI to 
dementia across a two-year period using a cumulative delayed recall index score. 
 
The highest levels of overall classification accuracy (i.e. 100%) are reported over a 2.5 year 
interval for a combination of the PAL, age and GNT (Blackwell et al. 2004).  High levels of 
negative predictive validity (i.e. 100%) have also been reported using the PAL in 
combination with the ACE (Ahmed et al. 2008b) and the GFNT (Thompson et al. 2002) 
across shorter i.e. 1 year intervals.  These findings have not been replicated outside the test 
authors group, in larger numbers of aMCI patients, across follow-up periods extending 
beyond 2 ½ years and where the mean general level of cognitive functioning falls above cut 
off points for dementia. If replicable, however, these measures could be used in the 
neuropsychological assessment of aMCI within specialist memory clinic settings, to provide 
information of a differential diagnostic and prognostic nature to this patient group.  Clinic 
based studies using combinations of other neuropsychological variables report overall 
classification accuracies (i.e. aMCI converter vs. aMCI non-converter) in the range of 72.4% 
- 86%.   
 
The present study represents the longest detailed neuropsychological aMCI clinic-based 
follow-up study, with an average of 4 years from baseline neuropsychological assessment 
until final review of the medical notes.  It is the only study with a follow-up period extending 
beyond 3 years, for which baseline cognitive screening scores for the aMCI converter group 
fall above the higher level cut off point for dementia (i.e. 27/30 MMSE), and is one of two 
clinic based studies to examine the utility of composite cognitive scores at baseline as 
predictors of conversion to dementia in MCI patients. Furthermore, to the best our 
knowledge, this study represents the first clinic based study to investigate the robustness of 
the, GNT, GFNT and a combination of the ACE and PAL as predictors of conversion from 
aMCI to dementia outwith the authors’ research group, and to report the detailed fate of 




Forty six patients who fulfilled criteria for aMCI and undertook an extensive battery of 
neuropsychological measures at baseline were followed-up over an average of 4 years.  At 
the end of this period aMCI participants were grouped in accordance with whether or not 
they had received a clinical diagnosis of dementia (as documented in their medical file) at 
any point subsequent to their initial study assessment. Patients were also classified in 
accordance with whether or not they met our own study criteria for dementia, based on their 
performance on the neuropsychological assessment battery and the level of functional 
impairment endorsed by a significant other at their final assessment session, together with 
the magnitude of cognitive decline in domains other than that of episodic memory, across 
their years of study participation (for details see Chapter 2, Materials and Methods section).   
 
6.1.3.1 Materials, Participants & Outcome Criteria 
For details of test materials and participants see Chapter 2, Materials and Methods, sections 
2.1 & 2.2.  The primary outcome was whether or not the aMCI participant had received a 
diagnosis of dementia at study endpoint.  Dementia diagnosis at study endpoint was 
determined using two methods, 1) whether or not a diagnosis of dementia had been reached 
on clinical grounds and recorded in the participant’s notes, and 2) in accordance with a set of 
study criteria that allowed for the documentation of significant levels of cognitive 
impairment, progressive cognitive decline and functional impairment at study endpoint.  











Table 6.1  Criterion for determining an outcome of dementia at study endpoint 
 
 
6.1.3.2 Statistical Analysis 
Independent t-tests were conducted to compare the baseline performances of aMCI 
converters and aMCI non-converters on the demographic indices of age, NART FSIQ, and 
years of follow-up, and the neuropsychological measures; ACE total score, PAL, HVLT-
Delayed recall and DI, GFT, Category fluency and TMTB.  The alpha level was adjusted to 
control for multiple comparisons using Holm’s sequential Bonferroni correction method 
(Holm 1979) wherein the p-value of the largest effect size was compared to alpha (i.e. 0.05) 
divided by the number of t-tests (i.e. 10).  If this comparison was significant, then the p-
value of the next largest effect size was compared to alpha (i.e. 0.05) divided by the 
remaining number of comparisons (i.e. 9), and so on until the p-value of the 10th test was 
compared to alpha 0.05. 
 
The demographic indices were compared on account of their established influence on risk of 
developing late onset dementia (Mebane-Sims 2009;Petersen et al. 1999;Whalley et al. 
2000).  Seven neuropsychological measures (ACE, PAL, HVLT-R DI & delayed recall, 
Medical Notes Study Criteria 
 
Clinical diagnosis of dementia 
documented in the medical file at 
any point following the participant’s 
initial (i.e. baseline) study 
assessment 
 
A performance of 1.5 SD or more below study control mean on 
two or more episodic memory measures 
AND/OR 
1.5 SD or more below control mean on two or more non episodic 
memory measures 
AND 
Evidence of significant declines in non-memory domains on two 
or more tests of a cognitive domain other than that of (or in 
conjunction with) memory (as defined by a decline of a 
magnitude that would be expected to occur in less that 2.5% of 
a normative sample over the course of the study. 
AND 
Evidence of significant functional decline (as defined by 3 or 
more ratings of 3 or 4 in 2 or more non-memory domains on the 
MCI ADL scale (Farias et al. 2006) 
OR 
Evidence of decline in two or more areas of the IADL scale 
(Lawton and Brody 1969) 
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GNT, GFT, TMTB) were selected from a total of 18 on the basis of 1) their high levels of 
sensitivity to aMCI relative to other measures of similar cognitive functions as established 
via our own cross-sectional analyses or 2) high levels of predictive validity as established by 
one or more clinic based longitudinal study of neuropsychological predictors of dementia. 
 
The percentages of aMCI patients who fulfilled criteria for dementia at the study endpoint 
were calculated in accordance with medical file and study criteria.  AMCI patients who did 
not meet study criteria for dementia at their final assessment were further classified in 
accordance with percentages exhibiting a normal vs. persisting aMCI neuropsychological 
profile, and percentages showing a progressive, as compared to a non-progressive cognitive 
course during their years of study participation.  Where outcomes (i.e. dementia or no 
dementia), could be reached in accordance with both the medical file and study criteria, they 
were cross tabulated to determine levels of agreement between these two methods.  
 
Sensitivity, specificity, positive and negative predictive values, together with the overall 
percentage of classification accuracy in predicting conversion or non-conversion to dementia 
in our aMCI cohort, was determined using a combination of a total score of <88/100 on the 
ACE or a performance of 2 SD or more below controls on the PAL, as this combination of 
measures has previously been associated with perfect i.e. 100% sensitivity and negative 
predictive value (Ahmed et al. 2008b).    
 
Neuropsychological measures for which the baseline performances of aMCI converters and 
aMCI non-converters were significantly different, were entered simultaneously alongside the 
demographic variables of age, NART FSIQ and years of follow-up into a logistic regression 
analysis. The FSIQ score for one of the aMCI participants, who received a clinical diagnosis 
of dementia during the course of the study, was missing, and the corresponding data for this 
participant are for this reason not represented in the regression analysis and final model. A 
backward stepwise procedure using the likelihood ratio was applied to determine model 
content and levels of overall classification accuracy.  Criterion for entry and removal were 
set at p=0.05 & p=0.01 respectively, with 20 iteration. The Likelihood method was chosen in 
order to minimise the risk of falsely rejecting a predictor that is a significant contributor to 
outcome, as can occur where regression coefficients are large and the Wald statistic is 





Figure 6.1  Flowchart of aMCI endpoint classification in accordance with study 
outcome criteria                  
 
Normal Neuropsychological performance is defined by a performance of 1.5sd or more below control 
mean on one or less neuropsychological task at study endpoint; Abnormal neuropsychological 
performance or MCI is defined by a performance of 1.5sd or more below control mean on two or 
more neuropsychological tasks at study endpoint (chance rate among the 22 MCI participants without 
a diagnosis of dementia = 0.83 i.e. less than 1 person).  MCI declining is defined by deterioration of a 
magnitude seen in fewer than 2.5% of any given sample of healthy elderly over an average 28 month 
period in at least two measures from either the domain of semantic memory or executive functioning.   
 
In figure 6.1 it can be seen that of the 35/46 aMCI participants where data was complete at 
their final follow-up, 11/35 or 31% met study criteria for dementia. Eighteen of 35, or 51%, 
46 MCI 
Followed longitudinally 
(mean = 3.17 years) 
Clinical Diagnosis of 
Dementia 
N=11/35 
(31.4%)10% per annum 
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either fulfilled study criteria for dementia at their final assessment and/or continued to 
decline cognitively over the course of their study participation.  Of those 17/35 aMCI 
participants who did not display evidence of progressive cognitive decline over the course of 
the study, 7 displayed persisting cognitive impairment of a non-progressive nature, 10 
showed resolution of their cognitive difficulties by their final study assessment.  Four of the 
10 who showed ‘resolution’ of their cognitive difficulties at their final study assessment met 
criteria for aMCI at the point of study entry (as established via performance on baseline 
clinical assessment) but not at their first (i.e. baseline) study assessment session.  Cognitive 
impairment in keeping with dementia or MCI remained present in 71.4% of the aMCI cohort 
over the average 3-year follow-up period. 
 
Figure 6.2  Flowchart of aMCI endpoint classification in accordance with 















Forty one percent of aMCI participants in our study received a clinical diagnosis of dementia 
at some point prior to the study endpoint, yielding an annual conversion rate of 10% per 
annum. This figure rose to 47% following exclusion of the 6 MCI participants who were 
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recruited into the study on grounds of filling aMCI criteria at their clinical assessment, but 
were no longer showing sufficient evidence of impairment to meet aMCI criteria at their 
baseline study assessment.  In 61% of such cases, the diagnosis reached was that of AD.  In a 
remaining 30%, (where specified), the diagnosis was of VD or mixed VD / AD.  Fifty nine 
percent of aMCI patients in our sample had not received a clinical diagnosis of dementia an 
average of 4 years post their initial study assessment. 
 
Table 6.2  Agreement in final outcome for aMCI participants in accordance 
with study and medical file criteria determining dementia diagnosis 
 
 
Outcome criteria were available for both study and medical file methods for 33/46 aMCI 
participants.  For these 33 participants, there was 76% agreement in the two methods of 
diagnoses i.e. in 25/33 cases the diagnosis reached was the same for both methods.  For the 
8/33 cases where there was a disagreement in final diagnosis according to the two different 
methods, in half i.e. 4 of these cases, a diagnosis of dementia was reached via medical files 
but not our study criteria.  In each such case, the diagnosis of dementia was reached at least 
one year post the aMCI participant’s final study assessment.   
 
In the other 4 cases of disagreement, a diagnosis of dementia was reached via our study 
criteria but not the medical files.  In two such cases, the attending Consultant Psychiatrist 
was notoriously late in establishing clinical diagnoses of dementia.  In a further case, there 
were significant medical co-morbidities, which may have conceivably complicated the 
process of reaching a dementia diagnosis.  In the final case, it was not possible to ascertain 
any clear reasons for the disparity in classification at outcome across the study and medical 
file methods of determination.  
Count 
19 4 23 
4 6 10 
23 10 33 
no no dementia 
dementia 
Dementia diagnos 
 study criteria 
Total 






Of the 24 aMCI participants who did not meet study criteria for dementia at the study 
endpoint, 14 fulfilled criteria for aMCI and 10 were classified as normal (based on a 
performance of 1.5 SD or more below normative control group on one or less of the 18 
neuropsychological measures).  Four of the 10 participants who were classified as ‘normal’ 
were performing more than 1.5 SD below the healthy elderly control mean on one non-
memory measure of neuropsychological functioning only; 2 on one memory measure only 
and 4 were performing within 1.5 SD of the control mean on all neuropsychological 
measures.  The latter 4 participants were recruited into the study on the basis of their 
impaired performance on memory measures during a clinical assessment but were no longer 
displaying deficits at their baseline study assessment. 
 
If one were to assume that the neuropsychological variables were perfectly correlated i.e. 
r=1, then the chances of MCI participants showing impairment on two of these would be 
0.07 or 7% (i.e. 3 MCI participants would do this by chance).  If the 18 neuropsychological 
variables were all completely unrelated, i.e. r=0 then the chances of scoring 1.5 or more 
below the normal control group on two of these would be (0.07 * 0.07) = 0.005 (i.e. 0 MCI 
participants would do this by chance).  If we are to assume that the average level of 
correlation between the 18 neuropsychological variables falls somewhere between r=0 and 
r=1, say at r=0.5, then chance alone could lead to 1 MCI participant performing 1.5sd or 
more below the normative control group on 2 of these neuropsychological variables, which 
represents a very low false positive rate.  In the interest of adopting a conservative approach 
to defining persisting cognitive impairment, the criteria for persisting MCI at the study 
endpoint was specified as a performance of 1.5 SD or more below control group norms on 2 
or more of the 18 neuropsychological measures. 
 
Of the 14 MCI participants who did not receive a diagnosis of dementia according to study 
criteria, but for whom the endpoint neuropsychological assessment was abnormal, 7 
displayed evidence of significant progressive cognitive decline over the course of their study 
participation, whilst the remaining 7 did not (where significant decline was defined by a 
deterioration in at least two measures other than that of memory i.e. either the domain of 
semantic memory or executive functioning, of a magnitude seen in fewer than 2.5% of any 
given sample of healthy elderly over an average 28 month period).   
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Table 6.3  Comparison of demographic indices and baseline 
neuropsychological performance of aMCI converter and aMCI non-converter 
groups 




T df p-value 
 
Effect size 





-1.53 42 0.134 0.23 




0.44 41 0.664 0.07 




0.23 42 0.818 0.04 
Cognitive Screening       




2.98 42 0.006* ~ 0.42 
Episodic Memory       




-2.32 42 0.026* 0.34 











2.81 41 0.008* ~ 0.40 










1.84 41 0.074 0.28 
Attention/Executive       




-2.58 42 0.014* 0.39 
+results were replicated using nonparametric equivalent analysis i.e. Kruskal-Wallis test due to 
violations of the assumption of normality and homogeneity of variance; ^ higher score indicates worse 
performance; p<0.05=*; ~ sig following corrections for multiple comparisons; PAL = Paired 
Associate Learning subtest from the CANTAB battery; HVLT-R DI =Hopkins Verbal Learning Test 
Revised discrimination index; COWAT = controlled oral word association test; TMTB=Trail Making 





Following adjustment of the alpha level in accordance with Holms’ sequential Bonferroni 
correction method (Holm 1979) as a means of correcting for multiple comparisons, 
significant differences in the baseline performances of aMCI converters and aMCI non-
converters were found on the ACE (t(42) = 2.98, p<0.01, r= 0.42) and HVLT-DI ( t(41) = 
2.81, p <0.01, r=0.40) only. 
 
Only one aMCI participant obtained a score below the 5th%ile (i.e. more than 2 SD below) of 
our healthy elderly control group at baseline on the GNT. None of the aMCI patients were 
performing below the 5th%ile of our control group on the GFNT at baseline.  Sensitivity, 
specificity, NPV and PPV values relating to the prediction of conversion from aMCI to 
dementia were therefore based on a performance of more than 1.5 SD below age norms and 
can be summarised, in that order, as follows; GNT 0.38, 0.68, 0.43, 0.63; GFNT 0.44, 0.68, 
0.5, 0.63. Using a combination of ACE < 88/100 and/or PAL > 14 errors, the overall rate of 
classification accuracy was 68% with a sensitivity of 72%; specificity of 65%; PPV of 59% 
and NPV of 77%.   
 
Backward logistic regression analysis with age, NART FSIQ, years of follow-up, and the 
neuropsychological measures for which baseline performance differentiated converters and 
non-converters (HVLT-DI and ACE total score), resulted in a final model, completed after 5 
iterations, comprising the variables ACE total score and HVLT-DI score only, yielding an 
overall classification accuracy (aMCI converter vs. aMCI non-converter) of 74%, sensitivity 
65%, specificity 80%, NPV 77%, PPV 69%.   
Table 6.4  Summary of all variables within the regression equation (Step 1) 
 B(SE) Lower 
95th%ile 
CI Exp(B) 
Exp(B) Upper 95th 
%ile CI 
Exp(B) 
df p-value sig 
Age at 
study entry 
0.07(0.07) 0.94 1.07 1.23 1 0.32 
Length of 
follow-up 
0.04(0.04) 0.97 1.04 1.11 1 0.31 
NART FSIQ 0.02(0.06) 0.92 1.02 1.14 1 0.73 
ACE total 
score 
-0.17(0.09) 0.71 0.84 1.00 1 0.06 
HVLT-R DI -0.40(0.2) 0.47 0.68 0.98 1 0.04 
Constant 8.68(9.66) - 5903.63 - 1 0.37 
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Table 6.5  Classification tables for the initial and final steps of the regression 
analysis 
                                                                                                       Predicted 
 Diagnosis 
Observed No Dementia Dementia 
 
Percentage Correct 
Step 1  Diagnosis              No Dementia 
                                                
                                                Dementia 
 












Step 4  Diagnosis             No Dementia 
                                                
                                               Dementia 
 













Table 6.6  Summary of final regression model 
 
R squared = 0.27 (Hosmer & Lemeshow), 0.24 (Cox & Snell), 0.32 (Nagelkerke).  Model chi-







                          95% CI for exp b 
 B(SE) Lower exp b Upper 
Included  
Constant 15.32* (6.74)  4501208  
ACE Total Score -0.15*  (0.74) 0.75 0.86 1.00 
HVLT-R DI -0.32*  (0.16) 0.53 0.73 1.00 
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Figure 6.3  Comparative accuracies of endpoint classification (dementia vs. no 
dementia) for three composite scores 
 
AUC percentage non-memory below 1.5 SD at baseline = 0.68; AUC percentage memory below 1.5 
SD at baseline = 0.69; AUC percentage all below 1.5 SD at baseline = 0.71 
 
The percentage of neuropsychological measures on which baseline performance fell 1.5 SD 
or more below a healthy age and IQ matched control group, was associated with the highest 
level of overall endpoint classification accuracies (AUC = 0.71). Corresponding AUC’s were 
slightly lower, although similar, for the corresponding non-memory and memory composite 
scores (AUC = 0.68 & 0.69, respectively).   
 
The high level of agreement (i.e. 87%) observed between the two methods (i.e. 2 or more 
memory measures 1 SD or more below controls, or 1 or  more memory measure 1.5 SD or 
more below controls) of defining memory impairment in aMCI participants at baseline 
prevented comparison of conversion rates to dementia across these. 
 
1 - Specificity 
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Forty one percent of patients who met criteria for aMCI at study entry point received a 
clinical diagnosis of dementia within the following 4 years, yielding an annual conversion 
rate of 10% per annum. In light of evidence to suggest that the evolution from mild cognitive 
impairment to dementia is time-dependent (Busse et al. 2006) comparison in annual 
conversion rates reported by other studies was restricted to those studies with follow-up 
periods extending beyond 2.5 years (i.e. 2.5 – 3.5 years).  The mean annual conversion rate 
to dementia among 5 such studies is almost identical (9.7 % per annum) to that observed in 
the present study.  
 
Performances at baseline on the ACE and HVLT-R DI were able to discriminate between 
future aMCI converters and non-converters at a time when general levels of cognitive 
functioning falling above higher level cut off points for dementia (i.e. >27/30 on the MMSE 
and > 88/100 on the ACE), and classify MCI patient in accordance with their prognostic fate 
with a moderate degree of overall accuracy.  Differences in the baseline performances of the 
aMCI converter and non-converter groups on these measures were not accountable for in 
terms of age, FSIQ or years of follow-up, which did not vary significantly between the 
groups.  The average score of the converter group on the HVLT-R DI at baseline equated to 
a performance 1.75 SD below the published age and education matched control mean 
(Benedict et al. 1998), and 1.5 SD below the mean of our own healthy elderly age and IQ 
matched control sample.  The corresponding values were 0.58 SD and 0.37 SD for the non-
converter group (i.e. both within 1 SD of their respective control means) implying that there 
is a greater risk of conversion to dementia among the subset of aMCI patients who perform 
abnormally on this task, and that such patients are readily identifiable on the basis of 
published norms.   
 
Similar values derived for the ACE, in relation to both published normative (Mathuranath et 
al. 2000), mean converter = -1.75  SD; mean non-converter = - 0.5  SD, and study control 
data, mean converter = -2.5 SD; mean non-converter = -1 SD, provide further support for the 
designation of 88/100 as a higher cut of point for dementia and suggest that use of this cut 
off score is appropriate among aMCI sufferers, despite the younger age group of the original 
ACE normative sample.  
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As such, in clinical practice, the combined performances of aMCI patients on the ACE and 
HVLT-R DI could be used to inform decisions about the frequency of future contact / 
monitoring required, or in combination with additional clinical information (i.e. levels of 
carer rated depressive symptoms (Lu et al. 2009), APOE 4 carrier status (Petersen et al. 
2005), corroborative history, neuroimaging findings, family history and/ or qualitative 
aspects of a patients presentation) to inform whether or not to treat pharmacologically.  The 
relatively small proportion of aMCI patients showing resolution of their cognitive symptoms 
over time also has implications for the clinical management of such patients, as a number of 
empirically validated rehabilitative methods for the cognitive rehabilitation of early stage 
AD are known to exist (Clare and Woods 2004) and could theoretically be used to enhance 
the day to day memory functioning of patients with aMCI.   
 
Furthermore, although it was not possible to compare the predictive validities of the two 
methods of determining memory impairment in aMCI, the high levels of agreement between 
the methods suggests that it is unlikely that a patient classified as aMCI on grounds of a 
performance of 1 SD or more below the control mean on two memory measures would be re-
classified as normal if the criteria of <1.5 SD on one memory measure were applied, and 
vice versa. As such, the application of either of these methods to define memory impairment 
in aMCI, within a tertiary specialist memory clinic setting is supported.  Similar high levels 
of agreement in classification as MCI or normal using these two methods of psychometric 
definition were reported in a recent study by Jak et al. (Jak et al. 2009).  The poor to fair 
AUCs associated with the numbers of memory, non-memory and combined 
neuropsychological baseline measures performed more than 1.5 SD below age norms, on the 
other hand, suggests that the use of composite scores (defined in this manner) are of limited 
clinically utility in the prediction of outcome in aMCI. 
 
Baseline scores on both the HVLT-R DI and the total score on the ACE were significant 
independent predictors of future conversion to dementia among aMCI sufferers.  Closer 
inspection of the regression analysis reveals that the HVLT-R DI score contributes to the 
overall classification accuracy of the ACE by increasing negative predictive value i.e. by 
reducing the probability of conversion to dementia in the face of a sound score. This implies 
that an impairment of a consolidation/storage nature is generally present in cases where a 
diagnosis of dementia (AD, VD or AD/VD) is reached within the following 4 years.  
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The PAL subtest from the CANTAB is also a measure of cued recognition ability.  Whilst 
performance at baseline is reportedly unimpaired in some Questionable Dementia and aMCI 
clinic based samples (Fowler et al. 1995), and significant differences between future 
converters have not been found consistently (Ahmed et al. 2008b), a decline across time in 
the years prior to diagnosis has been established (Fowler et al. 1997).  It is possible that the 
emergence of cued recall impairment is time bound, arising closer to the point at which AD 
can be diagnosed on clinical grounds and sometime after initial difficulties with the less 
supported function of free recall become apparent.  The ability of cueing to facilitate 
episodic recall may fade with pre-clinical disease progression, giving rise to an 
encoding/consolidation profile of memory impairment. In the case of the HVLT-R DI, the 
inability of aMCI patients to implicitly make use of cues to the same extent as ‘healthy’ 
elderly may be amplified by the semantic grouping structure of this measure.  Savage et al. 
have also demonstrated an encoding/consolidation deficit, that is prototypical of AD, in 
small groups of aMCI and early AD patients using a verbal list learning task (i.e. The 
California Verbal Learning Test) with similar scope for implicit semantic grouping of list 
items (Pike et al. 2008). 
 
This observation has implications for the recently proposed new research criteria for AD 
(Dubois et al. 2007), in which the requirement for objective evidence of significantly 
impaired episodic memory has been elaborated upon.  The new criteria emphasise the 
superior discriminative and predictive power of delayed as compared to immediate recall 
measures as well as the importance of establishing an encoding and storage deficit using test 
paradigms that provide encoding specificity, on grounds that reduced benefit from cueing at 
recall reliably identifies prodromal AD.  Our findings lend support to the specification of 
episodic memory impairment in this manner.  However, the limited range of scores 
attainable using the HVLT-R DI and resultant potential for floor effects, suggests it may be 
lesser suited, than PAL, for monitoring decline in episodic memory function over time. 
 
The newer version of the ACE-R (Mioshi et al. 2006) incorporates a delayed cued verbal 
recognition element.   In light of the added predictive value of the HVLT-R DI demonstrated 
in the present study, it would seem prudent to evaluate whether or not this measure retains its 
prognostic contribution alongside the ACE-R.  
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The mean total score on the ACE for those aMCI within our sample who had received a 
clinical diagnosis of dementia by the end of the study fell just below the level cut off point 
for dementia (i.e. 87/100). Despite this, for 26% of these patients, baseline ACE scores fell 
above the higher cut off point for dementia (i.e. 88/100).  This would suggest that where the 
ACE is used as the sole means of determining the likelihood of developing dementia over the 
proceeding 4 years, up to one quarter of all aMCI patients receive false reassurance of 
normality.  The implications of using the ACE as  sole means to determine the presence or 
absence of clinically significant levels of cognitive impairment are even greater, with the 
present findings indicating that 62% of patients who fulfil criteria for aMCI obtain scores of 
88 or above on the ACE.   
 
We were unable to replicate the high levels of sensitivity, specificity, positive and negative 
predictive values that have been previously reported in association with combined PAL and 
ACE scores, the GNT and the GFT (Ahmed et al. 2008a;Blackwell et al. 2004;Thompson et 
al. 2002).  In the case of the latter naming measures, it should be noted that a cut off point of 
a performance more than 1.5 SD was employed in place of the previously reported 2 SD cut 
off (Thompson et al. 2002) on account of the fact that only one aMCI participant was 
performing more than 2 SD below our control mean.  This finding likely reflects the shorter 
follow-up period (i.e. 13.7 months from BL until study endpoint) used in the latter study, 
resulting in shorter intervals until diagnosis, which are in turn commensurate with the greater 
magnitudes of impairment observed on these naming tasks.  It is plausible that the predictive 
validity of neuropsychological measures, or their combinations, varies as a function of the 
number of years prior to diagnosis.  This possibility underscores the need for careful 
consideration of both the length of follow-up and the levels of cognitive functioning of aMCI 
cohorts at baseline in study comparisons. 
 
There are a number of study limitations worthy of note.  Firstly, although a mean follow-up 
period of over 4 years compares well with previous clinic based studies of longitudinal 
outcome in aMCI, it remains possible that additional aMCI participants will go on to receive 
a clinical diagnosis over the longer term.  Secondly, the high average pre-morbid IQ and 
select nature (i.e. tertiary referral, amnestic single and multi-domain & primarily AD 
endpoint diagnosis) of our aMCI cohort limits generalisation of the study findings beyond 
groups that are characterised similarly.  Although the overwhelming predominant diagnosis 
of dementia, where reached was of AD or mixed AD/VD type, a small portion of aMCI 
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participants were diagnosed with vascular dementia.  In the case of 17 aMCI participants no 
neuroimaging was undertaken to exclude a contribution of brain changes of a non-atrophic, 
i.e. structural or vascular nature to the cognitive complaint. The resultant inclusion of 
endpoint clinical diagnosis other than that of pure AD, may have influenced the predictive 
validity of the neuropsychological measures within our battery, although it could be argued, 
in a more practical sense, that exclusion of aMCI participants on grounds of multiple risk 
factors is not reflective of clinical reality.  Finally, the diagnosis of AD, particularly in its 
very early stages, is notoriously difficult to make and a definite diagnosis can only be 
established by way of brain autopsy at post mortem.  Furthermore, there is variability in the 
point at which clinicians arrive at a diagnosis of dementia, despite a common bias towards 
avoiding false positive diagnoses.  As such, it remains possible that for some aMCI patients 
clinical diagnostic status at the study endpoint was in part reliant on the idiosyncrasies of 
their attending consultant.  Ideally, consensus diagnosis among a number of different 
specialists, together with longer-term follow-up to achieve autopsy confirmed diagnoses, 
may have helped to reduce the likelihood of false or unreliable diagnoses, however adequate 
staffing of the nature required to do this was not available in the current study.  In view of 
this, potential limitations in both the validity and reliability of dementia diagnoses reached 
by my consultant psychiatry and geriatrician colleagues must be recognised.   
6.1.6 Conclusion 
Just under half of the participants who met criteria for aMCI at their baseline study 
assessment received a clinical diagnosis of dementia at some point over the four years that 
followed.  The 10% annual conversion rate to dementia observed in the present study is 
similar to rates reported previously in association with clinical based aMCI samples across 2-
5-3.5 year follow-up intervals.  The vast majority of aMCI patients within our sample 
displayed persisting or progressive impairment of a cognitive nature over the course of the 
study.  Performance on two neuropsychological measures at baseline differentiated between 
future aMCI converters and non-converters and performance was predictive of outcome (i.e. 
dementia vs. no dementia) over and above demographic indices, with an overall 
classification accuracy of 74%.  Over one quarter of aMCI participants who went on to 
receive a clinical diagnosis of dementia performed above higher level cut off points for 
dementia on the ACE at their initial assessment.  The pervasiveness of the memory 
impairment in aMCI, the high risk of conversion from aMCI to dementia and the predictive 
validity of several cognitive measures have implications for the clinical management of 
patients with aMCI. 
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Table 6.7  Summary of clinic based findings pertaining to the prediction of 
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24 prAD 
73 48  7-8  NA 20 
 
(20) 
Logistic reg aMCI + 
prAD visual memory 
and age were sig 
predictors 
Logistic reg aMCI 
alone no sig 
predictors of C 
No details of model 
or accuracy of 
prediction provided 
ACE, Addenbrookes Cognitive Examination; ADAS, Alzheimer’s Disease Assessment Scale; AKT, The Alters-Konzentrations Test; ALB, Associative learning battery; ANT, Animal Naming 
Test;  BD, Block Design; BNT, Boston Naming Test; BVRT, Benton Visual Retention Test; CANTAB, Cambridge Automated Neuropsychological testing Assessment Battery; CERAD, 
Consortium to Establish a Registry for Alzheimer’s Disease; CFL, lexical fluency using these letters; C, converter; CSRT, Cued and Selective Reminding test; CVLT, California Verbal Learning 
Test; DRS, Dementia Rating Scale; DSST, Digit Symbol Substitution Test; FAS, lexical fluency using these letters; FU, follow-up; GNT, Graded Naming Test; GFNT, Graded Faces Naming 
Test; IST, Isaacs Set Test; LCT, Letter Cancellation Test; MMSE, Mini Mental State Examination; n, sample size; NC, non-converter; OA, Object Assembly; OME, Object Memory Evaluation; 
RAVLT, Rey Auditory Verbal Learning Test; RMT, Recognition Memory Test; SIT, Semantic Interference Test; SOT, Self Ordering Test; SRT, Selective Reminding Test; TMTB, Trail Making 
Test Part B; VR, Visual Reproduction; WMS, Wechsler Memory Scale; reg, regression; AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value; Spec, 
specificity; Sens, sensitivity; Conv, converter; Non-conv, non-converter; prAD, prodromal Alzheimer’s Disease. 
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7. General Summary and Conclusions 
 
Elderly patients with memory complaints, who exhibit cognitive impairment(s) that fall short 
of dementia, typically display deficits of verbal episodic and semantic memory on 
comprehensive neuropsychological assessment.  Many such patients perform above higher-
level cut-off points for dementia on even the most comprehensive bedside cognitive 
screening measures at initial presentation.  Patients presenting in this manner, comprise 
around one quarter of the referrals received by tertiary referral memory clinics. Hence, there 
is a clear need for evidence based guidance as to how they might best be managed clinically, 
with regards to assessment, investigative and treatment requirements.  
 
The findings of the this series of studies advance our current understanding of the 
neuropsychology of early and preclinical AD and provide an evidence base from which 
clinical management decisions pertaining to aMCI could be drawn.  
 
With regards to the assessment and detection of aMCI, both the MMSE and the ACE lack 
sensitivity to the cognitive impairment that underlies aMCI.  This implies that large numbers 
of elderly patients presenting with memory complaints who are cognitively evaluated with 
these bedside cognitive screening instruments, may be mistakenly categorised as ‘worried 
well’ or ‘normal for age’.  Our findings highlight the need for comprehensive 
neuropsychological assessment, beyond bedside cognitive screening, that incorporates a 
number of measures of functioning within the domains of episodic, semantic memory and 
executive functioning, to obtain acceptably high levels of sensitivity to aMCI. The sensitivity 
of a number of such measures to aMCI is well-documented in this, as well as other studies 
(Ahmed et al. 2008a;Ahmed et al. 2008b;Alladi et al. 2006;Dudas et al. 2005b). Measures of 
face and object naming, category fluency and speeded divided attention, in conjunction with 
those assessing of delayed verbal and visual recall and recognition memory are among the 
most sensitive, although none of these retains acceptable levels of specificity in 
differentiating aMCI from normal aging or depression.  These measures can, however, be 




The study findings have implications for the provision of information of a prognostic nature 
to patients with aMCI.  In just under 50% of cases where criteria for aMCI were met at the 
study baseline assessment, a diagnosis of dementia was reached on clinical grounds within 
the following four years. There would appear to be some consistency in the annual 
conversion rates from aMCI to dementia reported across a range of clinic based longitudinal 
studies of similar length, despite some minor differences in the manner in which aMCI 
criteria are applied.  Equally, following exclusion of 4 aMCI study participants with an 
unstable neuropsychological profile (i.e. impaired at the point of recruitment but not baseline 
study assessment), the rate of reversion to ‘normal’ during the course of the study (defined 
psychometrically in accordance with chance levels of poor test scores) appears to be low 
(15%).  For the vast majority of aMCI who do not receive a clinical diagnosis of dementia 
cognitive impairment either persists or worsens over time.   
 
On the basis of our own findings and similar clinic based studies, it would therefore seem 
reasonable to assign a one in two chance of developing dementia across the proceeding 4 
year period to patients who have been identified within specialist clinics as fulfilling criteria 
for aMCI on more than one occasion.  Where conversion to dementia does not occur, one 
could expect to see persisting or worsening cognition in a majority of cases. 
 
In the present study, along with others of a similar duration, a high rate of conversion from 
aMCI to dementia was observed.  The predominant alternative outcome to dementia in the 
present study was persisting or worsening cognitive function.  Two easily administered 
cognitive tasks contributed significantly to the identification of aMCI as it represents pre-
clinical dementia.  Together, these findings challenge the current standard clinical practice 
wherein aMCI patients are not routinely placed under review, or referred on for further 
investigations, and are provided with little, if anything, in the way of intervention(s) or 
prognostic information.   
 
The present study findings indicate, along with that of others, (Fowler et al. 1995;Fowler et 
al. 1997;Fowler et al. 2002) that it is possible to detect cognitive decline of an ‘abnormal’ 
magnitude on measures of neuropsychological function with relevant knowledge of re-test 
reliabilities, effects of normal aging and practice effects. In view of this, and the high 
likelihood that clinically significant levels of progressive cognitive deterioration will be 
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observed in aMCI over time, further consideration should be given to the manner and 
frequency with which aMCI patients are reviewed in clinical practice. 
 
At the very least, the initial clinical assessment of aMCI could include measures such as the 
ACE and HVLT-R DI with established prognostic utility.  Where indicated and available, the 
high risk aMCI patients could receive further investigations in the form of imaging (i.e. PET) 
and or genetic testing, where these are available.  Outcomes from these investigations could 
be used together with information of a qualitative/clinical nature to further refine 
ascertainment of prognosis and/or the appropriate timing of pharmacological intervention.  
 
Finally, the high rates of conversion from aMCI to dementia, and of persisting and 
progressive cognitive decline in aMCI, suggest that there may be a role for interventions of a 
non-pharmacological nature in aMCI.  There exist a number of empirically validated internal 
and external strategies to aid everyday memory function in early AD that could theoretically 
be extended to aMCI (Clare and Woods 2004).  Furthermore, it is conceivable that there may 
be advantages in introducing such strategies at the earliest possible stage of the disease 
process in AD, at a time when some capacity to learn remains present, affording the 
opportunity to establish new routine(s) prior to the onset of more generalised impairment of 
cognition and the emergence of co-morbid behavioural symptoms.  The introduction of 
interventions of this nature at an earlier stage would also maximise the patient’s capacity to 
contribute to and shape these in accordance with their own personal wishes. 
 
Prior to concluding, there are a number of study strengths and limitations worthy of note. 
Perhaps the most notable study strengths relate to the large number of participants 
comprising the aMCI group and the relatively long follow-up period (in comparison to other 
published clinic-based neuropsychological longitudinal research).  The latter serving to 
reduce the likelihood of false negative endpoint classifications of non-converter among 
aMCI patients who do in fact go on to develop dementia post study endpoint. The study 
represents one of, if not the, most detailed and comprehensive longitudinal 
neuropsychological evaluation of cognition in aMCI.  The study battery taps different 
aspects of functioning within specific cognitive domains (i.e. visual and verbal memory, free 
and cued delayed recall) allowing for a more detailed comparison of the prognostic and 
differential diagnostic performance of a number of different neuropsychological measures 
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that are commonly used in the assessment of the elderly.  For many such measures, the study 
represents a first attempt to compare their differential diagnostic utility and prognostic 
validity in the assessment of aMCI, early AD and depression. The heterogeneity of aMCI is 
widely acknowledged.  In the present study, however, the tertiary nature of referrals mean’t 
that all aMCI participants had undergone psychiatric/ or physician and GP examinations 
prior to study recruitment with the effect of minimising the likelihood that cognitive 
complaints were related to underlying medical illness or were sufficient to fulfil criteria for 
early dementia.  The minimal impairment of general levels of cognitive functioning of our 
aMCI group further reduced likelihood of observing ‘artificial’ inflation of the prognostic 
significance and effect sizes of tests, on account of a proportion of this group already 
meeting criteria for early AD.   
 
Study limitations worthy of note include the fact that study outcome criteria were incomplete 
owing to an inability to collect a number of outstanding functional scales for the aMCI folk.  
Furthermore, the clinical outcome of dementia vs. no dementia was reliant on the judgement 
of the attending Consultant Psychiatrist and was not independently verified via application of 
NINCDS or DSM-IV criteria. As such, and without autopsy confirmation of AD or other 
forms of dementia, outcome criteria in accordance with the medical file method, most 
accurately represent the numbers of aMCI patients who received a diagnosis of dementia as 
opposed to numbers who converted to dementia.  
 
A further criticism of the research involves the reliance on neuropsychological measures to 
recruit and in the case of early AD and aMCI, define participant groups.  There is a degree of 
circularity in using cognitive complaints and neuropsychological tests to define clinical 
conditions and then to compare them which must be acknowledged here.  The 
neuropsychological assessments were carried out by a numer of different raters across the 
course of the study, without information regarding inter-rater reliability.  As such, it is 
conceivable that some of the variability in performances of individual participants at 
different time points is accountable for in terms of differences in rater test administration 
styles, techniques or scoring (despite the use of a common administration manual for all of 
the neuropsychological measures was employed as a means of maximising inter-rater 
reliability).  Functional scales were administered to the spouses or primary carers of the 
aMCI participants at the studyend point only.  This prevented the tracking of functional 
status across time.  Consequently, functional decline had to be infered from the absolute 
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scores on the scale at study endpoint, as opposed to change scores from baseline to final 
assessment.  Furthermore, the Geriatric Depression Scale was  administered to the 
depression group only, such that it is conceivable that elevated levels of depressive 
symptoms were also present in the aMCI, AD and or CT groups with the effect of 
complicating the interpretation of the relative performances of the groups. With further 
regards to the depression group, limited clinical details were gathered.  This lack of 
information prevented fuller interpretation of neuropsychological performance in accordance 
with whether predominant make up is EOD or LOD, a distinction that is known to influence 
the neuropsychological performance of elderly patients with depression. 
 
This study highlights the prognostic value of a measure of delayed verbal recognition in the 
prediction of conversion from aMCI to dementia.  This measure, together with the original 
version of the ACE, added over and above the clinical variables of age, FSIQ and duration of 
follow-up, to the prediction of dementia.  As the revised version of the ACE (ACE-R) 
contains a verbal recognition subtest, it would seem worthwhile determining whether the 
inclusion of such a subtest negated the additional predictive power of the discrimination 
index score from the HVLT-R.   
 
Furthermore, we demonstrated that verbal fluency measures, and more specifically the 
differential performance in lexical and semantic measures, better discriminate between the 
healthy elderly and those with aMC, than traditional measures of delayed verbal recall.  The 
ACE also demonstrated greater (although still inadequate) sensitivity to aMCI than the 
MMSE.   Although classified as a bedside cognitive screening measure, the ACE is 
relatively lengthy compared to the MMSE, requiring on average 15 mintues to administer.  
This is a limiting factor in its use in busy clinic settings.  As such, it would be of practical 
import to determine the extent to which its discriminative capacity and sensitivity to aMCI is 
attributable to performance on the fluency subtests alone (which require only 2 mintues to 
administer). 
 
The present study focuses soley on performance on neuropsychological measures as a means 
of detecting incipent dementia.  As dissuced previously however, there are a number of 
different lines of investigation comprising behavioural, imaging and CSF biomarkers for pre-
clinical AD.  Future research should pursue a more integrated multi-disciplinary approach, 
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allowing for the determination of the prognostic power of combinations of all of the above 
markers and direct comparison of their respective prognostic values in identifying pre-
clinical AD. 
 
Clinicians views regarding the diagnostic value of aMCI and the role of neuropsychology vs. 
clinical opinion in arriving at such a ‘diagnosis’, remain divided.  On the one hand, clinical 
acumen is difficult to teach, arising largely out of experience.  Clinical judgement is equally 
difficult to measure, and methods of arriving at a clinical judgement are likely to vary widely 
from one practitioner to the next, making it difficult to research and compare findings across 
different studies. On the other hand, neuropsychological expertise, and indeed the time to 
conduct additional cognitive measures within the course of a medical, psychiatric or 
neurological examination, is not always available.  Furthermore, performance on 
neuropsychological testing may be influenced by a number of factors (i.e. motivation, 
fatigue, anxiety, sensory deficits ect.) that do not relate to the pathology under investigation.  
This together with the scarcity of comprehensive local normative data for a number of 
neuropsychological measures may complicate interpretation of test scores.   
 
Regardless of the means by which a diagnosis of aMCI is arrived at, the cognitive features of 
a patient’s neuropsychological presentation remain vital components of the very early and 
differential diagnostic process. The above studies demonstrate that there remains 
considerable scope to improve upon the manner in which cognitive aspects of AD and aMCI 
criteria are implemented, in order to facilitate earlier diagnosis and optimise the clinical 
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Screening for mild cognitive impairment: a systematic review
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SUMMARY
Objective Patients with mild cognitive impairment account for a significant number of referrals to old age psychiatry
services and specialist memory clinics. The cognitive evaluation of such patients is commonly restricted to brief dementia
screens, with no consideration to their suitability for assessing MCI. Here, we review the utility of such cognitive screens for
MCI and provide an overview of validated instruments.
Methods We identified papers published after Petersen and colleagues 1999 MCI criteria (Petersen et al., 1999) and
examining face-to-face cognitive screening forMCI from publication databases using combinations of the search terms ‘mild
cognitive impairment’ and ‘cognitive screening’. We also combined the former search with the names of 39 screening tests
recently identified in a relevant review (Cullen et al., 2007).
Results Fifteen cognitive screening instruments were identified, 11 cover a restricted range of cognitive domains. High
sensitivity and specificity for MCI relative to healthy controls were reported for two comprehensive and two noncompre-
hensive screening instruments, adequate test-retest and inter-rater reliability for only one of these. With the exception of three
studies, sample sizes were universally small (i.e. n 100), and prognostic values were reported for only two of the identified
15 screening measures. Sensitivities of the full domain measures were universally high, but information about their
specificity against psychiatric and non-progressive neurological conditions and predictive validity is lacking.
Conclusion Several cognitive screening instruments afford the clinician the ability to detect MCI, early AD, and in some
cases non-AD dementia, but they cannot currently be used to make reliable inferences about the course and eventual outcome
of MCI. Copyright # 2009 John Wiley & Sons, Ltd.
key words—systematic review; screening; mild cognitive impairment; dementia; Alzheimer’s disease; vascular
dementia; differential diagnosis; neuropsychology
INTRODUCTION
‘Mild cognitive impairment’ (MCI) is currently the
most widely used term to describe cognitive impair-
ment with sound functional capacity and (usually)
isolated memory impairment, i.e. without dementia
(Petersen et al., 1999, 2001; Mitchell et al., 2008).
Although ‘multi-domain’ and ‘non-amnestic’ MCI
subtypes (Petersen, 2004) have been identified, most
MCI studies have focused on the amnestic form
(aMCI) (Petersen et al. 1999). Petersen’s criteria
(Petersen et al., 1999, 2001; Petersen, 2004) do not
specify the means by which intact other areas of
cognitive functioning should be established. The
relative rarity of the pure amnestic MCI subtype
makes it likely that MCI study samples include a
combination of both amnestic single and amnestic
multi-domain subtypes (Alladi et al., 2006; Lonie
et al., 2008b). In this review, MCI is therefore
generally used to describe such single and multi-
domain amnestic forms.
MCI is associated with elevated rates of conversion
to Alzheimer’s disease (Petersen et al., 1999; Busse
et al., 2003a; Lehrner et al., 2005; Alladi et al., 2006;
Busse et al., 2006; Storandt et al., 2006; Tabert et al.,
2006; Palmer et al., 2007). Both neuroimaging (Hirao
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et al., 2005; Jessen et al., 2006; Rose et al., 2006;
Saykin et al., 2006) and neuropathological studies
(Morris et al., 2001; Bennett et al., 2005; Albert and
Blacker 2006) report intermediate findings between
those seen in normal aging and early AD. With the
development of disease modifying or halting agents,
recognition of AD at the earliest possible stage will
become increasingly important.
Estimates for cognitive complaints in the older adult
general population range from 3.1% (Busse et al.,
2003b) to 15% (Frisoni et al., 2000), depending on case
definition and mean age of the sample. The cognitive
evaluation of patients with MCI therefore forms an
important component of geriatric care (Petersen and
O’Brien, 2006) and referrals to specialist memory
clinics (Alladi et al., 2006; Lonie et al., 2008b).
In a recent review of cognitive screening in
dementia, Cullen and colleagues (2007) caution
against a ‘one size fits all’ approach to dementia
screening and advocate the use of a wider range of
specialised cognitive screening tools for different
situations. In recognition of the different purposes for
which cognitive screening measures are used, we
divide our review between screening measures that
provide an indication of functioning across a
comprehensive range of cognitive functions and those
assessing a restricted range of cognitive domains.
Comprehensive cognitive screening measures are
likely to be more suitable for secondary or tertiary
specialist settings, while the shorter cognitive screens
that do not rely on specialist theoretical knowledge or
training are likely to have greater application in
screening for cognitive impairment in the community
or in a primary care setting.
METHODS
Papers following upon the publication of Petersen and
Windblad’sMCI criteria (Petersen et al., 1999;Winblad
et al., 2004) were identified by electronic databases
searches of BIOSIS Previews, Embase, Medline,
PsychINFO, Social Sciences Citation Index, ASSIA
Plus, IBSS Online, PsychARTICLES, ISI Proceedings
and Web of Knowledge (Figure 1). We used
combinations of the search terms ‘Mild Cognitive
Impairment’ and ‘cognitive screening’. The same
databases were searched again combining the search
term ‘Mild Cognitive Impairment’ with the names of
39 cognitive screening tests identified in a recent review
of tests for cognitive impairment (Cullen et al., 2007)
(Figure 2). Non-screening tests of performance in a
single cognitive domain, or their combinations, were
excluded as were non face-to-face screening measures
and those that are wholly carer or informant-rated
(Lines et al., 2003; Giaquinto and Parnetti, 2006; van
Uffelen et al., 2007), although the latter may well
provide a significant adjunctive or standalone contri-
bution to MCI screening in primary care (Galvin et al.,
2007). Where more than one version of a screening
instrument existed, we included only the most up-to-
date version of the test on the assumption that
modification to a previous test version had lead to an
improvement in one or more aspects of the test.
Fifty-seven papers were identified. Seven of these
were excluded as they were not face-to-face or non-
cognitive in nature. The findings were reported in a
language other than English for a further three papers.
None of the screening measures reported in the non-
English papers were reviewed as part of included papers
that werewritten in English. The remaining studies were
excluded as they comprised duplicate data (n¼ 3) or did
not meet the study objectives i.e. ‘to investigate the
screening utility of cognitive screening measures in
MCI’ (n¼ 12). Petersen’s MCI criteria (Petersen et al.,
1999) were not met, or were not specified, in a further
12 studies that were excluded.
RESULTS
In total, 21 of the identified 57 papers were included in
the review. A further nine papers were added from the
reference lists of these 21 papers and the author’s
personal records. A total of 30 papers form the content
of this review.
Initially, we provide a summary of cognitive screen-
ing measures for MCI (Table 1), starting with the most
widely used cognitive screening instruments. An
examination of the usefulness of such measures
(grouped in accordance with their degree of domain
coverage and single or combinations of measures)
follows thereafter (Table 2). It is recognised that
cognitive screening measures are used for different
purposes in different settings and at varying levels of
specialist care. Within research and general practice
contexts the emphasis is on the identification of
clinically significant levels of impairment across a
restricted range of cognitive abilities. At more specialist
levels of care, knowledge gained via more comprehen-
sive assessment of each of the primary domains
of cognition (i.e. memory, language, visuospatial/
perceptual processing, attention and executive function-
ing) is utilised in the differential diagnostic process. For
practical reasons then, the screening instruments that
form part of this review are grouped in accordance with
their comprehensiveness. Those providing coverage of
each of the primary domains of cognitive function are
Copyright # 2009 John Wiley & Sons, Ltd. Int J Geriatr Psychiatry (2009)
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referred to as ‘comprehensive’ and those providing
partial domain coverage as ‘non-comprehensive’.
Table 1 lists the range of cognitive screening
measures identified, grouped in accordance with their
comprehensiveness: Relatively few provide coverage
of the full range of cognitive domains, as established
by neuropsychological profiles in different dementias
(Roth et al., 1986; Morris et al., 1989; Nasreddine
et al., 2005; Mioshi et al., 2006), requiring administra-
tion times of over 10min. The bulk of screening mea-
sures identified in this review provide an indication of
clinically significant levels of cognitive impairment
based on performance across a restricted range of
cognitive domains, without allowing for more detailed
analysis of patterns of performance (administration
times 2–15min). With the exception of the CDT,
recent memory is universally assessed, although there
is a good deal of variability in paradigms, ranging
from registration and later recall of words, sentences,
test instructions, to name and address. Recognition or
cued recall items together with some measure of
language or semantic memory function and attention/
working memory, form part of each of the compre-
hensive screening measures and the lengthier
(i.e.> 10min) non-comprehensive measures, with
the exception of the CAMCI (Lam et al., 2008).
In the main, copied drawings, incl. clock
drawing, comprise the assessment of visuospatial
Figure 1. Flow Diagram of Literature Search 1.
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and constructional skills. The ADAS-Cog (Mohs
et al., 1997) provides the only assessment of praxis
and the ACE-R is the only screening measures to
provide an assessment of visuo-perceptual ability.
None of the 15 screening measures identified includes
an assessment of general reaction time.
Comprehensive cognitive screening
While high sensitivity for MCI (i.e. 84–90%) is
reported for both the ACE-R and the MoCA
(Nasreddine et al., 2005; Mioshi et al., 2006;), all
but one of the subtests from the CERAD failed to
discriminate between a small group (n¼ 15) of
minimally educated MCI patients and age and
education matched healthy controls (Karrasch et al.,
2005). Adequate levels of sensitivity for MCI have
also been reported for the CAMCOG subtest from the
CAMDEX (Neilson et al., 1999). High levels of
specificity are reported for both the ACE-R andMoCA
in relation to normal ageing alongside moderate values
(72%) for the CAMCOG (Table 2). Specificity values
are not reported for the CERAD. ACE-R performance
Figure 2. Flow Diagram of Literature Search 2.
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screening for mild cognitive impairment
data are available only for a small number (n¼ 36) of
well educated, relatively young MCI sufferers of
above average pre-morbid intellectual functioning
(Mioshi et al., 2006). The applicability of the
normative data to older and less well educated MCI
sufferers of average pre-morbid IQ remains uncertain.
The CAMCOG is the only comprehensive cognitive
screening measure for which predictive validity values
are reported, although the level of specificity for
conversion to dementia would appear to be too low to
support its use for prognostic purposes (Neilson et al.,
1999). None of the measures report specificity values
for MCI in relation to depression or any other
neurological or psychiatric diseases of a non-
progressive nature.
Moderate to high 1-month test–retest reliability
values (70–92%) are reported for MoCA (Nasreddine
et al., 2005). Despite the need for longitudinal follow-
up in this specific patient group, reliability data are not
reported for clinically relevant intervals (i.e. 6–12
months) or for any other of the more comprehensive
cognitive screening measures. The absence of this
information complicates the interpretation of score
changes that are so important in determining prog-
nosis in this patient group.
Two comprehensive cognitive screening measures,
the ACE-R (Mioshi et al., 2006) and the DemTect
(Kalbe et al., 2004) have been validated for use within
a range of non-AD dementias in conjunction with
MCI. This is particularly useful in secondary and
tertiary care where cognitive screening routinely
forms part of the differential diagnostic process.
Without exception, patient samples for studies
investigating the more comprehensive screening
measures were drawn from specialist university or
hospital clinics. Their utility in screening for MCI
within community or primary care settings is therefore
unknown. Cut-off values with corresponding levels of
sensitivity and specificity to assist in differentiating
MCI from normal aging are provided for all but the
CERAD. Demographic adjustment equations are
provided for the MoCA (Nasreddine et al., 2005),
whilst cut-off values for the CAMCOG and the ACE-
R relate to raw scores, facilitating ease of use in busy
clinic settings.
Non-comprehensive cognitive screening
Table 2 also summarises the relevant characteristics of
the cognitive screening measures with incomplete
domain coverage. Of these, the MMSE (Folstein et al.,
1975) is the most commonly used in clinical practice
(Shulman et al., 2006). Its ability to differentiate MCI
sufferers from healthy elderly controls has not been
established consistently (Saka et al., 2006; Slavin
et al., 2007). Furthermore, significant differences,
where they do exist, range in magnitude from less than
1 scale point (Ravaglia et al., 2005) to a maximum of
just under 2 points (Slavin et al., 2007). As the
majority of MCI patients score above the commonly
used MMSE cut-offs of 24 and 26, there is a
considerable overlap in the scores of patients with
MCI and age matched healthy controls. The sensitivity
of the MMSE to MCI is therefore low with few
exceptions (Callahan et al., 2002), ranging between
1% (Sager et al., 2006) and 49% (Ravaglia et al.,
2005). Variability in reported sensitivity rates is
mainly related to different MMSE cut-off values and
comparison groups, such as a combined group of MCI
and early dementia sufferers (Lam et al., 2008) or
differing proportions of ‘pre-clinical dementia’
patients. Correspondingly, MMSE specificity for
MCI compared with healthy volunteers is generally
high, ranging from 85.5–100% (Sager et al., 2006).
Scores below the commonly suggested MMSE cut-off
of 24 or 26 will signify the presence of a dementing
illness (and indeedMCI), while scores above this level
cannot be assumed to reflect the absence of either
condition. Tang-Wai et al. (2003) found no significant
difference in the baseline MMSE scores of well
individuals who later developed MCI and those who
didn’t. Direct comparison of the MMSE with
alternative screening measures indicates that the
MMSE is less effective at discriminating between
MCI patients and healthy age matched controls (Tang-
Wai et al., 2003; Kalbe et al., 2004; Nasreddine et al.,
2005; Rami et al., 2007; Standish et al., 2007),
between persons with progressive and non-progressive
forms of cognitive impairment (Tang-Wai et al., 2003;
Rami et al., 2007) and is more prone to the influences
of age and education (Molloy et al., 2005) than a range
of other cognitive screening measures.
Levels of sensitivity and specificity comparable to
the comprehensive screening measures are reported
for some of the other non-comprehensive screens, i.e.
CDT, DemTect, Memory Alternation Test – M@T
(Rami et al., 2007), and ADAS-Cog. Sensitivity and
specificity values are not reported for the Short Test of
Mental Status (STMS; Tang-Wai et al., 2003) or the
CAMCI (Lam et al., 2008). For a further two, CDTand
the AB Cognitive Screen (ABCS;Molloy et al., 2005),
one or more of these values are too low to support their
use in MCI screening. The single set of favourable
sensitivity and specificity values reported for the CDT
(Yamamoto et al., 2004) together with AUCs reported
in association with the CAMCI (Lam et al., 2008) is
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likely to reflect the contamination of the MCI group
with patients in the early stages of dementia, i.e. in
each of these studies a combined group of MCI and
early dementia sufferers was compared with an aged
matched normal control group. The Six Item Screener
(SIS; Callahan et al., 2002) would also appear to be of
limited usefulness in detecting MCI amongst the
elderly in the community. Considerably higher
sensitivity and specificity are reported for the SIS in
a specialist clinic setting, however the restricted range
of items (i.e. orientation and memory questions only),
would possibly prove inadequate for use at secondary
and tertiary levels of assessment.
Administration times are on the whole shorter, i.e.
less than 10min, with a majority (CDT, M@T, SIS,
ABCS and STMS) reporting minimum administration
times of 5min or less, simple scoring and administration
methods without necessity for training, making these
potentially well suited to use in general practice.
Predictive validity data are provided for two of the
measures, based on longitudinal follow-up periods of
between 3–5.5 years. Correct classification rates of
around 70% are reported for both the STMS (Tang-Wai
et al., 2003) and ADAS-Cog (Fleisher et al., 2007).
Whilst issues relating to the differential diagnosis of
MCImay be of less relevance in primary carewhere an
emphasis is placed on the ‘need to refer’, the majority
of non-comprehensive cognitive screening measures
have also been validated for use as screening tools in
dementia, for the most part Alzheimer’s Disease, and
in a few cases (i.e. DemTect and ABCS) for non-AD
dementias.
Reliability data are absent with exception of the
high inter-rater (r¼ 0.99) and 1month test–retest
reliabilities (r¼ 0.92) reported for the DemTect
(Kalbe et al., 2004) and MoCA (Nasreddine et al.,
2005a) respectively. Practice effects in the order of
less than one point over 6 and 12-month intervals are
also reported for the DemTect (Kalbe et al., 2004) that
would benefit from replication in larger more uniform
samples. It is impossible to know what size of change
in test scores would represent a clinically significant
level of cognitive deterioration, i.e. how much
variability in a patient’s performance is attributable
to inconsistencies in test administration or scoring
procedures between clinicians.
Cut-off values for the detection of MCI (across one
or more combinations of sensitivity and specificity)
are reported for the bulk of the less comprehensive
screening measures with the exception of the
STMS and ABCS. Further breakdown of cut-off
scores for MCI in accordance with base rates (i.e. the
frequency with which the condition might be expected
to occur within the relevant setting), is universally
absent.
The age range of MCI samples appears to be
broadly reflective of that reported in the wider
literature (Alladi et al., 2006; Lonie et al., 2008b)
and relatively consistent across MCI screening
studies. Mean MMSE scores for the MCI patient
groups range from 23 to of 29. The range of mean
MMSE scores indicates that even within Petersen’s
MCI criteria there remains scope for significant
variability in terms of cognitive ability, with the
result of influencing reported levels of sensitivity.
Wide variation in education levels further complicates
the interpretation of MMSE scores. A mean MMSE
score of 24 in highly educated patients will signify a
more advanced stage of disease than in patients with
fewer years of education. Close consideration should
therefore be given to the mean education and MMSE
scores of MCI patient groups when comparing the
performance of screening measures across studies.
With the exception of the DemTect (Kalbe et al.,
2004), none of the most recent versions of the brief
screening measures have been validated for use across
more than one language or culture. The SIS represents
the only cognitive screening measure whose ability to
detectMCI has been studied acrossmultiple settings, i.e.
community and primary care (Callahan et al., 2002).
Combinations of screening tests
Several studies have examined the possibility that
administration and interpretation of a patient’s
performance on a combination of two or more
cognitive screening instruments may yield superior
classification accuracy than a single measure. Rava-
glia et al. (2005) compared the single and combined
ability of theMMSE and CDT to differentiate between
healthy elderly, Alzheimer’s Disease patient’s and
three MCI subtypes. Whereas the sensitivity of both
the clock drawing test and MMSE to MCI was
reportedly universally poor (< 50%), when perform-
ance on both screening instruments was evaluated, an
improvement in sensitivity to the multi-domain MCI
subtype was noted (75%). Predictive validity for the
remaining MCI subtypes remained low, however, and
the authors caution against the use of this combination
of instruments in routine MCI screening.
Beinhoff et al. (2005) report combinations of
moderate to high sensitivity and specificity using a
combination of the Memory Impairment Screen
(comprising the delayed free and cued recall of four
items) and an animal fluency task. By administering a
letter sorting task (requiring the patient to spell a five
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digit word, forwards, backwards and then in alpha-
betical order), in conjunction with the above two
measures, sensitivity to MCI rose to a clinically
acceptable level (i.e. 83%) at the expense of a decline
in specificity (i.e. from 84–74%).
Finally, several studies have examined the ability of
performance differentials between lexical (letter
fluency) and semantic (category) fluency to differen-
tiate MCI sufferers from healthy elderly controls.
Murphy et al. (2006) reported that difference scores
between generation of words according to the category
of ‘animals’ or the letter ‘F’ distinguished MCI
patients from controls with moderate effect size.
Using a semantic (category) fluency advantage of less
than one standard deviation or more than the mean for
the control group as a cut off however, sensitivity to
MCI was too low (i.e. 30%) for screening purposes.
Moderate to high levels of diagnostic accuracy in
differentiating aMCI sufferers from healthy elderly
controls (area under the curve (AUC)¼ 0.837) and
elderly depressed patients (AUC¼ 0.71) using fluency
discrepancy scores (‘animals’ vs. ‘P’ words) have also
been reported by Lonie et al. (2008a). The AUCs
reported in this study were as high as those obtained
using a standardised measure of delayed recall. Whilst
all but two control group patients generated a greater
number of animals than ‘P’ words across the one
minute time span provided, a good deal of directional
variability was present in the MCI and AD patient
groups. Without knowledge of the fate of the MCI
subjects comprising these studies, it remains difficult
to ascertain the potential clinical utility of fluency
discrepancy scores in the cognitive screening assess-
ment of MCI.
CONCLUSION
The dearth of validated MCI screening measures is
problematic in view of the high numbers of
community dwelling cognitively impaired but not
demented older adults (Busse et al., 2003b; Lopez
et al., 2003) and the significant proportions of MCI
presenting to secondary and tertiary specialist clinics
(Alladi et al., 2006; Lonie et al., 2008b).
At the most basic level, a cognitive screening
instrument should provide an indication of the likely
presence of clinically meaningful cognitive impairment,
and hence the need to refer on to more specialist
services. Of the 15 screening measures identified,
sensitivity and specificity values for MCI as defined by
Petersen et al. (1999), compared with normal elderly
controls, were adequate (i.e. 79%) in four cases. Each
of these four cognitive screening measures (ACE-R,
DemTect, MoCA, and M@T) requires average admin-
istration times of 15min or less. In two instruments
(M@T and ACE-R) cut-off values are reported without
the need for transformation of raw scores. Adequate
sensitivity to a wider range of early dementia
presentations is reported for the ACE-R only and
specificity values for MCI in relation to depression are
universally absent. This is surprising in view of the
frequency with whichMCI and depression are known to
coexist (Solfrizzi et al., 2007) and the well documented
difficulties clinicians face in attempting to tease apart
their respective contributions to cognitive impairment
(O’Carroll et al., 1994; Lezak 1995).
In more specialist clinical settings, information
gathered through the administration of cognitive
screening measures forms an integral part of the
clinical evaluation and differential diagnosis. Four of
the 15 cognitive screening measures identified in this
review cover domains comprehensively, thus facil-
itating this function. For each of these screening
measures adequate sensitivity to MCI and early AD is
reported. However, without exception, there is an
absence of reliability data for elderly persons who are
not cognitively impaired, and of the predictive validity
of cut-off scores. Both factors limit the interpretation
of score changes and the ability to supply prognostic
information. The absence of subtests assessing general
reaction time within cognitive screening measures is
especially remarkable, as a reduction in processing
speed appears to predate clinical onset of Alzheimer’s
disease (Backman et al., 2005; Rami et al., 2007) and
is a good predictor of which MCI sufferers will
develop dementia (Tabert et al., 2006).
Future research should focus on establishing a
wider range of psychometric test properties (i.e.
reliability and predictive validity) for those cognitive
screening measures where adequate sensitivity and
specificity exist. This would equip the clinician with
the ability to interpret the meaning of score changes
and provide some opportunity of likely prognosis. It
would also be of interest to compare the screening
capacity of further combinations of brief cognitive
screening measures or formal neuropsychological
measures to the screening measures described above,
as it may be that some of the equally brief
neuropsychological measures perform as well as, if
not better than cognitive screening instruments (Lonie
et al., 2008a). Furthermore, the present review
findings relate to the performance of cognitive
screening instruments in the assessment of the single
and multi-domain amnestic MCI subtypes. As the
relevance of identifying specific MCI subtypes
emerges, it will be important to establish the screening
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power of the above cognitive measures in MCI’s non-
amnestic forms.
None of the identified cognitive screening measures
wholly fulfil all of the criteria we have identified
as being important in MCI screening. Whilst the
sensitivity of the instruments covering all cognitive
domains is high, we miss data about sensitivity for
early atypical dementia presentations, specificity
compared with psychiatric and non-progressive
neurological conditions, cross-cultural usage, reli-
ability and predictive validity. Consequently, whilst
several cognitive screening instruments afford the
clinician the ability to detect MCI, early AD, and in
some cases non-AD dementia, they cannot currently
be used to make reliable inferences about the course
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Episodic memory is compromised in amnestic mild cognitive impairment (aMCI), but
lesser deficits in other cognitive domains are also commonly observed and may be
helpful in identifying this group. The relative difference in performance on lexical and
semantic fluency tasks may be a sensitive and specific measure in aMCI and early
Alzheimer’s disease (AD). We compared four groups of participants, 35 early AD, 47
aMCI, 24 healthy controls, and 18 depressive out-patient controls, on semantic and
lexical fluency as well as other neuropsychological tests. Early AD and aMCI patients
showed a distinct pattern of semantic impairment in the two fluency measures
compared with the healthy and depressive controls. The findings implicate early failure
of the semantic memory system in aMCI and AD and suggest that consideration of
the discrepancy in performance on semantic and lexical fluency measures may help in
the early identification of AD.
A recent meta-analysis demonstrated that Alzheimer’s disease (AD) patients are
significantly more impaired on measures of semantic than lexical fluency (Henry,
Crawford, & Phillips, 2004). Semantic memory impairment in AD is specific in that it is
not associated with more generalized deficits in verbal intelligence or psychomotor
speed. This pattern of impairment in verbal fluency measures is qualitatively distinct
from the usual finding of superior semantic fluency in healthy controls (Spreen &
Strauss, 1998). As the category task is thought to rely more heavily on access to
representations of semantic concepts than the letter task, the pattern of findings in AD is
presumed to reflect degradation in the structure, content, or activation of the semantic
memory system (Auriacombe et al., 2006; Jefferies & Lambon Ralph, 2006; Jones,
Laukka, & Backman, 2006).
* Correspondence should be addressed to Professor Klaus P. Ebmeier, Department of Psychiatry, Warneford Hospital,
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Patients in the preclinical stages of AD exhibit a semantic fluency deficit, at a time
when lexical fluency performance remains intact (Auriacombe et al., 2006; Beatty,
Salmon, Troster, &Tivis, 2002; Swainson et al., 2001). Similarly, patientswho fulfil criteria
for amnestic mild cognitive impairment (aMCI; Grundman et al., 2004; Petersen et al.,
1999) generate fewer words from a specified category than do age-matched controls.
In contrast, they perform at normal levels on lexical fluency tasks (Alladi, Arnold,
Mitchell, Nestor, & Hodges, 2006; Dudas, Clague, Thompson, Graham, & Hodges, 2005;
Lonie, Herrmann, Donaghey, & Ebmeier, 2008; Murphy, Rich, & Troyer, 2006).
A pattern of worse semantic than lexical fluency has also been reported in patients
with depression (Christensen, Griffiths, Mackinnon, & Jacomb, 1997; Zakzanis, Leach, &
Kaplan, 1998), although a more recent review suggests equal impairment of
performance across the two fluency tasks that is thought to reflect a generalized
reduction in processing speed (Henry & Crawford, 2005).
If semantic and lexical fluency discrepancy (FD) scores are abnormal in some patients
with aMCI, their magnitude and directionmay prove helpful in diagnosis or prognosis. As
an individually calibrated marker of performance, the direction of the discrepancy
would have the advantage of being free from the need for age, gender, education, or
IQ-dependent cut-off values, which require a sizable normative comparison group.
Furthermore, if depressive symptoms were associated with equivalent reductions in
lexical and semantic task performance (as the processing speed account would predict),
then FD scores might also be of value in distinguishing between depressive and early
Alzheimer related cognitive impairment. To our knowledge, no study has examined
semantic and phonemic fluency in aMCI compared with healthy controls, early AD
patients and patients with depressive symptoms.
Study aims
Here, we aimed to (1) replicate the finding that patients with aMCI demonstrate a
pattern of fluency performance similar to that observed in patients with early AD and
(2) to investigate whether their FD performance is abnormal when compared to healthy
controls and out-patients with depressive symptoms.
Material and methods
Patient groups
We examined 47 patients with aMCI, 18 out-patients with depressive symptoms, 24
healthy control patients, and 35 patients with mild AD. The 47 aMCI patients were
recruited over a 3-year period (September 2003–September 2006) from tertiary referrals
to our neuropsychological assessment service and met criteria for aMCI (Petersen et al.,
1999). All aMCI patients underwent comprehensive neuropsychological and psychiatric
evaluation, medical screening (including blood screen) as well as neuroimaging
(CT and/or MRI or SPECT). Thirty-five patients with a NINCDS/ADRDA diagnosis
(McKhann et al., 1984) of early AD were identified as part of a clinical audit of service
referral numbers and diagnoses. All early AD patients scored 17/30 or above on the mini
mental state examination (MMSE; Folstein, Folstein, & McHugh, 1975) and 58/100
or above on the more comprehensive Addenbrooke’s cognitive examination (ACE;
Mathuranath, Nestor, Berrios, Rakowicz, & Hodges, 2000) indicating a relatively mild
disease severity. As healthy controls we recruited 24 spouses or carers of patients who
had attended the neuropsychological assessment service. Participants with potentially
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confounding co-morbid medical, psychiatric, or neurological conditions (i.e. stroke or
cerebro-vascular disease, head injury, alcoholism, schizophrenia, etc.) were excluded.
In an attempt to ensure a control group of similar illness severity and general level of
functioning to the aMCI patients, we recruited 18 out-patients with depressive
symptoms from hospital out-patient clinics and day hospitals, who were receiving the
same level of out-patient care as our aMCI group. All participants in this group presented
with depressive symptoms, thought not to be primarily organic in nature, yet known to
have effects on cognitive functioning both during illness and after recovery (Herrmann,
Goodwin, & Ebmeier, 2007). We considered matching of illness severity to be important,
as in clinical practice the differentiation of severe depression and early dementia states is
less problematic than separating the sequelae of the milder forms of these disorders.
Furthermore, fluency measures have been shown to be sensitive to even mild depressive
symptoms (Ravdin, Katzen, Agrawal, & Relkin, 2003). We included patients with a
variety of disorders, as the type of depression does not appear to influence the
magnitude of cognitive deficit (Christensen et al., 1997). Patients with any co-morbid
medical, neurological, or psychiatric condition with the potential to affect cognitive
function were excluded. The mean geriatric depression scale score (Yesavage, 1988) for




All patients were given two versions of the verbal fluency task. In the lexical version,
patients were asked to generate as many words as possible within 1 minute beginning
with the letter ‘P’. The letter ‘P’ was chosen in place of the more widely known ‘F’, ‘A’,
‘S’ as it forms part of the ACE (Mathuranath et al., 2000). In the second task, patients
were asked to provide as many animal names as possible in 1 minute. Patients’ scores
were z-transformed using control means and standard deviations to be able to compare
lexical and semantic task performance.
Episodic memory
All groups were administered the Hopkins verbal learning test – revised (HVLT-R;
Brandt, 1991). Participants are required to recall as many words as possible
immediately following presentation of a 12-item word list across three consecutive
learning trials. Measures include: total number of words recalled across three
registration trials (max ¼ 36); total number of words recalled following a 30-minute
delay (max ¼ 12); and a discrimination index score representing a participant’s ability
to discriminate between old and new list items. The total number of words recalled
immediately following list presentation provides a measure of new learning ability,
while the number of words recalled after a short delay serves as a measure of delayed
verbal recall ability.
The paired-associate learning (PAL) subtest from the Cambridge automated
neuropsychological test assessment battery (CANTAB; Swainson et al., 2001) is a
computerized measure of visuospatial learning requiring participants to learn the
locations of an increasing number (i.e. 1, 2, 3, 6, and then 8) of abstract patterns
(Blackwell et al., 2004; Swainson et al., 2001). The score of interest was the number
of pattern-position errors made at the six-pattern level. Healthy and depressed
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control participants, as well as aMCI and a subgroup of early AD patients also
completed the Rey complex figure (RCF; copy, immediate and delayed recall trials;
Rey, 1941). In this task, participants are given a complex figure and are asked to
make a copy of it without time restriction. Immediately after presenting the figure,
and again following a 30-minute delay, participants are required to reproduce the
figure from memory. The measure of interest for this analysis was the 30-minute
delayed recall condition.
Attention and executive function
All participant groups completed the trail making tests, Parts A and B (TMT A and B;
Reitan, 1985). Participants were required to join numbered circles in ascending order
(Part A) and numbers and letters in ascending alternating sequence (Part B) at pace and
the time to completion was recorded. TMT A serves as a measure of psychomotor
processing speed, while TMT B also adds a divided attention component. By
subtracting the time to completion for TMT A of this test from TMT B, a measure of
the ‘executive’ functioning component can be acquired independently of processing
speed.
Statistics
Data were analysed using SPSS 14.0 for Windows. A FD score was calculated for each
participant by subtracting lexical fluency (P words) from semantic fluency (animal
words). Demographic variables and cognitive performance were examined using one-
way groupwise ANOVAs. As the group sizes were not equal, Tukey pairwise
comparisons were carried out on all significant analyses when the assumption of
homogeneity of variance was met, and Games–Howell pairwise comparisons were
carried out when this assumption was violated. Reaction time data (e.g. TMT A and B)
was log transformed prior to analysis in order to increase normality.
Results
Participant characteristics
Demographic characteristics are presented in Table 1. Groups did not differ in terms of
age [Fð3; 120Þ ¼ 1:7; p ¼ :17] or predicted pre-morbid IQ [Fð3; 105Þ ¼ 2:2; p ¼ :10].
The estimated pre-morbid level of general intellectual functioning fell within a high
average range for all four groups. There was a significant gender imbalance (F . M) in
the depressive symptom group only (x2 ¼ 5:6; p ¼ :02; in all other cases p . :05).
Patients with early stage AD performed at a lower level than all other groups on
cognitive screening measures (MMSE: [Fð3; 120Þ ¼ 30:6; p , :0001]; ACE:
[Fð3; 120Þ ¼ 30:6; p , :0001]); in all cases p , :0001. Total ACE scores of the aMCI
group fell between that of the controls and early AD (MCI vs. C: p , :0001; MCI vs. AD:
p , :0001) and was significantly different from both of these groups. By contrast, mean
MMSE scores for control and aMCI groups did not differ. Mean total scores on both
cognitive screening measures (MMSE and ACE) failed to discriminate the depressive
control group from aMCI or healthy control participants.
In keeping with proposed aMCI criteria (Petersen et al., 1999) patients with aMCI
performed more than one standard deviation below age means on at least two formal
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measures of episodic verbal and visual memory, such as the HVLT total and delayed
recall, the PAL task from the CANTAB, and the RCF delayed recall.
Fluency performances according to patient group
Semantic fluency
Mean scores and standard deviations for semantic fluency, lexical fluency, and semantic-
lexical discrepancy are presented for each of the four patient groups in Table 2.
As predicted, the mean semantic fluency score for the early AD group was significantly
lower than all other patient groups (in all cases p , :0001). The aMCI patient group also
generated significantly fewer animal names than did healthy controls (p , :0001). The
mean number of animals generated by both the aMCI and depressed groups fell
between that of early AD and control participants and was significantly different from
both of these groups (MCI vs. C: p , :0001; MCI vs. AD: p , :0001; D vs. C: p ¼ :04;
D vs. AD: p , :0001).
Lexical fluency
Lexical fluency scores were higher for the aMCI and healthy control groups than for the
early AD patients (C vs. AD: p ¼ :02; MCI vs. AD: p ¼ :002). No other group differences
in lexical fluency performance were observed.
Fluency discrepancy scores
The mean FD scores for aMCI and early AD patients were significantly higher than those
of healthy control (MCI vs. C: p , :0001; AD vs. C: p , :0001) and depressed control
groups (MCI vs. D: p ¼ :01; AD vs. D: p ¼ :001), but did not differ significantly from
each other (MCI vs. AD: p ¼ :72) (see Figure 1).
The negative mean discrepancy scores of the aMCI and early AD groups indicate that,
on average, these patients generated fewer animals than ‘P’ words within the 1-minute
time frame. The opposite pattern (animals . P words) was observed for the healthy
controls and the depressive control group, indicated by a positive mean score. Mean FD
scores did not differ between the two control groups (C vs. D: p ¼ :27).
To assess the usefulness of FD scores in classifying patients in comparison to a more
commonly used word list learning task, receiver operating characteristic (ROC) curves
were constructed (Figure 2a–c). Figure 2a and b demonstrate that the FD index has
greater sensitivity and specificity in distinguishing healthy and depressed control
participants from those with aMCI, whereas delayed verbal recall ability retains
superiority in the early AD versus healthy control comparison (Figure 2c). The area
under the curve for each of the three comparisons is as follows: C versus MCI: 0.84 (FD)
and 0.78 (HVLT-delay); D versus MCI: 0.75 (FD) and 0.71 (HVLT-delay); C versus AD: 0.85
(FD) and 0.94 (HVLT-delay).
Episodic memory
By definition, the aMCI group performed at significantly lower levels than healthy
controls on a number of verbal and visual episodic memory measures: HVLT total and
delayed recall scores (total score [means (SD) for controls/patients]: 23.4 (5.1)/19.3 (4.6);
tð2; 67Þ ¼ 3:4, p ¼ :01 and delayed recall: 8.1 (2.7)/4.8 (3.3); tð2; 67Þ ¼ 4:2, p , :001);
84 Jane A. Lonie et al.
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the PAL task from the CANTAB (7.9 (6.7)/17.1 (14.5); tð2; 68Þ ¼ 23:7, p , :001); and the
RCF delayed recall (16.8 (6.8)/11.4 (6.9); tð2; 66Þ ¼ 3:1, p ¼ :003).
Attention and executive function
The early AD group were slower than healthy controls and aMCI patients to complete
the TMT A (C vs. AD: p ¼ :01; MCI vs. AD: p ¼ :03). Furthermore, early AD and
depressive control patients were on average slower than healthy controls to complete
Part B of the TMT (C vs. AD: p , :0001; C vs. D: p ¼ :02). A TMT B–A measure was
calculated by subtracting the time to completion for Part A of the TMT from Part B of the
same task. On analysis, there proved to be a marginally significant group difference
(Fð3; 99Þ ¼ 2:8; p ¼ :046); however none of the multiple comparison procedures
reached significance.
Figure 1. Means and distribution of the differences (animal minus P-word) of verbal fluency z scores
in diagnostic groups.
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Discussion
Our findings demonstrate that the pattern of performance on lexical and semantic
fluency tasks is distinctly different in early AD and aMCI compared with healthy and
depressive age-matched controls. Specifically, early AD and aMCI patients show a greater
magnitude of impairment in semantic, as compared to lexical fluency, relative to healthy
age-matched controls (Lezak, Howieson, Loring, Hannay, & Fischer, 2004; Spreen &
Strauss, 1998).
The findings are consistent with longitudinal data demonstrating that semantic
fluency deficits pre-date the lexical fluency impairment seen in the preclinical stages of
AD (Auriacombe et al., 2006) and with cross-sectional data showing an impairment of
semantic fluency in the absence of any lexical fluency deficit in aMCI (Alladi et al., 2006;
Dudas et al., 2005; Lonie et al., 2008; Murphy et al., 2006). In cases where a lexical
fluency deficit has been documented in aMCI or preclinical AD, the general level of
cognitive function of the aMCI patients is often comparatively low for example mean
MMSE of 24.5, compared to our early AD patient group of 24.9 (Jones et al., 2006).
Our results implicate early failure of one or more aspect(s) of the semantic memory
system in aMCI and early AD. They do not directly address the question of which
Figure 2. (a) ROC curve for differentiating aMCI participants from healthy controls. FD: AUC ¼ 0:84,
p , :0001; HVLT delayed recall: AUC ¼ 0:78, p , :0001. (b) ROC curve for differentiating aMCI
participants from depressed controls. FD: AUC ¼ 0:75, p ¼ :002; HVLT delayed recall: AUC ¼ 0:71,
p ¼ :009. (c) ROC curve for differentiating Alzheimer’s disease participants from healthy controls.
FD: AUC ¼ 0:86, p , :0001; HVLT delayed recall: AUC ¼ 0:94, p , :0001.
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mechanisms of the semantic memory system may be at fault. The relatively sound
performance of our aMCI patients on additional measures of verbal initiation and
speeded divided attention would suggest that these specific aspects of executive
function do not underlie the semantic fluency deficit. Similarly, Auriacombe and
colleagues (Auriacombe et al., 2006) failed to implicate executive processes in the
verbal fluency decline characterizing AD. It remains possible that the semantic fluency
deficit seen in aMCI and early AD reflects degradation of amodal representations forming
the semantic memory store, or failure of the executive processes that help to direct and
control semantic activation of this store (Jefferies & Lambon Ralph, 2006). Detailed
quantitative and qualitative longitudinal investigation of semantic memory function in
an aMCI cohort will be required to differentiate between these possibilities. What
appears increasingly clear, nonetheless, is the coexistence of cognitive deficits in
domains other than episodic memory function in aMCI; most notably semantic memory
deficits (Adlam, Bozeat, Arnold, Watson, & Hodges, 2006; Alladi et al., 2006; Lam, Ho,
Lui, & Tam, 2006; Murphy et al., 2006; Perry & Hodges, 2000; Ribeiro, de Mendonca, &
Guerreiro, 2006; Vogel, Gade, Stokholm, & Waldemar, 2005). The original MCI criteria
have been modified to some extent to reflect this (Petersen, 2004).
FD scores performed as well as, if not better than delayed verbal recall measures
in distinguishing between patients with aMCI or early AD- and age-matched controls
or depressive controls (ROC). The discrepancy score may therefore be especially
sensitive to semantic memory failure in aMCI. There are a number of reasons why this
might be so.
Verbal fluency scores are influenced by age and IQ (Lezak et al., 2004; Spreen &
Strauss, 1998; Tombaugh, Kozak, & Rees, 1999), and performance on the two types of
fluency measures is known to correlate (Tombaugh et al., 1999). Applying generalized
cut-off scores at an individual patient level could conceivably reduce the sensitivity of
fluency measures to deficits of a small magnitude. Lexical fluency performance, which
remains comparatively well preserved in preclinical and very early AD (Alladi et al.,
2006; Dudas et al., 2005; Murphy et al., 2006) and is relatively insensitive to the effects
of ageing in later life (Murphy et al., 2006), may act as a personalized benchmark, against
which even subtle declines in an individual’s semantic fluency performance can be
measured. At least one study has shown an enhanced ability to detect cognitive deficits
of a progressive nature using individualized IQ adjusted rather than group norms (Rentz
et al., 2004). Based on a similar rationale is the use of regression equations to calculate
expected performance levels for the individual patient (Crawford & Garthwaite, 2006;
Rentz et al., 2004).
An interesting observation was the comparative lesser ability of the FD score to
discriminate early AD sufferers from healthy age-matched controls. Prior research with
established AD sufferers suggests that the relative magnitude of phonemic and semantic
fluency deficits remains constant across disease stages (Henry et al., 2004). This would
imply that the discriminative power obtained for FD in the aMCI group should also be
maintained in early AD. It is possible however that this argument does not hold in a
preclinical disease phase; at which time the greater sensitivity of the discrepancy score
may reflect semantic memory failure prior to disruption of wider executive processes.
There is continuing debate as to which of the two cognitive domains, that is
semantic memory abilities or executive processes, constitutes the secondary area of
impairment in early and preclinical AD. It is conceivable that as the disease progresses,
‘executive’ aspects of semantic retrieval may add to poor performance due to existing
semantic memory dysfunction on category fluency tasks. When this occurs, deficits on
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lexical tasks would also be expected to be present. As lexical fluency performance
declines, the discrepancy in fluency performance may become a less sensitive measure
of cognitive dysfunction than category fluency performance or delayed recall alone.
In our study, the differential semantic fluency deficit was unique to early AD and
aMCI patient groups suggesting that it may be of assistance in differentiating these
groups from the healthy elderly or elderly patients with depressive symptoms. Other
studies have found that comparison of performance on the two different types of
fluency tests is helpful in distinguishing between certain dementia syndromes ( Jones
et al., 2006; Marczinski & Kertesz, 2006). This level of discrimination may not be
achievable by examination of fluency scores in isolation, or indeed by cognitive
screening measures, both of which failed to discriminate between our aMCI and
depressive control groups.
The use of a single letter and category (i.e. P and animals), as opposed to an average
of three (i.e. FAS or animals, fruits, and vegetables), might be expected to yield a less
reliable fluency score, and it will be necessary to replicate the above findings in other
clinical samples using alternative categories and letters. One recent study, comparing
the number of animals with F-words generated, has demonstrated a similar ability to
discriminate early AD and aMCI patients from healthy controls. This study lacked the
important inclusion of a depressive control group matched for general level of cognitive
functioning and support needs (Murphy et al., 2006). Furthermore, the advantage of
the measures used in the current study is that they are obtainable within the context of a
brief cognitive screening measure (ACE and ACE-R), without necessity for the
administration of any supplementary tests.
In order for FD scores to be of value in a differential diagnostic sense, they must
facilitate discrimination between pathological and age appropriate performance at the
individual patient level. Only one healthy control and one out-patient with depressive
symptoms in our study obtained a higher lexical than category fluency score, but
there was a good deal of directional variability in the early AD and aMCI patient groups.
Hence the FD measure may prove to be of greatest assistance identifying those persons
who are not likely to develop AD over time (negative predictive value). We are
conducting longitudinal follow-up of the aMCI patients in order to determine whether
or not this is the case.
Two previous studies have contrasted fluency difference scores in AD and healthy
controls (Cerhan et al., 2002; Sherman & Massman, 1999). In both, the overwhelming
majority of AD patients demonstrated the expected semantic , lexical fluency
performance pattern. However, the existence of a notable number of AD patients
exhibiting the opposite pattern led both authors to conclude that the FD score may be of
limited sensitivity.
In the present study, optimal cut-off scores can be generated from the receiver–
operator curves in Figure 2. For example, a cut-off of 3.5 and higher for the animal minus
letter-P scores (or a difference of z scores of 237%) gives a sensitivity of 63 and 50% to
aMCI in healthy volunteers and participants with depressive symptoms, respectively,
but a very high specificity of 91% (Table 3). On the other hand, a more lenient cut-off of
greater or equal to 1.5 (z score of 272%) gives a sensitivity for aMCI or Alzheimer’s
dementia versus controls of 88%, with a reduced specificity of 58 and 70%, respectively.
Our results indicate that the differential semantic fluency deficit seen in AD is also
present in aMCI. They provide support for the presence of semantic memory
impairment in the preclinical and very early stages of AD and emphasize the need to
broaden the current conceptualization of aMCI beyond that of a purely amnesic state.
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FD scores appear equally adept, if not superior, to episodic memory measures at
identifying aMCI. Importantly, the presence of depressive symptoms in psychiatric out-
patients does not appear to influence the relative performance on the two types of
fluency measures, suggesting that consideration of FD may be of assistance in early
differential diagnosis. Longitudinal follow-up of the aMCI will determine whether or not
FD scores are of equal utility in a prognostic sense.
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The diagnosis of mild cognitive impairment (MCI) represents an
attempt to define features of the dementias in their preclinical
phases. Petersen and colleagues developed research criteria with
a cut-off for verbal recall performance as objective evidence of
episodic memory impairment.1 This approach has been chal-
lenged because it excludes patients who display exclusively visual
episodic memory impairment.2 Moreover, the pure amnestic sub-
type of mild cognitive impairment is rare,2–6 and mild cognitive
impairment case definition varies as a function of the neuro-
psychological tests used.2,7 It is not clear how the Petersen criteria
might best be translated into clinical practice. There is little
information detailing the frequency with which each of the
subtypes presents to memory clinics. Our aim was to examine
the diagnostic profile of patients with amnestic mild cognitive
impairment (aMCI) referred to our tertiary assessment service.
We also sought to evaluate a comprehensive battery of neuro-
psychological measures for their usefulness in this patient group.
Method
This study constituted part of a longitudinal project for which
ethical approval was obtained from the local research ethics com-
mittee. In accordance with this, informed consent was given by all
participants.
Sample
We retrospectively analysed 187 consecutive referrals to the
Edinburgh Neuropsychological Assessment Service for Older
People between the months of September 2004 and April 2006.
Referrals were received at a tertiary level, stemming from consul-
tants in old age psychiatry, geriatric medicine and neurology. All
of these patients had undergone comprehensive psychiatric
evaluation, relevant medical screening (including a standard
battery of screening blood tests) and neuroimaging (computed
tomography and/or magnetic resonance imaging or single-proton
emission computed tomography) prior to being referred to our
service. All but three patients were over the age of 50 years.
The original criteria for mild cognitive impairment set out by
Petersen et al require that a person must present with a memory
complaint, show evidence of objective memory decline in relation
to age and education, demonstrate preservation of other areas of
cognitive function and activities of daily life, and not fulfil criteria
for dementia.8 Because it has since become apparent that not
everyone who demonstrates cognitive impairment short of
dementia has a ‘memory’ complaint, we used the recently
expanded criteria that include people with non-memory com-
plaints (single-domain non-memory MCI), as well as those
exhibiting multiple domains of cognitive impairment who none
the less fail to fulfil criteria for dementia (multiple domains
slightly impaired).9,10 The Mini Mental State Examination
(MMSE)11 and Addenbrooke’s Cognitive Examination12 were
administered as a means of establishing the participants’ general
level of cognitive functioning. Level of everyday functioning was
examined by means of the Clinical Dementia Rating scale13 within
the context of a clinical interview with the patient and the
patient’s primary carer (when available). A total of 112 patients
fulfilled one or more of the following exclusion criteria and were
therefore excluded from the analyses:
(a) dementia (MMSE score 524/30 or ACE score 580/100, plus
fulfilling DSM–IV criteria;14
(b) depression, assessed either by way of formal psychiatric
consultation or, in a small proportion of cases, by a score
greater than 10 on the Geriatric Depression Scale15 or clinical
assessment by one of the authors (J.A.L.);
(c) one or more medical or psychiatric conditions that could
conceivably account for the patient’s cognitive impairment
(head injury, schizophrenia, evidence of stroke or tumour
on neuroimaging, alcoholism, epilepsy, cranial radiotherapy).
Of the remaining 75 patients, 15 showed cognitive impair-
ments outside the domain of episodic memory, 15 returned a
‘normal’ cognitive profile and 45 showed memory function
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Background
There is current interest in exploring the different subtypes
of mild cognitive impairment (MCI), in terms of both their
epidemiology and their cognitive profile.
Aims
To examine the frequency of MCI subtypes presenting to a
memory clinic and to document detailed neuropsychological
profiles of patients with the amnestic subtype.
Method
Consecutive tertiary referrals (n=187) were psychiatrically
evaluated; 45 patients met criteria for amnestic mild
cognitive impairment (aMCI). A subgroup of 33 patients with
aMCI as well as 21 healthy controls took part in a thorough
neuropsychological examination.
Results
Of the patients who were examined in greater
neuropsychological detail, ten had pure aMCI (none with
visual memory impairment only). Fifteen met criteria for non-
amnestic MCI. Fifteen had normal neuropsychological
profiles. Using more than one test increased sensitivity to
detect episodic memory impairment.
Conclusions
Amnestic MCI is an important diagnosis in secondary and
tertiary memory clinics. There is scope to improve the
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impaired for age (with or without additional areas of cognitive
impairment). We present detailed neuropsychological baseline
findings for 33 of these 45 patients as well as for 21 healthy
individuals from the community who agreed to participate as a
control group in a continuing longitudinal study examining
neuropsychological markers of preclinical dementia. Control
group participants were recruited through a local dementia
support group or were spouses or carers of patients who had
attended the neuropsychological assessment service.
Neuropsychological assessment measures
All the participants were given a comprehensive battery of neuro-
psychological tests. These tests were selected on the basis of their
demonstrated validity for use within a population with MCI, and
assessed the primary domains of verbal and visual episodic
memory, semantic memory and language, processing speed,
attention/executive function and visuospatial ability.
Premorbid intellectual ability
The National Adult Reading Test (NART)16 was administered in
order to assess probable premorbid level of intellectual function.
Episodic memory
To assess verbal episodic memory, participants were given the
Hopkins Verbal Learning Test – Revised (HVLT–R).17 In this test
participants are asked to recall as many words as possible
immediately after presentation of a 12-item word list on three
consecutive learning trials. Measures included total number of
words recalled across three registration trials (maximum 36), total
number of words recalled following a 30 min delay (maximum 12)
and a discrimination index score representing a participant’s
ability to discriminate between old and new list items. Visual
episodic memory was assessed by means of two different tasks.
The CANTAB Paired Associate Learning (PAL) test is a com-
puterised measure of visuospatial learning ability requiring parti-
cipants to learn the locations of an increasing number of patterns
– one, two, three, six and then eight;18,19 the score of interest was
the number of pattern-position errors at the six-pattern level.
Participants were also administered the Rey Complex Figure
Test.20 For this test, participants are asked to make a copy of a
complex figure, with no time restriction. Immediately after pre-
senting the figure, and again following a 30 min delay, participants
are required to make another copy from memory.
Semantic memory
Participants completed the Graded Naming Test,21 the Graded
Faces Test,22 the Boston Naming Test23 and the Edinburgh Exem-
plar Naming Test (EENT; further details available from the
authors). The Graded Naming Test and Boston Naming Test
require participants to name line drawings of increasing difficulty,
whereas the Graded Faces Test requires participants to name a
series of 30 famous faces.22 The EENT was developed by one of
the authors (J.A.L.) in an effort to improve the sensitivity of exist-
ing confrontation naming measures to early semantic memory
failure. In this test the participant is required to name 50 line
drawings of low-frequency animate objects with sizeable feature
overlap. Participants were also asked to complete a category flu-
ency task, requiring them to name as many animals as they could
in 1 min.
Attention/executive functioning
As a means of examining attention/executive function and visuo-
motor processing speed, participants were asked to produce as
many words as possible beginning with the letter P in 1 min (letter
fluency task). In addition, participants were administered parts A
and B of the Trail Making Test:24 in this test participants are
required to join up as quickly as possible numbered circles in
ascending order (part A) and numbers and letters in ascending
alternating sequence (part B), while the time to completion is
recorded.
Visuospatial skills
Visuospatial skills were assessed by means of the Rey Complex
Figure Test copy task described above.20
Comparison with other memory clinics
We searched the literature for studies employing neuropsychologi-
cal test batteries similar to ours to examine the comparability of
our sample with other published data.
Statistical analysis
We calculated z-scores to determine where scores fell below the
tenth percentile of control performances. Visual inspection to-
gether with a one-sample Kolmogorov–Smirnov goodness-of-fit
test indicated that the data were normally distributed. Group
means were compared using independent sample t-tests. To
determine whether there is an association between general level
of cognitive function and the consistency of episodic memory
impairment, we divided the participants with cognitive impair-
ment into two groups: those who displayed episodic memory
impairment on a single measure only and those who showed
impairment on two or more episodic memory tests. Their
Addenbrooke’s Cognitive Examination and MMSE scores were
compared using an independent samples t-test. Diagnostic cate-
gories between memory clinics were compared using chi-squared
tests for diagnostic categories.
Results
Literature search
We identified one other study reporting consecutive referrals to a
memory clinic using similar diagnostic criteria and assessment
measures.2
Comparability of referral patterns and cognitive profiles
A striking similarity in referral patterns was observed between our
Neuropsychological Assessment Service for Older Adults and data
reported recently from the Cambridge Memory Clinic.2 When the
150 pre-excluded referrals from the Cambridge Memory Clinic
were accounted for, over half (60%) of referrals from both centres
were excluded on the grounds of an established dementia or de-
pressive disorder, or one or more medical conditions that could
account for the patient’s cognitive impairment (w2¼0.015,
P¼0.90). Close to 40% of referrals from both centres fell within
the non-demented and non-depressed category (w250.001,
P¼0.995). Just over half of these patients in both centres met
Petersen’s expanded criteria9 for aMCI (w2¼0.46, P¼0.50), repre-
senting close to a fifth of overall referrals from both centres. Of the
remaining 40% of patients in the non-demented, non-depressed
category, half demonstrated cognitive deficits of a non-amnestic
variety (in one or more domains) and half returned ‘normal’ cog-
nitive profiles. Although referral patterns for aMCI were similar
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across the two centres, there was a greater proportion of patients
with non-amnestic MCI and fewer with visual-only impairment in
our sample (w2¼13.23, d.f.¼3, P¼0.004; Fisher–Freeman–Halton
exact test, P¼0.003). Mean scores for both the aMCI and control
groups across all neuropsychological measures were similar to
those previously reported.
Sample characteristics
Our final sample for analysis consisted of 33 patients with aMCI
(13 men and 20 women, with a mean age of 74.0 years,
s.d.¼6.4; social class I n¼9, II n¼12, IIIN n¼9, social class not
known n¼3) and 21 healthy community-dwelling older adults
without cognitive complaints (7 men and 14 women, with a mean
age of 69.5 years, s.d.¼7.4). These groups did not differ in terms of
estimated premorbid level of intellectual function. The mean age
of our control group was, however, significantly lower than that
of our aMCI patient group, a finding similar to previous
reports.2,4
Comparison of aMCI and control groups
Despite a mean ACE score that exceeded suggested cut-off points
for dementia,12 the aMCI group had significantly lower mean
scores than the control group on all neuropsychological measures,
with the exception of the Rey Complex Figure Test copy task, the
Trail Making Test part A and the letter (phonemic) fluency task.
These findings were confirmed when the analysis was re-run with
age as a covariate, with the exception of performance on the
CANTAB PAL and the Trail Making Test part B, which just failed
to reach significance. Demographic data and mean scores for the
two groups on the individual neuropsychological measures are
provided in Table 1. All aMCI group means are based on data
from 33 participants, with the exception of the final three seman-
tic memory measures, for which the participant numbers ranged
between 13 and 31.
Amnestic MCI group performance
Episodic memory
The neuropsychological performances of 33 of the 45 patients who
fulfilled Petersen’s expanded criteria9 for aMCI were examined in
greater detail. As in the Cambridge Memory Clinic study,2 not all
of these participants demonstrated impairment across all episodic
memory measures: 11 (33%) showed impairment on a single test,
9 (27%) showed impairment on two memory measures and the
remaining 13 (39%) were impaired on three or more tests. Mean
MMSE and Addenbrooke’s Cognitive Examination scores for par-
ticipants who were impaired on more than one episodic memory
measure were significantly lower than for those showing impair-
ment on a single test (P<0.05). Just over half of our aMCI sub-
group showed both verbal and visual episodic memory
impairment. Although a significant proportion (45%) demon-
strated memory impairment of a verbal nature only, none of
our patients in this group exhibited a pure visual memory deficit.
Non-memory measures
Only ten (30%) patients in our aMCI subgroup exhibited an
isolated impairment of episodic memory function. All the other
patients (70%) exhibited deficits in one or more additional
domains of cognition, most commonly that of semantic memory
function, followed by attention and executive function (Table 2).
Discussion
Referral patterns
In this study we have shown that people who are neither depressed
nor demented but who fulfil Petersen’s expanded criteria9 for
aMCI make up a significant proportion of referrals to our Old
Age Clinical Neuropsychology service. Roughly a quarter of all
patients referred during an 18-month period met Petersen’s criter-
ia, of whom a minority exhibited a memory deficit in isolation
following comprehensive neuropsychological examination. This
is an almost identical proportion of patients to that reported in
the study by the Cambridge Memory Clinic (23%),2 and is a very
similar figure to the 20% of patients seeking help in Lehrner et al’s
clinic who met criteria for aMCI.25 Furthermore, the observation
that the highest numbers of people with MCI were those with
more than one domain of cognitive deficit is in keeping with
the findings from both population-based and other memory clinic
studies.7,26
It is possible that referral patterns might differ depending on
whether the memory clinics are geriatrician- or psychiatrist-led.
Surprisingly, the level at which referrals are received (whether
primary, as in the Cambridge Memory Clinic, or tertiary, as in
our clinic) appears not to influence the proportion of referrals
of an MCI nature that are received.
Thus, it appears that both the concept and criteria are
applicable and, indeed, a necessary adjunct to clinical practice.
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Table 1 Demographic data and performance of the sample










Age, years 69.8 (7.4) 74.0 (6.4) 0.02*
NART score 118.3 (2.8) 116.4 (8.5) 0.331
MMSE score (30)b 29.1 (0.8) 28.0 (1.8) 50.01**
ACE score
Total (100) 94.8 (3.3) 88.2 (5.9) 50.001***
Delay (7) 6.4 (0.9) 3.9 (2.3) 50.001***
Rey Complex Figure Test scores
Copy (36) 34.0 (2.4) 34.2 (2.5) 0.729
Immediate recall (36) 19.1 (6.3) 12.3 (6.0) 50.001**
Delayed recall (36) 17.4 (7.4) 10.8 (6.9) 50.01**
HVLT–R score
Total recall (12) 24.3 (5.0) 18.2 (4.6) 50.001***
Delayed recall (12) 8.19 (2.8) 4.8 (3.2) 50.001**
Discrimination (12) 10.3 (1.9) 8.5 (2.2) 50.01**
PAL 6 errors 7.8 (6.9) 16.6 (14.8) 50.01**
Trail Making Test score
Part A, s 40.3 (11.2) 48.4 (20.0) 0.095
Part B, s 87.5 (31.6) 131.7 (78.4) 50.01**
Animal fluency score 21.1 (5.7) 15.1 (4.5) 50.001***
P words score 15.7 (5.8) 16.0 (4.8) 0.860
Boston Naming Test score (60) 57.4 (3.1) 53.6 (5.5) 50.01**
EENT score (50) 46.8 (3.0) 43.6 (4.5) 50.01**
Graded Faces Naming Test
score (30)
20.8 (3.1) 16.3 (4.9) 50.001***
Graded Naming Test score (30) 23.4 (3.2) 19.5 (4.2) 0.015*
ACE, Addenbrooke’s Cognitive Examination; aMCI, amnestic mild cognitive
impairment; EENT, Edinburgh Exemplar Naming Test; HVLT–R, Hopkins Verbal
Learning Test – Revised; MMSE, Mini Mental State Examination; NART, National Adult
Reading Test; PAL, CANTAB Paired Associates Learning test.
a. Independent sample t-tests comparing the two groups.




Neuropsychological profile of aMCI
The applicability of Petersen’s research criteria1 to clinical practice
has recently been challenged on the grounds of exclusion of a sig-
nificant number of patients who display episodic memory impair-
ment of a visual nature only.2 In contrast to the results from the
Cambridge Memory Clinic reported by Alladi et al,2 around half
of the participants with aMCI in our study showed impairment
of both verbal and visual memory, whereas all of the remaining
participants with aMCI exhibited memory impairment of a verbal
nature only. That is to say, we failed to uncover any case of isolated
visual memory impairment.
A recent study7 supports the notion that the type of episodic
memory measure used may affect whether or not impairments are
detected – a point we will return to later in the discussion.
However, the absence of participants showing episodic memory
impairment of a solely visual nature in our sample cannot be read-
ily explained in terms of differential test sensitivities, because near-
identical neuropsychological measures were used in previous
studies (e.g. that of Alladi et al2) to assess visual memory function.
Only a small proportion of our patients with aMCI demonstrated
impairment on the visual episodic memory tasks per se. Adminis-
trative procedures might go some way to explain this observation.
Specifically, our inclusion of an immediate Rey Complex Figure
Test recall trial might have resulted in higher delay scores,27 thus
serving to reduce the sensitivity of this measure in our aMCI group.
Findings of studies examining patients who are at risk of
developing Alzheimer’s disease suggest that measures of verbal
episodic memory are most sensitive to changes early in the disease
course, followed by measures of visual memory.28 It is therefore
conceivable, taking into account our aMCI group’s higher mean
score on the Addenbrooke’s Cognitive Examination, that our
sample contained a greater number of patients who were at an
earlier stage of their disease course. Longitudinal follow-up, in
particular observation of annual performances on these visual
episodic memory measures, will determine whether this is indeed
the case.
Several studies have drawn attention to the substantial varia-
bility in MCI case definition as a function of the specific neurop-
sychological tests used.2,7 Consistent with this, in our study there
was variability among the aMCI group as to which and how many
episodic memory measures were impaired. This finding was pre-
viously demonstrated,2 and highlights the inherent difficulty in
specifying the use of any single measure as a means of establishing
impaired episodic memory function in aMCI. Our aMCI sample
could be roughly divided into thirds in terms of numbers of par-
ticipants exhibiting impairment on one, two and three or more
episodic memory measures. A similar breakdown in numbers has
been previously reported.2 It would appear entirely reasonable
and indeed a matter of good clinical practice to seek to establish
consistency in performance across a range of episodic memory
measures in defining aMCI and it will be of interest to see whether
this is a significant determinant of outcome.
The variability in case definition of aMCI as a function of the
cognitive measures employed, coupled with the inherent difficul-
ties in specifying the use of a single common measure in the
evaluation of this condition, poses a major challenge for clinicians.
Our findings suggest that employing Petersen’s expanded criteria9
for MCI could conceivably lead to a patient’s condition being clas-
sified as single-domain aMCI, multiple-domain aMCI or ‘worried
well’, depending on the cognitive measures that were employed. If
the MCI subdivisions prove useful in a prognostic sense, the
means by which the cognitive aspects of the criteria are put into
operation by clinicians will require further clarification.
Mean scores on cognitive screening measures were significantly
lower for participants showing impairment on more than one epi-
sodic memory measure. This may reflect a more advanced disease
course in this group. It is also possible that the single-measure
impairment group will prove to be a less stable one over time, with
a number of patients returning normal neuropsychological pro-
files when tested again at a later date. Alternatively, in cases in
which participants show impairment on a single verbal memory
measure only, this might have arisen secondarily to impairment
in another cognitive domain, for example expressive language or
attention/executive function (in which case the person’s condition
might be more accurately conceptualised as non-amnestic MCI).
These possibilities and the prognostic implications of consistency
and pervasiveness of impaired episodic memory performances
remain to be examined by way of longitudinal follow-up.
Our study adds to the growing body of evidence supporting the
rarity of a pure amnestic MCI syndrome,2,5,6 and demonstrates that
additional impairment often goes unnoticed unless participants
undergo thorough neuropsychological assessment. Among 33
patients with aMCI, only 10 (30%) presented with isolated
memory impairment. This figure is well within the range of
previously reported rates. For example, Tabert and colleagues
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Table 2 Performance of patients with amnestic mild
cognitive impairment (n¼33) on individual episodic memory
measures and non-amnestic measures
Measure
Patients performing below




HVLT–R total recall 17 (52)
HVLT–R delay 16 (48)
HVLT–R discrimination index 13 (39)
Any HVLT–R measure 24 (73)
PAL errors stage 6 15 (46)
Rey test delay 11 (33)
ACE delay 23 (70)
Patients with impairment
















Animal fluency 17 (52)
Participants showing impairment on
one or more semantic memory measure
22 (67)
Attentional/executive function
P words 1 (3)
TMT part B 11 (33)
Total showing impairment on one
or more attentional/executive measure
11 (33)
Visuospatial function
Rey copy 2 (6)
Visuomotor processing speed
TMT part A 2 (6)
ACE, Addenbrooke’s Cognitive Examination; aMCI, amnestic mild cognitive
impairment; BNT, Boston Naming Test; EENT, Edinburgh Exemplar Naming Test;
GFT, Graded Faces Test; GNT, Graded Naming Test; HVLT–R, Hopkins Verbal Learning
Test – Revised; PAL, CANTAB Paired Associates Learning test; Rey, Rey Complex
Figure Test; TMT, Trail Making Test.
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found that, following comprehensive neuropsychological assess-
ment, only 19% of their aMCI cases were categorised as pure
aMCI,5 whereas this figure reached 35% in the study by Alladi
et al.2 It should be borne in mind, however, that the rate of cases
with purely amnestic MCI will vary in accordance with how im-
pairment is defined. For example, Kramer and colleagues showed
that the number of cases classified as pure aMCI was considerably
higher (27%) when a cut-off of 1.5 s.d. below the mean, as
opposed to 1 s.d. (resulting in a 5% rate), was used.6 It therefore
remains a possibility that our less stringent definition of impair-
ment (i.e. 1 s.d. below the mean performance of the healthy
control group) might have resulted in an overestimation of the
frequency of cases with non-pure aMCI. Identifying accompany-
ing non-memory cognitive impairment none the less appears
important in light of recent evidence indicating a higher risk of
conversion to Alzheimer’s disease in patients with aMCI who show
additional areas of cognitive impairment compared with patients
with pure aMCI.5
The results of our study are also consistent with evidence
indicating accompanying semantic memory impairment in
aMCI,1–5 with just 10 patients of 33 exhibiting episodic memory
impairment in isolation, and 22 of the remaining 23 displaying
evidence of semantic memory compromise. This finding may
reflect an increased risk of conversion to Alzheimer’s disease from
aMCI, although early semantic memory failure is by no means
specific to the former disease,29,30 and although some studies re-
port prognostic significance of performance on semantic memory
measures,18,31,32 others have failed to do so.33 The stage at which
impairments in this domain become apparent does appear to vary
in accordance with the sensitivity of the measure employed.4 The
intact performance of participants with aMCI on measures of lex-
ical (letter) fluency, also previously reported,2,4 suggests that the
‘initiation’ aspects of semantic fluency tasks do not pose any dif-
ficulty to patients with this impairment subtype.
In view of the sound mean performances of our participants
with aMCI on cognitive screening measures (MMSE score
28/30, Addenbrooke’s Cognitive Examination score 88/100), it
seems unlikely that consideration of such scores will be of
any value in ruling out the presence of additional domains
of cognitive impairment. Reliance on clinical judgement to
determine the presence or absence of additional domains of
subtly impaired cognition is similarly likely to prove difficult when
dealing with patients with above-average premorbid IQ scores
who are performing at sound levels on cognitive screens. Taken
together, the above observations raise the question of whether
global screening measures coupled with clinical judgement are a
sufficient means of investigating MCI, and if not, whether
additional resources or an expanded skill base will be required
to handle this population clinically.
Our results reveal an absence of any significant difference in
performance between the aMCI and control groups on measures
of visuospatial function and processing speed. In-depth longitudi-
nal evaluation of neuropsychological performance in MCI and
questionable dementia suggests that visuospatial functions tend
to fail secondarily to episodic memory and category fluency
performances,4,34 although some heterogeneity is known to
exist.35 It is therefore once again possible that our failure to
demonstrate group differences on a visuospatial copying task
reflects an earlier disease stage of our aMCI sample. Alternatively,
it is conceivable that the varied and somewhat subjective scoring
methods for the Rey Complex Figure Test copy task across
different studies might be responsible for this finding. Cross-
sectional findings pertaining to visuomotor processing speed in
MCI vary, with some studies reporting significant differences
between MCI and control groups1,36,37 and others, like ourselves,
failing to do so.38–40 The disparity in findings may simply reflect
the heterogeneity of aMCI or alternatively the disease stage. Group
differences in processing speed might be more likely to exist where
samples contain significant numbers of patients in the preclinical
stages of a subcortical dementia of a cerebrovascular nature. For
example, there is some evidence to suggest a disproportionately
strong association between perceptual speed and parkinsonian
signs in MCI.41
Limitations
Several study limitations should be noted. The significantly higher
mean age of our patient group opens up the possibility that some
of their performance deficits were explicable in terms of age-
related cognitive decline. Ideally, control for age should have been
better. However, aMCI group participants were identified on the
basis of their performance on age-standardised tests; therefore,
the discrepancy would not have influenced patient group
membership. Longitudinal follow-up of these patients will help
to clarify the relevance of this difference. Furthermore, our aMCI
sample was characterised by a high average level of estimated pre-
morbid general intellectual function, which introduces problems
of applicability. Similar issues were present in a recent comparable
study,2 although other socio-demographic characteristics (i.e.
gender, ethnicity, education and occupation) were not reported,
preventing further comparison between that and our study. There
may therefore be a need to replicate these findings employing
greater numbers of age- and IQ-matched healthy controls and
aMCI patients with average premorbid IQs, together with other
socio-demographic markers more closely resembling the popu-
lation mean.
Implications
Patients with MCI make up a significant number of referrals to
older adult memory assessment services, with the most common
referral subtype in our sample being that of aMCI, followed by
equal numbers of non-amnestic MCI and worried well. Relatively
few people with aMCI exhibit episodic memory compromise in
isolation and fewer still show a visual but not verbal episodic
memory deficit. Both the concept and criteria for MCI therefore
appear to be relevant and indeed necessary adjuncts to clinical
practice.
Our findings highlight the inherent difficulties of specifying a
single measure in the assessment of memory and other cognitive
functions in MCI, while at the same time emphasising the need
for clarification of the means by which MCI criteria can be put
into operation clinically. Initial attempts at better defining
neuropsychological aspects of the aMCI criteria have been made,1
but their application in a clinical sense remains inconsistent and
their poor definition has not gone unnoticed.42 The existence of
a number of neuropsychological measures of well-documented
sensitivity in aMCI and the strikingly similar mean performances
of different clinic aMCI groups on such measures suggest that this
need not be the case. Although the importance of exercising
clinical judgement in arriving at a diagnosis of MCI cannot be
ignored, it would none the less seem inevitable that further defini-
tion of the neuropsychological aspects of MCI criteria will be
needed to facilitate identification of the subtypes of impairment
and to further our understanding of their respective prognoses.
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Dual task performance in early Alzheimer’s
disease, amnestic mild cognitive impairment
and depression
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Background. The dual task paradigm (Baddeley et al. 1986 ; Della Sala et al. 1995) has been proposed as a sensitive
measure of Alzheimer’s dementia, early in the disease process.
Method. We investigated this claim by administering the modified dual task paradigm (utilising a pencil-and-paper
version of a tracking task) to 33 patients with amnestic mild cognitive impairment (aMCI) and 10 with very early
Alzheimer’s disease, as well as 21 healthy elderly subjects and 17 controls with depressive symptoms. All groups were
closely matched for age and pre-morbid intellectual ability.
Results. There were no group differences in dual task performance, despite poor performance in episodic memory
tests of the aMCI and early Alzheimer’s disease groups. In contrast, the Alzheimer patients were specifically impaired
in the trail-making test B, another commonly used test of divided attention.
Conclusions. The dual task paradigm lacks sensitivity for use in the early differential diagnosis of Alzheimer’s disease.
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Key words : Anterograde amnesia, depressive disorder, dysthymic disorder, geriatric assessment, memory disorders,
neuropsychology.
Introduction
Alzheimer’s disease (AD) is the most common form
of dementia, estimated to rise dramatically in the
future (Wimo et al. 2003). Research has focused on
early accurate diagnosis and intervention. The con-
struct ‘amnestic mild cognitive impairment’ (aMCI;
Peterson et al. 2001) has become increasingly popular
to predict those who are most at risk for developing
dementia. It is considered a transitional stage between
normal ageing and the earliest clinical diagnosis of AD
(Petersen, 2005 ; Petersen & O’Brien, 2006). Research
on clinic-based samples has suggested that the con-
version rate from aMCI to dementia is 10–15% per
year (e.g. Petersen et al. 1999 ; Storandt et al. 2006)
compared with between 1% and 2% in a normal age-
matched non-clinical sample.
While primary impairment in very early AD in-
cludes episodic memory function, many authors have
reported that attention and executive functioning are
also vulnerable at this stage (Parasuraman & Haxby,
1993 ; Perry & Hodges, 1999). In particular, people
with early AD exhibit marked difficulty dividing
their attention between two concurrent tasks. By
comparing performance of a synchronous dual task
with that of identical task components done separately
and consecutively, a deficit in dual performance can
be attributed to failure of the central executive that
coordinates the simultaneous operation of these com-
ponents (Baddeley et al. 1986). One advantage of the
dual task paradigm is that it avoids modality-specific
interference between tasks : the tracking task is pres-
ented visually and a manual response is required;
information for the digit span task is presented aurally
with a verbal response (Nebes et al. 2001). A further
strength is that task demands can be fixed at individ-
ual ability levels, controlling for individual variation
in performance in the component parts of the dual
task. Therefore, each patient is his or her own control,
adjusting for the generally poorer performance of AD
patients in the baseline tasks (Logie et al. 2004).
Research has suggested that failure of the ‘coordi-
nation’ function is characteristic of mild AD in a lab-
oratory setting. Participants with mild AD appear to
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be impaired, irrespective of task demands, and this
impairment has been found to worsen with illness
progression (Baddeley et al. 1986, 1991 ; MacPherson
et al. 2004). Proponents of the dual task paradigm
suggest such findings are in contrast to normal ageing,
which they believe has a relatively minor effect on
dual task performance (e.g. Baddeley et al. 1986 ;
Hartley & Little, 1999; Logie et al. 2004 ; but see
Crossley & Hiscock, 1992). The equipment used for
this test is often an expensive computerized tracking
device impractical for clinical settings (e.g. Baddeley
et al. 1991 ; Logie et al. 2004). Della Sala et al. (1995)
developed a modified pencil-and-paper version of
the tracking component for the dual task. This has
been reported to produce results comparable with
the original instrument (Della Sala et al. 1995 ;
Sebastian et al. 2006). To our knowledge the dual task
paradigm has not been investigated with a sample
defined according to recent aMCI criteria (Petersen
et al. 1999).
The aim of this study was therefore to assess dual
task performance in aMCI to ascertain whether this
measure can be useful in the early diagnosis of AD.
As AD is associated with a specific impairment in
the aspect of working memory that coordinates per-
formance of two separate tasks, we predicted that
the performance of people with aMCI and very early
AD should be significantly lower than that of aged
matched controls. Furthermore, the inclusion of a
group of elderly patients with symptoms of depression
would test the specificity of dual task impairments
in AD. On the basis of the previous research, we pre-
dicted that the depressed group would show impair-
ment in the dual task compared with controls.
Method
Participants
We examined 33 patients with aMCI, 10 early AD
patients, 17 control out-patients with depressive
symptoms and 21 healthy elderly controls, following
a protocol approved by the local ethics of research
committee. All participants also took part in a larger
longitudinal study of neuropsychological markers in
pre-clinical AD. The aMCI patients were recruited
over a 2-year period (September 2003–September
2005) from tertiary referrals to the local neuropsycho-
logical assessment service for older adults and met
criteria for aMCI (Petersen et al. 1999). MCI patients
had to give subjective reports of memory difficulty
corroborated by an informant and exhibit objective
memory impairments on neuropsychological tests
of episodic memory. In terms of impairments on
tests of episodic memory, 13 participants showed an
impairment of more than 2 standard deviations (S.D.)
below our control mean on two or more tests, a further
four showed impairments of 1.5 to 2 S.D. on two or
more tests, 12 participants were impaired at 1–1.5 S.D.
below control means on two or more tests, and the
final four participants performed more than 1 S.D.
below controls on one episodic memory test. All aMCI
patients underwent comprehensive neuropsychologi-
cal and psychiatric evaluation and medical screening
prior to study entry, as well as neuroimaging before
or during the study period, if thought to be clinically
indicated by the responsible specialist, i.e. in 24 of
the 33 participants in this group. Exclusion criteria
for the aMCI group were a diagnosis of dementia or
other medical/neurological conditions which may
account for memory loss, untreated depressive illness,
significant or predominant cerebrovascular disease
on neuroimaging, significant motor and/or visual
problems or an age below 58 years. Mini Mental State
Examination (MMSE) scores ranged from 24 to 30,
with a mean of 28.3. The final aMCI group consisted
of 15 males and 18 females with a mean age of 73.3
years (range 58–85 years).
For the healthy elderly control group (MMSE
28–30), we recruited spouses or carers of patients who
had attended the service. Potential participants were
excluded if there was a history of medical, psychiatric
or neurological conditions (i.e. stroke or cerebrovas-
cular disease, head injury, alcoholism, schizophrenia,
etc) that could conceivably affect cognitive function-
ing. The healthy elderly control group was matched
as closely as possible to the aMCI and early AD groups
in terms of age and estimated pre-morbid intelligence
quotient (IQ). The final elderly control group consisted
of eight males and 13 females with had a mean age
of 69.5 years (range 59–81 years).
Ten participants diagnosed with AD, in accordance
with National Institute of Neurologic, Communicative
Disorders and Stroke–AD and Related Disorders
Association (NINCDS-ADRDA; McKhann et al. 1984)
and DSM-IV (APA, 1994) diagnostic criteria, took
part in the current study. AD patients were recruited
from tertiary referrals to our neuropsychology service
or via referrals to the local old age psychiatry service.
All early AD patients scored above 23/30 on the
MMSE and above 65/100 on the more comprehen-
sive Addenbrooke’s cognitive examination (ACE;
Mathuranath et al. 2000), indicating relatively mild
disease. Patients had undergone relevant medical
screening and neuroimaging, together with compre-
hensive psychiatric and neuropsychological evalu-
ation as part of their initial diagnostic workup. The
final early AD group consisted of three males and
seven females with a mean age of 73.6 years (range
65–81 years).
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Seventeen participants with depressive symptoms
(MMSE 25–30) were recruited via local psychiatric
out-patient clinics and day hospitals. In an attempt
to match this patient group with the aMCI group in
terms of illness severity, patients with milder forms
of depression were included. Fifteen of the 17 partici-
pants were receiving treatment for their symptoms
at the time of testing ; all but two of these pharma-
ceutical in nature. As it has been suggested that type
of depression does not influence the magnitude of
cognitive deficits (Christensen et al. 1997), participants
with a variety of disorders were included. Eight
patients had a history of major depression, two of
bipolar disorder, two were suffering from anxiety
disorders with depressive features, three were con-
sidered dysthymic and two were considered to be
suffering with a subclinical level of depressive symp-
toms.Mean geriatric depression scale (30-item version)
score for this group was 13.2 (range 0–27). We once
again excluded patients with any medical, neurologi-
cal or psychiatric condition with a known potential to
affect cognitive function. The group consisted of three
males and 14 females with a mean age of 73.3 years
(range 65–84 years). Subjects gave informed written
consent to the whole protocol which was approved by
the Lothian Research Ethics Committee ; the research
was completed in accordance with the Helsinki
Declaration.
Neuropsychological tests
All participants completed a variation on the modi-
fied dual task paradigm (Della Sala et al. 1995). This
pencil-and-paper test of divided attention consists of
two components (a digit span task and a visuospatial
tracking task) that are each performed on their own
before being performed concurrently. First, partici-
pants’ digit span was determined. This involved re-
peating strings of digits read by an experimenter at
a rate of approximately two per s. Initially, two-digit
strings were presented and these increased one digit
at a time if the participant correctly recited five of
six examples of each length. When the participant
failed to recite two or more strings of the same span,
digit span for that person was considered to be the
previous length. No time limit was imposed at this
stage. Having determined the participants’ individual
digit span, participants had 90 s to recite as many digit
strings, fixed at the individual participants’ digit
span, as possible (digit span – single). Responses were
recorded as correct for each digit recited in the correct
order.
Following this, participants completed the tracking
task (Della Sala, 1999). An A3-sized sheet with 319
empty circles linked by a meandering line was
presented to the participant. The participant was in-
structed to trace a line though circles, following the
line that was already there, without lifting the pen
from the paper. Participants had 90 s for this trial, and
the number of circles reached during this time was
recorded (tracking – single). The final trial was the
concurrent dual task. Here participants had 90 s to
simultaneously perform both tasks : recite digit
strings fixed at their digit span (digit span – dual) as
well as carrying out a tracking task identical to the
one used above (tracking – dual). In order to take
into account the various strategies one may adopt in
performing the two tasks simultaneously, an overall
decrement score was calculated using the following
formula :
m=(1x[(Pm+Pt)=2])r100,
where m is the combined dual task score, Pm is
the proportional loss in span performance between
single (Xsingle) and dual task (Xdual) conditions,
[(Xsingle – Xdual)/Xsingle] while Pt is the equivalent
proportional loss in tracking score. Thus a score of
100 would represent no dual task decrement and
lower scores reflect greater dual task decrements.
A number of further tests were administered as part
of the longitudinal investigation of neuropsycho-
logical markers. These included measures of general
cognitive ability, such as the ACE, the more widely
known MMSE and the National Adult Reading Test,
revised version (NART-R; Nelson & Willison, 1991).
The NART-R was used to provide an estimate of
the pre-morbid level of intellectual functioning. Epi-
sodic memory was assessed using the Hopkin’s
verbal list test, revised (HVLT-R; Brandt, 1991) and
the paired associates learning test (PAL) from the
Cambridge automated neuropsychological test battery
(Swainson et al. 2001). Participants also completed
the trail-making test (TMT) part A and B (Reitan,
1985), considered a measure of attention and executive
functioning.
The HVLT-R requires participants to recall as many
words as possible immediately following presentation
of a 12-item word list. The word list is presented on
three consecutive learning trials. The participant is
also required to recall, and finally recognize, as many
words from the list as he or she is able, following a
delay of 30 min. The PAL is a computerized measure
of visuospatial learning requiring participants to learn
the locations of an increasing number (i.e. 1, 2, 3, 6 and
then 8) of patterns (Swainson et al. 2001). The score
of interest was the number of pattern-position errors
at the six pattern level. The TMT A requires tracing
a line linking numbers in ascending order, while
for the TMT B participants have to connect numbers
and letters alternatively in ascending order : the
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participant has to divide his/her attention back and
forth between multiple lines of thought.
Each of these measures has been shown to be
sensitive to very early AD (Chen et al. 2000 ; Nathan
et al. 2001 ; Swainson et al. 2001 ; Hogervorst et al.
2002 ; Blackwell et al. 2004; Stokholm et al. 2006).
Neuropsychological assessments lasted approximately
90 min in total. The order of test administration was
identical for all assessments.
Statistics
Data were analysed using SPSS 12.0 for Windows
(SPSS Inc., Chicago, IL, USA). Demographic variables
were analysed using univariate analysis of variance
(ANOVA), and Tukey honestly significantly different
pairwise comparisons were carried out on all signifi-
cant analyses where possible. Where the assumption
of homogeneity of variance was not met, this was
adjusted for using Games–Howell post-hoc pairwise
comparisons, given that the sample sizes were
unequal in the current analysis. A univariate ANOVA
was carried out on the overall decrement score (see
above). Decrement scores broken down into tracking
decrement and digit span decrement were also calcu-
lated and examined using ANOVAs. Two participants
in the early AD group were incapable of completing
the TMT B; in these cases a default ceiling score of
500 s to completion was applied.
Results
Participant characteristics
Demographic matching characteristics are presented
in Table 1. There were no group differences in age
[F(3, 77)=1.73] or estimated pre-morbid full-scale IQ
[F(3, 75)=0.55]. The mean MMSE score for the early
AD group was, as expected, significantly lower than
that of the other groups [F(3, 77)=17.70, p<0.0001]
(AD v. healthy controls, p=0.001; AD v. controls with
depressive symptoms, p<0.005; AD v. controls,
p<0.005). No other group differences in mean MMSE
score were noted. As expected, the early AD patients
had significantly lower mean ACE scores than did
all other groups [F(3, 77)=29.30, p<0.0001] (post-hoc
tests as above in all cases, p<0.0001). The ACE also
discriminated between normal elderly control partici-
pants and aMCI patients, with the latter group ob-
taining a significantly lower mean ACE score (post hoc
p=0.01).
Dual task performance
Group means and S.D.s for the digit span task and
the tracking measures of the modified dual task
paradigm are presented in Table 2. Mean percentage
scores for performance on the concurrent tasks, the
digit span tasks and the visuospatial tracking tasks
for each of the four groups are presented in Table 3.
On carrying out a one-way non-repeated ANOVA on
the overall decrement score, no group difference was
found [F(3, 77)=0.63]. Similarly, no significant group
differences were found for any of the other component
tasks or decrement scores.
Other cognitive functions
Group mean scores and S.D.s for the HVLT-R, the
number of errors at the six pattern level of the PAL
and the TMT B are presented in Table 4. On analysing
the HVLT-R delayed recall data, there was a signifi-
cant group effect [F(3, 77)=12.39, p<0.0001]. On closer
analysis, the AD group recalled significantly fewer
words than the healthy control (p<0.0001) and de-
pression groups (p<0.0001). Similarly, the aMCI










Males (n) 8 3 16 3
Females (n) 13 14 17 7
Age 69.5 (7.3) 73.3 (6.6) 73.1 (6.3) 73.6 (5.8) –
NART 118.2 (2.9) 116.8 (6.2) 116.3 (8.5) 115.6 (5.5) –
MMSEa 29.1 (0.7) 28.6 (1.5) 28.4 (1.6) 25.0 (2.3) Controls=depression=aMCI>AD
ACE 94.6 (3.3) 91.7 (5.0) 89.0 (5.6) 76.7 (6.6) Controls>aMCI>AD
Depression>AD
aMCI, Amnestic mild cognitive impairment ; AD, Alzheimer’s disease ; NART, National Adult Reading Test ; MMSE,
Mini Mental State Examination ; ACE, Addenbrooke’s cognitive examination.
Values are given as mean (standard deviation).
a Games–Howell multiple comparison carried out due to lack of homogeneity of variances.
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group performed more poorly than the healthy control
(p<0.005) and depression groups (p<0.01). No sig-
nificant difference was found between the AD and
aMCI groups. The performance of the elderly control
and depression groups on the HVLT-R delayed recall
did not differ. However, the AD group made signifi-
cantly more errors at the six pattern stage of the PAL
compared with all other groups [F(3, 755)=22.82,
Table 2. Digit span and individual component measures of the dual task (span and










Digit span 5.5 (0.7) 5.8 (1.0) 5.6 (0.9) 5.1 (0.7)
Digit span (single)a 1.0 (0.03) 0.9 (0.05) 1.0 (0.05) 1.0 (0.03)
Digit span (dual)a 0.9 (0.05) 0.9 (0.08) 0.9 (0.08) 1.0 (0.02)
Tracking (single)b 141 (56.5) 140 (51.7) 126 (38.9) 120 (46.3)
Tracking (dual)b 122 (46.0) 126 (58.3) 114 (36.3) 107 (35.6)
aMCI, Amnestic mild cognitive impairment ; AD, Alzheimer’s disease.
Values are given as mean (standard deviation).
a Proportion of digits recalled in the correct position (1=all correct).
b Number of circles joined in 90 s.
Table 3. Percentage loss of performance in component tasks and overall decrement score










Digit span 96 (3.8) 97 (8.6) 98 (7.6) 100 (3.3)
Tracking 90 (22.8) 88 (16.8) 92 (15.4) 93 (17.6)
Overall decrement 93 (11.1) 92 (8.2) 95 (8.6) 97 (9.1)
aMCI, Amnestic mild cognitive impairment ; AD, Alzheimer’s disease.
Values are given as mean (standard deviation).
a Percentage loss of performance scores were calculated as (1x[(XsinglexXdual)/
Xsingle])r100 and the overall decrement score as m=(1x[(Pm+Pt)/2])r100, as
described in the Method section.










HVLT-R delay 8.1 (2.8) 8.1 (3.3) 4.9 (3.3) 2.1 (3.7) Controls=depression >aMCI=AD
PAL errorsa 7.8 (6.9) 10.9 (7.8) 16.5 (12.9) 40.7 (10.6) Controls, depression, aMCI<AD
Controls <aMCI
TMT A 40.3 (11.2) 54.1 (23.1) 49.6 (36.1) 57.6 (25.3) –
TMT B 87.6 (31.5) 134.2 (53.6) 106.3 (49.4) 216.7 (157.7) Controls<depression
Controls, depression, aMCI<ADb
aMCI, Amnestic mild cognitive impairment ; AD, Alzheimer’s disease ; HVLT-R, Hopkins verbal learning test, revised ; PAL
errors, six pattern stage errors from the paired associates learning test ; TMT A, trail-making test part A; TMT B, trail-making test
part B.
Values are given as mean (standard deviation).
a Games–Howell multiple comparison was used because of unequal variances.
b After removing effects of TMT A (see text).
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p<0.0001] (post hoc tests comparing AD with other
groups were in all cases p<0.0001). The aMCI group’s
error scores fell between those of the healthy control
and AD groups, and significantly differed from both
of these (aMCI v. healthy controls, p<0.05 ; aMCI
v. AD, p<0.0001). A significant group effect was also
found for the TMT B [F(3, 77)=8.62, p<0.0001]. In the
post hoc analyses, only the control and depression
groups differed in terms of TMT B scores (p<0.05) ;
participants with depressive symptoms took signifi-
cantly longer to complete the task. However, once
time to completion on TMT part A (a measure of
psychomotor speed) was statistically controlled for,
a different pattern of group differences emerged
[F(3, 76)=7.76, p<0.0001]. Specifically, it was found
that the participants with AD took longer to complete
the second task compared with all other groups (aMCI
v. AD, p<0.0001; healthy controls v. AD, p<0.0001;
controls with depressive symptoms v. AD, p<0.05).
The group difference between the control and depres-
sive symptom groups was no longer significant. No
other group differences were uncovered.
Discussion
This study investigated the claim that the dual task
paradigm can be used in the early diagnosis of de-
mentia of the Alzheimer’s type. We assessed the
concurrent performance of a visuospatial tracing task
and a digit span forward task in four diagnostic
groups with aMCI (MMSE 24–30), early AD (MMSE
23–29), symptoms of depression (MMSE 25–30) and
healthy elderly controls (MMSE 28–30). Our results
show that aMCI is not associated with impaired dual
task performance ; those with aMCI had comparable
performance to healthy older adults and older adults
with depressive symptoms. Our early AD group was
similarly unimpaired on the modified dual task para-
digm relative to depressive and non-depressive
elderly control groups and the presence of depressive
symptoms appeared to have no effect on dual task
performance. By contrast, and indeed by definition,
episodic memory impairments were present in the
aMCI and early AD groups. The early AD group also
exhibited an impaired ability to divide their attention
at pace, as indicated by part B of the TMT.
These results shed some light on previous findings.
One line of research has suggested that dual task
performance is vulnerable to the influence of AD, even
early in the disease course (Baddeley et al. 2001 ; Logie
et al. 2004). However, such studies generally involve
participants varying in severity from minimal to mild
AD. When participants with AD are divided by
severity using the MMSE, only the more severely ill
patients (e.g. MMSE <24) are impaired on the dual
task paradigm (Greene et al. 1995; Perry et al. 2000;
Crossley et al. 2004). This result is in agreement with
the absence of impairment on the dual task measure
observed in the current study in early AD. The com-
bined findings suggest that dual task impairments
are generally not observed early on in the AD process,
with MMSE scores above 23/30.
Only one other study has investigated the dual
task performance of a group of older adults with cog-
nitive impairment without a diagnosis of dementia
(Holtzer et al. 2004). Cognitively impaired adults,
defined by a dementia rating scale (DRS) cut-off score
of <124 (Mattis, 1988), performed two tasks in dif-
ferent modalities at the same time. Two combinations
of tests were used: a visual cancellation task (where
participants were required to cross out a specified
stimulus type from a field of stimuli) combined with a
digit span task, and the same visual cancellation task
combined with a verbal fluency task. The researchers
report that their cognitively impaired group exhibited
a significantly larger dual task decrement than age-
matched controls. However, the cognitively impaired
group in the Holtzer et al. (2004) study was identified
solely on the basis of a DRS cut-off score falling at
or below levels that are indicative of an underlying
dementia. It is for this reason difficult to be certain
of, or to compare, disease severity of this ‘minimally
cognitively impaired’ group with other studies, which
commonly use well-established clinical and research
criteria to define patient groups. Furthermore, the
cognitively impaired group in the Holtzer et al. (2004)
study were significantly less well educated than the
control groups, while in the current study participant
groups were well matched both in terms of age and
estimated levels of pre-morbid intelligence.
Holtzer et al. (2004) did not investigate the potential
influence of depression on dual task performance.
This is crucial where consideration is being given
to the early and differential diagnostic value of a
neuropsychological measure. Hasher & Zacks (1979)
confirmed our result that people with depression
show impaired attention during effortful processing
tasks, for instance on measures of divided attention
such as the TMT B (Nathan et al. 2001; Mahurin et al.
2006). Only one study has investigated the effect
of depressive symptoms on Baddeley et al.’s (1986)
original dual task paradigm (Nebes et al. 2001). This
indicated that people with depression had a signifi-
cantly greater decrement in computerized tracking
performance and a composite decrement measure
than non-depressed controls. No study to date has
investigated the effects of clinically depressed mood
on the modified version of the dual task paradigm to
replicate or contradict our negative result (Della Sala
et al. 1995).
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A strength of the current investigation relates to
the availability of additional neuropsychological data
demonstrating the existence of significant episodic
memory impairments in aMCI and early AD and ad-
ditional impairment of speeded divided attention (as
assessed by TMT B) in early AD. The TMT B assesses
the ability to divide attention back and forth between
multiple lines of thought (connecting numbers and
letters, respectively), but differs from the dual task
paradigm in that its different components are not
drawn from separate modalities. Performance is thus
more vulnerable to reduced processing capacity.
Several previous studies have demonstrated that TMT
B is impaired in the very early and even pre-clinical
stages of AD (Lafleche & Albert, 1995 ; Arnaiz et al.
2000 ; Perry et al. 2000; Nathan et al. 2001; Crowell et al.
2002 ; Crossley et al. 2004; Alladi et al. 2006 ; Baudic
et al. 2006; Stokholm et al. 2006), although its specificity
for AD, as distinct from, for example, depression, has
not been established.
The Holtzer et al. (2004) study compared the dual
task performance of minimally cognitively impaired
participants only with their performance on tests com-
prising the single task conditions (i.e. visual cancel-
lation, digit span and letter fluency). However, these
tests are not, generally speaking, associated with im-
pairments in very early and pre-clinical AD and it is
therefore not surprising that they are insensitive to
cognitive deficits in the minimally impaired group,
as was the case in this study.
One important methodological feature may have
influenced the current results : While those studies
reporting general dual task impairment in early
AD used both computerized and pencil-and-paper
versions of the tracking task, only the modified
version utilising the pencil-and-paper tracking task
(Della Sala et al. 1995) has been used in studies that
separated participants by symptom severity. Thus,
while patients who are minimally affected do not
show impairments on the modified version of the
task, it remains possible that they would show im-
pairments if the test were more taxing – for instance
if the dual task paradigm included the original com-
puterized version of the tracking task. This version of
the task requires increased effort and attention, as
participants are required to adjust to an external influ-
ence (i.e. the speed of the light dot on the screen)
rather than working at a self-defined rate. It may
therefore be sufficiently taxing to identify those
who are not picked up by the more straightforward
pencil-and-paper tracking task. However, the paper-
and-pencil version (as opposed to the computerized
task) is more likely to be adopted for widespread use
in clinical and research practice, which underscores
the relevance of our negative result.
A further methodological issue is the variability
of dual task administration, which can lead to diffi-
culties comparing findings across studies. We ad-
ministered each of the three trials in blocks of 90 s,
while some previous studies set the trial time at 120 s
(e.g. Perry et al. 2000). Most dual task studies have
utilized pencil-and-paper tracking tasks that required
participants to cross out boxes on an A4-size sheet
of paper to form a chain (e.g. Baddeley et al. 1997).
The current task required participants to trace a
line through linked empty circles on an A3-size
sheet. While the initial dual task paradigm involved
recording the number of completely correct digit
strings (Baddeley et al. 1986), many subsequent
studies, including the current investigation, have cal-
culated the number of digits recalled in the correct
order for this measure. The significance of such alter-
ations to dual task administration requires further
investigation.
A partial alternative explanation for our negative
result is that a majority of individuals forming our
aMCI group may fail to convert to AD in the future.
If this proves to be the case, then the absence of
dual task impairment would not be surprising.
The issue will be resolved through the longitudinal
follow-up of participants with aMCI, currently under-
way. However, the sound performance of our early
AD group on the dual task measure makes it more
likely that the negative result for our aMCI patients
is due to lack of test sensitivity rather than absence
of underlying AD pathology. The impaired per-
formance of the early AD group on an alternative
popular measure of speeded divided attention implies
that the dual task measure lacks sensitivity to very
early changes of an attentional/executive nature
in AD.
In conclusion, people with early AD and aMCI did
not display impaired performance on the modified
version of the dual task paradigm at a time when
episodic memory, and in the case of early AD, speeded
divided attention, were significantly impaired. The
likely explanation is that the dual task paradigm is
insufficiently sensitive for use as an adjunctive cog-
nitive tool in the early diagnosis of AD. Future longi-
tudinal research is needed to investigate the use of
dual task tests of varying demand in aMCI and very
early AD participants in an effort to determine the
potential influence of task demands and complexity
on performance.
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A B S T R A C T
BACKGROUND:
Although patients with mild cognitive impairment (MCI) make up a significant proportion of outpatient and memory clinic visits in old age
psychiatry, their cognitive evaluation is typically restricted to brief dementia screens. We present an evaluation of published cognitive screens
in MCI, their validity, and utility.
METHOD:
Papers published after Petersen’s original MCI criteria were identified with 10 library search engines, combining the search terms ‘‘mild
cognitive impairment’’ and ‘‘cognitive screening’’, as well as ‘‘mild cognitive impairment’’ and the names of 39 screening tests recently
identified in a relevant review.
RESULTS:
Twenty-six relevant publications were identified, of which seven summarized the sensitivity and specificity of four comprehensive screening
tests, and 19 evaluated 11 non-comprehensive tests. A recently published meta-analysis of the use of the mini-mental state examination
summarized five mild cognitive impairment studies [3]. Sensitivities over 80% for detecting MCI among healthy volunteers were reported for
all four comprehensive and three of the 11 non-comprehensive screening tests. Equivalent specificity values over 80% could be found for two
comprehensive and five non-comprehensive tests. With the exception of six studies, MCI study sample sizes were universally small (i.e.,
n#100), and prognostic values were reported for only two of the identified 15 screening measures.
CONCLUSIONS:
Sensitivities of the full domain measures were universally high, but information about their specificity against psychiatric and non-
progressive neurological conditions and predictive validity is largely lacking. Conversely, non-comprehensive screening tests appear to be
less accurate overall, with relatively greater specificity and lesser sensitivity.;
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BACKGROUND
Mild cognitive impairment (MCI) is used to describe
cognitive impairment in patients who do not fulfill the
criteria for dementia. The presenting complaint is usually
recent memory loss. Amnestic MCI (aMCI) may be differ-
entiated from early dementia on the basis of sound functional
capacity, a non-progressive course, or intact functioning in
other ‘‘non-memory’’ cognitive domains. Although at ele-
vated risk of developing dementia, not all aMCI patients do
so. Cognitive impairment in aMCI patients attending memory
clinics is, however, usually seen to persist or gradually
worsen, with a mean conversion rate to dementia of 10% per
annum [1, 4–10].
Cognitive impairment is common, and patients with aMCI
make up about one fifth of referrals to specialist memory
clinics [7, 11]. Cognitive evaluation of aMCI, therefore, forms
an important part of geriatric care. There are no consensus
guidelines as to how the cognitive aspects of aMCI should be
assessed [12]. At present, clinical cognitive examinations are
largely restricted to brief screening measures, the vast
majority of which were designed to evaluate early- and
moderate-stage dementia. There is consequently a need for
up-to-date information about how these measures ‘‘perform’’
as screening tools for aMCI.
The utility of a cognitive screening measure may be judged
on a number of levels. The primary role of cognitive screening
is to detect cognitive impairment. The screening measure
must be capable of picking up clinically meaningful levels of
cognitive impairment where these exist in aMCI and early-
stage dementia. The issue of sensitivity is therefore pertinent.
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Conversely, cognitive decline(s) is also observed in associa-
tion with the normal aging processes and a wide variety of
neurological, psychiatric, and medical illnesses among the
elderly. Screening instruments therefore need to be specific
against cognitive changes of a benign or long-standing
nature.
On account of the slowly progressive nature of neurode-
generative illnesses, particularly in their early and preclinical
phases, it is often necessary to readminister a cognitive
screening instrument in order to determine the course of
cognitive impairment, i.e., stable or progressive. For this
reason, the stability of a cognitive screening measure across
both time and raters is important, as those instruments
associated with lesser degrees of random variation afford the
clinician the opportunity to detect smaller amounts of
meaningful cognitive decline.
In screening for cognitive impairment, there is an inevitable
tradeoff between the ‘‘time constraints’’ of the clinician and
the ‘‘breadth of information’’ that is obtainable. Ideally, a
cognitive screening instrument should be brief and user friendly
enough to facilitate usage in a wide range of care settings,
including that of primary care. The availability of cutoff values
for ease of interpretation is particularly useful in this regard.
Increasingly, however, more in-depth cognitive evaluation is
recognized as a key component in the early and differential
diagnostic process for dementia. At more specialist levels of
care, representation of each of the primary domains of cognition
(i.e., memory, language, visuo-spatial and perceptual func-
tion, attention, and executive function) is crucial, but of
course associated with longer test administration times.
Here, we review the utility of cognitive screening instru-
ments in aMCI with reference to sensitivity to aMCI and
specificity against healthy control subjects (and, where
information is available, other neurodegenerative and non-
neurodegenerative conditions that also give rise to cognitive
impairment). Test–retest reliability across both time and
different raters, administration times, availability and ease of
use of normative data, and the degree of cognitive domain
coverage (where ‘‘comprehensive’’ equates to coverage of
each of the primary domains of cognition and ‘‘non-
comprehensive’’ equates to incomplete coverage) are also
considered.
METHODS
Two literature searches were conducted replicating our
earlier method, and the results merged with the data already
published [13]. Both searches were restricted to papers
published after the formulation of Petersen et al’s initial set of
criteria for MCI in 1999, in order to ensure a reasonable level
of cross-study homogeneity [1, 14]. In the first, the search
terms ‘‘mild cognitive impairment’’ and ‘‘cognitive screen-
ing’’ were entered into the following electronic databases:
BIOS Previews, ISI Web of Knowledge, ISI Proceedings,
Embase, MedLine, PsychInfo, SSCI, ASSIA Plus, Psych
Articles. In the second search, the term ‘‘mild cognitive
impairment’’ was entered into each of the above databases in
combination with the names of 39 screening instruments
identified by Cullen et al [2] in a recent review of tests for
cognitive impairment.
The results of the two literature searches were combined
with our previously published database [13]. Duplicate and
repeat publications were removed alongside studies not in
English and those reporting findings for screening instru-
ments of a non-cognitive or non-face-to-face nature (i.e.,
olfactory, telephone, or internet administered or wholly carer-
or informant-rated instruments). In the interests of creating a
division between ‘‘cognitive screening’’ instruments and
more formal and standardized ‘‘neuropsychological’’ mea-
sures, we also excluded those studies in which the measure of
interest was of a non-screening nature (i.e., where this
comprised one or more well-known standardized neuropsy-
chological measures, not commonly utilized for screening). If
patients’ data had been published repeatedly, the most recent
or inclusive publication was chosen. Data were extracted
systematically and tabulated.
RESULTS
The combined searches yielded a total of 94 papers, 19 of
which were excluded as they comprised duplicated data. Of
the remaining 75 papers, a further 16 were excluded as they
were not face to face (n510), non-cognitive in nature (n54),
or the findings were reported in a language other than
English (n52). None of the screening measures reported in
the non-English papers were reviewed as part of the included
papers. Further studies were excluded as they did not meet the
study objectives, i.e., ‘‘to investigate the screening utility of
cognitive screening measures in aMCI’’ (n532), where
Petersen et al’s [1] aMCI criteria were not met or specified
(n57), where no full text version was available (n52), as well
as books (n51) and abstracts (n516).
A total of three new papers were therefore retained [15–17].
To these, a further 23 were added from Lonie et al [13], giving a
total of 26 papers comprising the focus of this review. A recent
meta-analysis of the diagnostic accuracy of the mini-mental
state examination in aMCI was also included [3] (Figure 1). <
Comprehensive cognitive screening
Table 1 summarizes studies included in the review, divided
into comprehensive and non-comprehensive screening tests. =
All four comprehensive screening tests achieved sensitivities
over 80% for detecting MCI among healthy volunteers, but
equivalent specificity values could only be found for two
comprehensive tests (ACE-R [29]; MoCA [16, 41]). All MCI
study sample sizes were small (i.e., n#100), and prognostic
values were reported for only one of the four identified
comprehensive screening measures (CAMCOG [28]). None of
the measures report specificity values for MCI in relation to
depression or any other neurological or psychiatric diseases
of a non-progressive nature. One-month retest reliability
values of 70–92% have been reported for the MoCA [41], but
not for follow-up over clinically relevant intervals (6–
12 months), or for any other of the comprehensive cognitive
screening measures. None of the comprehensive tests has
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been tested for screening in community samples, as their
longer application time would predict.
Non-comprehensive cognitive screening
Sensitivities over 80% for detecting aMCI among healthy
volunteers were reported for only three of the 11 non-
comprehensive screening tests. Equivalent specificity values
over 80% could be found for five non-comprehensive tests. In
only six studies were aMCI sample sizes .100, and
prognostic values were reported for only one of the
11identified screening measures. Table 1 summarizes the
relevant characteristics of the cognitive screening measures
with incomplete domain coverage.
The MMSE [45] is the most commonly used screening test
in clinical practice [46]. A recent meta-analysis of its accuracy
in the detection of dementia and aMCI [3] concluded that it
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Figure 1. Search and attrition chart
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‘‘offers modest accuracy with the best value for ruling out a
diagnosis of dementia in the community and primary care. For
all other uses it should be combined with or replaced by other methods’’.
In particular, its ability to differentiate aMCI cases from healthy
control subjects could not be established consistently [37, 47],
and differences, where they do exist, range from less than one
[35] to under two scale points [47]. Table 1 shows that over
half of aMCI patients score well above the commonly used
MMSE cutoffs of 24 and 26 in most studies, so there is likely to
be a considerable overlap between patients with aMCI and age-
matched healthy control subjects. The sensitivity of the MMSE
varies between 1% [36] and 96% [17], with a pooled mean of
62.7% [3]. This large variability will be related to different
MMSE cutoff values, and in studies not included in Mitchell’s
meta-analysis [3], to different comparison groups, such as a
combined group of aMCI and early dementia sufferers [26]. In
turn, specificity for the MMSE in aMCI compared with healthy
volunteers is often high, ranging from 58% to 100% [17, 36],
although Mitchell [3] reports a pooled average of 63.3% in
specialist settings. Tang-Wai et al [39] report no difference in
baseline MMSE scores of healthy individuals who later
developed aMCI and those who did not. Comparing the
MMSE with other screening measures suggests that it is less
effective in discriminating aMCI patients from healthy age-
matched control subjects [24, 31, 34, 38, 39], from persons
with progressive and non-progressive forms of cognitive
impairment [33, 39], and is more sensitive to age and
education effects [30].
Sensitivity and specificity were reported for the CDT [17, 18,
35, 36, 40], DemTect [24], M@T [34], and ADAS-Cog [32].
Sensitivity and specificity values have not been reported for
the STMS [39] or the CAMCI [26]. For a further two, CDT [17,
18, 35, 36] and the ABCS [30], these values were too low to
support their use in aMCI screening. The only sets of
favorable values have been reported for the CDT [40] and the
CAMCI [26], and these probably reflect the addition of
patients in the early stages of dementia to the MCI patient
sample. The SIS [20] appears to be of greater usefulness in
detecting MCI among the elderly in specialty settings than in
the community, although its items being restricted to
orientation and memory questions only probably makes it
inadequate for use in secondary and tertiary care.
Reliability data have been reported for the DemTect (inter-
rater r50.99 [24]) and the MoCA (1 month retest r50.92
[31]), but for none of the other tests. In addition, practice
effects over 6 and 12 months of less than one point have been
reported for the DemTect [24]. Predictive validity based on
longitudinal follow-up periods of 3–5.5 years are available for
two of the measures, with correct classification rates of
around 70% for both the STMS [39] and ADAS-Cog [22].
Administration times are on the whole shorter than 10 min,
with a majority (CDT, M@T, SIS, ABCS, and STMS) reporting
minimum administration times of 5 min or less.
CONCLUSION
The scarcity of validated screening instruments for aMCI is
problematic. The large numbers of older adults in the
community who are cognitively impaired but not demented
[48, 49], and the high frequency of aMCI in secondary and
tertiary specialist clinics [7, 11] emphasize the need for such
screening tools.
Of the 15 screening instruments identified, four (ACE-R,
DemTect, MoCA, and M@T) showed adequate (i.e., $79%)
sensitivity and specificity for aMCI [1] compared with normal
elderly control subjects. Two of these (M@T and ACE-R) do
not require transformation of raw scores, and all take less
than 15 min to administer. There have been no comparisons
of aMCI with depressed patients, which is surprising in view
of the frequency of comorbid MCI and depression [50], and
the difficulties clinicians face in identifying their respective
contributions to cognitive impairment [51, 52]. In general,
data about cross-cultural usage, reliability, and predictive
validity are rare.
In secondary and tertiary care clinics, results from the four
more comprehensive cognitive screening tests described here
can be analyzed in detail, and can become an integral part of
the clinical evaluation and differential diagnosis. Although
all these measures appear to have adequate sensitivity to
aMCI and early Alzheimer’s disease (AD), there is little
information about their reliability in healthy elderly persons,
and about the predictive validity of diagnostic cutoff scores.
This makes the interpretation of score changes difficult and
limits our ability to supply prognostic information. While
several cognitive screening instruments thus afford the
clinician the ability to detect aMCI, early AD, and in some
cases non-AD dementia, they cannot currently be used to
make reliable inferences about the course and eventual
outcome of MCI.
Future research should focus on establishing a wider range
of psychometric test properties (i.e., reliability and predictive
validity) for those cognitive screening measures with adequate
sensitivity and specificity. This would help us to interpret
score changes and provide information for prognosis. It
would also be of interest to compare the psychometric
characteristics of combining brief cognitive screening mea-
sures or neuropsychological measures with the screening
scales described above. It is possible that some of the brief
neuropsychological measures perform as well as, if not better
than, cognitive screening instruments [27, 53]. Although the
results reported above refer to cognitive screening instru-
ments in the assessment of the single and multidomain
amnestic MCI subtypes, it will be important to establish their
usefulness in MCI’s non-amnestic forms [15].
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Background: Cognitive impairment precedes the diagnosis of Alzheimer’s disease (AD).  It is 
unclear which psychometric measures predict dementia, and what cut-off points should be used. 
Replicable cognitive measures to provide information about differential diagnosis and prognosis 
would be clinically useful. 
Aims: In a prospective cohort study we investigated which measures distinguish between patients 
with amnestic mild cognitive impairment (aMCI) who convert to dementia and those who do not, and 
which combination of measures best predicts the fate of aMCI patients.
Methods: Forty-four patients with aMCI underwent extensive neuropsychological assessment at 
baseline and annually thereafter for an average of 4 years. Differences in baseline cognitive 
performance of converters and non-converters to clinically diagnosed dementia were analysed. 
Classification accuracy was estimated by sensitivity, specificity, positive and negative predictive 
values and using logistic regression.
Results; Forty one percent of participants progressed to dementia at the end of study, with a mean 
annual conversion rate of 11%.  Most (63%) showed persisting or progressive cognitive impairment, 
irrespective of diagnosis. The Addenbrooke’s Cognitive Examination together with the 
Discrimination Index of the Hopkins Verbal Learning Test –Revised (but none of the demographic 
indices) differentiated converters from non-converters at baseline with 74% accuracy.  
Conclusions: Targeted neuropsychological assessment, beyond simple cognitive screening, could 
be used in clinical practice to provide aMCI patients with prognostic information and aid selective 
early initiation of monitoring and treatment among patients who progress towards a clinically 
diagnosable dementia.  
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Introduction 
Criteria for amnestic mild cognitive impairment (aMCI) have been devised in an attempt to capture 
the pre-clinical phase of Alzheimer’s dementia (AD).  There is evidence to suggest, however, that in 
its current form, aMCI comprises a heterogeneous group of patients,1, 2 some who will progress to 
dementia with time, and others who will not.3 To maximise the diagnostic value of aMCI, criteria 
should identify a homogenous group of persons with pre-clinical dementia.  To this end, cognitive 
criteria should be defined in a manner that reflects our current knowledge of their predictive value.  
As the prodromal phase of AD is likely to extent beyond a two year period,4 studies with shorter 
follow-up periods are liable to underestimate the risk of conversion. In fact, only two of fourteen 
clinic based longitudinal aMCI studies report follow-up periods beyond 3 years (Table 1).5, 6
Moreover, low baseline levels of general cognitive functioning among aMCI participants lead to a 
greater chance of neuropsychological tasks predicting dementia, because of the more advanced stage 
of disease in the aMCI cohort. In eleven of fourteen clinic-based longitudinal studies average baseline 
Mini Mental State Examination (MMSE) scores for the MCI converter group fell below the higher 
screening cut off for dementia (i.e. 27/30).  In these studies, an underlying dementia might well have 
been suspected on the basis of such rudimentary cognitive screening instruments alone, begging the 
question of the ‘added value’ of a fuller cognitive evaluation. The comprehensiveness of the 
neuropsychological battery employed and the appropriateness (on both theoretical and empirical 
grounds) of test selection might also be expected to influence predictive power. For example, the 
combination of the Paired Associate Learning test (PAL), age and the Graded Naming Test (GNT) 
give an overall classification accuracy of 100% over a 2.5 year follow-up interval.7  The same 
classification accuracy (i.e. 100%) has been reported for the use of  the PAL in combination with the 
Addenbrooke’s Cognitive Examination (ACE)8 and the Graded Faces Test (GFT)9 over shorter (1 
year) intervals.  However, these findings have not been replicated outside the test authors’ group, in 
larger numbers of aMCI patients, across follow-up periods extending beyond 2.5 years, and where the 
mean general level of cognitive functioning at baseline (as indicated by performance on cognitive 
screening) falls above cut off points for dementia. If replicable, such measures could be used in the 
neuropsychological assessment of aMCI within specialist memory clinic settings to provide 
information about differential diagnosis and prognosis.   
Measurement of cognitive function represents just one, albeit an important, approach to detecting and 
diagnosing AD at a very early and pre-clinical stage. Other work has looked at the ability of imaging 
(for the most part MRI scanning), biomarkers (i.e. total tau, AB42 & Phospho-tau) and changes of a 
behavioural nature to predict the future onset of clinically diagnosable AD. A recent meta-analysis of 
imaging and biomarkers for AD 10 indicated some promise for the CSF markers in so far as their 
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overall predictive accuracy levels were similar to that of memory impairment four years prior to the 
point of diagnosis.  Furthermore, the effect sizes for the CSF markers were largest when assessed 
longer before the point of diagnosis.  However, atrophy of the hippocampus or other MTL structures 
was found to be a less accurate predictor of future AD than memory impairment, and the largest effect 
sizes, which are themselves likely to represent an underestimation owing to the removal of variability 
inherent in the inclusion of memory impairment as a selection criterion for a majority of studies, were 
seen in association with measures of delayed memory recall. 
In this study we present a detailed neuropsychological and clinic-based cohort study, with an average 
of 4 years follow-up from baseline neuropsychological assessment until final review.  It is the only 
study to date of high-functioning aMCI converters (i.e. MMSE > 27/30) extending beyond 3 years 
follow-up. Furthermore, it represents the first clinic based study to investigate the robustness of the 
GNT, GFT, and a combination of the ACE and PAL as predictors of conversion to dementia outside 
the original authors’ research group,8 and to report the detailed fate of aMCI non-converters in terms 
of their course of cognitive impairment. 
Methods 
Recruitment 
Participants were recruited from the Edinburgh Older Adult Neuropsychology Service, which takes all 
tertiary referrals over 60 years from geriatricians and old age psychiatrists in the Lothian Region of 
Scotland. As there is no substantial private sector, these NHS referrals are likely to be representative 
for patients with memory complaints attending their doctor. During the study period from September 
2004 to September 2007, 46 participants with aMCI could be recruited. In particular, 71 were referred 
from Old Age Psychiatry, 16 from Geriatric Medicine. Of these 87 patients, 41 did not respond to the 
invitation to attend or refused to participate in the study, leaving 46 to be investigated as follows. 
Further details regarding the demographic characteristics of these patients may be found in a previous 
publication. 11
Procedure 
Patients who fulfilled criteria for aMCI12 (objective cognitive impairment was defined by a 
performance of 1SD or more below age means on two or more measures assessing a single cognitive 
domain) undertook an extensive battery of neuropsychological measures at baseline and were 
followed-up annually, regardless of whether or not they received a clinical diagnosis of dementia 
during the course of the study, over an average 4 year period.  A 1SD cut off point on two or more 
episodic memory measures was used, in place of the more commonly applied 1.5SD on one or more 
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measures, in an attempt to minimise the likelihood of including aMCI participants with an unstable 
aMCI diagnosis as well as to maximise sensitivity to memory deficits within our sample with IQs 
higher than average aMCI participants. At the end of the study period aMCI participants were 
grouped in accordance with whether or not they had received a clinical diagnosis of dementia (as 
documented in their medical file) at any point subsequent to their initial study assessment.  
Twenty four age and IQ matched healthy elderly participants also completed the full battery of 18 
neuropsychological tasks providing a normative comparison group.  Sixteen of these twenty four 
healthy participants repeated the battery in full, an average of 28 months later.  The re-test data were 
used to established cut-off values and criteria for further classifying the neuropsychological 
performance of the aMCI non-converters as ‘stable aMCI’, ‘progressive aMCI’, or ‘normal’ at the 
study endpoint. 
Materials, Participants & Outcome Criteria 
Participant characteristics (inclusion/exclusion criteria) and neuropsychological measures have been 
detailed previously.11, 13, 14  In brief, the neuropsychological battery comprised measures of pre-morbid 
intelligence (National Adult Reading Test; NART) episodic memory (PAL, Hopkins Verbal Learning 
Test –Revised; HVLT-R, Rey Complex Figure Test; RCFT), semantic memory (GFT, GNT, Category 
fluency; animals), visuospatial function (RCFT copy), psychomotor processing speed (Trail Making 
Test Part A; TMTA) and attention/executive function (Dual Task, Controlled Oral Word Association 
Test; COWAT F,A,S; Trail Making Test Part B; TMTB).  AMCI was defined in accordance with the 
revised criteria set out by Petersen.12 Demographic characteristics of the aMCI converter, aMCI non-
converter and normative sample, together with their respective baseline mean performances on 
cognitive screening and selected neuropsychological measures are summarised in Table 2.   
Statistical Analysis 
Independent t-tests were conducted to compare the baseline performances of aMCI converters and 
aMCI non-converters on the demographic indices of age, NART FSIQ, and years of follow-up, and 
the neuropsychological measures: ACE total score, PAL, HVLT-R delayed recall and discrimination 
index (DI; a measure of accuracy of delayed recognition), GFT, category fluency and TMTB.  The 
alpha level was adjusted to control for multiple comparisons using Holm’s sequential Bonferroni 
correction method.15
Baseline ages, time of follow-up and premorbid IQ were selected as potential confounders for their 
established influence on risk of developing late onset dementia.16-18  Seven neuropsychological 
measures (ACE, PAL, HVLT-R DI & delayed recall, GNT, GFT, and TMTB) were selected from a 
total of 18, on the basis of their known sensitivity to aMCI or their high predictive validity (Table 2). 
7
Patients who were clinically diagnosed as suffering from dementia at study endpoint were identified. 
Patients who had not received a clinical diagnosis of dementia were further classified as “normal” or 
“persisting aMCI” based on their neuropsychological profile at endpoint, and “progressive” or “non-
progressive” based on the longitudinal course of cognitive function during their years of study 
participation. “Abnormal” neuropsychological performance was defined by a performance at the 7th
centile or lower in two or more of 18 neuropsychological tasks (this would occur by chance in 0.83~1 
of 22 MCI participants without a diagnosis of dementia).  MCI decline was defined by cognitive 
deterioration of a magnitude seen in fewer than 2.5% of a sample of healthy elderly over an average 
28 month period on at least two measures of semantic memory or executive functioning.  Cognitive 
domains other than episodic memory were selected for this criterion, because of the baseline floor 
level performances on episodic memory tasks of many aMCI participants.  
Sensitivity, specificity, positive and negative predictive values, together with the overall percentage of 
classification accuracy in predicting conversion or non-conversion to dementia, was determined using 
a combination of a total score of <88/100 on the ACE or a performance of two standard deviations or 
more below controls on the PAL, as this combination of measures has previously been associated with 
100% sensitivity and negative predictive values.8  These values were also determined for face (GFT) 
and object (GNT) naming measures. 
Neuropsychological measures, for which the baseline performances of aMCI converters and aMCI 
non-converters were significantly different, were entered simultaneously alongside the putative 
confounders “age”, “NART FSIQ” and “years of follow-up” into a logistic regression analysis. A 
backward stepwise procedure using the likelihood ratio was applied to determine model content and 
levels of overall classification accuracy.  Criteria for entry and removal were set at p=0.05 and 
p=0.01, respectively, using 20 iteration (SPSS 17; SPSS Inc. Chicago, Ill, USA).  
Results 
Forty one percent (18/44=40.9%; 95% CI = 28 – 56%) of aMCI participants received a clinical 
diagnosis of dementia (most often AD) at some point prior to study endpoint (i.e. on average 4.33 
years after entry into the study), giving an average annual conversion rate of 11.4% (95% CI = 4 – 
23%). The remaining 26/44 (59%) participants had not received a clinical diagnosis of dementia.  
Medical notes were missing or not accessible for the remaining 2/44 aMCI participants. For these 
participants, the most up to date information available at the study endpoint was that obtained at final 
study attendance.  Of the participants who had not received a clinical diagnosis of dementia, 8/26 
(31%) were stable, 10/26 (38%) progressive, and 8/26 (31%) reverted to normal, according to the 
criteria defined above (Figure 1). 
8
Following adjustment of the alpha level,15 significant differences in the baseline performances of 
aMCI converters and aMCI non-converters were found on the ACE (t(42) = 2.98, p<0.01, r= 0.42) and 
HVLT-DI ( t(41) = 2.81, p <0.01, r=0.40).  
Only one participant obtained a GNT score at baseline below the 2nd centile of our healthy elderly 
control group. None of the aMCI patients performed below the 2.5th centile of our control group on 
the GFT at baseline.  Univariate sensitivity, specificity, negative (NPV) and positive (PPV) predictive 
values for conversion from aMCI to dementia were, therefore, based on a cut-off performance at the 
7th centile (> 1.5SD below the mean) of age norms, and can be summarised as follows; GNT 
sensitivity: 38%, specificity: 68%, PPV: 43%, NPV: 63%; GFNT 44%, 68%, 50%, 63%. Using a 
combination cut off of ACE < 88/100 or PAL > 14 errors, the overall rate of classification accuracy 
was 68% with sensitivity: 72%, Specificity: 65%,  PPV: 59%, and NPV: 77%.   
Backward logistic regression with age, NART FSIQ, years of follow-up, and the neuropsychological 
measures for which baseline performance differentiated converters and non-converters (HVLT-DI and 
ACE total score), resulted in a final model, completed after five iterations, including the variables 
ACE total score and HVLT-DI score only, yielding an overall classification accuracy (aMCI 
converter vs. aMCI non-converter) of 74%, sensitivity 65%, specificity 80%, NPV 77%, and PPV 
69%.   
Discussion 
Forty one percent of patients who met criteria for aMCI at study entry received a clinical diagnosis of 
dementia within the following 4 years, giving an annual conversion rate of 10% per annum, which is 
almost identical to the mean (9.7%) annual conversion rate obtained on averaging the findings from 
existing clinic based aMCI longitudinal studies of a similar (2.5 – 3.5 year) length.  
Baseline performance on the ACE and HVLT-R DI were able to discriminate between future aMCI 
converters and non-converters at a time when general levels of cognitive functioning fell above the 
higher level screening cut off for dementia (i.e. >27/30 on the MMSE and > 88/100 on the ACE), and 
classified MCI patients in accordance with their prognostic fate with a moderate degree (74%) of 
overall accuracy.  Differences in the baseline performances of the aMCI converter and non-converter 
groups on these measures could not be explained by differences in age, FSIQ or length of follow-up, 
as aMCI converter and non-converter groups were roughly similar, and effects persisted after 
controlling for each of these variables. 
The average score of the converter group on the HVLT-R DI at baseline was equal to performance at 
the 4th centile of published age and education matched control values,19 and the 7th centile of our own 
healthy elderly age and IQ matched control sample.  The corresponding values for the non-converter 
group were the 28th and the 36th centile, respectively, implying that there is a greater risk of 
9
conversion to dementia among a subset of aMCI patients, who are readily identifiable on the basis of 
published norms.   
For the ACE, average scores of the converter group were equal to the 4th, those of non-converters 
equal to the 31st centile of published normative values,20  and the 1st and 16th centile of our matched 
study control data, providing further support for the designation of 88/100 as a higher cut-off point for 
dementia. We suggest that use of this score is appropriate to screen for aMCI, despite the younger age 
group of the original ACE normative sample.  
In clinical practice, the combined performances of aMCI patients on the ACE and HVLT-R DI could 
be used to inform decisions about the frequency of future contact / monitoring required, or in 
combination with additional clinical information (i.e. levels of carer rated depressive symptoms,21
APOE 4 carrier status,12 corroborative history, neuroimaging findings, family history and qualitative 
aspects of clinical presentation to decide whether or not to consider pharmacological or other 
interventions.  The relatively small proportion of aMCI patients showing resolution of their cognitive 
symptoms over the time of the study also has implications for the clinical management of such 
patients, as a number of empirically validated methods for the cognitive rehabilitation of early stage 
AD have been described22 and could theoretically be used to enhance the day to day memory 
functioning of patients with aMCI.   
Baseline scores of the HVLT-R DI and the ACE were significant independent predictors of 
conversion to dementia.  Closer inspection of the regression analysis reveals that the HVLT-R DI 
score contributes to the overall classification accuracy of the ACE by increasing negative predictive 
value. This implies that memory impairment of a consolidation/storage nature is generally present in 
cases where a diagnosis of dementia (AD, vascular dementia (VD) or mixed AD/VD) follows within 
4 years.  
It is possible that cued recall impairment arises closer to the point at which AD can be diagnosed 
clinically, often after problems with (the more difficult) free recall become apparent.  The possibility 
that cueing may facilitate episodic recall may then disappear with disease progression, giving rise to 
an encoding/consolidation profile of memory impairment.  
This observation has implications for the recently proposed new research criteria for AD,23 in which 
the requirement for objective evidence of significantly impaired episodic memory has been 
elaborated.  The new criteria emphasize the importance of establishing an encoding and storage deficit 
on the grounds that reduced benefit from cueing during recall reliably identifies prodromal AD.  Our 
findings lend support to the specification of episodic memory impairment in this manner.  However, 
the limited range of scores attainable using the HVLT-R DI and the resultant potential for floor 
effects, suggests it may not be well-suited for monitoring significant decline in episodic memory 
function over time. 
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The newer version of the ACE-R24 incorporates a delayed cued verbal recognition element.   In light 
of the added predictive value of the HVLT-R DI demonstrated in this study, it would seem prudent to 
evaluate whether or not this measure retains its prognostic contribution alongside the ACE-R.  
The mean total baseline score on the ACE (87/100) for future converters fell just below the higher 
level cut off point for dementia. For 26% of participants, baseline ACE scores fell above the higher 
cut off point for dementia (i.e. 88/100) suggesting that where the ACE is used as the sole means of 
determining the likelihood of developing dementia over the proceeding 4 years, up to one quarter of 
all persons with pre-clinical dementia receive false reassurance of ‘normality’.  The implications of 
using the ACE as a sole means to determine the presence or absence of clinically significant levels of 
cognitive impairment are even greater, as the present findings indicate that 62% of patients who fulfil 
criteria for aMCI obtain scores of 88/100 or above on the ACE.   
We were unable to replicate the high levels of sensitivity, specificity, positive and negative predictive 
values that have been previously reported in association with combined PAL and ACE scores, the 
GNT and the GFT.7-9 Our need to adopt a more conservative 7th centile (-1.5 SD) cut off for the 
naming measures may in part reflect the longer follow-up period in ours as compared with the last 
study9 (13.7 months from baseline until study endpoint). Their shorter interval until diagnosis is 
consistent with a greater magnitude of impairment on naming tasks in their sample.  The predictive 
value of neuropsychological measures is likely to vary as a function of the number of years prior to 
diagnosis, underscoring the need for careful consideration of both the length of follow-up and the 
levels of baseline cognitive functioning of aMCI cohorts in different studies. 
There are a number of limitations to this study:  First, although a mean follow-up period of over 4 
years compares well with previous clinic based studies of longitudinal outcome in aMCI, it remains 
possible that additional aMCI participants will go on to receive a clinical diagnosis over the longer 
term.  Furthermore, the length of follow-up varied among aMCI participants between 1-5 years.  
Ideally all aMCI participants would have been follow-up for the maximum 5-year interval. Second, 
the high average pre-morbid IQ and select nature (i.e. tertiary referral, amnestic single and multi-
domain and primarily AD endpoint diagnosis) of our aMCI cohort limits generalization of the study 
findings beyond groups that are characterized similarly.  Third, although the predominant eventual 
diagnosis of dementia was of Alzheimer (n=11) or mixed (n=5) Alzheimer/vascular type, a small 
proportion of aMCI participants (i.e. 2) were finally diagnosed with vascular dementia.  The resultant 
inclusion of endpoint clinical diagnosis other than that of pure AD may have influenced the predictive 
validity of the neuropsychological measures within our battery. It could be argued, in a more practical 
sense, that exclusion of aMCI participants on grounds of multiple risk factors or even retrospectively 
does not reflect clinical reality.  There is variability in the point at which clinicians arrive at a 
diagnosis of dementia and the specific criteria they employ, despite a common bias towards avoiding 
false positive diagnoses.  It remains possible that for some aMCI patients clinical diagnostic status at 
11 
the study endpoint was in part reliant on the idiosyncrasies’ of one or more of the 6 attending 
consultants. Finally, the relatively small sample size makes independent replication essential. 
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Table 8.1 Diagnostic and treatment details for elderly depressive participants 
Patient
ID No. 
Clinical Diagnosis of Major 
Depressive Disorder Y/N 
(Other) 
Antidepressant Y/N Non-pharmaceuticalintervention / only Y 
  Y Y 671
 Y N cimyhtsyD N 191
  Y Y 291
 Y Y cimyhtsyD N 202
  scityloixnA N yteixnA N 112
  Y Y 122
  Y ralopiB N 432
  Y Y 532
  Y cimyhtsyD N 942
  scityloixnA N Y 462
  Y Y 662
  Y cimyhtsyD N 282
  Y Y 933
  Y Y 153
  Y Y 083
  Y Y 183
  Y Y 283
  Y Y 383
 Y N Y 483
  Y Y 583
Totals
14 Major Depressive 
Disorder; 4 Dysthymic; 1 
Bipolar; 1 Anxiety 
16 antidepressant medication; 2 
anxiolytics; 2 non-pharmaceutical 
intervention only 
3 non-pharmaceutical 
intervention only; 17 drug 
treatment
 
Table 8.2   Assessment battery completed as a function of participant group 
and stage of follow-up 
 
 
MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; NART, National Adult Reading Test; 
MMSE, Mini Mental State Examination; HVLT-R, Hopkins Verbal Learning Test – Revised; PAL, 
Paired Associate Learning Test;  RCFT, Rey Complex Figure Test; TMT, Trail Making Test; 
COWAT, Controlled Oral Word Association Test; GNT, Graded Naming Test; GFT, Graded Faces 
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Figure 8.1  Individual scores on the delayed recall component of the ACE as a 
function of group 
















Figure 8.1  Error scores at the 6-box level of PAL as a function of   group
Figure 8.3  Individual total recall scores on the HVLT-R as a function of 
participant group 

















  Figure 8.5  Individual scores on the HVLT-R DI as a function of group 
Figure 8.6  Individual scores on the delayed recall component of the Rey 








HVLT-R Discrimination Index 


































Personal & Self Maintenence Scale 

